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A pros~ctlve pharmacoleinetic study was conducted amongst a cohort of 142 
patients with tuberculosis (TB) susceptible to rifampicin and isoniazid at Brewelsleloof 
Hospital, Worcester, in the Western Cape. 
The pharmacoleinetic profiles of rifampicin, isoniazid, pyrazinamide and ethambutol in 
plasma were derived from blood samples taleen within 1 hour before drug 
administration and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6 and 8 hours after drug administration on 
a single occasion, 2 months after admission to the hospital. Noncompartmental 
methods were used to estimate the peale concentration (Cmox), the time to reach 
peale the concentration (Tmox), the area-under-the-curve from 0 to 8 hours (AUCt), 
the area-under-the-curve from 0 to infinity IAUCi}, the half-life and the elimination 
rate constant (Ic), for each drug. The association of the pharmacoleinetic measures 
with patient and treatment factors (including age, sex, body mass index, acetylator 
type, HIV-infection status, drug dose/leg, drug formulation characteristics, chemistry 
and haematology profiles, and history of prior antituberculosis treatment, drinking and 
smoleing habits) were described using multiple linear and logistic regression methods. 
Treatment response was measured by proportional weight gain over 2 months from 
the time of admission, sputum smear and culture at 2 months after admission, the 
treatment outcome recorded in the TB-registers, and the rate of treatment failure, 
death or relapse from 2 until 24 months after admission to the hospital. Determinants 
of treatment response were identified by regression of patient factors (including 
correlates of immunity, demographic, clinical and laboratory characteristics) and 
treatment factors (including antituberculosis drug levels and formulation factors) on 
the markers of treatment response. 
Low and variable rifampicin levels were prevalent amongst this patient population. 
HIV -infection and formulation characteristics, amongst others, were important 
determinants of the respective pharmacoleinetic measures of the drugs. Rifampicin 
and ethambutol levels were significant determinants of sputum conversion at 2 
months; increased ethambutol concentrations and high doses of pyrazinamide were 
associated with reduced weight gain during the first 2 months of hospital admission; 
and higher peale concentrations of isoniazid were found in those with worse 
outcomes in the TB-registers. The prognosis at 24 months was predominantly 
determined by immunity. More vigorous whole blood interferon-gamma responses to 
PPD stimulation at 2 months after admission to the hospital were associated with 
substantial reductions in the risk of treatment failure, death or relapse. Higher 
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The project described in this thesis was initiated in 1999 in response to the request by 
clinicians at Brewelskloof Hospital to investigate whether low drug concentrations 
could b,e responsible for the poor response to fully supervised treatment of certain 
individuals who had drug-sensitive tuberculosis. The study aimed to address several 
issues unresolved in the literature at the time and outlined below, including: the 
normal patient ranges for pharmacokinetic measures of the first-line antituberculosis 
drugs; the identification of patients at risk of low drug concentrations; the 
identification of risk factors associated with low drug concentrations; the role of drug 
concentrations in determining the response to treatment and treatment outcome. 
PrQled oblectlves 
(i) To measure the concentrations of rifampicin, isoniazid, pyrazinamide and 
ethambutol in a large sample of the patient population at Brewelskloof TB Hospital on 
the outskirts of Worcester, Westem Cape. Relatively intensive sampling was used over 
an 8 hour time period following administration of the patients' routinely prescribed 
medicines. The pharmacokinetic profile for each drug was obtained in each patient 
on a single occasion after 2 months of antituberculosis therapy in the hospital. 
(ii) To describe the normal ranges for the pharmacokinetic measures for each of the 
drugs in this patient population. 
(iii) To define efficient methods for identification of patients with low drug 
concentrations. 
(iv) To measure patient and formulation characteristics in this patient population and 
describe the risk of low drug concentrations associated with these factors. 
(v) To measure the response to standard treatment regimens for drug sensitive 
tuberculosis in this patient population. Data was measured at 2 months after 
admission to hospital and outcome data were gathered until 2 years after admission 
to the hospital. 
(vi) To establish whether low drug concentrations are associated with a poor early 
response to treatment (measured at 2 months after admission to the hospital), or an 
increased risk of disease relapse (up to 2 years after admission to the hospital) in this 
patient population. 
(vii) To measure cytokine markers of immunity in this population and the relationship of 
these markers to treatment response. 
(viii) To measure the susceptibility of the infecting strains of M. tuberculosis in this 
population to isoniazid and rifampicin and the relationship of drug susceptibility to 
treatment response. 
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inter ',~ve !-'h05c ccmprise, riiarn,icin, "Oni07id. pYf07inamide <:T,d etharnt-AJ tol Iwith 
the addilion of _,treptomyein in !-'Olienl, who have previoo~y received tuberculo,;, 
Ircatment for more then .<\ weeb) _ Dur ing the inte",;"'e rhmc, the uclively divid:ng 
Ilog rhmej bocl li shouki be ei:minateci er,d the nl)l'lll:Jef o f ofgor',;';rm h(llboured by 
the pa tient reduc:ed 10 U lew I-'L~ '~sl;ng organbm thereby m irdmiz;nq the po_,~bility 01 
c:hJ g re!istance devek''-'. ',g durir-G Ihe cor,lir"<lalior1 plm,e. Approximately 9(f!{, 01 
paHents have no viooie M. tU/1f"fc[Jioc;i, in sp.Jtum c ",lure' OtlCf 2 rnonth, o! intensive 
phO'>e trea tment" The cor'l inuatior1 phase aims to eradicate thry;e p"'_,;'ting 
u flani"", and comprism Tilampk:'n and i'On OZl<.l in comhinu1ion Iwith " thUTnbdu n 
mJdii ion IOf 'e tTeu tTll enl PC1'ien~' i 
_~: Siomlod "lfl ,,,'.onl ,"'*,,,"',, (>.1''lf~'erl h)' III~ S,,-"" Aine,,, Tl.re'cvi:J>;S C",,<cj "'oq,an",~ 
fo< :x)Jill v.i lt" 1-"1>:) ,~J"-"I:" t"'" lvl:>erc,l.>Osi< :1''''1 ' 'h,' Soulh Ahc,71 Tw..cOO«< Co<,rrc'i <'"()(I'O""'"' 
p, x;.,;, .. ,,,, .. Jetn.,, lfUJ I 
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''''''-'-0T'''-~ ' ""'~ "".",> "" ''''''KO"d to 7Yl w, " pot ",",-, "",_" 1' ,_,,, " , . ,''', ""rl ' 0- "" :. ' .. ~, ', 11-",,,, CV,", 60 ,,,,->, 
'-' ",-,r' o;; ",O<;"" ' OV, 00",,,, ,,o;,"" ~"'" '''',''''0 ~,wt • .,~ "~' iT"" 'C'O ",," '"don 
kilompicin-txlsed , ho, t .. 1:o<rr_~, reg'm en_1 ".'Jd dirKtly obsr:.~ vGd 1,euirnent 
TilG w'tdely ,eco'1Hlle nded DO is lihe brond nOrTie 01 ihe inie,nutionully 
re co'-'-'n1Gnded luberc:,.,lmis conhol 1!r"legy: lJ~ectlY ObsGlYed IrGo1,nenl, SrlO,l-
cou " e) concentrates on cOle fin<.llnq and CUrG App,o,i'l'''-1t,,1y (,9% of 1he world', II! 
p ,,1ients li ,'e in orem nu.·.' cove'ed by DOTS p,cg umme,' : ye t II! con t' ol proqrorllrllc 
rel~,It\ nre ' tiI levereiY ri ndG'Gd by ihG lod of be1ter und affnrdnble dic,gnas1lCS cmd 
mqe effective rllGdic;ncso'o' Tile cun'enir,- ,ecornrrrended nn1ituberC'JIOSi \ tre,,1ment 
compr ilG\ , h<::>r'1 C0~lse chGrllolilG'UpGufic ,egmen< I\cq of 6 to iJ mont.~j. w:'lich 
conto in nlornpiC:" fo, uf lemt 1r)e l i,,1 ? months Id llfinq tile inten~ve 1:"lose)_ Tr)e 
6mmq 
I"Xl n" l 
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prelerred regirnHl' conto in ri/ompic in tt1rovqllOUI: lili' ,Jt'ow, the treatmen t cOU"se 10 
he shOftened to 6 mOnltlS 101 lilm" on m trea tmenl Ie.- Ihe 1",1 tirm,. I low'wer, 
COf]CRn,; 0/ increased resis lance 10 ritamp<cin !-KJVe led the Wor ld Health 
OrgcHlilOtion iWHOjlo , trclnflly r<"Commend that all rilampicin dme.< ,hould he striclly 
llP€fViSed. Non rilornpicirl -corltoin fl g cont inuation phme, have tilRe lore h"'''' LJ5ed 
w idely in countries l.JrXlble to support d irect I.,. oh,erved treoiment Ie.- tl1e lul l dLJra lion. 
Rf'C"nt evide nce sU!J0€.<lino Worle outeo,"e, (0) tllV-infected p<ltienh il IIle 
con li'"fL'alion phme 01 JpeatPll"nt does not contain ritampieirr"')!'; irlcremed acc"" to 
druOS th ough IIle Global Drug Faci , ly; arld inc.eas"d ,uppoP1 lor DO IS progamrne< 
by the Globni I LJr1d to I ir/lt A'llS, ,uberculosi, arx:i Maloria m ay lead 10 mor" 
pro(y(]mm", using rilomph n throughou t the tre<ltmerrt CO<.H e, 
The U"· 01 h"d-dme cornbincl liom if OC'j 01 an liluLerculmi, drug; is encouraged. 
Tiley hok::l ,everal advantages inc lwing simplified procurement and prescribing 
practKee, orld a reduced rilt: of acquired drvg res istance. Bec(]u<e the dr.)g5 ore 
admirjste<ed in comtjnot i0f1, rmilta nt mutrnt, ore In" likely 10 be se lecled wl1en 
f DC< ere 'hod in n·,,, ,,,l l irlg 01 erratic drug takm or treotment intefruption"'. Whle 
the llSe 01 FOCs is recommended by the WIIO (]nd th" IUATLD Ilrl lernal ior1al Uniorr 
AO",n.\1 lubffculmi< O'ld Lung Di,emej, reports 01 inler io' bioavoi l(]tj lily 01 ri fompiroin 
in ,,,velal fOC;'" Y; Ilave lead to (] joint It(]tement, by th" OTg<mimtiof\'i thai only 
thOle FOCs witll proven rifom PKe;' , lioav(] ilability ,hould be llSedJ:l·:<-<. 
Mechanism s to enSLJre (] r",i (] t>" supp ly of cTlig, .. -.own to be of good q ualil y ore on 
impo<ion t asp"ct of irnpiemenlaliO'l slrategies and are lupported by the rec"ntiy 
es lab,shed Global Drug locility [GDF)". O f 'pecini conCf>l'rl i, the boovailabi lity of 
rifornpiein; file quali ty o f the raw m otRi(]1 [the porticl " "le and crys ta lline form):" , lile 
noture of the excipien l, and exposL~e to heot (md humid ity dur"g Ihe 
m(mulocturi ng proce" ore repuled 10 be impor larrt lac lors, ReG'", t "'port; of 
accelerated d e(Yodotion o f rifampicin . , FOe, lindR cond itions of IJig il ambief1t 
lernpeTOh-, es [~O" CI, humidity 1!5%RI I) (]nd ligh t, imply that ' torage cond il ions may 
h" vff)' impor tan t" It " 11YVllhe,iled 1t1Ot rn in l eraction between 'c.onimid ond 
rffompicin. wh ich may 00 augmenled by I lle pre,ence 0 1 ethambutol under humid 
CO'ldiliol)';, i< resVln~hle''-· . I urthf>l'mor", th", d rug i, r8 atively insoluble in water, i, 
'ubi"",t 10 en l erohepatic c irOJlotion"· ·c" ond dlssolufO'l tes ting does not cor,,, late 
well with hio"quivalence'o. In vivo tesrn g 01 lile bioayailability d! rifampicin-
cor1ta inino product, ;'1 hum<m voll}Pl tef>l" " th"refor" a genera lly accepted 
requiremen l pr ior to regis l ration"". 
Ir~ lio l t'iol., of rifomp'c"n-bmed sec regirnenl hod success rol e" of morc 1110'1 95%, but 
(] ,mull proportiD'l of patients foiled treatment or had relop", of diocase In lpite of lhe 
con lrolled study environment"''' . CO'lceivubly, ,ut)-opllfTlol systemc drJg exposure 
coula pkJy 0 ro., in those PUlie ' ,11 wtlO 'xIve ° poa; treatment response evcn u"der 
Ihe ,\tLJdl comlitiom 01 excel ent end olsU'ed dnJg qlx;lr, ly CY1d ddivcry, luly di ug 
scn,itive (yganlsms, "';Ih clirica l clilCme cOl'li lled to 1I1e 1lJ'lg .. and limi ted u- no co· 
rnO<bid Jiroesl. If low dfl'9 eoncentrotiO'1< in ;OfTle Ifxjiv lwuls a re contributory uncte' 
optimal eonri itiOlL' of d ' ug dei very .. they might be C'1JOI II 0' even more impatu" t in 
widely IfllplcrTlenlect trea tment control D'"ogra mrn"". Low d'ug levels rnuy be mo'e 
criticol in the cOlltexl of i""orl'p letc drug d el ivery. sub oplima drug quolill. on 01"]'1 
of d iscose p<cse"tullom (the ,ite and metobdic 5tole 01 thc orgmllsm being 
relevant), SCV8!","y ill potient' "';111 co-rnorb'd disease and manu lrinon wtl0 may be 
vulncrobko to ultered drug prKirm=oI::inetK:5, and compromised im mIJnity. 111 
oOOi1'OI1 . the P055ibiliti \C>oIJkJ be c'ltcriuineci ot >ut)-optirnul quoily cYugs be'lng 
P(J tl cukJ rly poaly ob\.Olbed in pol~nh with mae severe dileose 0' mcJ"ul ril io~. it il 
i ke ly thot trea tment joJu'c 0' lubcrC' )lmi, rccunerrce rC9,)! t5 trOln u cornpkox 
cOlllbi'lu ti or l 01 luclors Ihu l vu ries from p alle,,1 to patie" t" The rd utrve fYlportof'ce 
o f the in ter",,~ng determnCY1ts o f oIJtcome L\ poor", unrJerl tood , (figtJre 5) 
1 r" . "1 ;<,;,,, " " " " . , 
" ,r. ,ji ,,-
"""'0""' t 
NO'l-adherer><ee to Ireatment regimen> i, the mosl importm ll ri.,k fuclor' "'lOW" 10 be 
oslociated willl poor t' eatrne,,1 OUICOfTlC, Howcver. certoin patient, o re mae prone 
10 diseuse mlup",; extcmivc pIJ ' nOllury cuvitation, ex tensive rodiogophic changes 
Qr1 the pretreatmenl d1ClI X-roy, malR ,ex, and odvuncRd '-'9R erR putative ri,~ 
I",ck.-s ' ,"" Smoi:ir.g, diabetCl, low bcxJy "'ClSl, am a previoL" h;,lury of trfX)tment 
lor :ubercuIOli, h(Jve 01.'0 beRn Clwxioted with WOfse treoj""'nt oulcomel",<",<I" HIV-
infected patients are more likely 10 r clOP'R olter rifmnpicin-,p,-" ing cllerr.:)thRropy 16 
month re9mRtl< with twice-wee~1y rifmllpicr , in thR continua:ion phas.e'", 8-month 
regimens with only 2 month, of ,;IClmpicin2:" 11 monitl reg;mRnI withOfJt r;fampicin""I: 
ond tile presence or extropulmon,-"y diY30se '~ l oddition to pulmonary tube":ulosis 
ond drug abuY3 are '~ldependent ri lK factor, in Ill;, l'l"XJp""". I urtl"termore, HIV-
n tecled patient> ere al 0 higher ri5k 01 relopsing willl riimny<: in re,istClnt M 
tUberCUblis thon HIV negotive potien!> wilen 11ig,ly Intermittent do~r.g regimens me 
used:", lhese patients may require dosel ot llle :op end 01 thR d0'R-rR<.ponse curve 
0: more freqURnt dows for optimal treatment wtcome. 
n.,., inilR,-en l SUlceptib<j;ly of M. l ub.-fCu!",!, to the unlilul:>e<culolis ooe nl, muy vory 
betwP.en d;ffRrent i.,dote, {even umongst 11lO'e orgoni,,,,, <:utcgOfized m drug 
-,emitrvel . A. mOfe refrcx:lory m e loWic stote of ,'-1ycobacterium tuberCUIo.~'5 may be 
responsib<e for the increosed drug tderar>:,e ob'erYed ;n i.,dok ... trom pClI,enls 'Nilll 
prdonged bacter>al per,;.;tence Of diseme rei(Jp,e '" TI,me pa tienls infected with 
streins hovinO higher MIC, Cml be expecled to requir e higl1ef drug dOles to ochieve 
llleropeulic respome, ond tlli5 may b e 'Important in patienll ochieving drug 
concentrotions beiow thR normal rung<-,,;. 
lile qual'ty of drug pro<--ju<:h (JIld delivery of odequole dug dOles is emphmized, 
However, Ul is eviden: from the studies summan7ed in the fdlowing ,,,d;url til" 
r.-latior1<hip bel\.veen dug pio,mo conccnlroliOf1\ ond I'eol""'nl outcom.- in 
tubercuio~; PCltien/> 1"1< nol been delined, (Jnd i(Jctors msocioted w1th low drug 
levels in pCltients hove mt bRen odeql!otdy de,uihed. 
Drug conccnl,otiol]J in luberq;iosi l DQj'~ 
Seveml ilolClted repc:...-t, of low (mtitube,,:,-"os;s drug <:Of)(centraiions in palients Ilave 
emerged in the i teroture 'lIl<:e the e'-Tty 1990' ,'. 
lhe cme of an IIIV-infeded patient wi lll 0 rWllot",xplive dilorder om dissellinoted 
tubercLJblil WClI described in a iettRr published in The New EnglClnd Journol of 
Medi()ne in I W2". Tile concentrations of rifampiCin, ~oniaz;d ond pyra7inamide at ? 
and 6 hours oller drug ingellion were fwnd to be low when compcred to tl1<::-
"nO"mal ronge" fO" t ile peak CO/Ken Irol"'". IT (Jble I, Cme II. 
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S<Jbseqvenlly, anol l'ler repc.r! from !he Uniled Siale, dc,criLed bw plasma 
concent rations ot isoniazid, l ifampicin, ethamhutol. cipooflomcin and, les\ 
dramatically, pyrazinamide 2 hours a tter drug inge,f ion in ? HIV-inkcicd patie'-'!;" ; 
(Tuble I: Case> II arod III) The leveh of '~ on i azi d, rilampicin and pyralinamidc ore 
shown in Table I. One pa1ien! had evidence of mabblorpti o'-, ICase 1111. the other 
did not (Case III· /loth acquired drV9 res~tance Iilc>a1cd lilampicin re,istCf1ce in 0 11 0 
palien t and re";,!ance 10 ooth rifampicin and ;;o,-riOlid in tho othorl durinn trea lme nl. 
Cases of low drug concenlrations in ,evcref,' ill TB patient; wilhout HIV-infectiOll were 
also described. A man w il h exlen~ve pulmonary tubercub'k failed to relp<),-, d to 
ora! therapy. Rifampicin concentra tion, meO'LJrcd one and three hours after doling 
were O.b and 0.5 mgil. res,-.ectively. C onical irnrxovement was noied 0Ilf,' alter lhe 
rilamr icin and i50ri azid doses were increased and given intravenou,Iy" . In anotl]er 
case repor!, bw rifam l:>icin concenlra liom wet'e imp!icaied ill t ile deatll 01 a woma'-, 
witt] drug ,emi!ive p u monary !vberculo";, and no known immuno.<urpre.<\ion. The 
c01lcentratioo of rifampic;1l at 2 11OUl< after inge,ti(,,-, was ?J~ eng/I" 
In thL' at"c"f1c" of ta rppt drLt ) concentra liofl rangL" 'a ,-,ot;.,n1\, "h., :Jlmm" 
c Oflcentratiom rnL'mv(C,ej WCi" (Comporeet 10 publish"d '.,,,,xnrn,,c,d,,ri riruq 
concentra ltOrl raflg", dL' riv"d lagdy from heal thy vd unleer , ILdie," '''. Tll"'L' ra '-g".' 
o r" ,.ot appropnate for potienL estabi i,h"d on ihva:JY IS00 d~CL~~or, below: Fur 
most of th,,,,, pot;en t CO'P \ , SCfP.,n inQ lor low drug c or',cL'nira tiom U'OO a .,;nqlp 2 
hou bood ,ar,,:JI,,: til" pm,ibM y of ooayoo obsorpiior', :whid, rnuy ooeur mor" 
frequently ,n pu l>en l, ti)an ifl IllfJli hy voll,nk,HS, eQ throuph dekJ:/ed 9m lric 
unpt0nqj wm noi occounted fa, in odetl l()!". io lhe (}msiblv SPlJr;OUS m,'l"" ption o f 
low dru9 biouvaikJbi i lv ifl "X"" cmu, othpr factors may l)ave coniribu led 10 th" 
p C>O" rpspOllse "0 trculmefll e.9. low drug dm",. 
Subleq<Jently TI'Ie f,ndinqs o f Several studie, dc",,,, ibing "fl l;tuoc'n,ulmi.' rirug 
corKentrations in poti.,nts hOV., hf,.,n put-. isnpd. 
P~CXlLJ i n ct of. ,t<y:j iL'd ·h" 'L' rurn COflCUl lral iom 01 ", ',t;jubL'rcuimi, drugs in a 'eire, of 
2(, pati"nL w iih AIDS . , lhe Ur. ted Sta tps and PUPrto ~ico''''. ; r ""y frn)nd thai mmi 
pa llen ls hod low 2-hO!x I.,vd, of ,ifampicin laboui 79% of pal ienL), dhumbulc:> 
':al)Qu' 83% of p"tiL'" ts ) (l,d i,oniuLid laboul 60% 01 puiiL'n-,) in c ompori s"" to th ", 
\wxx"cd ,-"-,,rnal '"ng'''' lwo IXllienl.\ had very low 1< 3l)% of th(C 'owe.- I;m;t 
:Jrc:Josed 2 Ilour cO!-"::,,n tro'ior,:' ",we"fl tr"tiom of ,ifurnpicirl afld isoniazid, ,n spite of 
In" pr"vo'"",:" 01 iow cc)!',cefl trot iorls of th., two ,nost a ctiv., on t i tuwCljo~S ag"nt< 
'i wus not.,d that ooliP,-,ts 9L'n",,-a lly -",'un"d to I,av" a good rc"'pome 10 Ire"tmeni. 
Unlorlunalery, no con tra subj"cts without AI DS Wde .,tl ld iL'd , ,"'ka d, Ihe r-,ood 
conCP,-,jratioflS rneasured were corl1pored TO thp rpcomm.,nrierl 2-llour 
concentraiior" ck'rived frorn vol ues in I he litera I ure and phurrnacoki'-""tK:: \tLdiPI,",5>, 
T'w pro:JOIed rcwoQps kJ rqply rpll",;1 Ihp conccr,tra ti O!-" i'" hL'a' thy volurl lL'c-rs and ure 
rrot ,uitab'e for pu lients es loo lish<'ed or, th",,-a py. In portiClJar, wosta,-, j ;a lly lowd lL'veL 
of riimn<:licirr m" eXPecled US aulanductior. OccL,S wilh r.,pG<:1kri rioSL" "">'. 
h_" t ~erma." dis,""s., a nd rna lrrutritio", rn ay a lter ab,or :J tio rr , di, lri b<J lion, rnetabol;sm 
and e':rr', ;r.a ti('l'l of rirl!fJ' by s.,veral meC'l m li ,ms la !tl"orJgh limited "vicience is 
ava iluble " lhis poorly delinpd flf,ld: liqurp 6} 
, 
f !;l,',Et§ :J:>easc "<l'f altCf ,c", phormoo;t h e lb ~: crVQs by 'C,,~nl mcchoci< lr" 
-----~ 
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,~~do'coo '" irr&<Y,,~' ·""i"iN ,' ~ '>-L<; "~""'fXJi :.'.'1<; ."'O!"",,, 'e,g , f'-g.\co._'o" 'ff 
SeJ,.;c·oo ,,,, ""cr"".",~' '''''''''i:y u,' ","'M ";'" o<ug ........ 1(l~.") b O,,·.'OC' "" .9_ C'."3114,""''''··w 
-Rec;,"c"a ,' ,,'~~' ,"" I'c>cjt '<nc 
S~~'v,ced P<'ri",",'1 .~' _IiTC "t ci'l<; atJ,u,~,,,," 
-Alte'ca c""m'" ~'~O(",-, ." _ ",d;.,,€O cecat\:; "".10.;'0<; 
-A"(",,~' rF)tc,'." b'.'>.~w 
""term cct,,,·;!), 0.'>.0 "'ve""'-' or' .Gi'-'''' ; iO'oo,',""';" " 
(J{ -.-J u! <:se .'; icotiugorion,1 ,Ol&'a/X>O:: ""1r" "e."'''-
-c~",.o; !x;.,(, c"",-x'M"", ana r<:<',_"",,,o 01 c.-)m~"ef;:' .'~.'\I ,'u o.'i",€a Oi;M't, ;:I."",,," 
~"cJ,,;c "'~i ,Y >'C',''''''OO 'cm' f' :",'.'0." (yyJ " xc'e!,'", '" 
'''<In ,'." Icc",-' i'-'."' ..-"! Ie"," u,,,' ,'",; ,',y' 'x~ci."'" i",,,~' '" ,_'<).; 
Fc..- rnc,sf pati;o;n t5, a ~ng l e hlc.-od ,crnple luken ut 2 hours of1f<f drug ingc-.;tion wus 
us;o;d TO derive th" drug cooce ntrotions, A ,i"gl" 'ampic cu"nc,f represent th" p;o;ak 
cc.-<-,cenlrotion for a r ",mocr c.-f differenf ctug;; 101 ;o;xompl" the rnuximu l 
conc;o;ntrotion 01 ;'c.-<-i u£id in most pat,,,nt, is achi"Yed ecrlic~ thun 2 hours o l t;o; r ctuq 
adrnin;, lru tion, und thot for "thamhutd Iak~'''-'''''' ioI3_ AI,o, scant ,omprlllg doc, nc,t 
occuro t"", ';o;II;o;ct th" pcuk drug concentrotion dLKing a dosing intervu! us fh e time 
to p",* drug "oocen lro/ion varif.5 wid;o; ly hdw;o;"n poti"nfs. Indeed, Pe loquin "t al.-
tc,und fhot th" r;fomp;cin " oo""ntrufi c.-<-, ut 6 hour> ul ler ctllQ odmini,tration was 
nighf<f t hon tho t a t ') ho<,K, in 3 ot the 4 polien\> scrnp led o t both tilTl<'ls , 
Th" irnplicotic,,.-, d ,everul of fll" ern"rqing repOII> Ihu t Icm druq cOlrcen lrot iOl-,\ cre 
link"d to HIY-lIlf6'C-tion 10f AIDS), ;\ 'l;pport;o;d by 'I,,, flndnql of Sahai "t 01", H"althy 
voluntc'-n and HIY-intcctcd p""oo, withc.-ut tu tx'-"-" LJlos i, w"r" giv"n antituhc-""ulc-"i , 
druqs fe( .j daYI, S;o;ri ol blood sampl"s w er" tren token over 24 hc<.Ks to qeneru le 
"on"entraFOIl-tim" "urv"_' for rifumpi"in ~orim;d ond pyrm;narn ide_ The m"an pea. 
concenf rofion ICmoxj ond 111e C>"e<.J undef tl1e cOllcenf ru lion--f irne curve IAUC) over 
/4 ho(xl of rifompicin w"'" d;o;u"asw by 4;% ond 32%, r"sp;o;ctrv,"y, in H;Y~ nf6'C-tw 
person" The exlent ot fn e decreme wus rekJ led to Ihe ,everi ty o t HIV-in fec lic,n. In 
;hc"e w ith a,ymptomati" H I V~ntediOll ond CD4+ "ell "c.-unt ahc,ve 30J ""Ik/mm', 
lI,e mean CtllOX ond AUC values w ere reduced by 36% and 2'1%, resp;o;ctiv<3iy, 
"omparw to tho,e of heullhy vc,luntc",,_ In tflOS" witn ,yn--ptc,mut>c HtV-intcclic.-<-" 
CD4+ c"u -,t, oclcm 200 und " d s! rryn' und WitflCN t dicrrhc.-cu the reductic"-,, w,-"e 
43'% and 3;%. r"sp;o;ctively: and in thc"e with AIDS a rd chroo>c diurrhoco the most 
mmked reductions we,-" se;o;n in p l-.aI'Olocokil-,.,tic lTlf<asIX;O;1. with va kJ ;o;1 of 44% OIld 
35');" re,pec lively, Pyrolirtam;d" showw 0 l ;ml 0, Irend , olthough tr " mean p;o;a' 
cc,n"en/rutic,n m-d AUC vo '->€, w ere reduced in HIV-infec led sub;ects to 0 I<>lser 
exlen~ Ihan lor rilampicin. 11m rn{]xim{]1 <concentrali on of ~onK]Iid wm >ignilicanlly 
delayed cr,d reduced In Ii)()se palienl, wilh AIDS und erronie diarrhoea. bu l was no: 
ulf""le,1 in AIDS rmlienls without diarrnoea IY those willl asymplornalic HIY-inledion 
Ihe a lered pllU1macoki r.el iu wiln HIY-intecl ian wm att riooted to malabSIYp tion of 
t he drugs, 1·loweye" changel '1'1 D-xytole absorplion accounted lor only 3170 mKl 1 n;. 
01 ~n" variabilily o l rilarnpicin AUC myj pY[(]7in{]mide AU C, relpedv~y , As the study 
dill nol ir-,cluc!e TB pUlien l, 1i1€ pharmacokir.ctie imp{]ct of tubf"ec} os;'; or <co-
Infectb n wrth tubermo>is and i IIV was not evaluated 
COrlve"dy, stu lli", in tubcrcubs il patient.< from Kenyu and Sautn Af rica lal ed to 
show significantiy lower dug concentral ions in pntien ts witil TH/IIIY co-infection, 
compare ,1 to tubercub,i, pat",nl\ wi thol.!' HIV-;nfectiOllx,-", Furlhermore, a , tudy in 
Thai luoocu mis p{]lienl, wilil AI DS dcrnon,tr{]tc,1 good peok e"",",entratiom 01 
nl{]mpic h Imc{]n Cmox 9.111 mgil " 4.41 11'9 /1). al'nOUf)h 110 conl rol group dolo Ilrorn 
tubc,cul rni, pufient> witTlOu t AIDS) wer e: ,eporled". 
In the Kenyan ,rudy. neither i IIV-infection nor d io rrl1Oea was oSlociated witn Ihe 
vmiClbii:ty in tile pnmm{]cokinctic memcrm Crn{]x, AUC Of termin{]1 hClII-ole of 
rifampicin, i,oniozjd or pylOlinamidc. In lil ~ ,Iudy 14 HIY-inkcted and 15 non-HIY-
infectec: I-'atien ls with tubercuk><; i, were odmi'led to i10"p1tal and commer.:::.ecl on 
,tmKtc .. lIILed dOl'" 01 ri fam!-)iein (6CD m g /daif'/ dOl" if "- 45 <g, 450 mg if " 45 <'1::, 
iSOI,;azid IX(J mg!day). pyrazinamide (1.5 g/day) and eiilam/)u'o! 1,'lC() mg!d{]y). 
Ph(Ym",;akrndic pwiile, of ril(mlJich isoniclLid Cr1d py,{]m mnide were dete,mined 
otter '2 w eeks of Ireatment from b lood satnJies drawn i-Jlt plilY to dr~'g admr-'; llration. 
ctld a' :).5. I . 1.5, 2. 4. 6. 8 and 12 nou" oil"" d,up ingestion. A, 'hown in tob ie 2. tnc 
k,vc<, 01 rilampcin and i,OIliazid were murkedf'/ reduced in corn!--,ol'ilOlI to Ine 
recommended ranges in the iitemtL,"" (]nd high", vmiClbie, w~ ;I,t those 01 
I-'yrazinamide were generCli ly wi'ilin tile re<commended range and ies.' vmiClbie. The 
non-norma.zed Cmax value., were below tne recommemed rarOes in the iiteratlfe 
n 9C)'7; Clnd 89'70 of patienll for rilampk:in and iloniaLid, respective'Y. Tne authors 
' uggmt thai m d nutrilion or WClsting rn(]y h{]ve contributed to m{]IClbso'ption in the 
palienh studied. MOlt of 'he pat~'nh "udied were cachec'ic; the me{]n body rnm.' 
irK/ex was 17.0,!2.1 <g/m '. Ti-.e con,eouence 01 suell low drug level., WQ.' not as.'esled 
in 'ilis I~udy 
lhe ,tudy in Cape Town in 13 lubercubSil patients wi~n AIDS am 14 patients witnou~ 
HiY-inlection aso demonstra;ed tnat HIV h fectbn Wa\ not associa ted with lower 
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I" 0" oo,erVal K::>r lal ,tudy", inve5tiga t;ng the concentration> o f rifampicin ar>d 
isoniazid at 2 hourI aite.- drug ',ngest'>on in non-H iV-intected aduits with pulmon ary 
tllncorc lliosi, who were not res.pond i"g well to treotme,,!, the drug rorr"uk:J tion a"d 
olcohrn use were aSlOciated with drug concent.-ations, ~if arllpkin concen trat ions 
were tound to be higher Ip <: 0_02) and " o"imid levek lower Ip <: 0_0-4) i" patients 
g've n a hed dOle combr lolion table l of the Iwo drugs compared to the 
concen tra tionl measured in patiellll ingelting single <:tug proctJct5, Alcohol LIse wm 
05.\oc ia ted with h igher ritornpici" c alce"tra tiom 1 p < 0.0 I ) 
Vall Crevel ct ar." tou"d that temales hod higher drug concen trotion, than males 
(tabie )i- However, the mmt important detenninord of the 2-hour rilompicin 
concen tra tian was the tormlllatiaL Thme p a tient, ta king tahlets suppi ed by o"e 
pa,ticuior manulacture-r had 5igniflcantly lower concell tra tioll." in "pite ot adeqLlate 
rifampici" conte" t of the tablet , 
The rec e ntly published filldjllg_' o i a , mall s t~dy investigati"g ritmnpici" 
con ce"tratio", I" the alveolar ceils and epHheiial l'w1i ng tlu'ref iobta;ned hy 
b fanchoolveolaf k1Vagej and pbg"a ot [>;\en and warne" with o"d withou t AIDS, but 
without tubercukl~,. iailed to ' how On effect of AIDS or "'X on pk:J,mo leveL at 2 or 4 
hall" after drug odministration, Howey"," a there w e.-e trends to higher d veolm cell 
ritampicin levels lobtained at 4lK'cm otter drug do~ng) in women than in men, and ill 
smoking women than in non-smoking women-"" 
',e, , 
In a study inveo.t iqatinq tiv'! impad of unocrnLJlrition on the pharmocol<.inetics of 
rilorflJ icin, ~o~aso et ai " fOLJnd that 8 sLJbiec ts wilh mean body mas, index (BM li of 
14.8 "g/m' had , ignilicanl ly lower drug ,~on,~entrati,-"" than 10 healthy subject> witll 
8M:, above Ie kq/m' (rneon 8M: )1 ~g/m ') after a ,;ngle 10 mg/rq dose; the meon 
Cmax(:!: se rn) values were 5(' I (+ O.;';D) and 11.09 (:!: 1.27) mq/I, respediveiy. and the 
AUC, 4:£.24 I:!: 4221 mg.hr/I and 59.12 (:!: 4.9 1) mq.hr/I, respectiv<"y. The author, ,~itc 
malabsorp tion. c hanges in dist(,Dution OI1d inueo,ed rff\Ol cl earance os I-lrobaDle 
reOS Ons for the difference, ob,er,"ed. Ten LJaderClOl-,";,hcd tubcrc u osis patients with a 
mean 8MI of 1(,.7 kg/m 2, estabi shed on a rifampicin contoi ring treatmen t regimen. 
had ILJrth,,;-r reductions in the biocr..a ilabiLty of the drug Imean Crnax (:!: sem) of 4.13 
I:!: OSl) mg~. and ALJC 24.11 I:!: 3.2Si mqJw/li. Unfmunat<"y the ,tudy bded well 
nOLJriYled tuDercu osis potient ,~ontro~, . 
~ed u,~ed bioa..a iklbill y 01 ;,oniand and rifampicin is obse!Ved in patiea\< taking food 
concom;lantly.':; ,~ J Lent e t al. fOtJrtd that inge,tion of a high c abohyd ate meal with 
aatituber'~LJlmi, medication deklyed rila r-r-picin obsorption, and deuea.,ed Cmax 
and ,",UC values for isonk '7id by ap~--",oxilT\ate~ )If;l, in a group 01 27 pottents in the 
Wes tern Cape. COr>Corlitan t ingestion 01 0 me ol hiQh in fipid ,~oused a ml(l iler 
reducliorl in isonimid l eve~. fyr(lliaarnide ,~oncen tratio", were lJllailected. MOl l 01 
t he reported patient , tLJ dies have em ured d ug admir1~trolio n on an empty ,toma,~h, 
t hLJ ' eliminating I his scxxce of vcrk,bi lity. 
The re,ult, of 2 rel-lorl>",,, suggelil hal a Il iqi1 lXopa-1ion of potienll respondng ~'X),""y' 
10 fOrs t I ne tlwropy have drug '~Or>C entrations Wow the targe t range, in the literature. 
Ilowe,'er. the drug levell in patien ts respon ding odequateiy to treatment were r>C,t 
rneosured in either study. Ih".-efofe. it ,~ann ot be ,~on,~ILJded that a h,gh proportion 01 
patien t' ,..,..;tl, low dnJg levels have inierior treatmenl resp::Jnsel 
Kimerling et a l." , mem,-," ed ilCHliOLid and rifampic'lI1 corlCentrotions in non-H IY 
intected ponents with 0 ,low clinic~al respon,e Ifa ' l"'e to ,~on',.u t the sputum cLJ lture 
,..,..;tllin I ') wee,,), trentmenl failure or dilease reklpse w;trMn 13 months of be:nq c l"'ed 
or a,~q lJir"d eJrvg r",~tance whle reu;;',.ing directly ob,,,.-Yed thDfDPY, Fcxxteen of 
the )) i64%) patient' receh'ing fir> t-line treatment. hod 2-hol'" rilarnp:cin 
'~Or>Cent ration , Ie" than 8 mg!1 Ithe lower ' m it of the l-lub l;,11ed target range) and 6 
01 the 8 patienl\ i75%) receiving a :oJ mg dose of isorimid had 2-hour 
concenlronons less than 3 mg~ ilhe lower limit of the 2-hoLJr rcferer>Ce range for 
;,orimid' ''': ta~e 2). 
1°, . 
Mehla e l 01. i, iden lilied 6 0 1 124 palien l, Irc~llcd fm pulmCJ(1ary tlJhereu l o~1 for ti l e 
In t t ime WllO w ere responding poaty oller 3 mon ll" on , I(]mjard i reClt",cni ipositiYe 
'pJtlJm , m;;Clf or e LJ lltJre , or p oor (.iniea l C<" radiogapllic response)_ All , ix pal ienl, 
we", IOJnd to Il(]Ve k,W CDnc entmtio", of rifampic in (leIS tll an 8 mq/I) at I, ~ and 2,~ 
Ilour; afler drug InQel lion under lasting condilio", (tClble 21_ The dme of rii(]rnp ieill 
WOl increos;;d from iff) mf) to 900 rng and til en 10 I XD mg in one pa lien l_ 
Di'-P'0pm lionCltdy inC".rcmed rifampicin leye., werc mUl<uled (]i th;; hiqher do'e'_ 
Improyed re\j)0(1\e\ to tr;;otrnen t were observed loI lowlIlg tile do~e increment,_ 100 
few p{]tient' were e.(] rnined to dr{]W eo"clu_~ens (] t:>:Ju t facte" awxia t;;d with th;; 
Iov< leveh, but CJ(1);' one ot II-.e pa tient, was intedcd wtil HIV and Ixrlf cf tile p;:lticnt, 
were a 'coI1ol,Cl 
Witlleul centrol ,ulJject> il ca,-,nol be conciLJded whether lew drug levcL\ Cl re 
~gnilicanl ly a"ocfated willl 11-.e inler'O' re' fxxbe 10 trealrllenl 01 the palienls in lhe,e 
studi;;\, How;;vec c ilCum,t(]rltia l eY irienee tha t low drUf) COf1(.;;ntration, are 
re'f-X1mible 1m poco- Irea lrnenl re>!)onse in ,orne pat ient, " pwvided by report> 0 1 
seY;;ral cases reslXHldinf) w e i to incr;;os;;d doses of ant ltuooculo,i \ d ruqs. alt;;r low 
eoncen tratiens hCld becn detected cn init i(]1 \t(]ndard dOle', ".".1< 
In contra.lt. NClfitCl et (]f. imply thCJt dnJg com,,,nirCltiom me not import{]nt ",cdictm, 
01 tiJbefcu l ,,~, recurr ence" I _ Tiley mea,ured ri!ampicin and isoniazid concen lrations in 
approximateiy half of the 1&3 pa tien t5 in th;; ~ , tudy rie~qn;;d to dctermir>;; the ri:;k o f 
rcnmence as,ociated wlh low ,erurn concentraliom 01 Ille 2 d rugs, HIV infedion, 
aqe, sex, ~r-= a du,t ;;'po>''''' injcctiOll drlJg lJ le, CD4 ccll cou nt k;._'1 them 100 "ell,/ml 
and HIY ~NA lood gre{] ter them L'':) ()(X) cope,/ rn l. rhc findings in 25 (13%1 pa tient; 
w ith tubercu l o~, reClXTence were compared 10 tilose beir>g Irea t;;d 10 .. Il l;; I t s! time, 
A multiy(yi{]/C Iogi, t ic ",ge,~on analy,i, wm u,ed to m,e" tile rd of recurre nl 
lub;; .. cu!osis associated with thc {]bcye-mcntKmed covmi(]tc fClcto", and nOne were 
found to be ~gllil i ean l detern~nan ts , Tile resu lts o,-e irconc lusiYe 10f s;;v;; rClI reO.lC"'_ 
The m\LJmption wm made 11'01 the mea'iU' e'l1en l, 0 1 eover-ia te laclors measu,;;d in 
pat ien t' with rcomcn t di,cme were repre,enta tive of the,e factors 01 tile p,-evious 
Ireatrnent period, in spi t;; cl no indic(]ticn in the report of thc tifT" to relap,e Irorn the 
p<cy iom epi>ode 01 tuberculosis, Tile assumption Il0lds fa' l ix;;d factQfs 'LJch m ,e. , 
and may hold for f{]cior, ,uch m ," icCl du,1 exp,mHe, injection dru g ule and HIY 
inleclion, d;;pendinq on the timinq thc p<cYicLJ ' cpi.,ode cf tlJherculo>i, (]nd the omet 
of tim riSK lacio,,_ Howeve.-, CD~ c;;11 count, viral load and drUf) eoncentrCltiom m {]y 
wei l b;; '1LJitc dilicrcnL 5ec"ndly, the ,c{]nt 'iCl'nr"ing u,ed to deter mine ,erum d ruq 
I 'J _ 
co",:entraliorlS [drug levels were measured ot ? CY1d (, hours oiler druy 
odminiltra l;onj m iqht not m:cUlotely rellee! d rug expmure during Ihat dOl ing in18fVa.' 
os the time ot the IJea\:. a-ug concen tral iOfl varies, Ihircily, tl,e serum d rug 
concenlralion was ciC!>otonl ised 01 the lower limit of their dme-'pecif[c eXIJec:ted 
ranges [ <::3 mqll ver_',-" .~ 3 m y!1lor potient< receiviny 300 my dmm 01 i:\ofliaLid ddly; 
"'1 myfl VC"f'U' ~ '1 my/I IOf IJal ienls receiving 'JaJ mg iloniazid Mice weeKly; and <: 8 
my!1 verSu, ~ 8 mgll lor t!>ose receiving ritCTTlpicin 6lfJ mg dai ly), As the_'e expected 
rcmges hn,ed largEOY Ofl data from healtlly volun tee" are not appropria te for a 
patient IJopula lion esla~ilr>ed on therapy, tl, e impact of tr.e lowest concentrotiOflS 
m ay !>ove heen mlsed ;n th;" or ln ly,;" , Lmtly, only 25 Vl"enl, wth reCUrrenCe 0 1 
tuhercUm ;" were included . , Ihe analyl~, If drug conc enl rationl were memured in 
approxima lely half of tr.e\e [the exoct number to undergo pharmocoKn elic nnnly>i' 
was nor reported) and tile va6abi ily r l drug cOrlcentralio", ;, Il igh as reported in 
otM patien t ltudies, the study may hove been under-powered, as wqgested hy the 
wKie y:,% confKlerICe intervnl ir n ih_ 
The rec:ently pu~ i'hed findinY' 01 Weiner e l 0 1." de>Grve a tten tion, even IIx)ugll Ille 
retrospective nature o f lhe pharmocokinetic eva luation has inherent weaKne"es 
The icvel, of rifnmycin and ;"Ofl;alid were evaluntcd in IJatient< emolied in to 
' w ercu/osi, 'r",11 Consortium! United Sta te, Public Heal th Service Study 22. whch 
compcred the octivity of onc:e-wedly tifnpentir.e pius L,oninzid to +wic:e-wedly 
ritampie~ l plu, iloniaLid during It>e con tinuation phale 0 1 antitubercu losis treatment, 
fn tl,e primCJY evaluoticn a mu!tivcriate onolysis fO<JOO lI,at ison iazid levek were 
m",()ated vvi!h an incremed ri sk 01 IJODI Irealmenl outcome, in Illose receiving tile 
once-weelly req imen, but not in the qroup receiving druq doses twice n week 
Ri lampic:n and rilapentine leveb were oot preoctive 01 Ireatment outcome in thil 
analylis. Ihil is tr.e li rst evidooce t t>a t isoniazid concen trotbns may be on impo.-tant 
dcterminont of tren tment ouicome, at iem! in highly inter rrit ten t dming re9me",_ 
It>e Ollociation of acetytator l lOilfi ,.,-itt> trea tment outcome strengtl'lens the finding 
and is ,upported hy ,-"eviou, ,ludic, if l<ing rOIJ~j ncelyto:or ,lot", nnd Irenlmenl 
failure on orlCe-wee~ly regimen, ' , :he daoa luqges ls that rifamycin and isoniazid 
leveis ore not important lor treatment ou tcome in palien!s w itilOut HIV ·inlection 
receiy;ny Mice-weekly regime",; 11OWeYer, Illi, pol-XJl otion -'lJec:ific: fimj ng ,hould he 
ink"fpreled with c:nution; the relrmlJeche natufC of tile IJI1CllmOco~inct;c 
inve\tigntrn m Ol t he pnrtic:u lorly lJnreliaNe for prenicling rifompicin levels nnd 
variot;on tI'erein. 
In summary, il is e,lablished Ihal in many ,turiie" paJ;f,nt\ hav" peak ar,t;!uberculo\'\ 
rirUCJ concentroti.cms lower thon ti,e therape<JIK:: range, advocated in thc lit."-atur,,, 
and that th" low cUl)c.,,-,tmtion, might In some drcumslances be reialed 10 HIV-
infection, alcohol use, underwtril;on, male sex or d")g forrnulat"'n_ Th" :rnplicat ion5 of 
Ih",e findirl9' CT" not known_ Appro~_,,;at" ranges, for ti,e dfug concentfatiom or 
olhe.- pll<xmacokinelic memure" ba,ed ry-, sluriie, e..-c-J uatin9 the effecti.,en"" ol)d 
toxiedy of treatment Illwe not been eslabl~lled, 
In ,pie of pour cllUrac le!isa lio" u f TB drug concentratior" in patient population', Ii, e 
unknown imp!;cotjol), of low drug concentrotions ond t ile lack ot volidofed mefhods 
for rie t"cting ,uh-QPtimal drug expo,ure, th" u'e of tl,e'aP"Utic drug monitorr ,g has 
been odvocoledY" " 
Rifm npi6n: pharrnacolinf',tic conc!l.['" 
Sysfemlc concentrahorll o f rifampicin il) the contexl o t tubercuK>s i5 treofmenl are of 
flO"ticulm conce", for ,everal re",or": tl", drug 1\ known to IlUve unprerl;ctahle 
bioavalobilily wi fh Iliglr, variable pkJsma concentralion>, il di'pkJys dOle-dependenf 
efficacy witllin tile d nically fe levol)t range; it is a drug o f pvotal impofiance in 
con lemporary sllO( I COurle a'lli luberculo,il chemufherapy; ancl i l il msocio fed wilh 
lev.,,-o! impo<kl'lt phafmacok'net;c drtJg-dru[,J inter=tlons, ' I' this the\~, greate< 
attenFon wi l t l,erefo,"" be locul,ed u" rifmnpK::in tho" th" oth.,,- f~,t- in" 
an tiiubercukJ,i, agen!> 
The Un"--1ue ,t"ri i>ing oclivily of rilampicin hm mod" il pm,ible lor Ihe duro liun 01 
tr"atment regimem 10 be reduced ,ub,lanlialy ;-''' ",,0' Tugether wilh ;,OriOL>CI, il 
form\ the hockbon" of mod.,,-n ,hort-cc<.m" cI,emuthe<apy, and rifampicin i, an 
in\lal~obie port of t"'otmel)t regimp.n5 where it can he afforded. 
Rifampicil) b ind, tu th" irdrac~ l u lm torget DNA-depend"nt RNA p""ym,,rme, lhereby 
inllibiting mRNA 5yrdll"sis"'_ Mutaik;ms il) I I", rpoll ['jBn" of M, t[JhE'rcuiolis confe , a 
high level 01 relislorce',\,M and are found in most resislan l isolates' >« , Approximate", 
I in 1 0' organi"", ore re-s;, lanl willlOUI dr~J ,elec liun p re"ure,.... .. 
lhe min imum ',-,h;bitory concentration (MIC) o f rifampcin for M. tubwc"kJsi, is aboJl 
0.25 mg/l in brote, and 0.':' mg/l in agCT2G Ihe minimum b=tericrial co"c"ntration 
(MBC) ;, oboul T mUll in Tween contoinin[j medium, and it i~ estimoted that th" 
plmmo rifomplcil) concel)l'otK)c, required fur the ,ome txJctericido1 aclivil y in 
infflctoo lung li~sue i~ TO fold to I:' fold thaT of the MBC' J, Iherefore, optimal 
anlimycobaeterid corCe<1tratiom >hoLJld thflrYfl ticcily apP"ooch 10- 15 mgt!. 
Refere!lce runges of 8 - LO of 24 1T'Jo;:111 are w ieldy qUoled for the peak rlfampk::in 
coocentratioo iCma4" ,''''',,,, Howflvflc the.'fI rar.gfls Cl'e based !argfl;i on hedthy 
VoilJntflflf data, and, os (j scus.,ed Plevi(lU.~y, ae not uppmPliule for pul ient' 
fI, tul-Ai,ll ed orl treu lmenl. Indeed, mosl repa led peok concentrul ion\ in pul ien l 
populations estabiOslled 00 treatment fall ooow tllis rc:nne ila~e /), with free drun 
COflcentratiam ik~y to be well ooaw tho<e tll0LJght ta 110ye optimu l irl vitro 
bacleriddal octivity in many patie<1ts, I'urthermore the concentration of tile Urlbound 
fraetior, at thfl ,itfl of oc tion muy be comidflmi::Hy lowflf tly", tlla t in tll f1 plusrnu. 
Concern rfl9(lrdiflg low rifampcin concflntratiom i, 'llflpatfld by thfl dose 
d ependency ol lie dug's acl iyily. Siudies in mice huve demomlrated dose 
dependent efficoci ave: the rangfl of 5 to 40 IT'Jo;:llkn"" A study in patient5 
dernomtruted ,Ignificunliy ,educed e{]fly buct8lic idui activity of u 300 rng dme 
compcred to 60J mg;', Patiflf1!> rec~v",g intravenous dosing with rtfampicin 
(associuled with Ili!)'1er w,lemic concenl rutions) ucil ieved u !legulive spu lum 
culture more rap~i than those who received oral rifampidn", I'urlr.ermore, a large 
clir k u l ,Iudy sllOwed IllUl da;e, less Illun 9 mglkg mfl osy)Ciul ed willl WrY.'C 
Ireatment oulcomes'l'i, ard tile corrUinol'i<)jl of "ifampk::in lin lie "ecommended 
dose,) und i.'OIliuzid !ui~ to p<event the emergencfl 01 i<onimid ,,,,istum:e in ,omfl 
patients, 
Wll i!e most palienls are cured by slandard trealmenl r.,gmes pwvided 1I1ere" good 
trflOtrnfln t d~iv<"y aoci odh8lflOCfI, it i< po<.~l--,lfl that incrflOSed dme' at lea.,t in ,o,-nfl 
putients, migh I be mae effective, und i I muy dso be pa;,i i::He to ';hor I en l ile dcxu ti on 
01 trflOtmflnt by such ClPP<oochfls'il". 
Ihe pharmocd:inetic measure that cOl'espandl best \Njlh antimycobacteflal activity 
lor rifampicin i, not estdoli<11OO. However, it i< her; hflfln 'W}'Je, ted tha t thfl Cmax : 
MIC ratio silould be maximized, as rifampk:in acll on in tracetlJlar target'>{'. Tile 
impatunce 01 an udecvate peak concentmtion ,utile tl1Un u \ustuined level is ubo 
\Uppc.- t ed by the lor-.;l pas t antibiotic e l teet demOl ls t''Uled in vitfo und tllf1 e fficucy 01 
ritumpicin based in lermitlenl Irealmenl 'enimem",";,". Tllf1 AUC/MIC was fO<Jnd to 
b fl u bfltter p:-ediclc" of buclfll';ul COUllt rfl(j,Jc tK)''', tllUil Cmux/MIC or thfl time tllat 
rifump icin concentrations rfl(m i ned doove thfl MfC, in u rn"infl mod .. " 
1\11110"gh ,()j,.e ,Iudie, il-,d icule uimml cornplde absOfptbn 01 rilnmpicin, dntn nre 
insufhc ientM, More recen t evide nce 9Jgqes l, thul l tis Ireque.-&,. i, nol lhfl cmfl, und 
ti101 roQ.-, ced biouyoi l nbi~l )' may, In ptlrt, be dL>e TO lo mulnlic)n 
c hnrcx;1eri\1iu,,",,:" ,t:,,'II,'''', Rdnmp>un ~ best nb\orbed On un e",pty ., Iornucll . D-,oyed 
and rcd ' __ ';:"Xl e-u,orption OOYO b"Dn rqxxiod when it i5 tnken wi1h lood:"';:', Gn5 tri c 
pH muy olIO r-,t1uence ub,orplior-, ; ucici l .cu lior-, with hi.,tmninu wm observod to giYD 
leYel, 1 1ime5 higher thn" thOle observed niter udrnini,l rution of the ul-,lucid Nu 
bjcurbo{1(]loO< Maximol concontrn ti ons (]Ie highly w ..-inble b e lwefln sludies nnd 
~ldiv i dJCIII, nnd nre nOfmnlly de1ected IIOfn I 104 IlC)Ul,""M,". 
Ir , p lulmn, 80 10 J'(ff; of ri tnmpicin i5 pr01ein bour ,d"',,"- The d ' __ ";J d is lribule, w~1 to 
lung, .,tomach wnll. fa l n l-,d brfK1st m1k; wi l h concentrntions greatF.r toon tho,e in 
plasma 12 hours ntter drug adminis1rntion! ' bu t not uppr<Xlching peuk plulmu 
Iflvflls""- Cerebrmpino l fluid {CSFI penfl lratior, e,timalfld by the ",Iio 01 thfl AlIC ;n 
Ihe CSF to Ihe AUC il-, picr;rf)U, i, uoo~t 22'% wi lh unir ,flurned mer,ing"'''. The 
concentrntion5 o f rifampicin ,ecoyered in salivn md nnln] lecretion5 n re les5 than 
m gW',lOC, " 
Thfl major mMabolilfl of rifamp icin ii th fl microb'oiog cally actlye compou1d 15-
d ""xe lylriinmpicin. It ~ rein tiYei ), wnter ,\(ju~e n rid il el'minnted niong with 
unchanged rifampicin lurgely thIOugll tJ< liu ry excle lion (]!1d 10 u le"er e xlent IhlOL";J ll 
rflr ,ul e1iminu lion. The excretOfy c np:'JCity 01 the liver" su lurnled at dOles of 3(() 
'1 ,'ilmg C"'J ~ ng the half-I:!fl ci r;fampicr-" and COlffl.'pond ingly, tl.e proporlior-, of Ihe 
drug o lirninuled :n Ihe L~ine to :ncren;e with lorger dose5:P,I~i. With repented do'e" 
rdnmpicin j<; flIirninuled m ore rupi dry nnd Ihe hulf- I le i, redL>ced. The ei tee t is mooe 
mcyked w ith 9(X) "'9 tl>nl-, 300 mg dm", ul-id i, muximul ul uboul 6 ooys',H'. ~he 
Cl'Jtolnduction L, thought to re.,, __ .t Inrgflly from induc:lion of dfl>UCfl lyfuting l .epul ic 
e5 tern le enlYrne; nlthougll imi)ct',on of g lucu 'onidahon may a lso piny u rc:He''''''"''''-lO'. 
Th e rflcove.-y o f rifurTlpic in und, 10 n g-eu le.- exlen l, Ihe recovey of delncetyi -
l ilnmpicin in the b ilfl me incremed u fle repeated dming ',~, ,uggell ing Ihul bi linry 
excre lion rTlny n~o be inoxed, Ri fnmpicin LI a rnown f'-gycoprot,,;n .,ubstrute UI-,j 
nn ind '.,,:er 01 Itli' prolein" " T~s rein tively non specific trnnsmem bi'nne proten 
trnn5ports many drugs nnd other ,ubltunc", oul of Ihe enle.ocyle und bnck in lo lhe 
in leltinnl ~Jmen, nnd il j<; oi ,o flxpres.,ed on thfl car,a ' u.;ur merntJ<ul-,e ci Itle 
hep:Jlocyte ,O',l o,,- P g lycoprotein expression may them!ore be nn imporlur ri 
delflrmir£m t of IIle exlen l 01 rifnrnpicin'l nbsorpl ion trom 1he int"stinfl, b'linry 
~imb'ltion, nnd first-pn\s mfllnbolml UI-,j I'le exl er,t of auloil-,dL"O: lior-, {us il is n 
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determinont 01 rilmrp icil-ir,dex,ib(A o,pre"ion of (xug mdoboii7r-'[J OfllymmrooJ p-
glycopro leoin exrxes.lion in sites lUcl, 03 ti, e blood txa ' l barric" Ihe bbod les le\ 
bar ier , the r~()(;Cf1to, (]nd lymphocyte eel i rrr'-~llbror,e,r'x,r"rC2 moy 0"0 (lfl ee t the 
distribution 01 rilampcin between t~Sl'0 and cdlula- c ompartments of the body_ 
Le\\ than ~ at n'e rifampicin dose was recovered in Ihe bil e and urir)e m rilorrrpicn 
ond demcety~riiomr~ ci n in siucios by ACOCA! lo et a i. MC<'e recent evldence \ugqe,ts 
Ihat it i, likeiy thai Ihe iow rDcovery rel>:;d, poor r-do,tin", (]j)';orption22 ond/or 
prehepatic l~st-poS\ metobo"m' , Altt-oug-, Cfl alterna tive metabol c pothway 
whereby r,fampUn il rnelatx)Hsed to a hi,;-dy pohr glucc,~or1~Jc conjugate hm beer, 
suggA,ted, the importonce ot thi, route hal rot been conh: med"_ 
Alter (l , i.-.gle, bOO rng (jo'e 01 ril(]mpicin, the ) 4 hour urinary excret ion is about 10% of 
n", dose, ihe amount excreted in the urine declrel with repe(lted dol'-"'; 10.\ - 6 % 01 
the dmAn Th!, " con,L,teni ""th it-", l ind!nq ot ' lcreased tiliory excre tk:ln once 
au tornductk:ln il estoblislled, A derivative 01 ri fa rrr pici n, 3-l ormylrif(]mpicir" i, forn)f'l(j 
,p0r)tonAOu,ly ir) the urir,A e'peeially ur~jer odd COnditiorll:;' :f., and conters about 
10% of thA urinary (VJg acti'/ity. 
Alier a ~ngle f:[IJ mq dose the half life o f ri iamp cir) ~ approxi' rro tcly ] ,.1 :+- U.8 hours 
Wdh repealed admini,l roli<::>n il ii rujex,ed to obout 1 ,7 ~,O,:, hours~I, .. , Patient\ witll 
I mpo~ed iiver lunctior', Idue to c n-ho,;s, chronic ilelXlt itis or acute vira l hepat itiS) hme 
r,--.zfuced rifampcir) d:;-CJor)ce",r",- ClemcY'.eA il (]I.so decreased in p0t!eni\ witll 
comprom~ed renol function, however, as the ciearance il elt imaied 10 be only 
about 177" of GFR dosC>ge reductior) i, 001 recC<'",rrended", 
There i, a Il iqh deqree ot variabl ily in the initkrl aoo ncjo.x;ed r~mmo coneer)i",tior-" 
of rifampicin, Ir) odd;tion 10 voriol ion, j",tWA"", Ir~jividuoi\, significor-,t day-to ,day 
vmnt iom mA r""'ogni7Ad _ Vmhtions ;,-, rates o t ci"Uf] dilso lul;on, gastric emplyi.-.g , 
metaooism or excrelion may c m,iitule rclRvml (tynmric elf ACt'''. Vorb tior', r-, the 
con tem m)d quolity of The pwduci i.-.ge:;ted may a~o be conlribulory. Indec-d, m 
deICribed rxAvioe,~ty, the requirement for in vi.o t~o(lvoilob ilty t.:;-,tng 01 rilompicin-
con laininq prodcx:: ls il wei recog--.i.led ~'X ,J< 
Ri lan-plcin t koown 10 imucc the activity o f 'Ave"': ""'tabo!ic er"Ym es indud;nq 
re."ro l ol Ille microsomal cytod.-omc- p4S0 emymes ICYV3A~ CW3A5, CY~IA2 , 
CYP2AIi, CYf'2B6, CYP2C8, CYP2C9, CYP?C19, and po\sibry CYP2DIi ), UDP-
g;ucuronyl tr(]rdero,e, ,ulphotr(]r,sfermA, the estems" er)"Y fl le cata ly~ng ritomr~e i n" 
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own Ilydroiysis 10 25de,ac etyfrifampicin and otherslil," , " j It a lso imix.e; tile 
BxprB.'''m DI thB tran>membrar>e dflux P!)lnp P-g~copeotBi n"". Whi lB rifampicin's 
;nler(Xlielrl wilh Ihe PXR (pregnane X recepk. ) e:.-pllnn nLlCiear ree.epi,:.- resLJli ing itl 
:apidly iocrBa;ed e~peBSslon of C"TP3M is d&,cribBd '" '" much is st it: unkooYvI1 about 
Ih& meiobolic effect, of the drug, The c:i itlicol felevOtlCe 01 itlteracliotls with mnny 
d/U9' via Ihele rnec.ilOnimll Ilal b&en e;labi ished Sy,le'nic e.Dncentra tio", of dru!) 
,ub,lratel of both P Olycopeotein and CYP3A~ a re pO/licularly affec led by repealed 
dose.' of filnmp<cin "', t .'pee. ia l y ,elevanl exomple., include Ihe (Jl1;-etmviroi prot&me 
K,r; bilor,; ,ilornpicin Ilas been shown fo drornal ie.oI ly ,e(Le.e concen lralicI[ls DI 
10pil1av;-, saqu;novir, ampr&navir, ind;nov;r anrj nBlfinavi,-1 lb. As Ihe exten l of induclion 
lnay he d",e '~nie(t Ihe magnilude of e ' posLJ re ID ritnmp ie.in and vmobil il y in 
,ilarnpicin concentrations may be of impoJ'lance in quanlitying the druO drug 
inl&roctions, 
',',h le ,; I"'"picin 11m a drarnatic e tfec l or , the rnelabo i l rn 01 many concarnita nt ly 
adrninist&red drugs, lew drug inte<octim.' rB,ulting in ol;erBd rifampicin l&v&ls hove 
been oo<c.rihed. The proteose inll ibitor, i"dinavir and the cornrnor,ly ingel ted 
pipeline (a constituent 01 b'.ad ond long PBPP&ri W&re found in <;mo ll .,h;di&s to 
ItlcrBme rilmnpicin cD""entralio,",. The IIUC of a ";ngle (IX! rng dose of r i farnpic~ , 
wcr; increcr;ed by 73% in I I HIV inl&ct&d pali&n ts aftef they reC&iVBd oral dos&, o t 800 
mg inclinnvir 3 timBS dail y for !4 dny, " , The AUC of rifampicin was higher in 
tube". '''' o'';, pa tien" treated ""Ih pipe,ine (e] '''<J.I 1 .I1 r) c Dmpared 10 pa lien II wilhou I 
e.emcornitanl pperir>e (~/ mgJ',h,-)'IS. Ihe elevaled rifampici1 concentration, may 
110VB been m a ,,,-,ull Df P-g lfe.oprD te;n arod, Dr, CYP3A4 'nh b;tion'''. Decreased 
bioovailobi i ly of rifampicin, observed when riiamp1cin Yvas given cmcurrBtltly with 
para aminosa li sylic =id (P AS) has beBn ascribed to adsorp tOon of rifnmpicln by thB 
excipient bentor';fe"'. The concarr,itanl admin istration of keloconalOle has been 
rBported to redLJce Ihe nb.m'pti elrl Df rifarnpic.in " ,l 2Q, hDwever thil find;no ,11OUk::1 be 
confillYled by I,--, ther studies 
In n study 01 thB pharmocDkinetic interac:fi''''' between ,i lU'r,picin, isol1iaLid and 
pyraLinamid& in LJrltr&nted patient' w illl pui rnO'lrxy tUOe;-cLJlm,, 12I, the '.emcmnilanl 
actr,iniltraf ion 01 pyrar.namk::1e ond ~c:-n107kJ was msocintoo with or, irK:remed 
clenrc:nce of rifornpicin reflected by bwer IIUC va <J es, conlpa-ed to th& 
concomitant mjmtli,trat iem Df i.mroiazid alone 1\, the C'''ClX value, w&re nol 
;ignificantly diff&r&nt and the reduction n AUC wns ,moll. thi, iniera,.iiem i.' un,kely io 
00 of d n ie.aI impollance 
ImrtiozKj 
l'oni[J7id i.' a fc mdamfmtal component of ClIly fr ,t-\ "F. on tihlberc LJ lo~, rF.g imF.n, It has 
mc>re po tent fKYly t:xJctericidai oclivity ago;mt Mycobacterium lubercuw;i, than any 
othF.r knowrl dug and i: rF.lativ~y well to/eraled, Allhough it ho.; F.XcF.ll fmt activity 
ogoim l odve~ d ividing orgClll;; rrr;, i,oni07id'~ 0I1~ bacte!K::>< lo lic in Ill e p-F.,ence of 
semidormant orgar"'m,; it i, "ot a go:>d ,tF.f;li71",] apent",,,,". , Ihe dfLJg is takF.n into 
th" orgorism by d ;ftusion and oxygen dependF.n t active trarlsport" . l>eri[J7id f" i es Ofl 
the myccbocterKJI e-nrymF. cotola;F.-j)F.ficxidosF. for octiyation 10 a moiety that 
prol)ob/y inhbi ts the l il10 l step: in mycoic oed syn thF.:;i,:!),"'- The MIC ClCjdmt M. 
lubercuic", in t:Yoth cu lt 'Ke.' i1 0 ,01::; - O,O~ m-;;1I1 ~: ard the plcm,"] cor lCF.(,tration< 
acrievF.d by admil: terir>g the standa-d dcily do", (::oJ rrq dOO:~, Of approxirnate~ ~ 
rrqlky ) ore gF.f)F.(aI~ rF.po<tF.d to exc"F.d th" MIC by a 'Nide rna-gn 
SF.vF.fa l mutation, con fF.rring reo iltance have been idF.r,tiliF.d. Ilgh levF.l, of ,,,-~:tOf1C" 
occur il mutaliom 01 tile Kat G yenF. 'F.'pomib/e for catala;e'pF.f01idme exp-ession 
OCCLJr , MLJtation, in thF. inh "'- gen" OrE'! fesponsiblF. ior about 25% of drug ,,,:darlt 
;o olotes, InIl"'- encodes the dug largel and rruta tion: ore generoi ly as;oc iotF.d wilh 
lower levF.I, of r",;:tanc", AbSF.llCe of Ihe ahpC gF.r>F., like tile mutation of katC, 
appWlf: to in tF.rferF. w th ac tival iOfl or isoniOlid. TllF. mecilon"m, of r"~stance al'" 
unF.xpioined for oboLJ t 1/3 of i.>enio7id fB.~.,tOf1 t stra ins"\' m . 
Arnorpfun;; ,8'dx;oo 'when i:or>C17',j ~ admiri stered with lood""--'- Peak concF.f1traticm 
of app-oxirnatF.~ :J 7 rr(l.,~ cm be expected 1-2 holm oftff iI>gp,tbn ',&MN 3'- Isonlo7id is 
widely di,tr ibutoo to a ll tis'LJF.' incILJd:ong thF. CffPbro:pina l fluid'~;N,~' . Pro tein bind;- \\) i.' 
n " g lig ib/e (0-10%) ' . Ihe halH fe i: appr01ima ld y 1.l + 0.1 hO\.-.' and :1 ,1 + 1.l ho\K: in 
fast and ,low ocetylo tOf.'. rF.'pectiyAr'''''. Ll iminatioo i:; la rge~ by renal F.xcrel ion of 
acF.t\lr~on i ozid and isonico tilk; ocd. 
Ihe well delcribed genelic polymo.-pil i>m of thF. NAT-? gF.n" confF.fri ng he pa tic N 
aCF.tyltromjF.rm " activ;ty i: a mojor determioont 01 the voriobi , ty In the 
phorrnacokirlF.tb d;sployed belwF.en indiv i duo~, and geQ('JOphk; YOflation in thP 
dislribu lion oi the oeelylalor type i.' comidefab lei,'-", J\ Sbw aCF.ty1ot= have 
dF.CrF.med expre,sion 01 the ilepa lk; F.myme fB.'POnsib/e for th" conver;io!l 01 
i'oniCl7id into the ~lact;,'" metoboMe N·ocetylimrimid , ."' K;h tha t thF. m"an ar"a 
"nd"r the clJlVe Irom 2 106 hoo" o ller drug ir>gF.,tion was 6 times h:'9h'" than that 01 
fast ocelylalors in a y'ooP 0 1 60 tubF.fCl Ji O';'; pa tiF.n t.' in thF. WF.s t",-n Cope";:', In Ihe 
,ame yroup of patient< a trimodal d i:triblJl ion 01 i';oo ialid e liminal ion was 
demonstrated with 35%, 45% und 2(J% ,hw, intermediate and tast ucetylutor, 
re>j:)ect ively , The respective halt -livc.,.; tollo"",ng a :; mglkg dase in slow, intermediate 
and last e i n~natc"l were 3, I j, 1.48 atld 0.95 hour> rewective~. 
Changes In the ocetylotor phenotype trom tmt to .\Iow hay'e been ow::x: iated ",.;th 
d ise<Jse progessi-on atld watinq ;,-, HIV in/ection'-'''. Clearmlee is d su reduced in 
neonates and 'J1 the ""derh,,~,, I2' 
As the p lrnrna cOllcentratium u/ iK,niazid achieved in patients e~ceed the MIC for M. 
tubercuiosil by a w:de mm9in, a "";(1<OIy held view;; that the standardized dOles of 
i>O<1ialid are effective in the valt majority of pa tienL wllhou t individualised dmin9 un 
the bm;; of weight or accty lator statCh. l iuwey'er, -lOme evidence points to a degree 
of dose depetldency in isor; aIid'1 activity: d llical ,tudies conducted by the British 
Medical Re\earch Coondl in Madra.\ /owd a 4()() mg dal y dme d lXin9 the ,eco",j 
yeu <)/ treatment was m:::>re effec~Ye thoo 3()) mg daily in preyenting the relapse of 
di,ease"; and lower isonialid cuncentrations atld rapid acetylator type, ere rnore 
I;~ely to be oslociated ",.;th interior trea tment outcurne, cornpared to 'low 
acetylatolS when highly ",terrnittent 1000ce weekly) regimens are uled ' ~·\ ' . 
The duratioo ot adequate ;Ior;;oztd exposure may be rnore p redictive ot treatmen t 
response than the pea~ leyel. al it il thought that bactericidal agentl acting On the 
microbial cell wall exhibit ,aturable ki ling at coocentra tkln, g:eater than the Micro,'" , 
Indeed, the AUC ,eerrl< to be rnore irnp:.>rtant t OOn Cmax in once weekly dming 
re9imens,',I, However, pea<: concentmthns ere probabr, still impor-tant for optima 
d istribu tiun of the drug to the ,ite 01 actiun. Stu,jc" coodlJcted by the lIfitish Medicd 
Research Counci in Macros foutld that once dally dose.\ with .oW rng of i>anialid 
were more effect;ye than 2(() rnq t.....-ice dal ly and 200 mg once daily": this /itlding 
might sUPpoft the notiol-, tl-.ot an adeC)'Jate pea~ concentrat ion is impor-toot. and 
together with evidence tor the cll icacy 01 intermitte nt dOl ing regimens 12 to 3 dales 
e<Jch weeki suggest,1 that the drug may exert a sign ificant po.\t-antibK.>tic cffec163. 
isO<1ialid i, an inhuitor of CYP 2C9, CYP2Cl9, CYP2D6 and CYP2El "","{', 
C",",equently, the level, of drug, i~e theuph:,.1line, phenytoin, curbarnUlepine and 
wartarin n~gh t increae when they ere U\ed concutTen tly'H"". Induction 0/ CYP2£ I 
attc! repeated dOles il probably 01 little importance for phcrnlOco~ine tic 
in teractiom ' ';; but may potentiate the hepatoxic it y associated w ith CYP2El 
substrates '~e pur-ac etumc,- and i,oniazid itself. 
Several drug-dug phcrmaco\:inetic inte.-action\ affecting i\oniazid cOllcentraffans 
haw, been sfLJrlied: Tm (]bsorpfinn nf isonimid is dim r i shed by )(J-3(l"h whf",n 
(]\uminium hylioxiUe gel i> given concomitant".' ''' : Th" concomifanf aumini> lrafion 01 
ciprotloxacm may delay fh e ab\orption of isoniazid' :"; The anfiretroviral dug 
za lcitabirK: irlcremed ~nni07id cieorarlce ir1 1 ',' HIV-infected flatients. with a 
crmseqlJQ,-,t reduction in the AUC JI 
Pyro , inomii.k; 
Pyrmin(]midc i5 (] nicntinic aciU i.k;rivotive with "scl,,1 5t"rilizing activity against M. 
iubcrcuim;s. III parlicula abilify to kill orgarisrns in the acd ml ieu ot the macrophage 
phog05omes cnnfe" ,dOfJS(.~prev"ntino fJ'nperties a llow ing th " dl}['atior, nf 
ireatmenl to be rewceu _ I;',aximal be.-.etit i> achieved after 2 month\ ot 
therapy" ''''!.'' . II is "sed dlJrino the intcnsiv" pha_,e 01 treatment, arld at k>w"r dmes 
th(]n thos" u,ed when th" urug we; first introduc"d, in nrcJ(;.,- to limit toxicity_ 
Pyrmir.am ide i_' a pro-drug '''quiing convc;'f_,inn to pyrminoic acid JPO A) by bncillory 
pyrazinamdase Inicotinamidmej. POA is excre leu trom the rrfc robe by a weak etrlux 
pump, and, ur,dcr acid cor.d it inm, proton(]ted POA is reabscrbed and (]cclJmulates 
irl the organism_ A, the cHI", pLJmp is inefficien t the metabolite (]ccumuklt", calJ5ing 
cel lula damage, Pyrazinamide il mOlt acf i'{e agaimt badli that are less 
metabolical ly active. possit>y becau_,e tm eneroy dependent e fllu' pU"T' is Ie" 
<effICient unde, more _,trirlgcnt growth cnrKJ:tion, thereby (]Ibwing the metabolite to 
accumulate more read iry' ''. Drug reli> tance i> confened by mulations in the 
pyrazinamidme gertC, 01 which _,,,veml h(]ve been described"'1. 
Pyr07in(]mide hm tess vcriobie absorption irl p(]tienls than rifampicin or isoniazid I V I "'_ 
Peak 1e '{eI, 0130-50 mOll cye a ttained alter a 20-25 mg/~g dme" , The drug i, d i,play, 
rapid (]nd (]Imost complete absorptior, with peal concentrations reached in 1-/ 
hour<_ It il wide". d islribu ted, hal eKek rlt penetra tion in to CSf, and higl 
coroeenlrations have been detected in fN1mc..-tClIY epithelial Ifi no fluid'''''- Protein 
bind ing blow 110-20'1;): the eliminaf ion hall i fe i, approximately 9.5 hour" The dwg is 
exterlSivdy metaooi,ed in the liver, and metaooite5 are eliminated brg~y ir, the 
uri ne lobo"t 3% i, e,,,,et,,d unchang"d)" Tm pharmacoidn.,tic flarnmde" in ",lult, 
are mpor100 to be indep"nd"nt of age, ,ex, h"ight and serum CfB(]tir,ine level. bu t 
ch ild-en appe", to have ,lower ab,orption ar.d more r~d Cimination thor, adults "". 
tthambvtcX 
rthm'llllJtol i_' txx: tP.f;mtatie nt th" n xrently recOI'Ynended dOles. It is added 10 
reg;mens 10 reulJce Ihe emergence 01 drlJg ",_,i,tm"Ce, Opt ic neur itk il a :,eriou\ but 
rnl'-equenl side ellecl 01 the drug. wr; ch is olherwi:\" w,,11 td",,,t,,,J, 
Ihere ore few pvbl ilhed reports of etr.ombut~ conc enl ra lion< in patier'll>_ \-Iow"v",. a 
2-hOlx torg" t range of 2-6 mg/l ha" been propo,,,,j:"', About I.'l-i'i.'fi~ of on "'G"s ted 
dow is absoi bed witl) peak concentroliom in Ih" ord"r of 2-6 mg/I w ithin /-4 hOlJ" 
folbwing a 25 mg/kG do~e:;" '< ADsorption rl debyed, and peak concenl'-a tiom and 
AUC or" ",due"d wh"n "tmmDlJtol ;.; tak"n with food ""'. Minimal 1<5%) protein 
b inding occu.'s The halt-li le ii app.'oximalely 3_1 [~OA) halJ"< _ Tile dflJg i, "Iiminated 
by Ihe Udneys: 1580% uncharlGed"". Clewance ollhe drug is Iherctore ,educed in 
renal impairn-.-.ent. 
SI,-eplomycin may add to the bactericidal activity of '-egimens dUring the intensive 
phase and provide additional benefit in th" prevention of 1h" "mO'G"nce of drU(J 
'el istance , It i, widdy lJ,,,d dlXing tll" i"t" miv" phm" of t",otm"nt for ,xlti""ts who 
Ilove previous,," received ontilubL"CuIO\~ therapy Vellibulo -cochleor loxicity and tile 
requ l 'emerll for paientera l ac/n'inistration ,mit pi oiorloed use_ It ~ not known to 
interfere wi tll th" phormacoi<i"8tin of th" oth"r a"tihJ{) " rcl.~ m;'; drlJG_' Streptomycin 
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d e ctc>d ,.,; th O!gcm~m; kn " """ i" he ,,'_,i, lun l I" ~ o nkJli::J 0' rila rnpic n , WCfC 
e xclu d ed . 
)hc targe t ,arrvlc ,ze wa, e , ti ma te d fro m rr"'v>o:'Ll"< p h ur rnu("c~i n" I'" ,tlldi "" in 
pa tie nt, al DP tv'u rais TR lIos pitui '" W""t1ukp, Capc Tcw~ la ;>pc rt':h 21 _ To dcte ct a 
",ean peak ("anc Gnlm tio n 01 ,116 njampi cin ph" jrug v:i;h th e mo, t ',ar:,J Ue v~ak 
e o ncen lra t)an ' i in pu: i"", !:; re'pa ndi"lg poorly to tre-a trne:<t that ' ·.'al 7YI'o bw0l' t~a n 
th " j e.f j,., P'-"P'<Ji (J 1'0 '1 " '"'0 11, 18 poor r C<PQnacm WOlJ;d be reqJ"e j rf they " OI'l":i , ,,,,i 
ID% of th" , tudy popula tion (pow"" [1 ,8 " t th" 0_05 'e yol 01 sigoaic (] nee) FeY. th .. 
pu'po,c, ef tjo i, cG'cJ 'ati ,~,~ a p cd r, G : ;o,uic'm c ultu,,,, a t 2 rn~n lh' w(l \ rega ,d <J a '" cl 
mcd", Gf (] pocr r C\pc~'G, CII>d it woo c ,tn 1Cl !Gd by the 11Cl'pitd rei ,,;::;(ms und fro m 
t~", l:loralLXc Ih" t app"',"rY'JoCl lcty 10% of pal", ,,I, wou:d h" .. , " , pu t Ur11 n At"'e 
pmi!i"e [or ,,, ,.;o l"ldHiLIm jlrl)", ,,"hsk at '1 rrc nth, "_ II wo> e imc,"" the reforc, tG 
re '''');! a p p ,,,x;IY'<J te ly 'lOO pn t"",,!; _ 
Ei<:ibl", , _"-, ~,_",,, 'At", held , ,,, ,ic l~ ;., th" hnS rlhi j"l' 't1 ~ ' ''' 'W;-" i''' I, ,,e We re 
a p proad,o-j to particp atc in thc ,tudy. I'htte n i~ fOTme-d come nt wm oblan e d n 
lioc pa ",,~ f' languagc IAfri aan; o r Xho,al by h ... attc ndi ng doctor . 'Mtll the nc>p ot 
a trcmJa tor ',,1\&~ nG c,mer, 
Dd a pe Tiaio'-i"'l to 'he pa ti", nV hdor,' and me d c ''J1 ' ecordc p, jo, to o a rrodo n. du tu 
from H-.c time of adrri:;,bn , data a! 8 "",eks afte r ad mi" io n, =d da~a up u,-,tl 2 ye m, 
of te l ",d '-' ·' ''''' n "'"""' c.;. lect"d, rXko ""'" cch k oj •• ' ·I· h ·"u,,1 pc,ji<; nt Io id"". " 'i',,cn 
we re Ilared in the Oki,j.-~ n o f I'tlw''''::lc"bg)" ~Iniy "" il i of C,,~ ,e To'''''' The dGta wm 
tramlerreoj !o e-",e!ro~ i c ' i ~ , [Mhosolt becl 2002! MIo,e '] t'JO'/~', 
Od" "" ' ,, c/;o n lorm' j"ppendix 131 w"'''' LJ,e d to "ompi~ d(J~" f'D '" " "ch fX-J 1;"ni 
b y interview ""d exa mO-tat", ~, [le rrn gr"ph" , d e tal. 'e cqded ;"dude d ,e x " ,yj aQe 
Prior hi,to[;0< of tub0l'e ul",;, alyj tubmcu.,,"; tlea tTr 9~ t we,e documer tcd_ Pm t 
mcdica ! hi; ~o'y as w .. 1 many al " '9;'" crl-" onic or int"c ~"",,", ~ i n",,, , (md 
concon~tant medica li"" ..... C«;; no tw, Rt-g~IQl u1c",-,,,,, u'" im ,,,,,,,,, i,, d by th", 
paii e nt a noj ;,, :erprete d by the a tte ~oji ng ciri c ian ), 'i/OS ~ otcd lOT ' he- ye- Of Plbr to 
ad n-;;sion !o the hor,pile,: <:tl d d l'lir.Q the }NO "'onth, 7011;;\'/" '9 udn-,,,,on ~j ,-- -;tct1f. 
'rrY), n g habits crd th .. u_,'" o f "annabil o r oth ...- rec!f"O~ion al d ,ug' wm ,,,,',,"d" d_ 
Dco' ai, ,~ , !h.-, ~u: ,t,,,! q)"uJ,," u l lub" , cu k)~1 \', ,, ,,,, rtK C< d",t I r,e, e .'rIL ud ed the dme 
01 DI'l ce t 01 '/"lO torn;, 'he rlal e 01 rl:cg"ocic "nrl th., riate 01 hOlpil,,' "rl"" ,,","', the 
date a nd re l",t; of 'fXJ tum ;n ve , tigotio n' a l d ioqnoo;;, a nd rl ,.t"l, 0' an y t,,,,,tment 
ta ke n belor" arl", « ion to the hO'pital. Symptorn. "t the time 01 ad mis lion were 
>ou[1ht, anrl pe<"nent exa mrv:ll'o n ~nrllngl on cd"""km i;"cll,d'ng the weight in 
koogram'i were documentod, A c.hmt x-ray 'o'ial routinely pe rformed on ai , patientl 
on ad,"k;'Y' Ie; th & ho 'Pi t"l a" ,0 G ';1;',,,1 & eub rr>J 'rring '+,u·u rn ,arnps ,va , cob cted 
for .~,amnat"Jn (ni'Cl'o '>(',opy for ,AF8 nnd eu lt".rc of tl'b')fCl' '''~ boc:rr:1 ., xc-cpt ,."hen 
'e cenl re 'l" ', of 'pv 'v m Irrve ,liQCl"OI'1 ' ,e n' f'c:<n 'he re ferral ce nler we re av,,'~able 
Poitr'ie C'J tlW' wel e reta n e ri anrl Iho, e of ,turi.,. pa!:", ni> were lJ,erl to rletcmi n" 
th ", m ni-.'/KI fe< 'ifamoici n a nd ison'a , :cI. Lirritecl ,kd v ,,' ,c< 'rc es prd>bit." j 
vaH C1teci arad in a of e he>l nav chcmacs for extent of eorw,ddion ard c(l\o'itai>an, 
L""v.i ' ''' '-l';n" tic 1~1 'l ..,. ~_·""1T1 ',1 n f Ilj,u,u, '_"" Irr'.l;m in tl~ T'ed'_'m to ,H f,, ""'1lYJk 
d isemc rckID,," from ,.,;-' fectio n was beyond tho ,cope of tbe ,t'x tv 
At 0 p pro ' i m.-:rje ~! 'O_iry" '-, ,n,,:-; 1","'''An-:J ~,'k", ",- ro--, I bl""" ",.,,...,.,1,,, "," r" 
col lcdoo to "etc.-mine the p~1'lrrrcc{)k"ek prolire, of rrf"m picin, ;"onia"d, 
;o ,;'LJ""''-' '' ' ,-,e eJ"J ",!i.u, nevt,,1 ill pm"",, ; bkood <ampie< were cO;io;lcl"d for 
hasn""tok;.gy, ;;he rro::o al pa thobg y, HI'/-,Ie!oiogy and m ''''_'n0bgy " val l!Gtbro: 
;Xl';""I , we 'e we ;ghed ogc:>n, and a ;n,,1e C(l; I', n'", ;r",',,;; >P":'"'' 'p"crr--.& n ',-,-c;, ,snt 
for rric 'o,,"opy a~,d cultvre ;0 deted M. IlJberc1.Jo<;j" 
Ark, u ,-"ick',:" 1" " ",)'1', " f m J ho ",:6,ont, were d~cha rged fro ~1 ~ r"'N"L;k ko ,,1 
Hospi;a l and ,., ferred to ciin"" n-eGr th,,;r ho me, lor anilu k:l tory Care until rr .. at men t 
co rrpl€t,=, n_ ,>;',m: pat,,,,,!. LJtt&nJ -.d th" c.-1inic; \y,"eH/ b mOl'1'hlv lor co lcc!ion 01 
their o~t;tubern~ o'is "''-'0', whU, we re tak e n w;th or withe<.rt the ,,'p..-viokon of a 
de <ignated ob'..,-ve r, In accorrlmx:e with natiQnal guidelin e s, d;-ed rricrmcopy wm 
routinely pe rformed after 5 monjb, of treatment: tho>e p:>t' enh with two come cutive 
po >iti.','" ""ul em " l1<¥J IO 'N .. re re lJ(lrd ed a, t,ea tll)€nt Idlu,"" ,::ncf ,.,;-ta--' ed On 
inte mive P'lase ~eotrnan t "ccording to the re trcatrrcnt re g 'H"m 
At the out,e , of tbi, ,t,-,-,-,- ii ,-,a, h"p,,"o ,hat th e ea.-Ii r;;'pG", e to tr .. a;l,-,a,':t 
"" e mure" b-, ' r;.ute,..., cvl;v' es ot two nxmthl after adn, d on '0 t"_" f",<;pi:al wovk> 
p rovide a" ad'X1uut" m:::d .. "" 10' ""red ;:", .of 'J pha.-r.--acoo ,,1',a rri c mood 01 th .. 
varia bf, ty in an:itubercub ~, eh", concentratiDl'l'_ Once it became de", that ihe 
c-orc entro,iono o ( Q ';" 91" J,ug , 'ila n '~cin, w"" ,' ':,f c c'nc-~rf\ if -Jim ra a i z"J Th ot i. 
rright be moo,t"n l io """a,vr .. ,1 e- ,;j'?i'Y.) a<:li'/ily mor-s dil"c*ly_ Th e p:oLx ;.o1 w", 
jice ,'ud, (litac May 2COO . Pr:""mt, ",<,""to ""od 10 ,.,,,iJm to the cl inic ... ·/h e ' " th"l 
,,,c,,,rvaJ rl'a r arrbJlotory treatm.,nt, at 6, ~, i ~, iii ond L" rl'on t~, olT"'1 th.,. 
odri<".ion 10 &ewei>kioot H0.ip\ioi. At ih.,,,,,, ,,"it". u 'putu !n >perimen WelS coilecie d 
and d"pe, tch" ,J t,~, th " ~,',l",,~~ bbora!c..y al Gr"",_", r'0in' k < d r., ,~t e_"",,,, " "','rG, eapy 
to deled AF~ nne! !nycbbn"ter1a1 " " Ture.ln add iti<xl, th e dnlc, We ra vr.:terl by n,e 
.,'. "" Iigulur c;( J~.>y.',ated m~,tani i",,,e n I='ible j, cor '-'0<;iLJcl",J laJaphor,ically to 
a'c",rkl in the fG:'" 0f ,My pai',!" t, and th e ,,,,"uit, of 'putu,-, 1 ",~c,,-,~ nahon; pBrlorm",d 
'n 'hc mwti1e care of th", 00ti"",t 1"'9, T'NC' ,ji r",d op'~'urn mears we r'? ,,,,_, t,,"'Y 
pertorrneci at 5 tIT)nths af'". tr",airneni in it",t",n (>nri i' the d nic ,taff HJ,pected <1 
" O',,,,ni"(l 0 ' ,e kJ p ,e vi """ m",j_ Or; dudy ':Qn -.:>I",tl0 n, th'" h" Qir.-",nt vulcon'<" of 
caci) pa l;e,,j u) recordad in lhe i\bcrculo,;, (Tol r"fJ i""" , "'->, Jocun >e ntad; aod th" 
detect di,,,,oo" ,.,"'pe, fdl~ing th a period up unti l 2~ "'ClnJl" aller th" I",t patie nt 
WU ' orlrritto>d t" th e ho,;p!toQ Th., rci<:;..."un < et'''', co.,...,.,lttee, "nrl haelli h el U I he< ok. 
opprcNad tha mrcndrncnts_ 
or.,opp.,nd.oJ lappa ndix 11_ 
Pi"arrr.cor;n",tico m,.,,,,,,,,,d Wel' "moeri "ut "n eo"h ratiant elf'",r nor rm irnu te ly S 
weeki of daly adrin;.;tatiQn of anlitub",ro.Jbz the rooy u"de< ob,e'vat:o" in th" 
hv'.jJiiai_ T;)e dug d05es wc, e p,",cribeu by <11" Ul h,,,',J;;','i pllr ;;c.,,,, who used the 
dO~I"g yu',J": ine, n tabl e I. Thes", fJ uid""~ ,,,,, d il l",r , ly htl y from Ihose 01 the N"tkJnal 
Tubc':ocil0i, Conhol Proqmnr'e, they udvucote Ihe usc d io'-,ve r r~arnp'cin und 
i,'o nKvid Jm"" n pntient, weighinfJ """ IhCl" 33 kg, and high", d""", 01 pyrozin<1rniJe 
cmd ., t"QrnL'cb: ire iO,,:,.ti,,,,:. '=: 33 '14. ~h ", druQ do,,,_, "" .. "", nol aH""",d "n Ih'" cj,:.', uf 
lrtLL:. .- ~'Q-" oc'"' 01 ."~,,' p;c ,, , ',"--i ",,<J, v • .-",-,,,,TK)e u',u e ' ~"nb,"',. , . d m 0 "';~. "'" b;- II .. 
", ,',e"",, ;; ,c ,V'"~"' - ; G, e. ,',;o",'Oot ~oi~ i'''' 
The ±u'J fcf",,~ atioe, u,&d on ~'Ie d,,,,, at phG'~aGoki"elic as,,,,,ment "",,,,,9 t"""'''' 
'OJfneiy a'iaikl ble 0" the wnrd me<Jr il'l e l 'oIle v', The p'<"X.i'Jd e",.,."",, b" 10, nutlbet' 
"nd e xpi'" d"I~, 01 e"d, ,.,1 Ih ~ /c'''"'_''at''''n , u,e;rl ,.,n th " <iay ,.,' 0;'",,,,,,,,,'1- we'e 
recO'ded, 
Th e .,."ece el'a lion' 01 rifatl'('c'n , koni,, !irl pyrn,.,am'd" "nd "toombulnl '.'ier" 
• .. "''''''r''d " " "" .. ., SOtl'P "" fro", ",ach patied ,.,ve , e'~ht hou" lo lowing drug 
ad rr;ni,trat:oc . 
Fa'i&n;, lactsd iOVS'CI >Qh t P':iO' to phocmacokic6 tic ,arr,c>ling, ih" d'ug" werc 
adm;nis t",,,,d with approxim.:Jt"'l 2C(),,-1 01 wate! and patie "!.. w"re "'ke d "01 t" ent 
or d,;nl un l:1 " lu.-l'-"" 2 he"",, aft"" hGj "'b,,''''d. TO,,,, drug, W-o',= '",k",r '_'nd "" ,'tic ' 
ob"" .... "Ii<ln Th .. ""C1C1 ti me,,.,1 d ug "d"' "i,tr"ti,.,e Wet" r"''' '''<i.-ri , 
SCfid """OJS b:ood sanv", 'Nc re ara'.% flam G:O aml vc ic ;h liOvg;' a" il dv" " I" g 
eacnula with in 1 hour betaw d rdg a<Jrrini<tratioo and at 0.5, 1,5, 2, 2,5, 3, 4, 6 a"J 9 
h" 'J ;' s oller d"J'd a-:in-;nHlat:0n Th", e,-:,d ti,,,,",, c-f bbod ,a",(,,!jng ,.'"'",,,", r",,~,~rd ,"d 
I.i'hi-.J",-heparin hJoo, with a g .. ' 6-pcr"tor wet" ",ed (or b..,,-,ct ccl",C\ion. After 
cd",c.\,,,,-,, Ii '"'' ",:m "":",, ,.6{~ ",,;', ""uk,;dy pLc"J ,A, 'IG" LJ..t0"" "-,,,,-,lifu;:; ... I..;,-, i2000 
rpm 10' 10 • .. inu I "": "I r",.,m Iwnp"'" I'_,,'," \"il hin 30 rrO-1 ',j I e '; " I cd"ctivn , F"'~ e ach 
b!o",ri cr, ! .. t:'ie-'1 t,_,be, 3 1""""'" '"''lO' '''' c,1 ,:>t "",<1 '.2 tll ',-"e re ,!",'e d I', 
polyp.-opylene tub"" on dy ice "nlil T"e,le , to 'h .. -llO"C-; Ir" "''''' in th e i')'vi',i<ln <11 
Ph"mn cO'ogy, UC, d LXing Jr.c e'ienin~ idkw~"g ,an--p ing The ,a~Ie' were 'h'ed 
01 -80"C ',mI'J an"ly~" 
Va idaTed HHC Ihigh perto ,n.:".,,,, e liq-Jid cI'. ,.,,,,:.ot,.,<;,-Llph yi r, ,,, II.uJ, ciBv",ojJb(j 
withi" th e rhcrmacdogy C;'.thl w"",,, ",ed t,., d"t"""n'" r;icll't Vici", i,,,,, i-i <"-i "nd 
p'ifc'Ein'JrrI--cC' c0nC''?nlro tbm'" !appen~x 3.11. A Idkiu l"J rne lhod US;"" rn'"" 
,paCtrOKOPY IcC-HSI was " , .. ri In d",te""ee e th"rrb )tol concen tr'Jtio"s iaopendx 
3.21. Th e lui " valicfoted ronge ' 10' d"t"",-.-joaF"e of ,ilnc, p d" ;'''''''''icf pvm,;rl<1nidc 
and e lhan--bulOl coecentrat:oe, wer", 0.3 to 2-~ tl '>iJ /I .- 0,2 10 ; ,~ rrl<J /1. 0.2 to 70 r-r"'.lil 
"".,d J . 1 - i () n yil. 1 "'p"'ciivdy , 
Ai,o on th e riay 01 phatrrnc,.,rinek aI""»,,-,.,ni cOrl'Plete ufine c~lc~tiorr; \ve<e 
rrYJd e trom 2 to 4, 4 to 6, and 6 to 8 hoLX' lo!Iow1e" dwa "d, rle;,;-h"li,.,n. The yo: urn<> 01 
m "Ikwots w{'re stored " 
:hc u:';,-,,,, i COO""", , "i.., ,,, " t tn", ril " ,,,*,,""" w,,'., d"wrn-,jr,cd by G v·G:>.:J",cd ,-,-re'" ,'''G, 
"','hid-, -,.,,,, " rmdifica,,,,."· o f t'-l e picErn", a"O'I rr->e thoo, 
N()nultl.."c:r'rne ntal anal-,-,is 
;he f(]W dala c:ornor~h? pia",,,, c:C'nc-en+'a'0", "'''''' the' c-orr':"JX'<1cfng time, we' .. 
,tare d 'n iv',c ro;ofj Exc,,1 2002 beior" n"nc;arrvarh-.an tal aMY';' u,;ng Wir,Non,r, 
(ve"",n 3_3) to corrpuk th e pha rrna ,ookin ~ 1,-, F-x"a ~ '€ te" <Jnd rr'Dasure,_ 
F,,, th" p"'-pme, d tile determna"on oi th e pharmacokinek """mu"" and 
p<Xdrr'Dte" , bb:1k va"e, we'e er,lerec1 fer plasma d'u\l cOl'.'Ced-aiion' beM'ea."· 0 
a~.d Ihe Iclwer I; m't of the · .. aliddled ra."·ge of detE-frrir,ation Wh ere r.o d",·ia tion from 
bm~ir.e woo ob, ,",ved o n tr.e HPI.C t'dd".g a · .. a'.Je of 0 mali wm a"umed, Th e 
<:xuc;i lirn'" ur b ",uci 'Qtl~ ! ng 'Nere ,-,: .. ~d f~-r thC'· .-:k tc.m -;na'c;n vi Ih <: 
pharmacokir.elic m"osure , 
~he 5'" 1<' q~," ""nfl" C'l~'l" d "", ,~~ ,'har~)']cokret:c m&mur~' wm '" oo,kd ir. <:'fej.., 
to ,,,ne d "he ~.ormal ra'"'g" ;.". thai ra'"'ge in which the · .. due, for 90% of pared, i e, 
Elmn"tiOfl rat" coml",-,I iK. 0< '- • ,mit',: he 'I: I "',I o'der ·~Qnst"r,t Q"ocote c1 
with th e t""-,,,ir,d liclg I'~.e ar) port<-)('. of t ~" 'C LKVe . I' ~ e,tirr'dt"d by lir,ear 
r",,,,,,,,,,,,,n of f.ffi~ .,'" [og C()rlc en~a tion, 
Hall-I;f., ft ",;,; uriis: h,) k,rrina l hull -lif" = Inl?) I)', 
lag"lime Ifllg; units: h:'): the nme e iclpsed fro rr' tty, tin1C of drug ad rrin~tf(] :ion 
un Iii 'h e 1;-, 1 rr lfl m .... dbiA Gonce ntratior._ 
Time 01 maximum ob,e rve d conc:enirat;on IT ~ 'dX: unit,: hr'; time "Iap'ed from 
tn", t i""" of drlig aarri n;, ~a tiOl'. until Cmax _ 
Pe "k pl"~m" cc·nc~nhalion iCmox.; ur,iL m;JJ1i_ the drug CQ"cetltrotk:m 
cQrr"''PQ~.c1ing to TrTidx is th e mox;tTIjrT' "",mu"eo:::: d " ~g coocen Yatb:-: c!LX:ng 
a docing inte,·,·al. 
Ar.oa und .o , the Cu.v. 10 lhe lo.t mc",u.obl .o conc",,,i,aiio,, iAJet; lflih ; mgJ-
' _hr) ' t!,,,, ar ea co-,d", th e con<.:ed'aliot)-Fme c'.rv" from II", tir"e 0: drug 
adn-;r,istr"ti0fl' c,il th " kd ",,,,cmxable drL'g co,-,ce,-,lraron _ 
Are" unde' lhe Cen''' 10 in/inify iA IJCi; unih 'ijQ,1 .1-, :, tlK mc'a und", the 
ciO c,cvn tration -r""" CLt'ie fron-, th" fmc' uf dr~g adninistrat'on , exh'a po kJ ted 
to ir,fn ;ty 
VallXne of di,trib ulion I, "L <>d ,',r, ;1',,, Idm';'-,.::I phme iVz Fob,; u c,lts: Ii: 
V'Com=do,e/ ). xAL:Ci 
Totol body deoronce ice ob,; v/"Iik l.hr '1' 
o Fob, = do,,, ... ,~JCi 
Covariale fado" 
r",'icnt !'Octo" ro!" d ",d b',' tl-, ,, a ttendng r h '/~ic"'n a nd doclJn..,.,-,ted ir the paHec,1 
data ciJ lcct"'n fc:.-ms aft" r 8 w"e'" of tr=tmed in th e hO';p'ta l inc kJ d ed age, ,ex, 'h" 
'1dory of sn-o ki1g ClC,C; aicohol cor,,'.'m''''n'' 11-", ,." ar b" ior" adtri,iion iwhet he<, Or 
c,ol, t he ,~bj"d hoo regu<Jrl,- eo",~ med alcol-<lI - by judg ment 01 11-,., ati"rd;ng 
.,ry, K:ia n, emu wl, ,,TI><o', <.Of r.o~. II',,, ,~l>jccl hLld ,mol,"'-.! c.1gur"jj",j, 1-'''''''0,,, 
t,. l::..,.-C'. lo,h treatm".-,!. concomtant i1ne", concomtant n",dicatiocl, h"'ght and 
w" igh t 
AI'iJ al Cli:;oriJxjmnlc~' 8 wec', aiter adm-,'oc" 10 oad ,a"1"<'e, w" re drnwc, hiJm ench 
p at>",rrl for c;-'",-.-k.::1 paIhok-gy i: A J mi croti",,-j l<Jwj, ,&-='09,. i1 x 7 ",I dotted 
tube) and haen-.:>tolog, 11 x ~ n' ED1A lUbe and 1 x citrat& eiJr,tah'rr g ESP. tu bej 
,, '~'d lJatior Th" ,arr..p." were ,"fr'o:lcrn'crt CIt 4°C b" fere trader with ... 6 ho lts tiJ the 
che n. cal rathck'9Y and hoematology klbaat", ;." of Goot" Schuur Hmoila l IGSHj 
"rd th o> I Jniv p,~t\' of CCl pe Te,';''''' iJeTi tor anal'i'~' O , ,,rrictry jc, ciud" d c,ua ,-rl";cC1ti'O" 
of ;C~Jm urea, (;fc ClJir.ir.e, tiJtal protein. al burcin, ,e rum a lan;,-,e trar,ani,-,a >e ,: AlT!, 
,,"'Lm a'ratal" tran<nminCl<C IASTi .. alknlic, ,, phosphatase r .. ~<l gamma-g luta rrl}' 
transf" ra >e I, -GT,I and toto i bil. '.bir_ HacrT<Jtclvg,- evaluCl''an ind.dcd a fu l bloiJd 
"~"uc,, n::cluc<n\l hacrn::;globin, mean cell YiOfvtn€ iMC .... ) .. white ""~ ""UI.t WiCC;' 
and platele!;!, a dffer"n':ai and th" " ')'lhroC)~c 'cdm" rJa;ion 'at", IESPi '1-, .. 
C ,c,;"; ,,1 '0/. 010",.- laooratory of liC1/GiII/SAw.R (Y:Jvth Africoo Ir,lil-.l" '" ,'v)",jkc LlI 
Reseachj '.,ed ELISA to de'ed HIY ; arc! ;o Cldbvd"" 
Ac",tylator g",notyp", md phenoiype were c.i eierlnir;e<J in a ,ubqj()UP 0193 parient, 
by a ;lud",nt in the o;-';'KJn 0 1 Pi lor,n'CD<O fJ Y '" pot I or hel Ine,;, fe( he, MSc Med"o, 
Tes ,a tio 01 '+ac,,'\' ;'G~,~":'c! c""ce~'mk,~ ,~, ~ """ ,:" "p., rlr' .. 'J ,~d~,inklr,,,"or,, to 
;' ~<1iolid cc-,ce nrrclion ir, t"", ,o rne p ':",na >OrT\=' I.,., wm u,,,,d to d eler rri nc the 
ph .. ,-,c:,~/pe rQ,' genut,pe dete<mir;o:cr" 0 '0rT\='i<t 01 bkJod woo caJect"d ;-, FDT,~, 
tub e ,_ DNA 'Na< extrade d and p'_"if KJd I,om the,e ",mple, belo'''' 'p"'clic 
':lmpiif''::,ati,c,o of th e N"'T~ g'>f;" s"<.jl)¢f',c;e,_ Th" ,,~.-:pI iI"' d m,-'A was u,ed to 
invest>]"te the t,' poe 01 polymorph"" N-ace tyl tlon,lera, e e ncoded fOI each palient 
G" not,p '" W"'" elm-iIi;;'" er , h'c.-rn:",',/gc.,,, ,kJw, 1"" t""'''eygC<J' (viith ,b w and lasl 
0 1",1e tyPe,) or ho tno:J!ygou; Imt, Allt10ugh a lri rnodal dd,ibutioo the phe nolype woo 
ide'1ti;:e d, lor th .. p',"p<e,' e . "I "-,r. ""d.,- "("'~i"'k< ,tall'e "'a, d ic he,k-,ccJ;:",J "'k, obw 
0' 'apkJ Iwhich inc','ded the f1 termed""te [JC<J p) The'", W'" th"'n exc"Hcn t 
"gtccrnont b .. lween the p"" nolllp" elr,d th e genotype !h"t,'fOlygav, ge~"IIIp'" wm 
·nc r.,ded 'n th", fa >! g" OLp)_ Th", g",,-,otype W (lS u,,,,d ir, l ,ubi"'d, v.ilh dr.corda nce 
o.,cw",,,,,, ti,,,, g"" ,c. typ'" ",,,:I pi', ,,,r.c.typ.;-, Ths p<,,,,,-.c.typ,,, was u,ed f1 0 ,','oject " 
whom ace lyio lor Ge no typ e we l"' 11 ir,,'lliun we" ~,,,i wcc",,! J _ 
.1 wry ''''pm,,, ("valuated? month, "Iff'< adn1i;sion 10 hocpitoi} 
'Nci;>h' g.::l h '::lnd ,~"",:r"1n'c;e 01!~ fubf'rC ub_"" /r·xn In", ,pc"um c.-& put,, 'i'.-" ,na ,ke" 
o f ih" ,e'pome la t,ea t""'n'_ A, th", "",u lt 01 >p'jtum cu lture at 2 month, i< v~d",ry 
rega ,d~ c, m, 6CV"i{ ""'0","6 GI the , t" ,; I: ing activity of a ircatrnerrl ,eg'mf!n", thi, 
rnto""U'''' WO:l v,ed 'or t"", ,an~1e ,iz", cok;vl" tiom_ 
j,lIhough th e- ,,",cc;":ltiun beh'ie-"~ a po,i;'.--e :;p~tum cu:tu,e ,,,j 2 m:;,,,lh, ,"00 d:.ea, ,, 
' '';0f-"e 00, b een de"""" t aioo ;n ,,,ye,al ,Iud""·",",, th", dete,m;'onl, 01 cL~ i",e 
coo,we"",n a t 2 m' 'dh' and the d ", termbm,t, we;ghl ':loin, 'putum ''''''''' cawe"";or, 
a t ~ mo nth , cr; d <:hease ,e "' p ,e may be dilfe ,-",,!. Fu,th",,-,,,,,,,,,, the ,eiatio mh'p 0' th e 
' p utum c ui:",,,, at 2 month, to oil,,,,, ",ao'ly ,e'Por,-e m:l,K",,, and ;t,,,, !G,-,g t"" m r""u lr 
0' t'e a!men t "'lOy Ya'y be tween d!leren t pa tie ", po p ,-,a tiom, .'0' th e,e ,<:-Om n< 
o d ditional rra-ke" 01' rrem""",t ,e;;;pon "" we,e >Cl'jg hI. 
t ach patient was we-gh" d at adrris,,,n and again after b week. of inpa ti e nt 
jre atn-ren t, T!1¢ d,ange ' " ''''",igh t (lS " p,'c portion cj ti~ od,-ri"io ,-, w",lg i rl wm 
Oo cvrTJ'ented, tigr-t wee" ofte , adrris'", n, a ~ n g", e ar" "",,~,ir,g ,!,u tu m Sp"'c"""n 
We! colk!~kd and ' c~~ k II", S,\ IM P hbC'atewy in G'"cn Pc,"'1 h r d;ecl $.,.,.,0' 
"";Cr0SCOPY 10 d e l",cf AfB . unci fc.r myccbacte<ioI c ulture 
O n corrpk-fi0 n 0' tr e'C) ' n .en' 0 1 :he ci i,,;;;. Ihe wkorne COicgof )' wm r,,-co' '-'':·'J i" II ,e 
tubcr cl} o,;' reg-,tc" ' h" dnic-,,,corcj ,,,d au/comB w a.' cak-qo riz.,d acc,,,ding to 
WHO d er.., i lion, 1 ,,:,,',J , .,"'''''-, .': 
CURED ' in itiu i y' ;"",,,,,,-pv~, i ,- ,,, put;;o l-,' w h" huc a negative 'putum <" .. ul ie, 
the ia,i I -, -"'rd ~ 01 .. eal ,,-..en', and 00 at Ie",t on", previou, occu~oo_ 
COMPlETED lHATMl'Nl • Putient w ho ~m c0rrv'e 'eci tr eatmen l b<Jt doe, n ot 
~.ee I the, c;te,'a 'or cure '0' fui ure _ 
DIED· Puj',ent ,,',t lO died ci LXinQ trea tment . re spective 01 cau , e , 
FAILED · SrneClr-po,j live pat",,,t who 'erroi:led ;mecr-pc-~ii "e , or b ecume 
,mecr -po.'Ii'''' again, a II " ",: 5 mantI>, alte l the , tart of traah"ant 
INTERRUPTED TREA1MENT (DEFAUllED) • P::Jtienf "no dk> not c ol lec t drug, lor 2 
,-,-",nth, or me< e uf u'-" rir.--,'" olt"" ' eQ;,' ru li <:'<l , 
TRANSFE RHD OUT ' f'utien l who wm t'unslarreci to une-her reporting IXI;t and 
lor whom tracriment ra;uh, cra not kn own_ 
For ' he anu ',,>',, 01 lu-:-Io ,> '.',i t~ Cl bear" 9 on -t1e regota!" ,ecorcied outcome the 
ou tcorrre wm ciJc"-D to rTIl e ci ", to ,ucce<>/ui treu'ment l 'c lXeci ' or 'treatrrrent 
',"c,nl"d;'-",,·c-!' ,I or u" " ','"clmt .. 1 1 , ,, ,,~t l y,,,',1 ('tfAcJ, 'tci l",d ' ,,.- i~'""r .. pbd tr"'Cl tn·"", t : 
ene ob;e<Vatic'n de';Qnu'e ci 't'CJnsferred 00" w m orri'tBd I 'om t~i:; eva,-,,,t>:,,, 
FLrrthBrm'l". t!->e o,dcome ,-,f ~Aatmen t Wa' eYCJ"cled wh."" FX"'j ble, by r"'vuhr 
aSlem,,,,nt of .,put·om ,a~, fc-, t~ e pra ,ence 01 At i"befC lllo",: ~ ati"",h were 
a,kcd to retu rn ' 0 'he dck ","sre the', rscar'1M t he~ arrbl '!e 'er! 're"t,,-..ent ut 6, Q , 
17. 18 ond 74 rY'!Qnth, olt", :!->e' cd"-.;,, jQn to & ewe;,;root Ho.,pital, '0 a ~n ql e 'P-J lu,.-. 
.' CJm;:-ie ccd ] 10"" ,,,,,n! te' thB kJ borClto",,; 01 t~B SA.I.~.P lor 0cro' =I'Y unJ el.~ ' ,_, ,, _ n 
addit ic-n .. the clinic, we 'e ".;,;ted by the irwe ,jiqutor Cor a ck';gn ated m si-i tont, Or 
cuntuciecl i e l epllOnico ~ y to ascark, n ine ~ CJ ie ur ctu(JY ",-, Iier, ;, _ 
" 
'{Ihi i" it i, r"{;o\¥\v.,,d II Kli 1>0' t irnlTlLmily j, un invortun I J"dom l~cmt of th" cuuroc- 0f 
inleclo n arxl d loase cC1u;cd by M. t~lxycu~,i" tl, ," co~e ., te , of Cl protedi .... 
ircn'J nc ''''''Pcm" '1,e " '~'T'",", ' a,,-j ir,~ '~<np" ' '''i c:h""~~ ... ric,,d f.. p,,, rlO' -hantl, 
celllh re,po", ,, an d th>? type of T _ ~/~hoc'lt", rcspon;e arc irrpoda ~t. 
In I I"" ,~'rly . C04+ CI)1\+ and C~:n ICD4 CDR-j T cd ,lb,cts 'Nere mcmexcd '" 
indica!:on, of !he c: e lL''''' p ro . re<a ljve re>pOn.:"'_ CD4+ ,uppr",';jon i: abo a rn:l t ~'" of 
th e prOiJ"""' '' 01 H;'. -h reclion Ihe cylok .. ,,, "",,,ef> We," ,eiederl to repre'''rlt 
expresoDn of type- I ilFI+yJ and Iy pe-2 IlL -5) re ;:.pcn'e ,. a.' we I co> ,uppre,~on 01 typ e-
I respon,,,, :il 10). p"""", ,"ve !., of e acl, cytok'", v"",;r e mem'Jc,"d,~ Gdd:j'on to th e 
whol e bklod p'oI if",a~ye re,po~,·" to .. 1't».,hlion '_<{;111 p~n [p udierl pro teln 
d erivati ve: "i,'cobc:c!clium !'_'!X'L'UY."" a~fge noJ '~nd rH,A, iu m'ogu, ",,-,d po~ti" ~' 
co~jo-o') Th.,. mo,," bb0d IFN-y Pf,:,duct",~ a ft"., ' "m.,IClF,:,~ \" ilh ,',' h'b<}rcuk',,,~ 
antiq e n, " r",qard e rl mane 0 1 !he most u,el" anrl pracf",al me thorls crva iabla to 
measure a p'o!ee live irrn" ... " . r"'pm'" to M. lu);.er(: "Jo.", " ". 
,'\, 1 e ight 'N"''''~,' af'", r ",ci"';,,"'~ 'J 'C' ml 'ie n,:,u,' bbod ,,,, r.p le '//a,', cV:wm I:':'nl " ,-,eh 
pa tie ~1 i~t" a hep"""".,.d IL!b". , T~ ,arrp'" wa, . epl a' rOOnl le m pe<a /c,re pr'o< to 
Ir",mter will'" 21 hour· fa th e irrmL!r-obgy I",boral""v of th e Depar~nt 0 1 
fnrr>Jnobg,!, Ur:T al G<oote kh<JlX Ho,pilal ~or anafy,,, of inYnJr>e marke rs lapperd< 
,1.l1 ' 
The pre' er>C" 0 1 an libodi"., 10 Human Im rr>J nodcl'<': ; e~ev Vr u, 1 "" 2 we>< d e lGf rrO noo 
by ELl<;A at 8 w " ."k< af le r oomi",on 10 th e ho;pilal. A tube of eblted blood was kepi 
01 "ppro';'-"'::>iely 4 "C pri or 10 d", i v"ry 10 Ihe C i n>:::al V.oOg '! Labomb', 01 
UCT/GSH/:;A ~'"' r In,,'" NHL5i .-.itl,in 24 h0u ts . 
~p<J lum rrierq;;eop:,: ",~d Cuiture 
Emly rnom ing ,-pulL!1l1 , mr,pe' wer e cc>leclea and dispo'chcd tv til", SkiMP 
!aboratode, to, mc,mcopy anrl cu llu re. 
Di" .. d ''T1'"':'': PrO- to , I"" ;,g, II", ,,:"}'um ,a"T'ie \'!C1' m;x,.d w;lh "nd aqu ,,1 "mounl 
of ,od:um I,ypoehlorite, The ''''rrple WClS ~en " I "",'ed 10 ,brod for 20 "',;"",Ie< 
to a low r:l ~ng "I ',"aN., or(l<l~tm< , ,A,ft" r ,crinn " g, the ",'perna tcml ",'a" di,=rd."d.,~ 
drop 0 1 ":.,."Ij··.-'O '''.'(1) ~bc".d on a g;ms ~ide bofore (]dd"" f~,:" "''O''·lf) il-:.:k Irocr1 h" 
,,,un -,pu'u;-n cmr,",kl fa rnokc !"e sn-." o r Th e 4 de wos c lowed 'a d r/ o~, a 6G degree 
h" f P'(]!,? f<:'f Xl m nu!e , b e fore ' fain ir>g Sr""cr, of ,outum c(];yp:e, were , ta i~,'?d for 
acij Im t bac i:i P"ia! to micro,copie G xo"i n (]tia~. i(1W""di~ 4.? 11· 
5=t.,,, PB mediurn wm '-'Sed to c,~t ')f C rn,cc-lxf..;.k<;c, by the· rodome",c R,, (;,ec 
rnc tnod a t the SA ,~\" hio"r'~'-'oj" blJc.(]:c< y ;" G ree" ~u(" :Qopcndix 4.2.21· 
The 'puturn ,arr-p'O' o' ~c"·'cI,kIOQ' f1cq;.;tn l "cj", nt< w",-" r",rti" .. 1v "",,1 h th", 
l"bJ'c'Of;e, o f h '" SAIMR i ~, Gree~, Pc'nt fo r e,~tu r€ of .M. ,l ubcICUkJ~~ T"O'''' o f 
pollenj, potenti" ,y e l.gj bl e for th~ scud,. wer& ij&niifre d "/ii!h coiv-"re d ;:id." " , Po~ti ,to 
cullure >p e eime", were retd nE'd fo r dcterrrinotian of rf,ocrlOk;"'. md '''''nicuid cr;n, 
i'-dC::, "I i"" mrcrub".o", ",borotor') oi wrl ol)(.e 'h" patie:'" ~,(]d b"e" e nrcj ie d , 
UdGrtu l-, a tall, d~" to lo gi,heal pmiJlarns ,,,,d ad ","in','r(]iiyc error'. ~.)m t 01 !he ""<J tum 
" ul'u re 00,11 ,,, j.,ct >houl d !Y>'.-e been zlV'?d for ,--,--;~,i-MC de' .,..n*,atio~, W ef'? 'o, t, 
Tlw "",t"c..::J Ie .. m rri-M C de terrr'ina!,-,~. i<+>pe ndx 4.3i " lowed dete."·" ,,,tion o r Ihe 
su,eeptibl ity 0 ' t ... ; ~ "ul'u:~ ",gar,;:: m, 10 0 ,01)5, 0.025, 0.05, O.! "" d 0.7 "'9/1 
",,"cell tmjklns of ;,oniazk) cr,d 0.(',(" 0 175, O.2~, 0.5 1.0 cr.<) 2.0 ""'].~ cOflce n;-atb m 
0 ' rifacr-p;:on u ,i~.g i~ &>c t"e ,y,i" '" 
S~mlnary ,'oti,i ic, tor 'k0"Ncd var ia ble, 'oNCle cl,prcs:;cd as " ""d iam with """tie 
range, la binornia l method for obtcini ng cO:',fd encc :n te~/,,*' 1"0' cr1Or,c." no 
m>W ITnforY:: a, to th e ,:~d""'i i ng di, jribdlcrr of tho variable. w", '!Oed) . 
No~,para ITCT;·~ tC'lts wcr" used ' Of u~,ivaria!" andv'e' of sk"''''?d d a ta, ,.Arc h 
;"'.rlLJd e d cr""j "I th " p"arrn:)colin"tc data, F"r ~'orrehiiom, Spearcr1Cm', ran, te,' 
wm \J"""ra ly '-"eel For " " rrp<>ri,or, of C c ontW, l!Ou, var i"b'e bdwe= 2 gr OUP" "-' i 'hi~. 
the pop ula'K>n, t"e Kru.,' aI-'f! a l;,; eC}JcOly of pop"aro~.s ran k tes t wo s u;cd. 
MultiF"'ie lin",,, f"9'e'~ on ar,,"]ly.,;, wm u,e n 10 d e le1 n, r", tl", n fi u ~nc" v i yarrOUS 
pa t:ent ar<J drug tocior, l i r; d epe l-d~"t .... alboles, o r co,ario t",! Of, jhe PK-rnemure'; 
: deF'e nden I '.-nrime,1 T~e f<"">l 10"""9 <tcnrl nro rrc>c".o'~rc wm fo lk"">w0 d 
st"p'.'!;;" h"dword r",.,r""bn ldng t~,,. ft.' ! dota ,,, I ' ... ;th !ern.,; ,,,,nYl'i .. d I,on' 
bo 'nJdol at a ,gri~~aneo !ov"'! cl 0,075, and rcontorod into til<) ""Odol at 
, ion l >:-nn" ... r .. v,,~ nl n ,n,~ 
2. r ·:e ind"""",den' variable, ' eiecte d in ,te", I we-e u,e d in a ;ceond 
regre"bn, to tn:lyjrriIe I!-e sarrp>e ,iIe I"", ,, ob,ervation< lor v~.ich relevant 
eoyO'iate factor data was rri;sing werc not ·"dJded '" the "'Cde'l the ,arne 
r"rT>Jya l ur ,ei ,,,.,,,, I,y ,,,,,,,,1> a, in I w"" ,. lJ''''V. 
3. ~~c1.,ded .. aria~", we,a th "n raent"rad o"e-<;y-on" Iv ,<"e il Ihe y ''>' e'"e 
c;onth\ ,torv once Ihe number 01 ob'ervation, had t>een m:::t<irrized, 
4. The d~;,-ibu tkJn of li,e ""kfua~ wm ,tud:ad and ti,a oresef'c .. 01 'TlJlti-
e0lire ariTy wa' chc;ded; the tn:lOO was rIOt accepted il a higi" de;1ac of 
cc !nearify exilted arreng the coyatiat,., or if t"a S"apirc-Wi h te,t Ihowad a 
"",,,,,,d di!lribulic". II th o? ""' gro? " 01 c0ino?atily was klrg " Ih'" j; , t 0! 
indo?pendenl vorkl~a, wodd be ,tud io?d a~d rational;led w;th axp lanation> 
" iv,, " and -!,-", "",d,,' buildin" P'OC"",,, lo e gun again. II Ihe rec,wal, wet~ 
,k,.,.> ... d, Iha depand"" t va,bble was tramfom'ed !by u~ng the ~al,-"al 
logarithm, ., the fr ,t in,ta~c e; or Ihe ,quare roo II and 'Ie f." 1 OI"'d :2 ",,,,ra 
repeated. :! the re,rual, of li,e "",de l w ere ,Ii i ,kewe d Ihe de",e .. ,ti"n' 
var:ebie was dichcro",,,ed lit thIS wa' app-oo! ia lei and bglSt~ reere".::m was 
lJ'aU. 
5 For rred e!'J "ilh "orrrolly d;';'-butect rcsidLJai> , potenlio ty in~ L'anl;o1 
ob'e< .. alia~, were identified lusing Ccok ', ddancc and DflTSI and d'opf)<"d 
from th e !Ycde'. j ne\v cLl',oriote !,,~ tor, ',VCf~ i!)C;uded in th,,' 'Y"Cck l ',\';t:oc-ut 
inllL'ential ob 'e< .. atb~o, theoe were incu ded in li,e "'Ca.,.! appr"'d to th e 
whole Jat<-l ,at ii" el J<Jin~ II Ie put"'ntK>") inlluenfu l ob,er,atiom un less there 
wa, I/ood ramon tLl .. , el l da thaml , 1 he j)·coell~ienk of tt", inciu,ive "",del 
w~fC ched~d 10 en>ure ~) at th ey did not difl.,..- "Jb,tan ~ia lly fmm the Ofigl",,1 
model. 
6. fina ly, the rnxkl msur,-pl iOrr> of c"""tant variancc, ,neCf;i-,- "n;J if;", 
appropria I", l orrn of the c"vwiate, in t·: ,. erode! '.".",e c:·:eded I ,. Ihe r, " ,." g 
;J'=~ ica l pklfs ohe;idlJah v",",u, f'tled valL'as c< ve"u, eovar'.ata yal.Jac. 
7 Any e,d lded oruervation" and Ihe ,ea>on, IO! hair eXC< J;ion, ara reported 
dichotomced i e.I/ , '< alue, of (ver ItJnction te,!.< were diehatv""'-.,.-1 in ,'ome 
eval. Ja ron, in t" norma; Gnti rac.,dl. 
cerlai" da~"dent vc .. ,~e, w",e dichotom.ed a"d klgsik:: ,ege,~cn " .. a; u,ed io 
"",del Ihe co __ '-ar,al~ effect>, eil:oe r b ecaus e th e eonr~UOLJ' depende n~ '.'Griable 
CQulti ecl be oC9Cfib.,d w.,.1' by th .., ' n"'w ' ''g ,e,;ion 'ncde~. or beccu;e thGfc woo 
good ,,,, ,,>o n tc cCl .. g::o-iI .. I"" ootccm" voricble ie,g. Fo' em;1X " "" 'oin CCYO"" t" 
I",de<' mew be 'nT"ortool 0 ek rr 1)'''o~ t, cf drug Coo""" t'Cllion, b,, ",w a <;ri\\:: c! Ie\'ol ~_ 
T>-'" "",thoo u, oci Ic sC:oct thc ",oepende nt vc,i" h e , 01 th e f...,ai rlDU" was ;ini h r to 
th<J ! a p!~ ie d Ie< th " in""r, "Jr .. , lion analyse ,_ lK1gnc"", ,tai"ti"" we, e ""'Hc;uh.!e<i to 
ide"';;,' O\rt,i"" ond inl,u .. n ik1 : o",cr,'ctiom and to 00""" '!'>c ycl id;t., of j';", rn:; d,,1. 
A ,u,'/iva cnc lys" w,,' us ed 10 (""'" !he bl" ? 10 74 rn:rn thl r(>'po~sc . Thc Fmc to c 
po,iriye 'p<Jtum ",,,,or or cu ltu, ". or decth i hetwccn 2 a~d 2~ r1'Of'lh' "fie, o d ,-,-; , ;ion 
to R' .. w,",~bof Hcqcital.1 Wel , Il'od;'" t), c ancl""iI. w"ich 'Nm <ee morcd if thC' f)C1,,,, nl 
wa, ci"" cnd did not hovc c IX'>ilivc spulu", c~ Ihc lir ne 'hey w"'e ;0,;1 tc tclow-up_ 
Cot p'opo'<ionol >-'c!Cl'ds rn:rd d ng 'ym ,",cd to d elc r--ine th" dk'·~ t of ,,,Iec!eu 
COYC1"",t"" on the r .. 'al;v" 'xnard of on un,ovooroble oukome wi'h 'ilk v",iabl e 
,,"<>ctIOn 00 o",:::tib .. d b",o,,'/ 
~ eg'e,~ol" ap pr0cd"" w"'''' ai m u, ,,J '0 >':;"",i;;·, :odor, :'- " 'Rnci~Q 1.110 me""ur" , of 
re'rX'!'.e ~ o 1,=~t1_'_ ;"ic> ,il-' Ie I ,,,~,,, ' ''g, .. "io" wo' u,A-J to io"mi'y lactors 
J"b",-illil''i! t~ " I-'''rcentuge #5ig ht gain: To identify r'" facto,,; 10' po,;ti"e 'pu tum 
,,-; c,o>,-,op), '" 7 rn:rnth ;. oositiy., "'''''Iy >pl"um c u,h..-". ',,,d tr" C1tm",,1 int"" '.""tio n 
j.-"""trncnt faillJ'c 0' oo C1th accorci ng to Ih .. r'O", ter rocC'dc d outcome. mJlt:pic 
Iogi< t:c r(' gm,;io m WC"e u<co: To ;den"~y covorblm influ" nc.,g th .-, r~k at d;, ,,,,w 
r .. ,,' .',"""C., '" cj .,,.,lh , C'!y p,,,prrl"'''''' ' ""''''0' rr<lrJ~r<, '} \'1m u,~ rJ, A ro tioc,,'iled 
C1ppm",ch woo n "c"'''::.y for ,eie<::lio n of th e 'elewml vO 'io hc:. /ro,n 're Ye,1 nu"u c ' 
COVn"" t .. ,_ 
<;,:b-nY'd" l, '!.-e r" bul t wilhi ~ ·" ",,:h ~·I :3 ,')b-?""J'o, 01 c,-,vori;J ~ .. , IIh",,, 
de,cribi ng pC1t:MI foc ~o ". l"-o, e de,aibir'lg ,n-r1-u ne rr<lrk .. ,, ; anu t'>o' e 
ds,C'ibhJ elrug f"c:\'", ;;,d.,,~ i~ g d rug levci" elme p6r Q"grC1m ,~nu 
fe<rrlJhlbn chn'ncbi,!ic, ); 0 backwma sl"p-w~ .. C1 ppr D(:ch w". u,= 
w"·:o,,,by vmio b le, '_"'Or" '''''1Oveu I,om Ih e "'cd~l, nt '" 'igr ilk:"nc", leve! of 
0_12 nnd re ""te ,cd ",10 the moO .. , if P < 0,1010 ;de nlify IX'lcn\iol~ im lX"<anl 
? Th" coyn,i"te , f'o'" t"e 3 >ub-",<>del; o .. ,crihing oe<eh re '!JOmc n-...o<ur " 
w., ,,,. thco~ 0""'''''''-] taC1ot"-er h ,e <), e ,;ion ono""", u,oo Ih.,. txldward; 
; t"pwi, ,, npp<occh 'Nitn ;i[1 ils lor if1 C>J ,\Jn 00 Ie< Ih" ; uto-rn:rue l" 
3_ Th" im"",ton"" 01 th0 <C ve'hble , not inc 'ud "'<J " Ih" .,,'b-"'Q d~ k by!»c ;, it'", ; 
, t" pvv;; e p'oce d lJ'e, bu t rckltod to the r"'pon'e vn,i"b., wit" !J " 0_ 10 n 
l)nivClrio te ono~"J<. WO'" "s90".,.d ngrin {bi oOOit"", 01 eed1 ""'kl b k:. on" 
at a time. la me m:;",e li. and vWKloie, cc'llYbvtng ,g"ifica"t~ to th e m=el 
wsr", included. 
~ 1h" mode l "'''' 'm:-ii.::om w", re chscked b 'i imoectina the d li\but'C'n Of 
re,Kiu als. an<J th e sklbl ily ,)t eovarials, . , ths r'T'Ddsi wm cheel e<J by removal 
signilicarl tly b th e m'YJe! wilhout oetential y idu sntia l eb 'erYatiom, were 
rsrmved trom the r'T'DdeL 
5 Th09 l inal modsl " dJd",d ali ob,,,,,,,ati.::om w;thvut n-;,,;ng data lor the re le ',anl 
covw", te, 
~tc.t" Stali, lied So llw",e i.llaia C,-"pom;i<l r" USA) re lca,,,,, 7_0 1=1) m,d 8-2 i:::tXJ4j 
were used tor r'T'Ds t ,tatlilicai analy,,,,. Sta ti,\tica .:StatS"'it. In,~ " USA _ 198~-:'(Xq wm 
u%·d to< n-,::;,j of tho graph' g;;-r,;;.,-"t&d. 
Po t: .. nlo w"''' fu l ), ir,IOfmfId aCou t th", , tud',', ;nc lJd;'-'g the fact 'itla t ~ woufJ b e of no 
medical belneM to then., and v,~itte" cora,nl was ob'a. ,ed before enrolm sni. 
VoIu rrlary coumer"9 and lI i\-' te'~ng wm offered. but no t mandatory_ SefOClf,ate 
IMitbn com"" t wo' ob tai r,," eJ h r HIV tiding 
A" 110" f''' I it;~t, "nrdi"d "'..-"''' " lwJ;,,-J -Jorir ,g ;1'; " . ir',V-' li",; t , 1" " ii,,,-,- '"..-",,, no I ur, d~ly 
ine')n VenieIlC&U, Too-,e pollen I,. wtn re lurned to the cOnic, f,-;; $pulJm , aervi ng al'er 
cor1'$>181"'" 0; the;- ;H,alrr.e~t. were renlUnerale<;l ',.,'i lh a toed parc .. 1 on "aeh 
ocea"",n 
The ;;'" , ,,,,-, r<.h £1 1>,,-, C"" , ,.; I;,,,," 0; i i,,, HeGith Science, Faculty. lieT and the bcal 
and regional health outhoritie, approved rhe p..-otocc> and protoco l amsndm8.-. is. 
The Univ.,,-,it, 01 Cape 10wn " ,Jb,dbe, to an ir" c.-un~'e pd,,-y induuin\! lioLil ly eo,'8r 
I,x "talf and , f.Jd"nts "nga9"<-l;~ r .. "'arch activilie " reb:ed to their en-poyrnent o r 
, tudy under The a u'pke, of th e unive<;ity_ 
" 
Th~ dud)' (~'''d " , (J resu lt 01 co,"c ,o"1> oyprc<;od ,Yi 'ho c! i n i ~K>n' o t ~r""~: ,, I ,ldod 
HO'fli<a, For tI-;, r"osOn th e >Iud'! WnI co,"dud.od a t an O'J"0 ", g ,;t.o and wit!l a 
",,,,t,vei)' <rca bl,>dgm. 1- wo ' 'n Ih" nalur " of Ih" ,-u d'l tc d<rup' ,,' l,l1le ,,< pOI<lbie 
th c ,',c-rma i f"occ,= of adr";'~ o,, , ;,-,ve ,tig"'k:n,, Ir 6"'rn6nf, d<cnC>'ge, , uoscc\l'cd 
dn ie' baceJ c,,,,, cr,Q 1., ,0 ',",0', k: ad of he I",a,t~ - 'C'lf " "tCltt. 'Nh i;e Ih" "b,,,r.,, j' o% 
Vie ,,,, iK'ro'c-ro m crc Io< cl), to 'cfic'Cl th e " ' ,' ~l u",i<Jn ,6e ~,'J;c rigc-r woo 
c-,omprc ,n,ed in >orne blenK',e s IrOO-ed :n the seekns be>:lwj "y Cl Ia~< cot 
,t"noord:w:k:n o,"d d 5ceplir,ed i"",1e mentatic,"_ 
Due te n-ojor , tali chon:;)c, a' BrO\~.'",!,f Iod HO',pit"L th '" ,Iudy ',·..-a" ,,,,rri~. C1' .,.d b.,.b,,,, 
tn'? kTg'?t nurre-o' of 1Y'<;"'nts he,.-:! b ",cn 'cO''Vit", d, R e-'Cah,~ at;on of th e ,,'q u;-ed 
oarro:,l·c' ~~C ju,:nQ the nun-"' '-' of ",,'ilut e p;J>i'iv,~ fY',ie nls m S wee", aile< ho';>,I"1 
ad rri,wn, and the va";anO'c of '!1 e Cmax of 'ifarnririn fo,rn d"l" f"e v'oL'ily co le c1 e d 
;,., r",l>e~.1< " I rJP Mnrct< Hc,,.,.,,,I! hdc-",'",d ,~"t 'he ,I'".jy w,,' "de "!',,,I""'" rowe'ed 
to de'eel a 30% diFference betwcon '!10 grc-ur'. It wm ' hc-rclc-ro decided not to 
rc<fru thc '-l'dy c-r ,er up onotne.- ~re, In 'et,mpect, t'"O qreate.- varklbi ~ t'i :n The 
r;larnpic; ,-, peak >eve l' i,', :hi' ,t'Jdy oocreme d tnB power of the "'Jdi, ,OJ,,,, tna' 
',>d, ' eli~n ~f 1/2 ir, tne- :c",ar c(,n :",,-,y,:rticn d r:i:".,'p"~'n ,:,o,·kj b~ ~i",t,,:ted 'r, 
patients 'Nith a poo' ro <pon>e to t'o"tmcnt ca rrpored 'c the 'e,t of the popuklt'a ,-, 
y,ith a pO'.'iC' of 0,75, w;oc'om init,-:,.:iy ,',-0 o;rno;)d to ddc.:t a 25% .Jif'e'e ,-.c,e "f/i~ a 
r",nIi"'1 nirl .. , ' ' '' r ",rtiv .. I, ', cO" ,kj Iv> efd=tnd in '!1 "" '" w;th a rx' litiv() 'rUN rn "" _'fl,<o 
at 2 momt!" wi,h a rcwc-r of O,,~ , 
F "rll'~ r rrY>r " '1"it .. bv cmnc" , n "'/;""n'''' "'_'rri:><:>r O'f ' h'O ",a:;"', ',,, in tri, ;:uef\' 
,e ceiv"d b<"l'c;I..", 0'" <uo-;tandoro rifarr{' ,:in con:,,,;ninq rroduc:i Im<ocklted wih 
rTOQI'C vC"iab' e ,O+:n1"'" c<:>,"c" ,-,,,,,t i,,, ', , 0'1 rifarrpki n) on Ih'? c av o f ph"""Clc oi<inek, 
, nrn;1hg, thu , r""iJc~lg tI,,, powC'" to dctcc< the offor! cf ,ifa"",fc~: co~,ce ,-,tmtio,'" 
on cukc-rne and addi,-,q c crrt?""ity 10 tn", , rt"" v" t<iiion 01 <o' r.) of 'ho find in'ls, 
The 'naio;ty 0; 1.,,,e ,cu lo~, rx>tic nto in t!1C rcgkln r&,~&i',.'e dnic:-bmed cere On ,,', 
<i rnbulatory bm;, "1rcugIXl 'Jt the;r trea'rne nt CClK",, _ The vnrie iy of ,e "son, that !oct '0 
<idrri, ,;on 0' rxltion'; in t!1i; ;ll'dy to the hO'pital rIlo:1)' diffe rent"" e ihe~" hcm tho 
a'.';:;[('.9;:; p.:Jtl;:;nt , CQ'~'>Jn i, Ih"""",I",,,, war,ar,!;:;d :n drav,i',g conclusion, tv b;:; 
arrl'e d to th .. br"ade r tub .. "c'icl<" comm...o".;1y , 
~~o, t -~'i",bl,~ r')l'~n t, h'~'rit,"\:", c1 j",T~'::; th ", "..-r;:' d 01 th~ ctuc1y \','" .," ,~~,~k c1 
coc", pt;:, n, incJuded thv, e adrr;t!ed tv one lerrde ward lrom which no patien1< ,-yere 
"'~'r'"i'"d d ue Ie "turr ruc:;Jcr>, 'md p<: tie nl , who were udmil l'?d UUJin.g per>od; when 
the colaborotn g ho, ,,tal o/>y,iciano; were away, N0 hx>W" biase, in ,,,",,,clion arart 
f,,~,m pa!;"' nl ' ,"' r",'clu,'oo C" f" m<J ;"'c in th ", ooo,,-,,, .. ,,,,,,, nli-o n.,.,j word) C'ccc",,,,d 
becam", of m"" e faclo, <, 
The onoivticCli me thod, '_',,,,d tC' d e t .. rrr;"", th .. drug cC'nc:;entrol;:,n, ;n ""mr.-a were 
well ",otob lol hed, rob,-" t ond vo >:l oted, The !oboratory ~ recognized int e rnaFona!y for 
i!; ant;lctJ er cukJ,., Jrc'g o"ay'_ 
Ihe plm..-.--.a ,ompie pr"'O(Ho~on wa, by a staeJdardi, ,,,d pr'X" ""re, 000 there 1-"00 
ve ry il'l e d e!a,' b e fore the tmmf"'r of <pec imem onto dry ice , Th", ,arfTlle ' 'Ne re 
_,Ior .. d at --80"C unl i the', were m,oyed. 
/\ ,e"' tiv~~' ntemi've ijC'oo ,orrr-lir.o ,,,,h .. d d e 'Na' u< .. d Ie> rr>'" o""" Ihe drug 
concerdro tio",_ The ..-.--.ax;-nol conc-entrativns vf th", 1 drug, cOcti Ih e re b e be 
reflected reaovnab~ occ LXotefJ using ""nccrrpor/mental anafJ,;" F(~ rraarrYl jit; 
'emvm, the kld bbod <omple wm dmwn 8 hou" olter dr'_'9 odrrin;.; tration: will e 
ode(1Uot", in forrr>alk'-n regarding th e te ,minal .. rmina tb n ('cw .. 0' th .. drug, wa, 
genem", obtoir\",d '-"ing thi< ,chedu:e, i" ,C'rne COS"" with dBlayed ab,orptio n the 
~.'im ", C'tinn ':-"·V" ,,""Id nnt h.,- OC':", ~C"~ ~! r, .. ,ck""d !;n 0 kw """" th .. I, ''l r,.,.<1 ry"", 
c",~c e"C l ,ali<)~ wO< r .. ,x>,d .. cl a1 8 hDur,'), ancl '",r pyra/ina rrid e , which ha' a kJ ng .. , 
ha lf-liIe, Ihe,>, UCi wo, e xterr.fJely ext'a pcola tecl 
Ph<:lr rr""cor .... e tic ch<:Tocie r" otK>n ir.cWed or.l, one do , ;--,g intervoi Ioi aac i1 patkmt 
The re,;j,_,," ' .. ""iativn [not atirr.:,,-,k.j Ie, "~,,,'_.ed <:0' .. or",t" fodor'i in dug 
concentration. wlthn individual, ['lnter-occO$ional varia r", ~ ' : ' ~ , t'a-i"uiv\Jual 
vmiatio" - IOV) c'C'Jkl the-rBf0r .. not be e vc1 'J<:1te-d. 'I is irnportont to 'ec0gnize tha t If 
10\1 is Q' eal, pharrn:"cokine tic me '",',re "",nh f,om on .,. occo,;o,n """"r' no t b" 
, .. pr .. <.,." tativC! Dr th e J",Cl " 'f'G'U'" ove r ',e tr eatme~l pe ,ioo , and J,ug 
con"e ~lrat;C' '' rr)()n.ilvr i ~q on. a ,ngie occas;:,n " Ie" l iIo.e~'- tC' oredic! th ", r""pem'e to 
t>-ea lme nt 
• CovCHiale lac/oJ deJ Ic: 
A re klhdy h",:,.,oY""<O G<):' f""l-'u ,A u" vf 1-'(.;"" ,1, "-<'"" ir,ci.J6u i,', tl'", "" ',,,,1',,,,_ lhe 
covGria te, co!octed wcrco b',' rY:l "",'en, c"",,,,eh ~,., .;i ,'e 0' a ~ dBta ", ','<'~;'ch rre-,. 
have n~lcatiom /m the pharrn::>eo , inel"" 0~ the .. dn)g' ,-,,,,mur0d _ p"lativdl 
;",'o>iye , e,pen~,' e and e <,eje ric ;"vestigatk>n , we re avvided: al thu.gh go,t, u 
inte<tinat pI-' p~ +"tiV,.,V infl'-' 8f'c '" r;fanv ;dn (lb'OIp!'cln'" il wa, no t mem . ;ed· 
a ;tho uJh eme<gny I\" rai ur " fX';" h to Ih" pol"" t;a l pi'o<,-,,,,cc ' ;"eHc "" '>'anc e of 
druy IrO" :;po"iny and ,-,,,,1 a bdizing onzy""" to! ""' ~y drugl, invmtipa lk>n tOl the 
p rC.'iCnGc oi poyrtlQ.-r ro sm; O! qUent,f"",g the " 'P',,,~ on 0 1 1he,,, " nz), f1"" ',\'a, ",oj 
b"vo~d the '.<;<ope o f jh;'. Plaice! lo",;.::Je, d.cradcri!at ion of ccet)~a jO! Itatul in c 
','JOg-our 01 the pat", ,,tsl 
'Nhik fu " c ',! COYClfck fudor; ,ck:J ti vo'y cC Il~d" dolo was gothe.,.d. incon p lele 
data 'm ,",,>co covariate; leg ac"t',-Ia tm , tc, iw "1m deierd n"d n IU bset of pat;"' nts 
o nlYI dec reasad ih" jX¥Jer of <Cl<IT' a"e"n-c nt" 
I'c;&nt h~bry wm f& l€d upon f", gatl\8f ing into",,,,tion a bout pr &Yio u, m"d,:a l 
hi,t",y, ccnc Ul rent 'y"'pi"rn' s.ch as dkrrt>Oea """'''9 hobii, 000 the c",mu"1" tion 
oi o ':oho and ot ha dr~g._ '0; r~agrr<) r" reO'""", "'0" 01 t h~ da,o was not vent ed 
by olhe ; , 0 lJre ", 
Whne th .. dwg form;"!'o." ,,,,,d'md th", batch "~r'-~r' w€re no ted the d ote vI 
"",nwiactwr" was rrv t ' ''cord€d a.,d ,h,-," f cood,!ion , subs€que nt to '-'lOn ufadu re 
were not ' "o\·,'n_ P"c,,~t ilerCltur " "'99", 1, the, th -e- oog racbFcn en the ' h'?l f ,,/ 
Ii/a"'rjcin I :~ P",tic wkJ ,1 and iso.,kJ , id may be subslantia L espooa ly .., rix.,J do,,, 
c ornb i'lClt""" , and ~nde r conJ:tKl n. v' h;'gh te"1"em lu; e l a nd I'r unlditr . 
• fuet"" i,fluencYlg treatmen l re'pon,e : 
The rc'pamc 10 trsat,-"ent of t~b"rcu,,~, ~"<lti".,L i, "I'_dy tv ~ the :oemequence 0' 
"'cdip!e interading and !!-defneJ IOG1 ot',_ Tt-.. , ,j udy Ivcu,eJ vn the L":-:p0ftO"c " vf 
aug concentratk>n, : howe"", it to; li' ''iy 11>01 " 'J:oil of ih€ yqiabi ity in treatme nt 
respon,,, i< d " t" ",';"" d by ol he< la-atCl/', and Ihe," w€ re "ot cerrvehe miv,,1y 
qua lified or quentified, 
Trea tmen t ad"", .. nc" " a rgJObiv Ih" mcd ;".,=,tant de termina nt 01 the 'espo",e 10 
a ~ea'\""' nt r€gr€n, Co rrpi ianc" wm m , u,-,-r€d to be " xc" l" nt dUr i"J th" p" r;od o t 
ha,p;i"i a(j',,,,,,",,n ,"';'''''' ~""Im<;n: w,,' lJ .... "r, ur>d", ci,,,cI ab,,,,v{li""'. Howev,"", 
Ih e r", wm ver'! lI'le c0!llrol OHO< 'he ,-,-,:".,ner in \·"o,\::;h ;realme,,1 'Nm d~pem,,(t 'uken 
Of rDcorded once Ih o pal''}n l, wer'} (Lchct",)'}d '01" a",b'-' \:1'o,;: ca 'e U n>cc var"e d 
wilh '"sp""" 10 "-,e '-"'''''e n ,-d re in b my 01 crU\j di,pen~ng d nl.., md n lO,i potier," 
,:i~ I',,-.i r"'00:,"'" ci ... ...:.-bCli."',:i 00);;_ "ii:-,,-'-Jgh ud,-,,,,'e l',c",, ,:;.-."Vki pm",,-_t'NY a':;c,-,u l-,i 
10:..- ,hJd, u~ r"e , al~bli'y;'-' ir",aim",,-,t aukc'r,-"" m ,C: el i"":,,",, ,"':ap,,,,, m "",,,,-.enl al 
Ire aIrrl€' nt a "'-,e re,-,<"'e wm O'"toj·::!", W,e ,ccpe 01 f", '-Iudi 
11 ,." _,Iudy ]-Jc,!:,,!lui'-'n in c ",ded Ll Jiv"",,, pLl'ie ld ycoup: Ike,,, on IlJ"e 'cw:"j, 
Ilca lmcr,' fGf ih') 1",1 time Icqolhcr wii h !X1iicnL w;ih a h~fo ry of vev'oul d ;;cm e "' r 
m -'Itir "" r",b r'c<c Ih .,. "r c ch'm ,,/ d~=, .,. ;cvd:iv "":" "tide- ' '''''6 :=tieni' had 
cGflconi lant iln",,; i,,...n mity wm v(Jidll,,_ Wh j\e cx len ,",c e ixTocleriLalion of 
paiie ,,; pro i.." '.va" aHe"T'i;cd, a"c~'a ;e q<J<:J1; ih::oa lion oi o j ' h;c faciO!, rekv"n l io 
""atm",.,t uulCo'"" wc;' :,r-p:",ibl<' "'ithir, th>; r.Q ntin ~' 0' 'h" , j'JrJy , ~, '_;!J' I",.. n l o· 
fiCO trncnt ovtco,.-." f", patic n t factor ' wa, it1crofofC en.-,dc . 
CO"",lctc, Of C rrc,-Iocii','-o ' '''''''-J~'O 'cspc-n,'O "" '0 co~l s" and noT 'ic i 'u ti 
und""dcc<i: mse"me,-,t 01 n-.-.-nme ,law, 'n ,. ;, <tudy wm ,uperf","' _ In...-n.m e 
rne""""n",,-,\', I,YlE",,1 0( ' h", cytol','n 2 re,?:·n,,,, k- ,limJid'J(', of w')C~ 1:..'':-0d wilh 
pu rified r:'<"kin d "'';''fativ,," 'Of !vi. f'J!_' .... (' .-A"~'_ Whl- " OI n" cytokin ,. re,por-"", ,,,,, 
lhouqht to bc i"T'Ol"lar,1 f0< Im'l'lJnlty "ga",,' M . tv/x",-,,!/C»i.., ttley ccmpril'" on ly pClft 
01 Ihc p-o'cciivQ rC'I>omG, Fur lh0' mor c, ir,t",prcialio n 01 Ihc Id e of Ih" qlok"", ~ 
co rTT'l caled, 'or e m rnp le 1'_- 1 0 (a mar' ", 01 TH2-lvp" re spO r"e l 'nov e n'-,(1nce th" 
ob:liti 01 dcnd-ilic eel' io inh ibil " tlacd uklf growth 0' ,.-.ycobacreri,:] 1<1, Furlh",,,,,,,r,,, 
fir.cncial ard practical cor"haint, dic lat..-,d thai Qr, ,," a IMlcd nu,.-.b", of cvtakinc 
rC5PClnse. eoulcf b e '0Srn; urcd Cylcloxic T ccll ,ub>ei, (C D4+, CDB+ a rd C D3+ 
Iyrnpi'.<xy le" i we ,e qlJCt' lif iecf but the e ylolQxic C"fx:>C'ty o~ effector cell' "la' no l 
,,,,,o.Uled _ F;,'n ~ y, il ,i ,uu k; "'" rro;"J 11,..,; I'll" ""v"i. of Illnl '"r, oi ; '" n"~l iiy cilm,y" 
\'.il" I:",e """'9 til", cC'.!lse cI "'n~'ub",c lh,'i, [, ,-,alment, the ' '''''Xlmec rrre..,Sl .. " d 
",j' c r B wcek, c' TrCaTmcnt 'n hcsp:tc1 prcv'dc, c mere g li"lJ,e of p<:1 f", nl irn 'l'lJ ni1y at 
"r, .,. r D'nt in til1"" _ 
',,vhl e pre,ence c,f KiV---i nfec ikm Via:- de l.-edcd , '(f "'! I~""d ',<,'m ~0i l'_' Cl ni;fi"d ,:j ,_,,,, fo 
bLJ<:f"eiary cor"heinl-';, A, only approxjrrJClic1y 10 % of 'he ,Iudy p<:1ficni, wcre KIY'-
-,-,f",,,t,,d t' -,e rower "f ih" , tl.d v to d" le rmn" th e ir,l ,-, e nce of fhis factO'" wo> li"'icd. 
Too d<e lor,. >upple.-.'.enl> vjl","l ; n A ,-.r,J ne,o.; 1-"-:1)' k:,*" :oy~' ihc [cep'"""c 10 Ir"'o::imcnt 
" dep \:o tcd pa'icnh' , nutritb na-I , ICl I\;; Clnd die l' Were nol eVCl[uoled in 1'-;' 'tudy_ 
Th ~ e ,t"",! " f "a"'tat;.~n Cln chef x rai ic m,ClC,", led wi! h disem " re klr, .. , rn thk ' h !ri',' 
cavitie, were not murnely m,e;,ed m avdlme perwnai k>cked e'p",;ence lor thl, 
evallKltbn. 
V",<ub~ ty aiTribuT" a b y the pCllhoger. wm (~<;(> inc,:.-),,,,, ,,t,,,,, ':"''''''6(.0; '{i hi,c, j,-,,,, 
,u<cepm):<i!y of the ,'~. !ubc<cul<x,~ i,oIate , k i,of'iaziJ mJ rilar 1 opiC" we i e mea.Jeci 
'n come poFe nh b ',- de ternlmlt"", oi tI, e mini- M O, in rna ,t ratien t, no ~'c-h 
os",,,,,,,,ent v;m mooe: cmd no rre,,",ure 01 vi" JeocB wm ~ea~b le , 
A,mth8f :r,,:::orlont ,ocrce 01 var'abl:l/ is ;n troduced b/ the va,jab" ~englh 0 1 
Ireatment re c eived by pati e nt< prb to r.:", pita' Cldm,>ian. w!>;., "'::my patioot, were 
"",jrr;" ed ""Tn" 2 wee" 01 a ag'10<;i" th,x e odm ,ted 'g ' ea,on< 01 p0'C< T,,,,,lment 
adhBfe r.ce or pcxlr diric,,1 re 'f)On<e Ix:d g ene ra l,. been ,e c e'y" g d in',,-bmed 
t'Batmen t 'or klnger per",d" 
The ,en',iti',.ity o r ihs te ch ro'q ue Icr the d s te ctiGn 01 Ai8s b-,- d ir e ct rric IO'COP-,- i, 
rs",ti'".o" ~'A': plobd,:/ crounJ J() - .. 0% 'f 0 ""'gle 'I""'c'n.&n ~ em,dnBu, incr&a;ng 
to ~5 -1.5 % "iith muhi~e ' pec:\-nen,'" cmd vane, accord;,g to Ihe crgcr1Lm benJen 
the method u,ed Icr 'pec:rnen preparation, lhe , kill 01 th e ob,erver and the lme to 
IG",ie',,- each , ' d&. fu;i"' ""rnore. IClpkli,- glGwi ng rTlycc-bacT e.ja y""y in 11l et- abiliTy 10 
retain acid,lmt ';Clir", The c..',acf ,,,,,,,ar I, ,,,,pc;;,,,,j 10 '''he Cl 'p",df'dty 01 > 99% and 
CT pJ,i,i .. ., pre Jdi'"'' VChO .of 91.S - 98% ler me d bgnmis al 'ub6<cub,;,· . Ho", e ."", 
,m",,,, po,ili'.-ily rrtCTy bB can'erred b/ artiluc h , non- v'-:J bb .'.I . tlJbe,,-,~hl ,e ,pecb' ly 
i~ pcTTOoont, o r€a0y +u,,~ .-~(,tiLb""c'A.'± Th"'''P'ii Cl~d mycoboctC'1Kl of:--.e, than 
t"IOefcda;i,. 
I,.,j'!cobactsr'a! CUlllX'" ~ m<y e 'e,,~liv., ar,J >f>C'X,C, tI>,,,n ;, lho '~-r",ct ",,,,,or Icr ~. rb, . 
Se rdivity and 'peellidty ratB' far putn-v-na-y t "b",c u(o ,;, IKl'~" been a,tirnated ot 
81% anu 7£.5<::', r ",p~ di" .', .. I)' ''o. Th ", ' ''' ', ~ h'-ity 's ;ncremed to upprox;" .-;c;t,;,!', %% I"" 
cavitary di, eme'·'. False nega!'",e, rlYl y aCccr if c lJlt,~ .. , klos e yiabi ity and 
conk"",-"" ti",r, I','"" re,~:t ii ', ful,,,, po~t,',,, re ;; II" 
DJS to cost com/rein l,. onl )' >lo g e "pAL',,", ' ,,,",cime n, ',v."re ,ent ler bacte<bloqical 
evaiua tion " t l~ , study 1 hefeby d egeClS;, ,, Ih e le njhitv 01 the 'nye'tiga~lom 
Fa' 'E'mor" ej'£><:! aIYwe t,." ,""'af "",", "IIIi"", find~,q, a'e n,,1 ne="arly 
rOrYXlldant In thi. ,judy the cultum r",ult at 2 month; was u;ed as th e p r;n "HY 
treatment i,-,;jiation il os>ocklkJd ,..ith an int'tembd rd a l untnx'"rabl" h " ,~t ""'nt 
ovkame" a ;,yh p<oporro n of tho,o wit" a po~jivo ,outum at th~ time wi' be ,,",red 
by >1,,,,1 oacme eherm!~erapy", "'ofl INI ",x,hJ'" culture· at ~ ~nth, 00, a low 
'perifi<citv 10 pr"oic l the 'tori,;j~g acti','i~,' of t' e al',,,,r,t 'n ac i,-'d'Adual. I' " lJ~r"'nr 
how a",""Hatdy th .. markors 01 oarly troat.,-,en t ,e'OO~le retle,,! irnprovernenl in I~,,, 
t uber(Clj o;~ di;c""o 
,:,~';Ii;: ir'\l aehity ,; best reflected b', ti,£> "uk cI d 'kUS" 1,, " ,-,,';r ~ ~C '" "'k' ;:.1 ir,iE"" 
rcopense flak lroah'€nt tuoltr" ()' roklp,,, or o;"eme "I~"r eOfl1)lef",n of t'eatC!"l6nt) 
LJdc<;l ;on oi """''l,e ,,,,,,"c" ,/ .. 0. "ot cbndard iocc d h ali eme,' m many 0; Jr.o 
,,,r.,,dul,,"" mutu m opedrnem ",It=r jr",,,,t~t 0:0,"1'",,"0(1 wer .. not ""ra ilab:,, _ frstly, 
'" m.,~funed pre---.-icu,,')', Ii.,.. oro !oJuj l ,-1m arc,<" nd __ d '0 ;r; ,~!; ; cl ~ th", c:o l-- cl0n 01 
daia r",,, tinq to thc oatlent, p'oge" "ftC' rf, "horye f,om Ih ", hNpi 'a !. oJn~ aller 
_",,,eral w llent; hm; ","eoJ), b"on ' ''Glllt",d ~..cor>dll, ;rr1Oic~"'''latio ~ at dnir-
M,ed loi,-,w-vp wao OO'3rou;: Th", ",nieo '''''>ere pa:",n i> reccr.cod lho;- a,,",,,ulaj,,.-), 
I,~'ul:" -
,~ oi!"ci'"" 01 _,p"',,,, 'a~" a r-n a-;cuta" inq the wal:-beng 01 paik"t, att"" 
treCltme"f e,;o"'l' letio n we ,,,, r.v t pc»;:'I;; '".t;-.vui O",(; ~.g "",,,,,,anaUe de'nanch om 
d~;C; ,jd'_ PaFe nh were the, .. lora r"'~".j "'-', ;:.-",'hap' unlady, ;U re ll"n 10 d nic, at 
the a 'o lt"o 'ime, 0' their own accord 
Cli.c.""" ,eklp'c couki ,'JOT be diff","',' ~;,-~'~d I'''m r" -H.,,,ti0n 'n thi< ,Iw', a, strain 
eot"rT'm"on i "'9 _ by re;trkf<ln Iragmen I 1 ,,~,,1', po, .. """,phi,;m a oolv, ',:1 'Nm not d or,a , 
fOa rl)' Uqc;t"JicKiai aC Ti'iify i ~"A. a ,n,,,' '''' of ~', ,,, aciNI Iy or drug, ag",,,,t 'ho, .. r~ly 
di"' <ihg a'yunim-,. i ~ ~.e aerobic on'!ironmenr 01 PVImon01)' cayitle'i wa< no' 
rn",mvr" d ;,--, tnh ,judy_ Ihe it"rT'()(ia~c e 01 dru\) conr;;<"f(,tion on EoA ,.,a, th" rcforc 
not ",,"o,,,,,,,J 
W~ile we;ght cr~-;n9f, is u,,,d by physicia,-" on a daily ba~, 10 m, .. " ihci r"'p"r.' " vi 
'ub<t<cvk;J,j; pa I; ,, ~ I, to t, .. utme nJ. it" c-o nfourxl,;.j by r,"al-,y adraneou, facto,> Or,(l i, 
r,ot a "al >dated tOO! 

III 
THE PHARMACOKINETICS OF RIFAMPICIN, ISONIAZID, 
PYRAZINAMIDE AND ETHAMBUTOL 
'n ~h~ ch',pte, th 0 r--ha'~-.:lGcl.i.~eiic c' ,oract,c,ri,t;.~: ,,,I ·"') !,',p;c .n, i,ooK:::id 
pyrazinarrid-c 0~~; .,, :harr Cwlol i" the ,tudy cohort ore d e,erbcd 
Se'kJ l b bod , 0~'PIc " we'e drO'.w, e<' 0"" =,",([\",r 'n l~~i pa'>e~I' r,c,cei'{ir,g f., t lir..::.-
',aa tmard ' .. g:rne~,\ two rr<l~lh ' a fter tho. odml;io~ to BrewekHoof HO'f)il([1. rxL!~-' 
p,O':iou ,,, dc,abed rre thQot, 0" .. p,-,I\e,, 1 w,-" .. xdu,I"",f as he di d c.-oJ ~-"ct Iho 
,,~h'lv cn l"" , Ith" dk'9'''-';;; of t, 'b"r""""~ wm ne,-'c r \,('oli0:1 bv m~r9'=py 0' 
cu 'ILJrc J ' T~e f"" ull, 1,0m 14? p(}f i .. ~ I, ""., p,e'B~led. 
e xact I""e lrom d,ug '~ ge, tio~ la , (}~:i ~g lor "',<o h 01 Ih'" oh"~,,d ,aty't) li~g tirn,,,. 
0" Ih " whol " Ih ~ " ",d Ii """ ", ,,-,.-.o,r' i ~Q ,1" ,,;,-,1""<1 v .. ry i it .. hom Ih'" phn~"'1 ~""" 
~ Ex",;, '"r plitoJ "'I1e" j 00d <on'o ",' ,,"" d< o--vn "'il,* 1 h",,, ':><'" to drUJ oo,-"'"IIot'= ~ nd ~' 
C,', I, I~, <,"-'", j, <," Q'~i" he"" '" ,""'N ,'" (h~ uu,"""""""",,, the " ,,01 ' ''''' '" Lobud '0 f"l',n~ ,',, 'e 
'C"O'uc'J 
1:1 ,, " 
" 
p =""d t.-,. i_'_', c, ",,"0" ;" ,''-'' ~' " "';~ .- ,"c" " " ''-. ',. ''''" " " 
nurbo, '" o oFi ""j""",,,,,,d <--, 6· en d 8 ""'" '*',"'" """"",!Ie v"e OXt ';",,' W"'-C' 'v" 
' c>cluui "'n',x"~ ""'"' 
,,)biect crc' prmcntcd" Aooe"dix 5.1 . 
RifAMPICIN 
of "" ','~f", I 
" 
A "roup of 54 of th., Dnt;e~" 'ecd:cd ion t~" day oi p"cr~,,,,-,okinetic ,,,,,,, ilo''''gl 
b,-,Ich "" 0' , ;r,g',c drug rila rrpicr-, for,n j atioc", 'Nhich wer", ' ct" .. que~l~ withdrawr, 
'" the national """d cinB; 'Bg u (}luJ, uuillotii" u, , u'fic;i",rt bk.x.wa'obilily data had 
r,at been ",b~-;ttcd to th" Lluth ority a ll", wI",i t n., r,.ardach,'er had con"d",sd 10 
De "",or tOfmJk1lion ci"'''[J'''', i'''p<JdLlntly, the re",;b of d"oIutkm ie,lir'g 01 1f, ,,, 
,ub.tandLlJ'd furcr--.Jkltior" Ipro"cled by th .. "..-:lr,ufJ<oturc1'i t,'Ll t were' t.:;f,en by 
patienl' ir, t"" ,Iudy md the reguiator'l ,,,,,v, eI He,,l, ioppconJ" 3; ' co:ovaaiivc 
,,,,,,!I , 0 ' di"oIulion te ,ling for the a"pr0ved ptcdude 'c, ed in t h~ ," .• d1 U'" n01 
(]vuilob'e. 
AISunkg tne ,eiea" Di rifa n l"cin-conto;, ing producl' not <:0nfornmg 10 the 
rcgucw')' <eq ,""emenh i, jn ',eq.;e,,:; :he phe>macok;"etic pru"cr;m ,no<15l.XoJ 
,' .. hE,,, Il,,, Clf'P ' OV.,,; IO ' tT1ukJ!ion , we"", vsc-d n,,,y b i> n-,':J,e ''''~·''''''''r,t'~: 'ie i:"~" I!'~·e" 
of '00 .,. nt~'" coi.ort Ii", p i·,urrY"<lcol;""Ii:; mea,u re , for ';fQr,.~:"': ; n d",r+v",d e ft>?, 
;'··g e ,'hn ot I he tu r, apP'oH,O forn"" lc ~i0r., J" 'h>?r>?for~ ,un"""';,,,," ;ef)(lra tffly ",;o'r 
tho;e of the drJg bokhe, no: opproved by too ffiiyJ atory o.,li·,o'ily Oti ,,,, CGynria' e 
" ,Il. " " ,-,,," "'" I "p"r I "J in Ih" neAl chapte r. 
11'"" "i·,uri·,..:..-.c","ir, ';/l.:; , , "''-''"e" 01 .ric", ",,,,,in d e Tived from 'he ",cii',idlJal 
cor,cenlraiior,-I;"", pro tHe, a: e tabukJled be low 11 aij e 2) , 
~ The c hh, i "" " '< """,d",,t ,:<1 h,..·it~ ' '''' ""' " , to-n . 'n ,~"", t ", r eo' c<Y1cent,otioc !T",a.<) 
he pook ""n "'n ' Oku" :cm"<J, ' >C ",'_'a ..., cJ.-_, '",' c""".~n"~bn·to-n , c. .v~ to th , ,,,,t ""' ''''''010<, 
cc<>c""t'a""" :Al'C'), ,"" "'" und,-- ",_, conccn'"I"'·n_H"" , ~-"'.'. to int·" ,," ,:A L<':i:, h " yo:, .no ", 
Q,t,it>~"k<' o:\~ f obl) ondh" "",,,,,,,,,,0 Ie , ubi, 01 "·crn,ocn. '", c","." ,.q"" I," "crt ho ~t·~, ~",";,""" 
t" ~'o",',"*,oof rlo,!,l", :' T",' '''aI~<" i" ,.q,"" " W-00 Tee';",,' Qm duc" not ~pp'Ov.d b-,.- tl-.. ,",) ,"-"ory 
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'10" -" """ ''' '"C'*' ''~"''C n«~ ' ... ~, c" , ,; . .,+ ~ e C'*'.AG1 ~'; d, .. 'c· ;.-," ",;c;".,+ n' ''C'' , .n!-..... "" ,'1 
c e, ,,,c ,,hl,,,, p""~" 
" O~lu c'c bjoej ',O rt +"dh " aOO<"" b ec~', .e th e 'JOQ'*'e" c·I', o t ·c • • • _doc, -~te C_De",,,,,t to -" " 
<fu IQ;' po, i.'A"c" ' " ,,,';''' 1~ "'1OO.",J: ";: , ,,, - IJ.I·,;: ,,,,; j"" v", ''', 01 <: ao-J h("_"~ ~'~ , '"' ~ '~~JI. 
Oil" ,, ·, 
'la+o excL * ,; ', 0M IIK'I ,,-"''''i''' a, """c .... ~ "'0' Q"" ",·.-.Tot,·. ,.,t. , '"'''' d : . - 't'~l ~'Jrr: "" t -"t'''n 
'rr·", an'; ,\ ,,~, vcr,," d ,e Mqil ,,~ , rn"" .. d '0 ''>C,. ,-_m., ':-"'- OC' "'" "" w"~.~ ' oc pe,,' 
o",,,,e o'<""'" ~,(~O .-.0 ; "I1 "a~ . "-"" as :j'G, H """ .... t, '" v,-,",Jot'id """'. 01 toe ",,,a, 
,," ,,'. r ;",· 1· ,,~ "," "'"~,." "' .... eI'" c"; ' ' ~' , '-' '0''' '-.U '",,, ".",; W"" ,-"-"c'''"''''''1 w ,h"O'.'" by 
:t-.e 0<]:''''''' It',,,. ,.,>"", 0), ol;thc" ,y. ~, <It , "..-,: " ""av"",,eA d, d<:t~ " , d "'0' b.~" u"'''' '''ed al'c" wh l 
'--,. COO "" ,,,,,,,'. , C,,' con"d~<cd '" be Q ',';ro' ;o"""d",,, chcr"", i,~c Ap ~c'dj" ' co ' ", I"", odd 'i 
Th .. a"tlliJu tlOil I)' the dam tar ead1 pnan n:;lCOklf1e Tic mecm 'e ).; il " ,t'oted ·,., l igll<<O 1 
Ti\B :) ,op ,-o-',,,il> t .. s! t01' normaEty shO'HHi that th e d ala w e le ' kewe d (ar ,,'.I ill e 
~- " . b,. c-" 'c, c.-.d """." u c,~;,,6,- -- '"~.~,,: of l.-",.; , ,, ;r," " ',.", ri<,I,l,,,,,,, ui -' ''' G~r" ," 
1 Ll P"""''' I" "'''''' ,.,~",,,~d ., ~~' e,,1> ","" Ie", di'"",' buld,~, "'-'f" c,,"' 0, I"" r~".Aal c , y "'-.Ie",", ,, ~ 
,~p.-~jc'clc J ~, c;uo.- ~ ·.cce ,,,e~,,-,"d ... pi"',.-:.- ·,,1;0 -,. cl ,-,,,. ""'" O','oj bciel .- eo J e 'e o-e .-e< .jea in -,,;) , 
I , , 













< 'I __ ·'-:·C·' ·'·-"'-'·'· ",' -
," ,",--", '" ", .. ,.". -
Rcklt;-,dy intc"siy", lJooo sarrpir.g iev",ry 0.5 hour> lor Ihe m l 3 hour> all"" d-ug 
odnin ~l ral "'n) al lo"""d -"c:;O"'obly aCOJ rotc detc r"';nalion 01 Ih'" I' "''' ' ' ril']rrp;c;n 
conce<1lrario n in mod pcli",nt" reak ceneenlralio n: were ctla 'n",d 1,0,-,0 0.5 to 2.5 
h",·u" 'n 98 ea l"'- 172% el Ih<o 13/ ea-e , wtlcr", 'rrYlX was d .. t",,·,rined,' . 
'h'" sa'rf" in'J , cfl" rl, Je rl,,,,, lin c ,.,," '"i e<ll."'" k)1 <k~"cli'-'Q Ih e a .- erall d''''J 
exvxl!I'e in ..--,cll pct'cn". In 1/ 01 fh e 142 patie nt' imutf",,,,n t """,a<Lycbl ,, cJ-ug 
cenee ntrakm w,,"" obtoi r.ed lor the oete,mncrtbn cr t tr,.", " ... , .n crt ... n ,m" C<c< » 'ur, I. 
e! Ii',,, '"",ui ni '>g 125 p rofl"", on ly 23 118%i ha d a ,aro 01 I',uct to I',JCi of I"" Iha,., 
O.Be Cl ~C. cd', 3 If.'i:.i "f Ih e ".-o p,,,t;le , co(1d a ra tio 01 Ie » fl an 0.75. 
Th ~ "--.,,d'(] ~ r e<Jk -ila rrpi-dn ,;c' 'lCe~lralkl n wa.; 5.28 rr<]~ (?5% eonlklene .. i" t""'1']1 
IClJ of Ihe ,n"d an.- 4.62 h 6.011- on" Ihe meoon lITre 10 reach the p e a k 
("",c""l ro l'-, n wm 2 .5 hocxs i'!5~ U : 2.:.0 10 L.->11 I,,,, '''''dia n peak GOncant 'anon 
was ,;gnikantly kower lor he pr::xJud balch .. , nut appru,.",d by th" regula b)' 
"")th,:,,ilv !~.82 "'?ir 05% O' 2.f,3 10 5.361 COI~ )(,, ~ j 10 the-I I,:,' h i lv approved 
prociUct, 15.89 "'9 ~ : 95% C 5.00 ~o 6.$31; p=O. OO II . Tho pook cOf,cenh"tion 01>0 
"pp" ,,,,,d I·" hc1V~ a bim"da l di , tribd':Jn for lhe non-Dr"ro"" d prorluci, IFiquro II . 
Ti, e ~ "'ne 1--:0 r"nch th" pt'ak cooccn'rotion w,-" not ,,;g ri lic antly 'GngW' hr tht' noo 
opproy'ed ba ter"" II" - 0.76371, howevt'r, th " log tl rr..o was goater 'Of the,,, lxlTd,e, 
II" = u.uDY6j. ','},Ih 43% 01 the uon-app r0v .. d [""lch", having ""-'0"-""01:,,,,, log time; v,. 
26% for HH' approved prod uct" 
It hm beoo ""d9",I""--1 11, ,,1, 1'-" ,ifoll l' icin. the rr.:d if'rlXJ,tant f'~la,,),-,cokir,diG 
m::lTI.;", o f activit.,. is th& Cr'(<>A ',/IC ratio 10( perhap,. the proportion 0f th", AI)C 
above the M C). Ti,e. fOIUfO'~1 r:U"" of p"lit'r:~' -:dr, rna,o,;m::ll pia""" cur,c<o·,-,jratiol·" 
below 8 rr-.gl (lhe io--.-v" r !: m t ,:,1 th .,. p'Jbii,h'?d re-fe.-enc e range to; ihe peelk 
concen lra llon"."!; 4 "'9,~ I'h" Iow..- irri ! 01 the """rna I ,ong" quol"d 'n '''' ''1''J 
relerence;/" cmd 7 r"g~ a .-t' >urrtnor'Lt'O in kbl,-,~. 
T I "" P' 0fJ'->11br: of COS!). in wi""'" the peck conce"t,u 1"-' I tu;l. 10 I ,"ud, Ill" 10w,"1 ",llii> 
ol lh& r&"_un"-'"" '~j",J roneW; i, c o."e lor CQnc.,. rr-. Wi,k th" nGn-appro'.e,j buiche" 
p e lio 'lnca fO- "' rrcul'C>'~i V'.~.",/ ',-;ith ·~'·/e r ;~. ",f II", CtWJ~, vo :C.~' ;ying beiow 1 m;J/I, 
tor !he" GlPPfov" d prodvc1, ov".- 20% 01 cme, i,,,,j , ,,,uk concen!",t",,,, beb w th ~ 
The rrrrl'cm ."- 'Iet cr nd A.!JC, v-:O'.'''' w."" 20.31 my.rH. I' I?S7c 0 : I c,2Z I" 21,.'.·~1 ~.n -l 
24.12 mg.h:-J ' .:95% a 27.07 I", P.17,1, r..-';:x-d ivdv. ~. , for Tho Cmax. th e AL~_: '"alues 
wcr~ la ,\'c' for tha:c prx' .'d ~terl '" not ap pr ov,. rl h. th,. r" <l"lotory a uth<>it'i 13 ."3 
mq.h rY (';>;,% CI. 8.24 10 :8.391 v,. 7:,47 rTlUJ',-J' (95% cr, 2O.I R to 2i .611. I" O.OOO~. 10' 
t,lIe!; "ncJ l8. 3" ""9 Cr .I-' (OS%. CI I~ 01 Ie> 2' .6(,! '/S . :~.£2 Ing .h rJ' 1?591'. c: 73.~1 tel 
:10.011 . p=0.OS~7. 10 ' MID 
in.. r,-",Jian conc"" lrotion ·ti~ cuve fO( rilalyopidn ifl\lUI" 1. ii ,.,;th er .. "r Dar' 
depicting the rang" col conce"tr":i,.,,, " t e-odl ,omprng I,rne anLi n'." box", 
','p,,,,,,.-,!irrg ih'" 2:),' to 75" pac&,-,tl e; ii!u,i:(Jkos ill<! "xt" rr ~ ." .,.".'iobi ~ti c,f th& 
cOflce ntrat,,,,,, 01 th ~ drug in Ih" ,tudy pati<-'"n i,; with th" h gh.,;t varlob lity r,-, 
c , , , , 
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Cl F 0'" = dose! ",ICi 
ab.orbed hldior· iF) i:I a"Jgned a value 01 I: vaiabil1ty in bioava iI;Jhi:;ty I, r.ot 
Cld.~"I<>d to< by thi, """ thod of ea>c,.,'alion. The yariab le, Vl C oh, arid CI Fob, Olre r.ol 
u,ed ~lXIher as Ihey a .,. ,-,, ~'.p l·u l: ih" yc.-iabii ty Jr. Ih" absorb"'" frac;;Of' being hiqh, 
~, '~cc,,,'u" , co""c':,,·, b":,,~~" ,-., '.'o''':us p--.:rro""d". 'rc ' '''''' .. "'' ot """'.".., " C"l-' ,-"cd 













. A.ltho<Jgh 'h '" ,-r,."Car la'] tim<'- 'Na; 0: in a ,~b,ta nt:d """"ilv 116, 0' 32%1 ot (0"'." a 
''',,<'zero lag 'i,-r,., (ra"ge: G.44 to 3.0h hoursi was r",corded. No t ',-"pris",;:;!y, the lag 
H"", <i',.j "',." 1,1',-"" T0 r.ou..:.!·, iI','" f>-"GK cOllcentrmior. wer e -Signi ficantly cond"I,,"; 
These 2 "adobie, oh(>Ned ~:;n'~cCl<'1 n ~ gal"" " <,-",,,,,kl'ior., ',-.-ith II,,,, Crflax and AUCt 
and Ih,. Iu" time was a~o ~gnitica"tly nC'Qativ",!y c",r.,.h'.,d '"i'h 'he f'.tC: 'l; ~ 
rehtion>hi>,s beN'''''''' th", t;,-,-,., to reach th.,. p eak concent,ation, G"d th .,. Cma< or.d 
A UC L r"''P"c-t iv~''', aI'''' ,hown in fi<Jure 3, 
A ic'Q t:ene oi J i>OlJ r> ' ... ·m ""ocoled with >igMicant~i ,,,BalBI' bica-.-a-;ab ' ity than lug 
Ii""" gr"aler than ~. !""",d;ar .. :::, llCtX Y96 m;J/1 'IS. 4.40 mg/1. p - O.C(){j7' rrcd ian ,~lKi 
22.8° rng.h'-'l .". 16.0 1 rng.h,;-', 0 = O, CO) l' median AJCi ?~.XT mg.k<.l' v,. 19.::>0 
m;:),h,y, P = 0 ,010 .1) , Thus d " h y",d ab,o'p'ion of rita~icin wa, ",,,xia l,,,, 'Nilh 
reuuced oio;wal ab i ii y. Ilow&v"" as il u,tmt",d in table ~, the cited is siqn t icar.t only 
fa- the non-approv"d podUCl batch"". The effed coud be reialec! 10 (iehyed 
dbduF'O n with rmr:xJrli'O r<:1 le lv grea ler pr.,.,y,l" rri<: "", Iah c>;, m a rd Of, reduc9d 
d i«o>.Jlio n 01 low"r drug e; o ntent i,-, e;ar \ulc, of fhe; non-appoov"d bate"", 
~'rlo" oll~~ p"e, .,,,,,,'0," co',co·~;·,ii"" li<. ' \~~",,,. ,,, , - 'ilO ' or. V"" c" ".,~,,~, ,.,-j .".-,:;1 r~, 
So, orm ",,', rhO ' -<1 .'''', p ' 0 .00;31 ,,_ ' k li'ne to r«>Ct1 oe <:>< conc""" a foo-, ~""", Ihul ,,"'" potiffit' 
I'il", de k>/eo roe", c""" . ol'a; o", >,,,,, 10" ,X'",- =>Gen~ob'--! 
, 
' __ ' ...... _n'_~.'~_,~_,_, 
"-
, I , 
, 
, 
'" '" '" 'I' m 
~_ I; '" u"""i",i",., ""I"e,,, ;' '" ", .,e·'" 0' '_' r·_._ •. :,~, ,"'" . ",", .• ~ U," uvu"""', I,;,"~ .... ~J '-'-, 
Cmm, AUC, On" AOCil 0I-l un1,,'"o--, U'"" to, ~"-J"-aI ' ''~'" t.,I, oori tho ""DC-""'o"" b~" " ,C'cn or",," (x'~ 
C,-,,,,, A.Lt ,,"'n MU aI rlarr.o>Oio u,",o '",,"'MO<", co".",I·"",_ 
the; ha lf-l if " was , ;g rifie;ar,tly pO~+rvdy corrd ::ltc-d with Crrox {~g lxe; ~,\ 1;-;, e;oukJ 
,ell e c;1 , allJ tak-n 01 ioo drrinalK.>n f'aihway' at h':;lilCf dug "(>;l e;c~,tratio r" ia n 
"ffed d e, c;tib " d in ,h" li' ''rat" " w:th ine;r"", .;i ng do'''.,'''· "'j , co: it e;ooo ;--,dlcat e tha t 
n J ivid uob with g raal"r pre -' ),>i,,""', rrctav'Oo> m of th" d 'LJQ a l.,o d m na Tc 'i,te rri " 
dr ug c"n"e-n' rat iutH ,,~"e rapidly 
l h ~ " ,.., di<1n drug ccr, cer,tratio" , for each ''' tn' , n[J t'me (1[ e ,havtr' i" ioN .,. A. lh ~ 
c onc;e " lraliGn o f '_ml i l ubee; LJIo~, 0 9 ",, 1, i, oft .,,-, ,,'<'-"',[Jrc'd at 2 h" u15 a t:cr drug 
o o,,;ng: and Ihe Crf)"x ,o-rge 'Of 8 - 74 " '9 / ' r"e; " ,,'rne-ndec In th" ' krat " c' ~ thc 
,arne 'y 'hot ",I th", p''''C>C1s€d 2-holf ranSleo""'. In Ihie , tudv. th", meooc, I'm" to 
rea"h Ihe pea' cOr>Cenh,t'an ITm::Jxj was 2_~ hoi", Th e 7.S-I""" 'a "ping time wm 
' 11''''''' ' ''''' " rrr'- "."--'N .. 'n d,~o t')r ",I 'h" p<e ak rlf''''·';'',,·n "'cY,"- .. r,~" t;nn in th ... ,,, 
palienh. (md thi, is SO whether they received the apP'o v<>d dru,) hale"",. or not 
approved jorrmlatlan and 2.87 mJ,~ lor ih" ~=-""poro'!ed batche,; p=O.OO2j. Th e 
r,,,,,eL m ·~·c'c,C;;!-,t'·~·IG" "'! ?nrc wm 3.56 tn;Jil (:: C';'" :d0, ,,,di '0\·,--er thc " Hr e 4.47 rrg/l 
a+ 2.-5 h", , ''') Th""e r"'''''3;vhg the ""~-<1?,--~oved batche, a,,- htevGd a rrl€-dkm 2-hour 
"''''·nc:""d '(Jlkm of on.)' 2. 1 9 r, ";; iT (95% CI : OS; J.c 3.3C'j . . ~",c"'d"'((Jbly ;ower than tha i for 
th e "ppr0ved prOO LJCf; 14 _3~ rrqII19,,)'f. n- 1.,'i9 to ,'i ,9)- r=O OOli . 
i"'e ~e-cJu,€ rifuIYp ,·:.c_ co"",-,,,,,!,di:o n woo 0 ,ngii b d~ ~'aji€nt; '''d' C(j ~I'd t~,,, llh ,, 
do,e of the d<1y Im!"re ""cr, .,.omnot"d fr0m the sy,te rrie dculatb~ willi n 24 h<-'}I"s. 
,," -', '0., ~"C'C"'rn h.,,,,",,, c;n -",~ .. ,'>1 ,,;~ :. AI 'Ic' It·. '1_' ". "n,,', ,>", _ O.?''''. n " OJ)()'\'; 'me' 'h ~ 
~i 0."",,"," co', GOO""".! I~; 'c>eJ """,,', ,»0 0 2'''''-'. ~ _ n. "'" 3,' 
... 
------------------- -- . ~----.. '--"~.-
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. • ~ . . ~. ~ ---·-.--1 . .. . ~ ......  ~ .. 
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,·:t~'d «"_""";,,,,, ""··-"""'~-O" ,-,' ~ry"" ;~"'~"'~ ';'.,.,~ . ,~.-,1 fl-. co',,''''-,'' "f .' ,,-- 'c'_ ;,,_.'f,~!ic·c. 
""," '..-ne ,,(", jr o (:rco, ere' ~UC c"·", c'''',uro'~ b.lo-~ 'no '.,,,,-""'..-J rcr." Q' 'he ,, ~ ,", (I""".d 0 
"a,,,, oJ ° rc,,/l 
["f""'P "" I 
I ~;,)tl 
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ur i" " cviis dQf1 "tLly plOy.ao a non'''wa~vs 'ntOo,,' " I", Ih " Ll,,.,,,,'oe ,,t oi drug 
e xpo'L"' _ 111 ", rdatior'~-;p bet",,,er; 11 -,"" arnoL':1 I, 01 rifa~i~ irifa,-,-p ic-in 
c-one"f1t'aFC'n X VO'J"..., 1 " th e L'fine 'md t"" Crnax and . , UCt volu", ,-,-,'Ore -~xpk.>red 
l)(;~ " c olect;"n, w" r" rnJ d" lrom 2 ~, ~ ·6, 6-6 wKJ 2-8 hoc" ulle< c:fc\,; adnin ~trot,.,n 
in ln~ pal;.-, ~t" O'1d from 0- 8 hour, h 10 V' ti &~ts. Thevo lurre olur"o was ; .. e')['d ~ d 
"nd tI\€ conc"ntot",~ of "if",rp iein was cj"" Ofrri ,-""cj for "oeh eol~ct",~ . Ths arrp." .t 
of riio"",,,,n .,·xe,eted dc,i ,-,,) e-.~ch t:",e i ~ t e<.o l ,;<Jiurne x cQ(\ceniro,,,,nJ ',.,'m th " n 
cokuklte.j , ord t~ cor ,ool'o'" b"tweon the am,) L'r1 t 01 rifa,"pcin exaet",d, and 
of bbovailabUy, bette' evrdo"cm were derrr:>r1d'oted lor th... pl~m"" 
con<:,.~l rLl';-m , 0 1 ,n ul., t,,,,.. p oinl, I<,' .. r tll,-,n 1 hoUl " lfe r drug ad rrini, Iro t",n 
I:.l..tt:_LJ"'" C·_"""'lo,,, 001"0" 'he ""Yo<. -, c,· 't~-.pc-n ~'c"',, j "nd -ho ptnr""""""""'ic ""~"'v .. 
,., ,'r"",;_", C'"'U' ,,-'n AlY''-





(0""" ",.,," ' 
rho . (p_.~."'e)) 
""'iUi"" "'i 
I,,,,,. !. 8o"_c.nd_N""'" ~Ir'" or Ih. 0=';'-" d """,pi",., .;;cr~T' o " "'" Co"" c'." ,,,,,,; i' "'"" 
pur, .. ", ""iii, '-''''' .'" ,Una, < " ",.,1 , li ....,c Ai a-.c """ i""""" '" m,~' 'g..,. ': "1",,,'0 oonc"i.alior·, 
01 th o "u~ 
, I , - ~ I , - ~, 
• , - ! '=1 , 





.J ~ I .~ :!l ~?,Il;" J I C' I-':'+. , '~'-'~'."", T ~;:-"'''' . "~-. - .-. ."~""" 
Urir>Ofy coIIectior'» could prov;&. 0 proc1icoi .crecning method lor idcnlilicolion 01 
palienl' wilh kJw nlorrpicin concenlrotiom. The figlXe. 5A ond B lobove) .how the 
umory excrelion 01 rlforrpicin in patienl' ""';Ih very iow (Cmox < 2 mg~) ond low 
ICmox < .4 mg/I) pk .. "", drug l eve~, re'pedvely. compored 10 lho,e with Cma" 
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ihe rne<ian err.::" vulue lor hOrl;(uiJ wm 0.47 rng!; i%% Ci of media,,: -0.90 - 7.DO). 
wiih ihe 5·, - 9~ ' " ., ,,iile ,u"Ye 01 3.55 - l?O;- [\lgiL iwn;"zid <OUIlceni,uli()n; WBf e 
th",d or iO wi lNn and 91 "ak~ them th e 3 .) mgl1 rC"",0rnme r.J",d ''''''9C'''"-'''''''' . 
The r(""Ji'~I " ti")02 tL' rea"h ~',e I'",ak cqlcenh:riion \'"j, ',.5 j-",·ur, i5" , - ,,~-- cenhle 
rang9: (> ·5 - 3 i'ou" i. Only 9 patie nt, had rneo,urLble klg tir"', fa i, onklziJ and the,,,, 
patienT> dd r.ot have lower Vlaf. conc"nl'"atiom of isoriazid i n-.eO"n o-na~ k< It"-o", 
with Jduycd j,ooimjd absorptlor'_: 7.9i rr"vt 95% Ci: 4,05 -- 10.52,,_ 6.39 "~jli; '15,. Ci _ 
~90 - 6."'" 101 ity-" e with nO "',,mura ble d" kl y 10,-0.75351. ~"v., n ",/ th", ,, "-'bi"''':'!' wit!> 
d.,"'yeQ on,et of ub'orption re"eived a i'xeci am" cornl::<nation 0' isoniwid and 
ri;'~'~J"'''' on the Joy ,,/ l~l(l1rn",,-olinet,-- >Cl n",", ir,\! and Cl' pmi<'ms wdr- d"oycd 
or.,et of j,':oniaLid ob=pFQ~. 01.0;0 hod &;Ioye d (i.e ° noozem "'9 tirne) ,.:ton opkin 
oho<p\on. 
The rn",dion AciC' wo.' 24.96 rrg.hrJ·· 195% CI 23.23 - 27.01i, onJ 1",,1 0; th e AUG. 
32.51 mg.jyJI i9S", CI: 2'1.lG - 35.33). T'".e rneJi"" ha~-Ile 'NOS 2. 76 hOLY> (95% Go 2.57 
2.wJ, 000 ihe di rr i norion rate cQn,tant had a median valv e of 0.25 hr· 195% CI' 0.14 
0.271, 
'1o ObV>Ol" brnc-dd if, we; obs€fved ir. the dbtrlb-ctiO" of tha holl-lifa, th e e l rr i na'ion 
rate" the peak concenlrati"", or the "'lIe II\';),-"e 6]. T~e cf· or tri' cr-olomiwtion 
""n/.,.-,.,cJ by ace lyl'lt'" , ialu;'" ".'a, Ih""., for ., ob'DJreJ ro,.';bly by o,r,..,r lac lO('; 
contribulir.9 >ignifk:ontly 10 pham::lCo~j:leJ'c voriobJity or oocc .. "e of potie"t lact= 
'''''King the phef1 Qiypic ai lfer€l1ce, JB" w~i del"e&~"· . (;OYOlimB facTors 
inlllJe~":ng Ir-e pr-alTlo"okine iic "",mere, ore eXlj ore o in th e nexi chq::o''''- , 
The mecFon c0r.cenitotiom of i;oriOlid at eocr- time poirJ are repre,emoo in figvre 7. 
""''* " Tho ,roJU, C",'.cLT~,,,fo),, V" I- ,~. c',,~e t", ;'orim~J. FHo' ba" 'ndi c"'" -'><-, ' ~''''''' QI 
c"'''''" ,'"Ik,-" ~I <,,,,,I. ,~,nph" --,~ . ",d "'" c"'" ,.p,., .... - "'", ,,,,, .. 75'" .",,,'0 ";" '~'''J'''_ 
,,<CO ",,, ~u;U~ ",,-,-, "' ''" Of' '"0" ,,,-,,0 AT EACM SAWFU"G -, .... io ' "" 
" 
Most pa;;".-,! ; had " lm-.1ated til " previau, da y', do, ,,, p rior ;o blood sa~[ng , 
f,boa "a n l , ;ng at ;'<1O C'I ,' y:eId, concen'ut '-:J m re u ,ona b y c Ql re>.:l le u w il h the pe ,, ' 
conc en trut;ul-' iSpean-,1Ur" rhu: 0.192) 
~ "01 ' "'''' conconr,at<>n at ."",h blood ,,,,r '. "J '""", C",,,,:e,,,,,"''''''' Dek", -'.e ~ "'= ,", ''''Vo 
01 f;e ""cy ",,,,cnea,, v'"'--'c uf" ,~ ".-t 
'MG.,,', ,en. or 
>"crvf"~ 
;hr :, 
c ",',c """ atro n 
,.mo'. , '0" h. 1 """;ec-
'I .,,," ",CO G 
V 'Pea '""''' ,ho i~-v~"" : 
I " 
1 ;;d" -q- S""""""", .,o".k*"~ bc-I~-,- "" te,. '-a'",,-, P'''''",,,",,"'' . ,lo ",,'uou 'c-, d 1''''; ' '2>0 exO'C-'K'D 
;;> ,-m.",,-or cc'c~r,, ;., "' ip-'c J.>e) 
os_i odaTed wi t~ a d~ayeci peak cOJ)Centration 
D"':G'ie -:i ab:orpt;Vn ',-iU, m;ociatc-d wi :h loWe r p.,a:" concentration' as e'.idencea b 'l 
t~_e ">]r<l;cant k-t 'Nea , ct3,cciation b etween Trnax a n(; Crn::,, _ in cont'act an 
m,cciatiGII wu, nco ' e rl e de<J uetvveen Tmax rnd AUCt or Al!Ci. 
T~ e peu~ ;,;oni'l/;d cancemration was not aswcbTe d with The e .m natroo raTe 
constant 01 t~ e halHife, indicat;",] ;,-,dependenc e of the latte' 2 pmameier~ as;" 
com" lent wil'- f~,t oraa- errmir'C1f'O,-, 
A, e,<pected. Crnax was ,h-OI1giy and '>]n if~antly corr<>lated w it l, AUCt and AUCi . 
A.UC va'e-e, th e AIJCi in pcrlicutar. 
C1 eao'anCe and '/clume cI di ,i,;i.>" 1:0'-' I >cd strong anu ,;g",fica ,d IBgahe COo'( dat:or" 
with AUC; and C ... <lX_ For the reason; cite d in the ,,,,dbn on rifampicin labove), the 
variabie, VI f 00, arxi G fob, m e [)OJ "'00 texth", 
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o [;~t" ",ClJdOQ ,,,'''' ' e, h " ",."".", (" ,""~" "" ",m C<'I'>' Qv(1"a ,,"' Loti C< I'o~ I """' "'''1 am"",""',,,,, 
t, ::;""'>_'" V" 00 , "'~ " " '*', '._,"'," ,.," to , •. "~. 'ow AUC; ncl "cbj " "''' ''''''''cry ,Ia l;,',=,_ 
HC!!-i>O<Jrly :cnl" lj,',·;; jr(,m 0 to 3 ho c~, pr-:·,icJ2c.i f:!i ' ly Q~"urat" (ktcm~nat:0n of the-
peak conccnlloticln of p)"ol inanidc 0' 1~6 189%) of (X,,,,, had pe<ll co"centr"tio ~ , 
Iv ing bc/v'o<m 0 Dnd 3 hOUr>. 
Th e ratic 01 AUC'to AUC;".'m b,,'own.0 in S6';!O of th" case" In "",Iy {)n., CCl,eW"" 1"0 
,,,Iio greot0l' than O _~ _ The rotio ranged I'om 0.33 to O.B I, lh~ i~dcotc, tha t tho 
Ju,ciiJr, "j Ih e "",p li ",,, ,ci,,,Ju ie u l 8 hoc" w,~> ,ub-"plj",-" ,-", ci,ur,"cr~ ii.,g 
pyrclir'o,me CO!1c"" tru'Kx" JUri,-.g th" " , n-;nal ion ~_a; ,,_ and :ha l Ih" valu"" 10< 
! he d,l,butio" of e ach p hClfrr¥lCokl'1etic rc .emcye i, ilu,trated in fgu re 8_ Th .. Sha piro-
'N1k le,t lor oorrrdity ,hav_Iw Ihat all ihe ph0'"rr¥lco/<""tk- me0'3ur", were ""ww_ 
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A, d cmon \!loted 01 !~.8 fl(Jrro· .... ~llr.!e tq,,"'ti1e long'" in ~;g"'8 9. Ie" ..... lobil ty WO' 
,e~" ill th" pyra:inorrkl .. CO'1cen IrOP., ,,, D,,~ .... e .,., "dvidua', +"on 'C>f ,~arry:i.;i n and 
r.."}rJio:i.:l. ;" .. dr~ iJ "'0 • ....:>=roc;:! t8k>o1j 0 ,,<1 ; ... pkn, . Il :OiJ :irrot wm not ")io(;~~,."d in 
any =TienT and ]ile "",d;o;m iir,.", io r'Xlch the ""'" <.:once~irw0n wm I_Yd r>0l " 
:'15% CI: 1.5 - 2) 
lhe ,,,ediG" Cmaxwas 57.70 " >;l/' ,:95% U; 5 i. iL - ~YLllJ Nn ety-one oar",nt, f64%! 
n,,,, Crnax .-duGS above me pubi,hed 30 -;,(J " g il "mg" ·" , " i:ng f'vTn a 20 25 
rngl '9 do ,,, " nd QI'lI\' ~ r:>ai':ont, 13%1 had valo€' below t il i, m"ge_ 1h" h~· r",,, ,,.j 
p"ak cvnc"n tra t;a~_, h ,>-0, gnup of p(1iicnts QCCUIT"d n <.pik of rrorG Ta,,-d 
per L;'-':7' ''''' Q' b,,;i, ,.-.-,,;g ll; iter""" 35A~2 rJJi.;/I{j; c'd " _3~). TI',_ ,-:",,,",, ,' ,\L'C: ',·ie;, 
?ERA1 '-:g ,I1,_" (95% e!: 273 _°:'>_ 302 ,13)_ 111 " ,~.l\:; WOs con,;d"mbly great"" l-,n_68 
mg.h!.1 " '-., ; "54.0' - 52:i: .tsdl as 'he drug "'as n"Q~ci""ry' d rr;nakd aT d i-;vu,, _ 
! r.e ":editm vo lum,· 01 dUribvtk> n wm 25.731 19~% el, 24 34 - 27.44! Kowev~r (1 ' jh<:> 
fraction(11 "bS0rptiQ~ i F: i; un,now", fhe 'II f ob md q f- ob, -,-olue,. re<pecti.-ely. do 
no i ,,,,,,res...-,' tn '" ','Oi, 'n',.. of di<rtrb..t'=>n mn denrance va k)e , 
" " ", ,,~ py""", ,,,,-,,, oc CONCI:"H,-'- . K>NS • , [A~j' 5~,""U"~ , ... , 
;, " 1<2) 
o , • 
.. ~ 
Own g to The Tebtivelv bnq ~,alf-~'Ie of pVfQZn Q..,.,O:Je residl'QI GQ.-",ent'Q'bm of the 
drug IW",: t"C OI"",io .,,; oo,;,-,g ink",,,I) w"'",, dd=kd ai tho pr" 00;0 ,,,,,.,o!c . 
mod'" Ie< 1mu' , 
'*" I? '';"'0",,,,,,,4 c""ce<"iro''''-.. '" "ocr ''''''.'''~ 
""".c",lra' or., 
"~"",,. , ''''' '0' ' ""'," __ c1 
,~,_. '" n' C<" "." i" "'" u. ) 
r&Iuts ar& ii usirClted ir', tClb ic 13, 
- '~" Ie, "",,,,,,,"', """""""", """W~~" ' '''' \,.-,'0.' ",.-,, ' -.-,oc ...... fc ".00",..'" 01 Pi'''''''''''' '''' 
~,,,,·~,,~o bv "",'·,:c'''" '-0"1"'",", ':e 'Ie '" J, 
~--,---~--~----~--
c()r.c~t'a ticm " DeO'f",j ,~I:, >VC,c·!;.. __ ;,-, ', ,- ,~, th e reto' e 0"0"""\;0-.:1 ',-,-;:h ~'N"r p .. ,,' vCl II'e' 
Ll5 in ~h e cme oj -;tornpicin , I.,:;.·, .. ·,-al G ~gniliconi cOrfe kltkKI ... ,0; ",:;1 'eM btol',,-een 
Tmc:x "no tiM AUC va lue., ".dico li~g that oeoyed ab'".-p1io', wo, n"'~ " '';0'-'9 
u " ,,,;mnant of o yeroll bioo,'oiial-" i, i OY", 'ime. 
CmaiC s, ~ r.uet '/~; e ,tr·:-~Qfy and i-;')',I )' " Jr,ikar, II', cr,,, .,',~ t .,, d, '~nd !~ 2 rr",a;UIB' 
w""" hiG~Y 'i<cn;kan~'y msocatad with Ih'" ,~lJCr C1lthn''S ~ thc corre'al:om w 'th AUCi 




them i, the cOle fOl AUCt; the ctin-rniiur, rate co~<!a nt and the hait :i!C were 
,ig;iticantly al\ochted 'Nith ttl .. AIJC yo,OJ" '. w'th th" ,tronger rei ation<h" beng 
dsplayed ",ith Alld. 
WhiJ.o th .. Vl F 00. and CI Fob. \/Olve. ohowed a l.1eoter degree of independB<lce 
Irom the mark"" 01 biaavaibbility, Crrnx and AIJC, thon they did lor rifampicin or 
,s,ori aLkl, ihG)' wore . t~ >iW' 1icu"tly oJ.«>ch t""" ,',Hh th""", n"'o;U/~, and ae not 
adiu,ted lor the Iract>onal ab>Otption. They cannot therefor .. be r~garded as t ~,e 
reflections of th~ volume of d~ tribu'\on and cleoranc~, re.pecweOy. 
HI1AMILUTO l 
1,,,,,, >. ' ..... "',,n,,""'" '01~ ~ .... '",l ~.l """ •• "'" ''''~ ..... ~ lu ,oooct "'. ~"'" ... ·c_"''''~ Ib",,) 
_~ r~ = .. ~, ... "',... " . ......" " ... a"" ........... • .,...·".. • .,""n ..... oo ""' ..... '0 '''~ ,,..1 """" •• 0<"." 
cO"oce"~,,,: ..... ,"J('tI. ~ " '" , .. l~· I ... c ............... """ .... "", .... 'Q ""'~f I ...... " "'" ..,.,...,e <, 
d." ..... "'. ".., , ..... 1 ,,,,d ' .... ~...,.~ .. ·v 1..:1 f ."hl ,~ e1I"~r~""'" ,~, .~ ....... .".c' ~"""""'" ,,"~, 
"<h>,,,"" '" ~_._ ""'r'I<> , 
""" ' '''_ "'0 ~ ''' 'I --J~1-. tho-
1"'0' I ,.~ 
" 
C,~ ._ "' I ",'",-__ ~~" . ....L......:i'.~ 
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"'''''''OJ "',(>"'0,,0';,,, -1.- O' ~O" .~, '-oth« ' ;-"", ' '''''~ ·o,,.r~~~ nab "",I c; "'"""wi codd not be 
e "" c' u-,.J j '-"' 1" '" '-' IK,:. '" ~ "'''' cO "'''' ~''-') CO"". c/, ,-,' '" "" " ". 
[)ato e"" ' ;~.d h·o", "" ... . "",:,.,', c . c o",. H-. "pO<ir ,." ot -, ·ot t~e "'·'''' n ( on ·al. c·ombt to 11;" 
"fn ;, ,"",0' ,-,,,,,,.eI .-,.,;'-.1: .... n "c_(U"; ; .'" ' .• c_r,.; .,~, nnd tr. ·m ' .'" Q" ""0 r o ' _,,~ "'~. ,-" " ,",,_,t. 
cui ,,--
. 'cujech 'h i ,.~'I lee''-'e et"'-",~01 if the "", " ,., " '.o",·. ", ,. c/ 
",--,p,-. s~ '" o :." '", " ",",-c'; 13. 1 1" , .., - '" w , • ' 0 .;1 r,·"" t-o . tr",""",,,, co,)C~r," ~ lor c ~t.,,-.-~",tI ·on 
the c,~- ax vc:O ue, ohto inoo fa' IYO;t ",a tien!; 
Allor "",du,"o n ul ,I ",b;"cl> in whom Ihe ~ op;> 01 Nl a larninal elimno ticn CUNe cooo 
no; be d ele, rein ea. and tha 2 subjects \ ',i I~ ; d a<a li<t;r-,g ihe; "i mi n",tiC'~., .ote conskm t 
pu",iy , 56 of 123 146%) had AUct A UC i ral io, all",,, Ihm 0_8, cmrl 15 : 12Joj o f ~h ".'" 
hod 'OPo< 01 "'" n'"., ".I. 1h .. , .. ",.e. n 0,,,,,.1 hO.1 0' I., .. 'l'~OjO?Cl> fr,e ... UC, "o.\le 
,eIie. E'~,,,,,,.-~-.:!i' "'" E'~:ropok'th'''' 
4 ,56 _ 5.35) Th r .... ,,"hied: (~I """ C ""'" vnl"", mrer Ihor. 2 mgfl :n (IMI>I hod 
C.,."'X 1:I • .,ole, Ihon 0 mg/ i ana 1119 dose/ ' ll ,,,,,gad ;,,,m 12_BB Ie 34.19 rTl\J/ ~ i:l. tl<"!l eQ 
a n il1\'l liie.aIJ'e, a ran!J <e ef 2 - 6 mg l' al-: .. . a , i"gia 2S mgik i:l aOlil mould be 
c~pcdc c:t,', '1 1. 1, ''',~ .. ,,',,;.;~t,. 1 ~"I'".i '.<Xi 2-0'lOU ' c"",-""tr"~i<'''-'I less Ihan Ih e 
propa,ed 2 mgll '-'vel'<_ The med"on AIJCl and A~K:' were 19 _9~ "",hI r' (Q,~% C111!.~:l 
20.9:.>1 o"d 24 .13'1 f!'g iT} (9!>~ a 221>1 - 2.~.9~ ) "."pec [~ .. ly_ 
Ihe hn li'l"" oi aMarrbul0i "0" 0 m&<rinn 01 2. .... 110 ... "" j,,5-:t. 1..1 2.4 ~ - l~1 ono " 
.n'1ge ot 1 JS1 to 8.11 ho",,, 
Th- """dkm 'fOlu""",, " I d;<mbo .lion "''m 160.::" i (?% C' J.!9,61- :'?"6~ '1" '=' t~e 
~<J'"" dec.-aoce w," ~~ 99 i,hr-' r9S~ C1 40 ,~4 - ~7.44! Ilowevfir, ,,' it1~ Iro<:I\ono l 
ob,;:-rr:f,;>n :Fi " LJ,',ln e'".,." t;·~ Vl foo, I,m : 1 '_-I ' ob. vell ' @-,. I @-~~cti~ery. do ~~ I 
repre<en l In " .. ""Iu"",,, ef dk t,h It<) ~ a nd c w-o n<"e ,'a~e, 
.1 
I 





A, n ~.,,~·at&el , -, figc.-e 10, the CrrXl> "I elh,-"-,,uJtc< ilDd a " n,r,d cl:,h-iU.Jtkn i, -, Ihe 
, 1o.4y p"p cJ ohm whi 'e the c;s l, iblJ lio n o f H,.. "Ih" pmrrraco kin e jic ",em',"" wm 
,kewed (p<O,05 u>ing Shapiro Wlh te,t for norrrc",:ly d" Vtc'Jt ed Jato), 
15. Th' ";ng le ti''''' pGin: thJj corr e kJt e J b e ,! ,,~j), n'e C"",X W(15 at 3 hour>, 
co're,,~ti"n belNC'en -,o<ur,c of d bt'ikt:cn m,d l,:a.>, I(..:l ', be au" b poor 
chq,ad ... "a'i'", 01 th e j ",rrinol .. Imno/ion CCfVe In 'vbjecl s with a lal e peak 
C0"G",-,/rul;"". leading to 'fC~r''''u,.y b"'j el n'no:"'" co,",k",I ,_ ]h" , ",mg (;(J"ei(Jl ",n 
b etNeen C..,-.::!x and AUC"i, Q"d te a !"IS., r ext",,' '.l!Ci j, em~ct", d; th e'! Cl' e a, 
""'r," " 01 bKxJv"' la b~iy . Th e ne gqrive corrdatiQ rrI ,o f C m:lX and AUC, v,;lh VI ,- and 
CI f' "re . in purl, !oe=",e the cakubtion "I yo l""'''' of dillr'b<Jiic n and cieacqnce ;, 
u rre iab le rrcarker, of yel""", 01 d,jrih ufi<m ane d .. "'anc .... p'" ,e .. a nd are not used 
in flKther analy, e ,. 
~s .... ,-.>J' o,·.~"'-·"c'" ... ''''-. "J.el", .'''''''''''':'"-




,, ' --,---;.----;---.;---;---,.;---;.;---;.----;---.; - "'" 
0, • ." ~~ _ ,..,.-~ .• ,~. 




~ .. 'r~o'''o~, <.~.,~ ... ,,<> ... ~< ..... ~..., ..... , .,.1> •• ,"'~~,""Qb,d" "." .... ~, 01 4""'~W~' .""«,"'" b, ~,..",,"'ro~ "",,'fC'tf,' I" ...... 01 
" 
PATIENT ~ATTE~NS 
certan $L~"'.:ecl' tend<xl to a chieve rehl:',e l'/ '"W drug 'CO<1centrotlonc ()t <nQl e I'''.'n 
ono drlJ9. Fifteen subjed, hod C.,.,.", 0' AUC va lue, 013 Ot 4 drug, in!ho I0we'<t 20% 
01 the value, recorded with" Ihe po lionl cohofJ. The dug co",;en ~'Jlk> n v; limo 
p',-,ffle' 'or t l>:;" ,~ ""'(:;eel> I' ~, ~2, 13 15, '10 5~, &1 p, B!, 92, 110, 1?5, 135, 153, u",J 
160) can be viewe d in ApperJdix 5.2. 
Eleven patiC'nh hC1d >:'['(1' 'CofKC't1lr(1l,=,m 01 ';fa"""';cin "'50 than 1 ~~. All fOC1lle nt. 
v~ l h rifa r!'p;,:,,, Cme:" bdow I mg~, rece rved dfurrvici n e:ooio"''I1g p"oducts 01 
batct1 C:-> no ' uppro','ed b-,- :hc rcgtlblor', cL th co:I, <on 'i',,,, rui ",r phOI""""'0' i' ,ojl:C 
,a"Ting, Th" rm}xity 0' Ih"," patien!, m;Heved adeqJa le concootra~k:Jm 01 the 
at"""' "'" "Y "',,,,,,,' 't " d Pn li ,-.nt ~4 harl (1 pear. eeneenl'at;c,n of etha~bJlci of' ,~O 
mgiL ~iiJ1tfr b",ow lh", 'cnge- e xpe ctGd'","'''' Su tiect 87 hod pcnticuknly low leve ls of 
a M 4 d> ug~ and the eme dc,,,,"vC" furlhe, d ,oJ""". 
Subject 37 'NC' '7 i""r~ co'd \,i" el', ",,,, wCl; ' r-:; I J;ag~o,ed "'ith ,m"a: o"ltk ", 
pu lrronary lubcrcu",«i-I in ,~,~C1y IOQQ, '1e r p,,,violJ, rnedical '-j,iory wcs urfC'm-:1 r".oble 
"",,,,I /<,.,m tr"""t~£nt lor "F"IJtamok o n',,,m'-.' '.'NO<O,itlXlI"y? 'rea, p,e\';o u ~y Sh ~ 
wo, ' Ia rted o n reg imen ' eorrp-i",g ril'.' mp'dn, i>(' niazid, pyra~narride ond 
.. t'"m1""."" Lrder th e auspice , 01 h"., k--CC11 cTnic. Lt "'", .. nc1,.,· Ihe: monti ', ir,t e'-,~vB 
p hmo h"" spulum "" e cr wo, neQa'ive, co pyrozinarride and doombulc> w.,,-e 
droppad trc,~' til ", ·" gh'e n C1nrl "'(1tl1 pirin '1n-J r,,,,n'(dd '.'!a·" con:inlX'd. ~a,/i"'v", ' by 
~ve mon;h' " ,p;!o 0f aw."", nlly ",~c"l", nl con-pliance 'he had gain ",d only 2 kg 01 
body we iii't. Ih '" "'''' ''' wa.' '.'g o;'" po':+ive and the c " llXe grew Myc abac!cfium 
lubercu/a,,, ,;;mitive to rifa"Ticin ond i,0CJ(ozid , S',e was transferred to %3w;;I>l-:loof 
Hospital fe:< " ""xplained tr",a',""", nl fru ure. Strepiomycin was added io he< reg;--,-,c,n, 
Art", 2 ,,>on ll » in i"" !-A I"" when Ihe li,,1 poorrmcokindic a"o,,,renl wa, rn-:xie a. 
pa< I 0: ; i ,i •• 1 LXJy , .1", 1,a<J gained 6 . ibgra"" and i10r sputum we; >t r..,<>" c,," (;ull~r", 
n"'gc~vo, T~c chIQ' we r", \,J i'.- ", ~ on '.m e rrY,>ty cia"Xlch o n the day of PI< ,crrving 
Pifc:n 'p i"il ' 4~,~ "'09 ': l.'nf.-,rt, JI""'''~i in one d bale";;\ ~0: C1ror""j~,:! 10'/ th e ·" gct;,I0·/ 
aulhcr;'yL iso n azid 3IJO mQ, p"-minamid ,,, 1500 mg a r<:! dhambulol 12'Xl "'? were 
cdrrin~i","",d a .' 'op<>"ct", ,;ng lo d> uy fom''''.,tion, v.i Ih a g •. ,,, 01 waie' . Co ncotl. tani 
mod catiom were dairy <ITcopio,""ycin 750 mg inl".'~l"'"h rly, o"-ida <in,,, ?5 m..J daJy 
arid '.' la'-' le i ",r ' or, " -'P I,'.,I" 3 ',In," do,),. 
T" ", cO:'lcent·",ti""" 01 ribrrpic in , ';onkl:d p,,-'Jzinamide ond a lhcmbuto l '''" f""" hr 
<uhi<o cl 87 ore,hown in Ihe g 'oph h ebw (figu re 12) , 
~r",",·,,:n 
,,,,,"''''d 
'Y'"~ ' o:M d ~ c""c'_'nl'o -on "",,,cd 
ov " 1<. -_10- 0' 'C 
,"""',""'"'' 
2 3 .; 
.o t Ihis da,w !he en", TD'Yl(]r'aH~ crne-',' ..."., r_"" wa<; microcvt': anC"' rlYl 
[haerr>:lflOOin B.O g,t MeV 62 fll , wi le a o w se<um ire " I3_W ~moi/ I; nor"Xll 'aroge 
8 .10 - .'OAO: aO.d trcw,/e-tTin :at'_'rat'Gn [4.5 %; narmal 'onge 25 - 45 %), o,',d ncmnl 
, e rum lYamlerrin i3.0~ g ~: norrr.:1 i ranga 1.75 - 4,001 and ,arum fe rritin i8 I'g/l; nc'frCIl 
range 7 - 2'l21_ The anaE'rricl sh"",ed little ~O'.'errto?nt on antihlb ",c LJo;:, thcropy 
and iron ' LJPPiementatioo N<O a OO Ofrr.:1 b >o od loss wm KJentilied, al tf,augh 
;Y'1O'rmcopy 'NH ~ ,y,tr,," '~I'd tunda l b>op'",s tound Il e !icobnci.'r py.brl g.::"Iril';, which 
wa, treated w ith antib"t;.:s and SClc ra/at,,_ 
I he ''''-'Wc' wa> d"cha 'ged tr~ &cwel,~"x' ! Hospital/or a luthe, 6 r1'x:",I" , 0' ,,1"'Ko-
bm.,d i, e Cl men t with rilampic n 600 mg, isO"ia;:\J 3O'J ,,\), r',rai " Clride 1500 "'9 
ufld elr"",,,,,,,tal aoo r,'rg, c,u' rra ,t,eptorlT)'C;n_ 0" Go rrvle l;cy, al ,I'", treat,nen i 
r&'Ji'-'>ej, 'he w m again sputu,-,-, CLJ tU'2 ra"ti. e , ., ,pite 01 good corr~, ance_ rh6 
argeni''''' c LJ tl}(<"'d were aqain ;"""il1",," h i,orliarid and rita rrvdn Sh .. \va> 
continued on 4 drug trea '"", ,,t <1 hospi ta l and drug corlu. "tralio", we'e "",,,,,~ed 
again On 7 occmiom, 
FllI' ,he ' dni c al cl eta ,ls are no, a'!(lilau le, but ',-0 montno oiter t"e p",\-iou, adrri,~on 
,f,e wm to<Jrld to be ' rutum cu ll<xc Ixd!ive ter ' e n" ti'"" o'Qan;'m, oncc again- and 
ciTug L"d; wc< ~ measLXcd " """", th, lat", c-n irW1'c·ry;ed dTtJQ d0,,,,, ""hen ,he; wa> ' til' 
not re'P0nciing , at;,tactorily 10 treatrne nt, 
Drug concen tration d ", I.,TrincH'on '-vo1 'epea;6c1 0.,. tI~ dud., t., (lm at the reque,t 01 
The patient', ""do, on 4 occas<Jr, afte' th e in itio i rr'Jecr;u, ,, rnent,, On each 
occa>icn 111 e dr ug> were giyc n 'O>Iet~e< unde: 'trU "b''''·, atKln . on o n e"'ply 
, toH'OC h a nd whh a g/m, of",aler_ 
The date 0f PK ",,""'rfnoJ ond the cVuq detail<. are ,ho',<m in tnbl» 17 
N,\; pruooct l,a,c ~, not ar,om""rl b,' rt-,c ,e~ .>u l"' )' uort-o' f,; u<'M CS,OJ p'"JJCts ',~'e Ic"" alX""vo rl 
FC'> f~o~ ~ul . ooO't-nct'on: c",.,a,' . d -o"""";O'~ we," ... '" 0 d!u~ lo ~, ' .>u ,'on1 
1;0..'1' I} ~'J9 c",,, orl,a-; on--,., . m","", 1o, du,,.,:" '" '>o<;clid ~V"o'-~aO'<t. cr<t 0",,,,,,,,,,"",.-1 . 
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Repeafed me-osurernenh confm-.ed ' hot Ih" low concentrnt"m were not dU9 to 
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and i'D,'li",CU 11,-· " '~""" '. ' hi' pa tient h<Jo ;.,;,,,! ~,I ~~ -, alh -, r r;,k factor; k);,;',n;"" '"'' 
'""luc" d d,,:g b '"avai"'b.1ity_ It i' po, ,,,,l e Iha' gastrit;., and "' , nicranutrie nt 
d""id"r><c~, CC<1tri!) I.'t" d t" pClOf d ug Clr.;orpF"n but i' the ,e were 'he i'Yf'O"c]nt 
ri e t""",x,ar.h of dug a bsorption one wallkj e xpect rrIO" e patier.t, in trHS cowt 10 
Iru-.'" "'"l ,'<:' i fc, ',-, ccc)[ ,"~nt, ,,I""n:, O'f 'e'",''"<,,'; drug, ~bweve r. ~h" ""',, '~;';Y"''.L I heft 
tnere a r'" c",'ain pa~ie·--ds in whom sta ndard dug doses fajl to r0Clcn ooe qua te 
"0r."""tr"tl..-ms thnt fh" inn d""lwJt" <vs'''''-';" dn,''l " 'pose<e cClr, r e,,--, I~ ;- , t>- =trrKO nt 
fa iure c]rJd dke m e rehp,e, and thai h>g h dme, 0' ora ly arinini, te 'ed d 'ug' "~ly 
averco,,", the rtlCI'~e dly reduced b-oavailabi ity of the standa rd dmes , 
Trte indivi~al pai;ent d rug cor.centra i;"",. profile, over t;,,>a are di-,ptOye d in 
Aopendix 5_2. In ,,-,aCl'f patiem, II, e p ,oii :e, ,,1 11 ,e ri ill",,,,,: dug; C(T, ed'Jibit Cl ,irr, lar 
' hape . whM in dhm c,c c·t.-· .. ':·u< ;c,d k m i, '~'i'd,,"nt. /---, " 'ld",,,Ii ,;! n l: K)(il y 01 the 
conc"Il twlicJ n t'""" p'"fjle; I", rf/O"Y!picin , ~onia:id c.--d " Ihambutc>! ex""'it"d 2 
peak,. WhKoh cO'-'''' "xhibll ""'t .... o-he paTk:: reCirCUlaT'O'n In the cme of rilarrp,c '" ",--
erra!:' : dug abm' pi"-, ,, ",I" irte w;te rllc c l eu",t"",_ 
DISCUSSION 
, .• . .• - - i,on'~' --d ,,·,'~r.arr;d~ and I"", pilorn>OJ"cJin"k chOfac;o;~ "c, ;)] ".orr p "',,,, ,~.", , .-
k • ,. k .. , , .; , ~" _,+ ,., ';~~i ,-,te~,;,\'C 
~thllrrbu~d w.",e dG,ub.,j ;~ a Ill'ge C"" ,0/, 0_ .c'r.;G'Cc"'~" ~,,",~ , >, -~, '" 
,arnrl inij an-:i r":,nc;o"1"c:rn-,,",, \,,i ord -,.- o" . 
Ii the ph,c_nnXlccr,;n ~" ~' cA if," d,, __ C;', hCL'," pr,,'-,>:J,d; . .- h-oEn mecC:--" 'j 'r, G P'lt;,~c' 
co,",o<i of lhi, ~'" Ihe fi,-,dif'lg' are [)Ot in Ill<' pu 'oI'c rlomdn Pubj:", erl dafa an 
ethamblJ!oI level> i ~ pal,>:n' ., " ccpec;ally 'pa"e _ Iho ,Iudy of a '--",,6 =00,1 
c·-,Iablih .. d Ih" exislencc vf Cl m~. ' IY.d pole~li aliy mpadcml m:r..orifv 0; i,-,rJi','<:Jull l, 
AI !v' ,&verc,1 ,_,the- r"hf~, "' -i ","f;~r,j ,' u-':>,", (I .:,t-,:" 2, 1,,!r'Xb c.-\iOl' : H, ,, rl",Cl 
cOf)Ccnira liom rncm ure rJ in Ir." .,!ucJ,. W,", 'O clea '" d:f1e<e,-,\ 10 ihG 'dcoref)CG rur",c' 
rub h h " rl ;" Ih" Ii I",crtv· ",_ Ril (]rr" irl,· (,nn,.."",I'a I""" w~'o g"r..erar,/ bwer, ClOO 'ho.\& 
01 ,,"""'lid, py,a/""lt,.rle a~d ","'a rrbd,,1 \" ,yj" rl lo be hi~or loon th", pubhh<N 
r.,nQ"-' [t.,N--- lQ) 
I.t='<> ;;;' __ 1\ ~'M'r-Kr'- c- the --..o<rr '~ "-"".-JC1 '" '''T ,1-.., "0'" ",,,,,,,,,1,,,1'0--,, of , '- ,..-r~ oC>·, ;'-O<'uJ.d 
~y -o">rr''-o . ,,,,,, .j",,, ... ,,,--, .., , .. " "",X< "c'" t 
varbbTiv I,, ' within ;ubj",d cj,-,_y_IO_"Cl" v,,,;abi ily) c0~\,·""rt",d ",bs i'lf)lia ''1 Ie fuG 
vm"t"", Gb.\er'V€C 'oetv.-een - ,,,,: ..,-.t, C':Gnvarx+, rYlO,t pati..,-,h llchGverJ aooqual", 
or hi gh ce>ncenlml" ,-" c f "or,ialid pym';mlrr,jd." ar,.j etharnbl!lo ' corrpco-cd Ic 
E' lim')ti·~n 0f s)"ll"rni-c: rllanTK:ci" I,,'--'''' ~ bv QUur.ri1icak~ 01 rilarrpid,c ,~ Lo,n" 
co l",ctio~, rnay prvviac a ,r:;e'u l ,o-e",n't1 g b d IV' id","tify~, g pllti",-,f, w'th IJW <ovel,_ 
Sblaliy. vi~!Cl1 il ,+,edivrr 0 1 urine wi lh compo.,,,,, ,, 1<.> u cokJur c:i1ai wm u;e;j 100 
d""t,,"c~ng lr ea lrn«n l ,xl:-,,,"',,;-,c-,, " Malawi' .c· HONe',,,"', " ong' e pbm1() 
Cone;", ,',alion af:cr I ho, K 'efl ect" J (;, n::lX a~J J', lie va" "" "' ... e accura:cI;, DuG '"" 
ot 
ii,,,,,, con, I,ainls 'be am", "I, of \irirx>r\' i,on>cdd. flyra.:" un-roe and e 'hmmu 101 w€'roe 
rei d a le'n; ne d 
e 'e Q"'V Iha.." ~nd", cW\l rifarr~';""' - con lainina prod ucf ba ld,e, Ihot 'Ne!e not 
app''(l v", d hy the re gukltcry outboril y hod ;" Ia rier bio O"voilob i ity , Irrp ortort!y. tbe;a 
batche; ,;Cd <.J~>o lu t i oo p'otiles In linD ""In the '~ PlJlatS(j "EIq ' '' '''me<1 t, o~d had 
undergcne, plJtath,e !y. m '",)' rrY$I'k,,,h.in'l c''<>'lge" iApp"rdiA 8i_ I,one the",,,, 
V<YV >CW r~arrv-cr conce,-trotklns were a';cl cJe'''Cn ,~al ecJ in 0" ." 'h ,tO"~ I",1 
propc-.-ticn cf potier " who r" c eivecJ f,il y oFT'fOve d bot"he" ond thefe ;vq, wid e 
vC>"Qbi i ty cf 1'"" 6fO"rrop< " ... le ve~ orr<:mg,t fXlti e~I' receiv"g ful y O"pprcved batche,_ 
Whi~ ')I'! """"'" ,::tug e-'pmLWe ove,- a >i~gle c:k,>ir,g ;nte-~_'al " .'''' ace!Irate-l/ de,erbed 
10; rilampic" and i.oniaziJ, the :::O 'T e ntrali<.,,--lime C'lJrv .. , fer :,yrc7in"moo and 
",tha mbutc-f r""Old mare ~.eav"y on .. xtropohFon due to a re!ati·,e l'liong hdf-!:ie aLd 
late Tma x. re'p",ctiv,,"_y r'QncQrrvart""""tal onClly,;, rde., lageiv Qn th e 
rnemurernent ,~f ad'_"" j'-,g C'c,nC'"," ir''Jl i,,~' r .:lth~· ih,,-. prcodi:: li"n e,1 ,-,onc"n~a '",n> 
lram a modeL Tho,;;, Joe,,"" """aO)"'e, contain "O"obm y Clttributabl€' te the 
e~pefi m,"niO; O&~n rot het then ,,,dily Fer a~a rn pla. Cnn~ i, refl",ct ed rnore 
aCOJrutsl/ n pat; ",nh, """. 0, by cllO"nC' e, ooc',.""" ,',,,,/mal ,y, tc,mic dr~g 
ccrcertralklr, Clt a ,a~ing tim"" than in paF,,~I , who aC'h'",,,ed max;,,"'; drug 
concen tratian> b "lwe0n 2 sa""" irog ti""",_ Th .. reiati",,"y in'"",.,,, <c nVIi:-.y ,d>eJ.:le 
r" dcJeed thh " ""'C& 01 ", ror . V a iotio,-, OvC to """"" in-.:.nlo , erf'J1 "'''' m~i .. ,-; ,,,d b y th" 
use GI stQndcrdi~ed proceour&" but can nover bo cn t,ely exC'h-Jed Mere i ~Clr lanl 
Im i!Cltion, in dc,,,,;bng d,,-,g c.xpc"u, .. ,"'o t " to !he '-,uc"';'licah,- 01 cJ-L· a 
ccrcartrcticrs C<\ a singl " ClOC::-O';O., on ly Ii .... inlrO"-i.,divid.:d "",;"'1 . ", wc, '-0 1 
qUClrtHie,j l _ A ~o conconlmti,,-· n-,.,."" 'r .. _~-p.nt' W""~ i n-; t~.-j '0 ['i"""" in ! h .. oy>lemc; 
circ"btic~ I ancJ «ine, tor riIO"~-pi<:-" I, .,.,h'e the CorlO","ll,ulic", a I Ihe ~ I" ()f inl e ctlon ;, 
mcre dirc.octiy r""vanl 10 (If'',,, " Ik aoy_ 
Petient and drug prodllCt lodcm 0.I<06" ' ,, cJ '''i lh "", iatian in th . cJrcg ox", oc .. "h""LlrlO 
ae exp br " cJ i~ th e ~ext chapler Th e irnpuc! 01 ciru\! = noan lrati"n !re p.--e,ertw by 
the C rnJx, AUCt <'''''' AUG valu,,' fa euch ""-'9) em "ee,,,"'n l re 'P<>rl<e ~ r",ported in 
Chopter V, 
_ '8 _ 
IV 
PATIENT AND TREATMENT FACTORS ASSOCIATED WITH PHARMACOKINETIC 
VARIABILrrY 
It dl, ,leo.1y n,,;;),;,rICl'lI ~a,"l:.Iro'y 0<. .. ..0 bel ...... ''''n the U.-...y con ..... nl,onor» ., ooHer", ,I 
irov,dUol> I: ,'''', it may b., u,e'ullo d.,te'mir·" Ill" <l',o::;io\io" 01 lho.> ~<)nob:i ~y .... l1h 900;:1, 
Ide"'l.foe~ =voroatt 1octOf'l. in :hil chopt .. , ;v"f1m::rr,r ,tali,liu of pat:.,,1 0'10 d-vg 
cov.:,ri<:l\e fodor. ;" Ihc !hldy ~ul(;llon O'f.- p'e,ar.~ed , l;eto.-a \i'1ccr ¢( log.ric mlAtiptG 
'egell'o., ~od:;'_-; jelC~b<r~ ' 1'10 eovaiol e lad:;,\ acCOCK\t;'1';l !¢( tile '/arid;:ir- { 
ollt,cl(l t",d wilh \h" phar'Tl oc()~; rel:C m"'OS <..("'1 o! ,,(leh drug 
COVA~IAIE5 
;m 1~:! PCl:'::111~ ' .... ith d'\..CJ-'-0~ti,'e h..be'c,-,I~, who ware a"Ierao inlo Ihe ~'v.;/ ,-.. e:" 
::hcrT-Ie!".::e::! ==d;rg :0 11'1 •• too.: lc", r\l r j II' 11>:> ~u .... "ory l<>hle hPlow (labl", 1)_ 
"ol'cnl d"m<Y:'l''Jphic I=t'.'~ d1rtirY" C""Id "".,..if'''':! haN!, 'J'1~ tr-alm"rt ~'IC'ri"'S ,,1>(" 
obtolned hy m"O"l' cJ a , tcr<Jord q~~<.l'1r<)'" ccmold....J by \:,,, wor<J docte<. AI f .. " 
,(II"" i"I<t'''ltow, (".'>f:'H"Mm.:rlely 2. mor>lnli oil", vdl,.. ,~e" ;0 .... e I~pilo·._ pol,~"I. We'" 
w!iOli""d o 'ld 'he .. I"",,,hl " ,.,owr"d. Blood 1,,\1, 10 del.,.-'Tl ;"" Ih .. c l, em',ca i pol l'>O!og y 
ard hoar"ola<ogy pw fi iH, a' w"", 01 H I V.i~t"c t "", ;\0IU1, ",,,,-e d 'OWI1 01" In,;, cIa-,- o f 
h!ooo lorrv li~g h r II.., phQrT1(lcok.l'1!; I, c f"'K) prdile, of 'itQrl1p ic ,r, ilOl1kUd, 
p,/.o::!raml"'" (jn'i "'!I'>'J'Tlb<,.'lo1l: morl~ ' n'i .... o+ni .. k:>r to Brew~hrloot 'kY.P'!O'! AI Iii", 
$om., 'i.,., ... ° blood ,ampl., wO~ d'owr 10 delermr" Qc"lvIolQ! lyPti 0 " 10"'lg:.1 a 
Ivcgroup 01 po~.,nt. T·,,,, d'UC dol..,.l ono:! drvg 'or-ulo!'",,, de-I aill wer.,. oblci'l\<d or !he 
day 0' blood ,omplirq for I: '" I>t( r .... ::lfile\. t>v .,. ' omo-""lio" 01 the ;:.oI,.,.rM drvg d"" .. ~irg 
,;i;Qt!I. Woe jr..rg d'p.ar'.;,rg cart, ~ lbe w~"-' ord olrecl ubl6r'lahor 01 Ihe do .. " 
admirislered. Ihe "110.1" datal~ reC:lrde<:i "PCI, l::.r the <l.-.yof P( orofi1e IO'l,pli-lg 
c" "''' Inovgll ;hey to ad 00 .. " t. .... ' I.,r;I 1<)1 I u/.>erc,," O'oi:. in he,,,,I,,, Ic. 2 ~nlh. ptio< 10 It; ... 
• tudy ob,,,.,.,,o lb,,,, 'Tlory ~oli"I1 IS hod c n l~c(ll 0"Id loIx)"O'ory l"'a lo ....... 1 oIly,'e"~c lin"" 
,"~d chrenic i'lkdon, ir", !uci~ 10\'11 b<xI/ I\ 'O\\ indire" low Cllb'~r,,;n, hOI!r11ClQI<.Jbin c~d 
:;rcol;":ne !avel<: o "d ee-ml"d told proT"'lI ... ya~, plalele1 cour t. and erlthlOcy!r:! 
~ .. (jmtlnla;i"'n raj"" I~':;;<i . Ch,on,c, avg e>'p:»~I" "'oy b .. oartly 1"'jj(>r~bIe 1=.0- Ih .. 
.,.j .. ~ol\<d All "'51. AP und rG1 !", .. ei~ obse ....... tt inlh!< ,tuay cahan. 
' '''-,,- i 







Ne w .. _"ji."t N'", n,,, ,~"d,'d I"" Ih,," 
one •• ·",i~ 01 T~ !'<,d "" .. n' p"-or ;o 
aj- j, ,;c<1; , et'~a. mo o; p...'1i: ~" i, wi'v IKJ<J 
I:>e~n ",,"'pc! iN T~ "',,"'" "'Y. 0( 'cc,,~·u~ 
! I m C<"1l'1 0/ tre atm~nj prior 10_ odrnio>iorl 
70 0...: ,:" " ,,::IOj8 p/" e nvtyp, w'"' th"'~tore u,ed n 4 
" tup<j ",t;..~I' Ii., prt~r~';""" a n d u~, ><>fy p." 
~V:I "'""" d , c« c'<Y1t: n ,h",~ erne, IN; 
'j~ " I. ~ <-1 ects Q el·.ot\'Tj "~ wa; '_x",.oco~"tc· 1 
ffY-frl~Clotl:~ __ i-'~'~'===~s,":'C'~i':~~';~J~E::: '~:'~~':~~.~ .. :'~:~':"~'~~~~~===== n Meo ko." 5~ -95" c~ nt"": 





53 _ 98 
68 - 9' 
24 43 
.- ~ 
11 _ AO 
.\.'l - 150 
, 
75 - 115 
~-'~}--­
~5 - 5() 
1 _ 25 
_co- ,t" ,'." C~~ ' '<,d ;.,hc'; -,- c.;.b',.; ' ",ili-,,, _ :>. ,~_" c' 'co ",_,-c'",,~y, r"o,, !-, ,>!llea;h S~ienGo" 
Un'vc'S;ty of Cq)O 10 .... " XX).3. 
, lor m-,a loo no:.< "ncw,", tor 4 'J '-+;ol' 
:.4 " .),,~,," rc,,,iv,-,j ~ 00:( .; d; ,;J 'i fao-r."id~ tc,,,,C~'1t:CA' Ih.:t ""''''' ~c,1 ""peG 'c d C" ,i,~ ," ~"~ "I ""I 
outh",;ty '" th~ da'j c< PK p.c',," oko"'mn oh'<1" 
, 9 ,"b:"oll ",c~;,"cJ UC ~ • ~~irn em ~liK'JI ~lrcm",,-,tcA 
t,.,,,, 1 01 the c"vor,ot " fo c.; IUI vO l"""" huu " \,ew;;o ,blr.b",t.cm II", "",rrib",tKJ'" of 
olbtllllin. meoJ) cell v..,h.m ... piol",~j count or"; th", 6a",; pllt hlvg'uOl oj i\.Cf1\(,zi ci 
p1;<~lnomdv UlJd dhomwol w ... r..-.. ",.:.-.. (IOImllily UI.frl"..;ul",.:; ISl,OPIIO N,Il. '" l",sl.,.."u, 
o p vdu ...... :l.O~I _ it>", Chr r ..... l JI·~·;.)1I6 ..:md SPOOllrlO"-' ,,,...,, wa' e ~d to ,,~plu,6 II"" 
' ",:oti~mbP'> oe-i .... >oen me C~, Cl riCt'" f=:cn: me t,,'!nn, a'c i; .. ,\!..:.tud:n the !..:.~e' 2 ... Jt'd 
2b. 
-;P, ;,. MlG<oO' "" mrr-", aI pal 
·~Idi .. nI.,. 
- ," "" ... " 
, """ """" 
D<Jt' tI'~ la,,~ ~"'"'" oi <=-.... "~" ... 1.-., !~e <e"" ".", ..... ,..,..,., " "" t-l".,n'>lJ <,Al'" '" ,h .. W"<i"" 
~,", ... ,. «~ CO" ~n=c" -r<'h" I~ "'" """"Cl,q ~ .. , I> 
! • , , • , , , • 
~.~~",. "" ..... iJ S ~ , , 
" 
, I L • • • , • 
J 
• , , ! I if • 
, 
I I • , j • I' !' l , , ! ,i • • • • 
• • 
! 
1 • • 
I 
I 
"'-, --~;: ';;; ';; '.~o ',~ ,,~; '::; I -:2:: ';~ ';:, ';.;; ~ ::'.~ -;:'; ;,;: 
,._'1' ., __ ~, '" " " _' , .,.- ,_" _0'-' ,,, " "" 
,~, '" , ., '" ,,., I.. ''', • '" " = 000 
' Now Of ,,,"c,', ,,,c,,' pot)e.ot "'; doli ',oJ :r' -ct·, c 1 
, ''''nl '_I.a- i ~r botc he, ~.,,"~ (i ,'. ,<:1 ,>OJ ",, ~r"'.' ·o d "'I the ' e ~palory ""th'<i 'y, a-- ± "r.e c " Ic!oi , 1 
• ~,. ch·orc~ <:~ : K\-' -<-1e" I(.',1 ~"t;~"" ,~ c e;', , '" -. ',r-"" c", 1';(ffi. I """,,, 
T ,... g_,,!]; A"nc'ot",·, mai(;" rJ "0~", n c hc,,,;,try a" d hoe ",,,, o+o'-! , 'e,h . <1"*."",,,! the , tet" lic d " '_~ " ' :' C>" c" 
Of the rek:rl i ""~ •. '" 
[] p ' J.O';;) 
C J .O~ ~, p<J.F\O 
L~...I SDQcrme,,, ' mrl cwelu' or" ·""CO L,cd r r ei eI ~ er,,;, e ,r_ .,:r"'J: r",,"aLC 
1,,"-,"' oJ C," p · /a Le 
" ,,,,,,,ill,-' 
rjc~ - ~ e " 'Qe ,,-,,",be! rJ ~(_ , .. ,-,cr"' '' ' 'M~" " , >'.""''' ,die"!'(¥ - ~I.-.- it " ~ 'ey I~ '" lOme o' II "" w.-.-elko, 
co'" I" i"", "'~ ,hence h>CI'1 ;1' ir .. ,-, p,.-'cC: ", '~'"'P:~ ' 
c_ ww. < , I 
""' .~, • , , < , • , , \ , ~ ~ ~- , . • • , • ." ~ • , 1 • • • • • , • • , • , 
,h" dUlibul i(;n 01 fOO1;"nf agas was 
c,,-,m;,r,,nf witll The noh.,·a d tha 
bbercI .. 'ry-;'. palr., t po<oulo' iotl , with 
and 
comp'; ~"1.l th .. mai".;:!'/' l,jors r"mo:e; 
[551'01 'he>"! ,,',ala, w"re e,..-ry! ed itl Ih" 
,tudy; e'pecimy a",ryng,\ The Y'-"0noe,t 
ar.:! alde,t ryt th2 p:::lfioo\>, but the 
d;,trib',.di ,C!/l of til" ,Wle, wa; 'iml c.- h_ 
rnost age groups. 
~-~",,, .,.,.-------~ 
r ,tOQ'ra,n ",,,,,,,''''' tt, e 6,lr;bo.';;,,·, c~ 0,;,' 
,>" ~.,.,,, ... ;; I~ ,ex. " :'H ' \''C!I ,c·,,~;e 
k1m1 poknb in t ~" ,tudy p0pr.Jo lion 
i,ad received m".-e tho" ryn-, "v:'nth of 
a"!iiU<J",c lJrm~ tr201me"t pia to ' ileir 
od"",~0'1 !,,-, 6'ewehk'ryDI He-,p,!ai 
~etr"ot",,,,,t patient' ;,od lower boJy 
rna" it'lcj'c;", fp = 0,038), ALT value; ip = 
O":.DG ,I ana AS; vaiJe; IP 0.0331, '.1'10 
li gher do,,,, o' i,oniazid ip = 0016) and 
rilompicin :p C.046) Ie:; Ih"ir weigllt 
them patie'''' rec;u 'finO e>"!tiilJbercu'o~; 
I'"olrnent fc, ti,e f:"t time The 09" 
c1,lriouiion .( polienl, 
treatment for the lid tim" W'-" bin10daL 
,',illl patients ciLJ, ler "d 'rfl er.l ly and la:e 
The ~"'Ji'C!rity (53%) ,,-,f Ihe ,Iudv poti"nl, 
"n::Je j c;iQ:;rdt oc' and con,;umed 
akohd 'eg',.'Ico;ly :n t he year priO" to 
n",ii i lC" ""0kd ""'" dran>' alCO<-101 
rc;glh x!v ce-n1pr;,,,d 24'l'; , Wllikt ti,me 
who ;moked oui d:d noi drinK ,,-,ou:c.-Iy 
r.Kce-lJrl:ed fO" 17% and th-,-"e whe-
dr"'~f' "'V';10 ' reQ"-.~:)r l 'f bJt did flot 
,,,','*e o.;,;c;cU'1ted lor 670 of the ; tudy 
~"pJ LJt:m. 
-", ...... ., 
male' ip O.OSS) <l '''' ;~'ot:cnt' with 
total c rofeir, p ~ 0.04 ';: 'ow ClIh'lmin p -
0,[:(10; low h~mo(.Jhbin. p = 0.020; 
pla~det CClK1t" P = 0.000; O!ld incremed 
fSR, t;>" 0 rY:(1 ) h"d lower BMI,. 
,G 
Lower BMI, were olw c('neloteJ -.'>'iih 
hidler drva do,e< rer '+>qrom [D = 
O.OOJj, In odd!'"", fl.'.',1 '.'lOS rositiv8y 
c orreloled with totol bil~l.'hin ~ I T ancr 
'.Irea anrl negatively con"ated -.'>'ith 
alkaline; pha'pl lGla;e aCId (-GT. 
Onl\' ,8% cI: the 93 P."JtieClts with known 
oCetylotor t\'pe ",'O,e , ION metaWi,,<-.''': 
-.., comrori.or, to the 35% lovnd by 
Pork;" ct 01, ;'1 or,oilwr '.'ic$terr, Core 
popu1otion jalso wiih a predominonily 
rr" ved-ra"e ancestry but well "",O<..,]h to 
be treated as outpatient, altef an irjjial 
to 
G 'OouroDli co ','onolim, withn the 
rcgiO!l, In 1rI<' dicltJ)(Jt:O;'l of the 
uenctype, cood exdcin the difference 
Ilow""'H. tho; 
in:ormodiate and rapid o"et.,-Iafo-'. a,o 
mor" ~i'0Iy 10 b,. homitd ized CO!lno' be 
excluded. 
AnJ;bcde, to 1·lu"'O!l Immvnodeliciency 
Vruo w ere 'ovnd in 1M of POt'e.-1t, 17 
fema", ond 7 flY.]le,], I nV-i'llectiO'1 W"'; 
co<r'Olotud \'1:th r,nr,-Irnoker ,'0\<-'.' 10 
0.022) 'Aore II IY-infeded "-'bjee!> were 
rece'',':ng treoiCYX'n' for tho fi"t time!p = 
0.021 ) ood rbI' ::-I1ooce] ncne received 
onlitvherculoli, r<ocJuc ts Contah",q 
,ilampici,', end "cr',jedd 1'. ccn,binat':-.)r. 
ID = 0,04,,)). ~I() roti"."f ,=eiv8d 
ontiretrovird treatm ent. 
,,~ .-,. ~ ~ . . '--
HIV·infecl ed DOfient. hod lowe, CD4+ 
c&1I COL!'1to ip = G.003j, whi le c&1I CGU'l t, 
Ip = 0 ,0101 ;Jr,d ':>Iot~et COlJ01t~ !p co 
0 00 11 , FSP ip ~ O.O,n) anrl mear, cell 
volumes Ip = 0,0001. HN··infedion 'lotus 
was Clol cC>'Teioled wdh Broil. I·IIV-
inf",eko paknls \prxkd 10 '''';;E'ivp 
, lightly Iowa rilam tidn do"" "'" 
" ilo'l ram ~I boov \"Q'qht :1O?'>. m g/kq 
VI _ 10_98 mu/ko, p = 0_0681 , 
" 
,' .... :;\1 -icj'.>C" ;~ I !'/<nfec le () (ToG ~"" H \/ n ecleG 
I-'u:;"",> 
<rrletir;q SIatU1 
haem oc>lcbin, non-omor9!'s ter..rled to 
b e 110',<7 a bimexla! hoemc"I:l' vbin 
ci,trib.Jt 'on 
with a rrend to irv.:remed haemoglobin 
in 0 go'!." of ratient" Tn", died ,eerm 








Dr.Jg dOlE'S !w:f; 'J,tE'd lor putiE'nt w c i!Jht! 
were higher in th<.:he with IO'-"er f'./;\II . 
and ('orH",por"Ji'YJ~'1 tcnriGd to be 
"orrd aled w ith inrlicators a t m :x-", 




a lrd ine 
pl ,mphotme arLd I ba"wr;J d l ',al' luut''''1 
d9Crel1<;ed M_; lev" I, Irx r"ctll:o rio,e s 
kihg'arrl "fampicin and 
,,,),,annam;QQ w ere msoell1ted w rt h 
increm9-d l'-G; I;,-ve;" AI" ,,,;I 0<, oatknt, 
recei v2 a a 'iandard 3()J 'ng dCN' at 
i>oniazid; h &l lee l em de, "',ad ::: higber 
rio; ", p€1 Ijlcgram o f 8 00\' ., .. 'C'i:jhl 
[0=(1.0041_ 
i- illy-Ic<! r [38%) 
batches c-f ,i"!i'~' d ,u;J lo""'_':alio,,, of 
ri'l1mpiein tm] w ere not app'o',ed by 
II",,,, iv',ed;c:ne, Control Council of South 
Africa, em the day 01 ohwmacdinetie 
mmol" IO_ It j, 1101 '-r,c-'Nn whetl-,.",- tne'., 
reeeivpo 111e non-aop-G','ed batche, 'Of 
the ourl1tior. of fire', hmpitd adrni,~or. 
S,J,.:;,equant "mart'si' o "mon,tm,ed tila, 
lower ri'arnpi cin ::'bod concEmlrations 
were a"hieved In patient, who were 
dilp03'-" "'O t,-,e non'approved bawl-,,,,,,, 
and it i, intere,ting 10 note thot tho,e 
patient' who rece ived the dme' r'arn 
the ink' ,io ' batches or. the riay ",I PK 
'a -di'1g also !ellG2d tC, I',a-,.-", lowe' 
w.;r, __ hoomog!ooin allri bilirubin leve is, 
,:md t-i9h<.r putclat ccunt, them ihmc 
',".' !-to receivBd fully appro',ed prc-:Jcx;~,_ 
Thi, PU"jl:;.;-i irdicata, tnat tno,,,, who 
received tOle infB'ior bdehe, we<e not 
rmpondir;J to treutment m well us the 
other pa tients. However, rhe trend 
<could aba be rebtcd to tr..:.· ta c t that 
patient. weighirl9 < SO kg iwith rEOa ti,'ely 
bw B.'-.il,1 were """,e Ii, ely to !ec eive t~ 
nor,-approved batche, Ia-; the rY)I"1-
batche, more 
CW"lverlient for 450 mg da<e, them 600 
mg da<e<l_ 
then muia, i30%} rece.-ived the rlO'1-
day of pr; ,m,-,pl ing ip~O_0 64}_ Thi, COrl 
be e"piair.ed by dillerent ward ,bck for 
the mde -:md female w ,-.;-d, (md 
the ,ame ~xed 
cornb irlCltiom of rifampicin arld imni"zid 
wer~ recd,ed by 16% of tamale, orld 
29% of rnale' W"l the d",y of PI; ,,,,mpiin9 
COrlComito~t illr>e" ond medicatk'", in the "udy population are Ii,red below It"bl", JL 
Ai ,ubject; 'eceiv€d ribmpicin, isonblid .. ond pyrminam de. and 132 :93 ~';,I received 
c "hurd"u;d ',',hil., ,.,-,Grul drug dr...JQ irlteradiom -'fiith ih2 OIltitubHCUa<i, -"gerl;, CQuid 
b" "'rlticipated. few wOuld be eY.peeled t", "'ffec; 'he con contrations of the 





' te~hmyc n 
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THE RElATIONSHIP BHWE~N COVARIAT~S AND PHARMACOKINETIC M EII.SUHS 
f~!'gre,~on o'lCiy,e, ',')",e l',,-,d Ie <",pere tho "lllue",-;e 0,' t'1c pal'e<lt a.-.J dlug !ad~r. 
!i"1d""".-,0ent vari·a':ok,) 0'1 II ',., phrmm;aLirl"Ji.:.. fl'>e''''_~'=' ,:Cmw, A,UCt. ~.lIC' h'uJ( 
lag-time o',d ..,('/.t-lile arid e limirla:'oo ro te coootc:ntl 01 'i'umr+:-;.-, ::aniazid, p'/ra:i'l(l''' icJe 
and etr.C1rnbulol_ 
yea"), ,ex 10=femde,; 1= m<:lit,'i, 'mc,jrg 'N ;Ih n tho-:' v'Car prior to admi"iorl [0="0; '=Ve"), 
regular abJhol c0Il,ump!ic<l ir H',,, ,'eO' ".-I<;,r k o.Jm",~Qn IO=r.o; 1=,.-e,), heatment 
mc..-,th; 
\ =tel teallll"nIJ, HI-"-,,',Je:J;od iv=no:l=ye'i, dn'IJ dmei,-g Imgikg), lormeJiu:iV!, 1-,-"., 
IO=~rlg'le drl'g lormulaticrl; l=FDC), /--xmu:atiorlO 'egu:aJ.-::ry ,tatl'S IO~r,-, iy aPl-,,"o,.e.J; 
i=nvt apprvy"Ji, """Iylwlor t,pe il'or i,OCliGoljd; O~'low, i _,i"tcrrnediate or 10511, bod'y 
[II), wce fc d , A 10'/:), ,"ah::ld cou·,j fA 1O'/:!, ESR ':'""'), CD4+ c"I'/mm' _ Wherl Ihe 
;nd!'p"ndert Cl' dep",nd",nl vanod"" "re-", did-.."Iorni~ed . i t is descr'wd ir tr.e text 
~O a.oij ckc:'eme, ill the 'ampe "ze amlYl.eo ir, jI",. r"'gr;;";'71 alai--,-se" ar.."J re,ult"9 
1m, 0: pov.;;~, c0rklil1l'11i'~rllJ val"es wge repbced a' de>cribed '0;010-'-", 
Age -.vo', rDt knew,,, ;0- ",--;,e le,-"al", "Jbje-c l: Ihe ,,, ,,diG'l ag'" itx that ,e, · ..... as ,,,,,,,,led 
fmed'an l€omc:lE' auo: 36 lear,), 1h" jyxly me:<' in-..--JE'A is,,",I) wm rn"-ling b, 21 '>UtJjE'c.ts 
Ir." r",:-:1io" ,'-'x ,p~c'I' c tJ...~1 'hm ,-,sed Ie) r('[, lacC' th-C' 'Y">sirlg ',alue Ii" ~-':.JI~·, 17 6·1- " 
le male, : 8, 701, In tr.i' 'i,/o--,- the i",'kJerlc€o 01 '€ox ard Ro-'I -'l1 tho::- mod,,1 melY r..-we bE'E'n 
lXder,:d;mated, but there wac yr",,,ter pc"",!, to dotec: :hs i"f;CJ e rl(;~ 01 t!w rC fl"_"" ng 
vaooUe, 
The rd "I 'pu;" .~Iy ,i<j r'ificarlt ,;;,,,11, ;, 'rlcreased '''hen '''or\, m>ClI\'I ;;' 01';; r'"r/crmed on 
1'18 ,ame dolo ,ei. Ihe n,k h·,,, Ix", ,, oIb.A b y I"e r~ ati'/e!'f strid "y rlilican~e 10;'1""; used 
who;n ,e;ecing covc:rnte,_ 
" 
RIFAMPICIN 
va lva, were Iram'crmed laking Ihe;' I';uare root 
Iratl\il>lmalioi' \'va; Ihal rneanil1gfu quanfifiea;i,m of I ll'" "'ffeef of th", cv,orio;", Qn 
Crr'QX woo not possible. ;"ltr,QCJgl" II,,, con lribvl ion 01 lolai bi, r"bin 10 Ine mod,,: w", 
,iQ:lir;c;or,1 (;1 a level of only O,Obb, ;; w"" included 'I" til,. n'Cd,,1 "" il made':1 ,ignifio",nt 
contril:u tion if pot"n li",lIy inlluen tk,l ob,e~JoEom were dop;::ed_ Table 4- 'LJ('lmQri~", Ihe 
::r ',O;C>' rcgre",ol' cquo'ion dce,,,:'ibiniJ I h'~ \:;ua,-", IV':' I 0; CnXlA, , I '''' rnod,,1 accounted for 
28% of I"" wXiabJ: ly oberiiOd ;cr the ;quare 1'001 01 Cmax, f'ol ien's who reoeived FOC 
'o-rl>ubtions c~ 1)OI1-0pprVJiOd ba'(.he, d rff·omobn ",+,sule, h·od Imver p"aI< 
c oncentra'iom of rifo~,pcir,_ be , ... "sene" of HIV-ir,fect;on, 11)01" sex, lower 














" ,'. -. 
F( 9, 1281 5.72 
~."p~ .. ,1 -C.:11'!h~ 
Aq R-"'l'- JOcc _ C_?,16. 
lhe di'lerence, in Ihe , .oed< rifampcin leve!' ~;'f Ine IcrmUKl I;on 'ype iSO '-" FOC), II ,,,, 
in ligL.re L Th"oe le'/e l\ or" nQl aqu.\'Bd fo r Iht cll,;;!!' cov:xiai&,; "&n<:& 11-,;:; m&dian 
C, .. aA for FDC, i, il ighel Ihem thai of "'ogle drL.g formu a liom "lofer' Ihe n;}!l-qpprov"J 
, ... oduct, exe inciLj.:J."J in II"" wto ,,,,I ii."" i n"re m e 2 eUtere,,1 dfccll within Ihe lingle 
::rug to< " lL.~a:'o<) VOJP: approved ,;1 'J! 'd~'<J produ<:. Is had gr"~ 1'.0: bioo-,o,laL'-i,;1' than 
FOC" '''' ',iie the n (1n-o woved ""'g1e d ~",g product, had reduced b:oa\' ailob1 it'y'l 
'" ' ' plot, d' rilcrr.r;c<c Cm", I"" """.j cf,~ d=='c,;,lko" "" cr1d f<I " i'/ ed"" ,Id,-" 




~ I I ,! I I I 'I :1 





u" ,;",,- 7'''' '5'''- M'c->,1<Jy 
,')b,t;luli ",,', o f .AST 0 00 A L T b y the reltic (',I A <:;rl ~. l T \;"ld",<.1 '" ~ 1~J" tj,/ , t'onger m od",' I tdo le 
51, and ex;:Jbt"i<"d b<>tter the r"'a' b "rip (11 tr,e 'ran,()rninme, 10 Ihe peak ' ilarnpic;n 
concentration 




!o:J c,~ _.~ 
AS!} ALI rat", 
A'O...mn 
Haem~obin 
" l'/ .. ;'LJi 
>2.2542 
1'):.5779 
, .'" J_&&:;;; 
" ,5.01 ;; _ -<I , 
N.""hor " <t., _ ; :;" 
I ,~, , - 65. 
"rob> , - 0 .. , 
When th '" independent vCl"i ab l .. , t(1ta l bi li n.;bin. AST Al T y-GT and ~, r w ee .. d ic ho t(1m;,,,,d 
occO"ding to th " normal rano'" i " ,,"I,tO" g-eotcr than th " up P"" limit 01 t he normCli ronge 
were a c,,;:;nec.i a ',alue o~ 1. while va lue, Ie" tha '1 or equal to the upper limii 0: the range 
were ao>igned a va lue of C) totd bilirubin wm tmm d to c O'1t'hcJ te 'i ly1iTicon~ .,. to The 
",ode i. buT AS! crm ALI wen" not in'PY·".:mt i;'ade &1 The o ther vemabte, cO'1 tflbuti'1g to 
~h e mod el we ,-e the ".,,....'" a ,...,j nod ,i n~ IDr coeffi ci " " ' s to tno model deri~ ed wlwn 
T."~ .~.:. I " ee, '''~'c,.'''' cnay<-j< cI c0V"'c1~, "" 'h e ' e>.", e ,,,,,, d (I ~I'l C'e"",· cti~~l d ",,,iw-J 10' " 
t;nrub<1, lIil IIU, ,GI md AP 
Sou co " 
, 
.'·,vG": ;:o,n~-, 
~~""t"j $(l.b';)b , ~ 
T 0-'" . ~1.5!!9 ." 
M ....... ;" 




for"!c'_-J 0" r~ 9UIC1IC<y '!..cr " 
cod",,1 
.~,.\ 




Nl .-n;bc, cI obi _ '; 38 
r: 7 1:;0: 4.82 
h ,*," r ~ 0.00:-" 
~02~2 
0.0 1 '5 
-1),0148 
Logi,tic rc",,-e; ; iot', ar.a.y ,e.1 ,., ,,,,e usea to a "e" tne ri'k at tributed to covariate bdor; o j 
iow ri L .. "picir. p e,', k concen trc, tiom 1< 4 mQ/ I: YfJ', below Ihe re ferer.:::e I<1roge o ften 
qrJOkd in II-e lit coro!L.ore"'·",1 and v<''Y iow ritamr:i ci " peal- level, [< 2 m ';1 ..'"! TIw r:-I"its::rrc 
show n in to b'e, 1 and 8, re,pe cti~"" '{ . 
I "'ft '; '_'X.'il li-'c reg.'_,"'" ""01",,, of cOYClrk"e , Of' Crne., 10 d . · ~,rnir", I~ ,hi< o! I"", riIClr"p:c; 1 p~,-* 
c(>, c"" I, a I k>-" 
I. '"1;" tic ree;'~' ""'" 
lo-;: 'ke lnood c. '0 " 0-18 
" ,~ " be ' (J en - :)!) 
if< ch21SJ 
hob> 
'mO"'i'~" ~-~~:=:~f=1I=r:F1ri~~ ,= 
0.000 
0 .004 
Pc ;;,,,,t , re::eivi'1g r i~ ·"m pi::in -conbin ',g product.1 net ~uiiy r", yi~t..r.,0 w ilh Ihe . " .. "Iu/cl",' 
l1uthoti' v were 11.25 time; rnc.-e :ikel'{ . th"m thme who re eei,'cd lu lly apprcwed p roduct " 
to have Cnmx va lue, <4 mO.n. '-'1 \I-ir,f ee t'o'1 wm m,'X'iated with on 8. 18 time; ,-e!ative ri, k 
fa' C mo, < ,j mg~ . When ALi a'1d AST w ere dk:no ~omi7ed a; de,c ribe ri :;;;oove i'110 
values W ow tne upper i:m it of t he no"" a! range a n..--:f ",joe, above thi' rG'1ge .. they did 
I ',ot C(A,tribute io th" ,."oJ",1 ~\]:I ificCtltl ,/ How"',,,r, w l ',en AST and ALT ",,, ra ol1tereJ as 
con'inuO'JS ':ar iaUe,. there wm a 9 ?" incfQmed n<k 01 Cmox '" 4mg ..'! O'cox iateJ w ite. 
eacn lX1it inaoaoe of /-,1 ~ Cuwer;ely. ead1 Ullil incr",ry,e ,,1 ,'lSI wm o>:>ocided w ith 15 7c, 
r"d~~10n in the .-;, . of e.avillg a Cm= '" ,j mg/1. 
,,,,'_, 0 ;', I ~/l;"i.c '0gre""", Ct10vZ cJ ccy ",i~- ~, mOna' I 0 J e l ~ ""',.,,.' Ik .I" '" vrp¥ b" , rrcmDkin oe"" 
~c 'lCo otra'ior, 
"<C"'h", "'"'''' _ '.1 
l~c·ilr.',! -'4&1 
crob'c~,2 - 0 
~"urning aWJoxima;f'ly (;0 - 901~ of rifampidn in pkl>ma is pro t";n lx.>und, 'he free dflJ(-J 
concollira'ion of 0.2 - OA mgll corre,poncl, to a to:a1 dn.><,J concentratiu1 012 n''',Jr, ar"j 
tN, r,,,,-,,]" Clpp,j", imCltec II'", Hie d <>n:-c-,rt:b" _, 1-.1 , !ur_'Pfcu,'",,, IO,~5 '0 O_SO m g nl t" 
,;fampicin Th e ,~a'i'l e ri<k oi a Cmox < 2 ma/I wa' incr"ry,uci 3CW3 'in-"." if all 
~nregd"'r8d et-ug produd wa' tal<en on one day 01 pharrnacoKil""tic as",»""","t, HIV-
illf"dion wm aI,o a",oc';aied w;ih a m-Jcoh groot",,' ri'k of a very :ow Crnax: 9_99 limo" 
"1a' in Ix<Fonls w itho<.;i 'ii ,i~l,i"""ion. Lach unit increme;n liST and toral b, ~ubin ",,,,re 
a",ocimed wiie. rd redvctiu1S or I S% and 2oj'i, ro;pocti',ei'r', for a c.-nax ~:2 mgii, Ode, 
~'aii""rI, wa", 1m, li kely to ha,'e Cl ' ''' ''y ;0,." CI"",,", with a ri'k redLetior, of 7;, Ie.- 00.)C;1 
Te.", 'aucre '00' c' Ihc d,+,endeni variubie wm l.lcd ;n a rnrJltit:,I<e linear regression 
alldv,,;, :0 cie,errri ne ' I-;o;e oovaria lo foetor, that influenced the AUC' ,iQr' licall'ft 
:lablo?i Te.e model accol.,,., il->d fa 34% "f 'hp 'm~ablilv rliopkw ed In Ihc 'C1'..Klm r(XlI ct 
,\UCt ;\, was ,hown fe:( tre ,quare root of Crnox, the formL'la,io<, type and regulalory 
wtchEos of rifamr<cin cClp"Jle\ w",re a"oc;al',d with low", peal< cOllcen"Cl:;o m of 
nfm.,picinl_ ih'" pre,,,,nce of HiV illfectioll, malo ,ex, bwer haernoglob;ll, I'ci,.r-tt alb", _Ill , 
h igher AcT. lo\,er AST Cl,xI lower blOreJbin :"vc;, wme again as,ocklted \,ijh ciecroa'cd 
" 
T;JI,?I.- 9 "" I ~'" ' ..,~", " ",e l' ;"o rI ~ C>.'CT"" ", ' " Aile v.;th .\".,·~e ",,-,I '(",.~ , ,,,,,, ,'- ,,. , '" 'h ~ (' ~r , ~n J~,' 
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,-i '; , 
,W><-''l II,., AS T/A .. r rotio reploced 1',$1 o r,d AlT in the model 0 , trD'lgsc ,elo tic·'l , r ; ., 
beb'eer, the i,-,depe'lde'lt voriobl", and ~h<c ,qvore [081 of A.'JCI emerged (lob!e 181_ 
Two*" '" l..ut;pje I. 'ear ", ,.re, ",,,, r:- ode< _ c .;c·,;,--,;, ." '/.' " ,nP , nnd ol ~~ , "O 'i(T" cte, ."" tl-.e "q.Jc:r~ ,Dot of 
Ac'Ct 
~~" ."" . ; 
T ,,; '" 
, 




4 18 .5C':» 
"' ]7 .7048 
2.1 .:J(l 
3,0//2 
._" " , 
O.li'\. , 
A, fu the rll"",,,i d eArib;'lg Crn ax, Wil e tl the independen t vonabie, to ta l b ilr ubin A$1 
A U , 1-GI and A" were dichotomi.ed accOfding to the ncn nul rUll y el, AST, ALT, -,--GT '-'I \OJ 
AP did net cantribut e ,i9'lif1car,jOi to the mod" d co crihi rQ A uCt IT obi c I l l. 
.. ",I';' ,,, In-o cr -eQr~.d,., d ·c0'.'cri cte<> ' ''' ,'"" n' Clf~ roo; " .' W' , ~hg , __kno;om;.'~ d ,,"';ab,e , h 
T Ali, ~ __ ,; ,,,d Ar 
lO Jr~e 
"oo~1 
Re ",,_ ~ 
In" j 
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'I I 1"', r 5.71 p.,,,, ,., - 0 
R , ,,"- c<~.j - 0 ['-M 
A,,-; 'l SO'J(Jr~U - 0 ' ')1 1 , , 
mod", lab~la!ed below (table 12j expiai.-" 26% " f the variabil ii y i.-, Ir'(AUOj , 
)c .... ,,;,,· " " ,',1\ ,Y.cde, '",0)9: , n:«, 
~~\ 'C''''' ~O, I222 I I! 03 420 
Intel 0'.IJ;9 " 0.44(1., 
All O.O-ll)~ ,,, 
I "'" 0 .. ,,,11 U'l l '.Wll ON \5 J24% 
~"q"'y----,tdu\ ,., -0.14;':6 n , IC(l~ , .. '\(I O.l~ -<1:,59, 0.01"-2 "" - --" (,-,,, ""I <'3.':£. :;.IIoi!; Il.on 0.= Z,~-'06 3,:lJ?O 
.A lth0'YJh p>005 tor '8> the variable i< 'p.j'yied ir' th" mod", becO'.J'le wher'. r"'t<>niid lv 
in!I'~e~ t ia l ohp,val ion, wew rel~-ved, it con trihul ed ~g'lirican tly: it ;; therefore 0 
,iyn'ltica.-,: d",:""mnan: !or a r-mel inciLX"lQ m::d :..,...,-O'~t;yingJ ob;eIYCl:ion" ~kn 
approved prori'x i o ',ieee awx'iatcd wi lh a 24% -ed~cti()'l ir the AUCi , HIV inreclian WC)' 
",«"ciated \vith c 'e'::h:::t;C)~ C)f 213% ;n the AUCi a l'hovoh Ih .. a,,':>eia'ion was no' 
';gr,ficant at 'he 0.0:> level ip = 0,0761 , U~ it i ~crea;e' It' tota l b' i rubin a'ld AST were 
m,eciated with S% ,', rd 3% irY."ea;e, ir the AIJCi, respecl ".'''' Y. Ead1 I '~ ~ it deorea s.e it' 
A L~ 'N O S msoc'o l ed w ith crl irxoreose cI ?% ir1 'ile ALV::i . Fon-nublicr1 type 'N',. ""I 
' ignilicon~ in Ihe model de,eribir-..g In(AUCi): albumin ond hoemog'obin were 01;0 nOll-
con l'~) l)l orV. 
AS fq Ih" mocl<Jil o,,'nibing Cmax ano AUC t, a slronger mooel was gel1e(Qled w hen 
lheASTiAl T ralio repiaced AST and A LT in Ih" moc:iEO liabie 13). 
s(~~~c.------------------,"c-------co.------ccc----------------------c,".c_,",c.~CC~OCoO""-CC"C,.-S,' , ", 
.\<XQ 1:0.' ;,4" 11."'" --'" . . 0 ·.·.·. 
Re;>:!.J cI r ".ob > ' _ 0 :;9.8.';28 , , ~<>OQ 
To'd ' ''l'.·rud ~ C'.?o35 " 1 \ 19 : :IJ ';LC\J " ~ 
It>{AUC i) 
C oo ,i(n i 
~e()reFjon of covarigle .!",; t<;n. on Rifampicin ellminalion rate eOll,tenl Lki!J 
l ogarithl-,,;e tramfam aHon o f " '" wa, l.'Sed in the mLiII ", le lil1eOl rege>sion o nO!y';, shown 
below Ilabie 14)' 
So c'o e " " 
-',," rL",, ~ o , 01 08, _118 
' ·'.ode l ~ .9Ii • , .i ~52 " , '."':,- !O 27 ~ o rl,,,, ? 9 ·,Q) 'W .Qn>B r;-·.ob > f-G 
Total 1;'N:l1 , " ,~ ~ "'f JC>' ed_OA2'l1 
Th" m~,! ,, 1 exrJa l"",d 43% c f Ih .. vo.'iClb:"'i '" '11 ( ~"! . HIV-''1 fe,~t'''d p;'}lier1l , ,em·j l il :>,,, -" -,'il::-:, 
,mo,ed in ihe Vecr pri"" 10 c<jm,,~on had ;[lcrecr;ed cI"o'once, reflected by 18% end 
12'% increase\ in Ke , re-,peclively, HiDh-er tolol bi>rJbin leveh w ere Q'.\O(:':'lted w ilh 
"''''dCO''''';; ":·crnpicin c!e·::;r.::;nce: lor &c: .;-' unit inc:recc& in lotal c·'l i:Li:o;n, a 3,5": ,,,,judion 
wos 'e" n ;n h :: , Higher Me\; v oiu&, .,. .. ac ossccia te;d w ith minor ine,,,mes 'n , e;, cmd 
inueCl'_,,_·J 'Xle, Cfell ;,' ,.";, , wi',ite c'Ie:: ('o~d end E$P ""Eor" mmciaic,J ",vitn d [· ~"L,,"·:~,j 
rita mpicin "Iim'na'ion_ 
:;<,,',ik] I,/, ;h ", r.atlJlui Icguoil!Hll "I th'" 11·:.it-lits NO> u,,,d i.- , a multipls ['-.:0 "';1 reg r""ion 
c rKJ ll,> i,_ ~h9 m.~-.J01 h ;ummuriz",d in tabl " I : . Ai e)lv",ct",d, 'hs IOn'"" eO\f(J-iute, 
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111" nuil-fd l0(,;ul i! I 'I l'r of 1m", wac u<.ed in t~" moo~ 1 dF"Ocribed in tct)i,,· 10_ D(':o/cd 
p ",* w,temc c ooc on l'aiiom wcr l' awC'c",ted w;<h ,,0n-apPf0Ved p'oo;x;:f\, FDes, 
pdienl, on r",l r",ch' ",,-,t r",:,"me''''' );1\.' -i ~fpdion dC'/(lled white cPl! co -, ,,t,. toto l prol"'~ 
cnd ~,."a, HiGh",- FSR .,. aluo, and h(lon-lo q I0b;n level, w ere mSO<" iotr-d w ith mor" r(lp,d 
at ta inm ent at peed c.OtK" niralion; 
Ii '; 
log time wos therctote d cho lO!n iLcd. 1\ ~i,'ic ,egre"ion mOcRi itcicJle 17) wa' 'J>ed to 
de,er"ine the ri,k at a iag-lirll e > 0 m ,ocialed with the covariate, The ,;,e of r'On-
oppro.·,,·d iJoouc h wo. o.,=io icd with a :>.,~? r"'e, 'YRate.- "" of,., nor17Rro IOCI-t'""" 
compo·ceJ to apvoved p-coduck Each unit il )(:re-me in U",:K:l wo. a;,=;at"d w ith a 5~% 
irx:rem"'d li ,k o f 0 no"ZetO 'faU-tim e , ' " c rec"ed age ond hocmoglcbin "' E-f e 0<50cialcd 
w ',ih 0 deeremed ri<h of a nonzero lag-time [7% and 32% ,,,,duction>, ,,,,,p;cclive ly, for 
each J ri ti. 




Tled ment ca'~2"...:L 
I I V-WocfiN'l <f atu, 
White c oll covnr 
Toi all"otc in 
logo l ~,rm 'n, 
'. <X ' ,~~o)-,,·d · _H~;47 
'''>I ·tm. > a 
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Nl..-,.,tx, 01 (Cos u 13] 
c,: , 1:0) :', Ie h'" > .. - o .[)}:) 
R 'q.<J'~ d _ C.n'9! 
,~.,~, 01 o£,, · I ,2 
LR m 2( ·jJ _ JIJS 
~ <.>l' ~ ~" :2 - 0 
O.88.\t 
2.2602 
The patient and treat,nent facto r predictoes of the PK memure, :or rifampicin are 
,um"'orized in table 18. 
,:lb., 0- Surr.c ,,-, V ,,, 11',0 ,' o,(]<;,,- e teder; ,. ,: k",' o('..nq r;;c.-.p c." ~, ;~ . • ,,:,,,).OJ<: mc"," ' ~ ' . ~. Jd(. w .ned 
by th;; r"",e''' ~l ,-",,,,,e ,, lhO'e v,-,"'-"-""_, ~otn-OJth;l to Hl e I:". ,,,,,:J.cI, ae "'''''''I~d~, I :".-, .--.:reae n 
Ih', ,., 0',"'-,1 ~',~ i able WOj ",\",kj0d with cO' ,"cre e"", ' ".0 ~d_1C or tr.e f( m~cr.u ' " 1 ", 1 :" aecre Cj e '" ",,' 
," "- ,,,,, : ,,;uL ,~ .',r" ,~:"~ _."t" ,, ,, '" " " ,,-,,,, v,,,,,,- I,, H,c C' cc,·c '. 1 "" ,>--.. '" '" '' ,-,~"k "' COX',,'') '. 
1~·>O.C'i ,,0 .- -, x CJte c " b«x:",h ,Vd l";) e lneo: r e"r~' ,..x ' W(~ C·"" C "or aI dope""",, 1 Ye>' d.*o.\ c:<c e pl Tlag, 
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, h" lcr y cI re '>l-"'" '."""'.,~ COlY,-.,,~lk)n " I~ ,., y~'" ~''' r 10 aetnA ,~' 10 ~,0''''0k<,-,'- ""-~ ~. 'a 
" , 
, D'~ ,"nl' iI' f'e' ..... ~ct~py naa ,-d '0~0;V0C ",,"' " ' c.m 1 ",,,,,In e aru~ T'Oc 'mOl'T ~·rk" Iu od r .. ,"''''' Da'·en!; 
It' 'Ole , ~ tr~C>''''''nt ccte7"'Y ,''''; ~.ev,,'-J"y ;~ ;;~"~G ",hJo~ ,c, lcli, ct,,,·~ ie. .. '< ", 0<' ,', or 'VI,,,,,,r 
• ,rY Ih,,!'" C,U.., i"'''''''k:r'''H wece ,-,"e1, Tab"'l, or ~,,,,"-' 0' e",.'" ~;.~"'''''''''''' e ' ..... 'e c ,,.. "'0,0 """ 'i" "~ ,~d 
ta-;,e ,r." 
' rx:, "1''''"'I,'·,-in_, ' .w,' ''; ' "'0" I ; '~ d c'~,~ Com':<na -iOl- r..." d c>I ' 'F ,,~, ~ '''~--J. o,=~" WCO c " .. "tiro ,' ,'," ~ 
'~.""'J<id 'f' ~1"'an~ ir i em picin J~ ,,,,', '" I" ''''''''",i c I.~':; -" cr ri'e-picin I cD ".-. -.-- ,1 " i""" J<id /~ rn<J i: ,:"" Ie 
etL .... r"" wa!'on" - """ ,,;,-,, ,,,'(!e erC e -harrbJU w",e "se c 
' _'" >Ct:i~cl, r~cei,~ c a ' ..... e d-L" ''''m~>ic,I' [o'" d dl"" Ihal ' .... '" rIC, Clp7c·.ed by h' ,u"kl"" a.,-"h.>ri'y ' ''' 
11r~ dGV J! P< proo<; e c e ' e rm ''' ''on'~_ 
The impottat't laden a\s=:at.od '·.v1Ih r ,~<iu(;ed " /.:>mpkin b>'~':: ',-, ciIClbilili , m re ~l " ct ed by 
d"C''' CX L~j C''Y--1X, AUC I aCld AUCi value" wer", Ihe uw of 'he nem-approved ~bm,:kit' 
product hatchel, 'he UK · 0: fixaJ do\e ro,-.r:ina tiom (~tampicin formu' al " d lc<:'Fe th"f 
wijh i,oniazid), mal" ,ex and H I V~nl"dion 
Ivrrrruiulivr1 .. ' ''' ClXJ' ~£':..j ,u l>e u" ;mpor iuni deiem-wncmi of ri'L'rnpicin 
ah\c<ptior:" " .n.,,'. Th(' quuli;y of th " raw rila"1C':"it), '!'Ie exdt-"')ienl\ add"d mld the 
condition, cf heat and humidily d'Jr"'ng ihe manufactcoing proc",,,"". are thoughl io he 
importat't. That in yiv" bio",q~ival"'nce t""t ing 01 ,i'omp:cin-contcining FOC, i, r!'qui,,,,d 
prior Ie the'r '~~ e in patiH-,L i, geN,ralf,-' a"eepkrP."·", t,ythHtl10re, "xpos~"e d rDC 
prodlJct\ to heat, h<cmidity a"d Ifght was ,hown hy Sing!'l et 01. to acc~erate an 
intNodk,n 01 , ifompiciCl and i,=iazid fo ''''ng tl,e decompmition prodl>Ct i,onicotinyl 
r-yd,cno'l'" 01 3 famyri!amycin and isoniazid"'. Dramatic mdudion\ in t!'le ~Iarnpi"in 
cont",,, t ar'a l"l\ef redudions in imnimid "ontent were demonstrated with exposure 01 
tfv> prodxh to 7570 relati'.'e h'JIl1idiy al 40"C for 12 day,_ Thl>! Ih'" packaging a"a 
IbraIW "ondit;om c-f pmdU( tl I', aving 'ilampi:::;r. and isoniazid in comhinaji<'ln il 
i"lOorlant. The f OC product, uwd hy <\1" path,<, in thi5 IhJdy !'lad '-",oo-gone aCld 
p m 5ed bioequiva!ence testi"g be'ore r;;gi,'ration ' ''ilh tr>e natiO'1a1 '''OLAatO'y C>Jlr>orf<\' 
lh", redtJ"",J bioovailabil;ty J",ma"trat",a h",'", i, tr>r>refc<e of ca1Cern, E,<dud '1Q the 
dota irv" 1 t tx;.o;e w !'la ,7,: ,-,i y,.a 10rr11' Llations not arr'''G''"d by thp ''''0' .-Iatevy a' ,tr>orfl-y' 9% 
aCld 13'l(, red-cJelion, iCl tr-e "'ediaCl Cmax end AUCt. ,e'Peeli'.'efy. wd a 25% increase iCl 
tl,,,, me d;an Tma)\, 'Ad'" "b",v" d l:..;r f OC ;.;,,,au<; ' , w i: h,,~1 o~u,t'tI "' nl 1:';1 tI,(' vlhN 
covariate, (p=Q.094<'->, ;:.=0.1016 aCId p=0_OQ2S, '''''pEciiv6ly for C"'= AUCt and Tmaxl_ It 
j, n,,1 kr1"'N'l '-'.,hetr.c-r the- rr''1';vefy 1O'.,'e, Cm,-'" a"d ,AUCt '.'ryl,_,(' \ J,-,termi"ed ,~ t fv>, ,, 
pati",nt; ;, r",loted 10 a",t",riaation whik l 0" I;"" ,1,,,,1' (al ir-ough no prool>Ch wer", 
exp;-edl ,e,,"i'irQ i r1 reauu ,d o,uuvaiiubi<ly, 0, 10 inf6'ior oak:, qualil y ;; .• com;:.cx;oon i·:> 
tl,,,, batct1e, Ir-at und~r,\'s,-,t b<~quival en-:;6 te,ting befms product 'egislrati ",,), '" te-
" ario t;ans in 'he, b'oo'.'dlabi , ty of th'" comporator mod'.x::: t \ li t' lhi~ , judy and 'he 
bioequival",nce ,tudie,), q to d i'r'<l''-'-l-''oct.Y..t intrracti",,, (weh tha' bioequi'.' cO"'( K. e 
t",tilX) ;Jro,.""l'..-I '" in ,'>ealtlly YOI~'1Icor5 c.-e not adequate to as" .-e bioavailability iI" 
patients,_ ,!'Ie median ti",,, to "xj--'iry "I Ih(' products u;ed v" Ihe day c-f PK ,ampl;nQ WO> 
: -: me'lt!'l" \vitr- a run;;;e el 3 Ie 4~ rnonlhl. fOC p,odlJCtl r.u d " ior.;)", lilT,6 Ie expir, 
In,ediar, of 39 mO'1lhl) t!'lan ling", drug j:Oreduct, :",edioCl tim" te exp;r,' c:! 14 month\)_ 
Nlureuve r, I:,,,,;· :u expL~/ d'd nol contribute sign;ficant;y to th" re gr"" ion m::.>d<:ll 
describirg lag 'i.~'& and AUCi. "Hher it w as a ddad as a c,~, ',_'c:r'.::::t&_ ,\,u ti-cGii r ecr;; '/ 10 
high d"'7ep ct correlation bet-.veer. 'im& \c ",xpiry und the formulutic-n \ype; p=O.cX10) 
Dre'ienkd an ar.a l\!;I, cf it, eff"'c\ C'r, thc rcgredvl rnadol'. d""cribing Tmax, Cmax ord 
,,,uet, 
Th;,· f:l'dinQI i,-, thi, "lidi thn' the non approved p'-oduct bn'c.~ e, had interio, 
bioayaikltiljty Iffg,,~e 1] ond 'hal r1On-approved batcke\ Wc-'fe ossociClted wib a greatly 
il',craa.;ad ri,( 01 very low dPJg COr1cer trotiorc (labi& 8i, ;u;:;;:·ut \.~a naca;,;!y 01 in vivo 
biooqlJivaicnce te,tira of ~iampic;"-contair.ir.g prOOl:ct, iincluding ~ngle·drlJg 
for~ ",atiom a_~d ev",,', aft .,.- OI" Y .","ncr ch 00">9'" ir, tl-;;; Illarufad\.!iI'oJ proC€isl_ 
~ N"" ,d"',I ',>k", vi<)h . ,,,t, ,-,,, "J Ii-,~ dli,,, "')(;<" n (;111"'-< All<:- CJt'" AleO tc~ 'hD'0 ro~~ivng cppr(}'_'~d 
Old ncn_m"'~'_'ed ,:r\g~t _ ~and >ide ) ba\ct)e,_ The ~atislicd >iQnh'OlG~ ot tr,e cffte!ence, we>; evaluate d l-'>ir><;l 


















Slower di\solution rat e, migh\ e"piCl;r h'" aelay'ed pea_, concentrafon; cmociated with 
U"" 01 'he cDC, and nor-approved prodlJcl,. U,e of ihe ron-approved producl, was 
ClI;o Clsmclo ted wilh an increased r;;k ot oJ rlonzero lag-time, 
The a<cocia tion of HIV inr,"d.a_~ ·,.vi\h 'e,juce~ anjitl>Uercuc0, drul) bioa'i'Qbl:,; ~" i ha, 
been reported previcldy"·n"'".'. i' ,eem, b be ",,<oc;med to ,ame "xtent with Ille 
,e·,er;1')· of HIV-;nt",Ct;c:", ar;J diarrhoea '". A n-,j,-.,yit) at puti.",I, in 11--;\ ,i l:dy had 111'. _ 
illf",ctkll'" o_~d th" vClriab;i ty 01 tl',e Cnlax and ,A UC value, w as "x::h tilO l "dtple 
reg"miot'. araj'i~; w e, ,Lc:;Jc: j Ie ·o·jju,i for c-ther fact"", cau,ing 'i(A.··'eUit·" ii', 7der for 
rifampic;" p'2ak conc'mlra~ivn, wcr; ?D% gre ator I h~l "hat for t"a rail of I"e ;~ ,-,dy 
pOix dalv)n (lolJ r~ 8,1 fhe,{' findir;g\ or'" lim ik:Y 10 11'01"" o f Saha; .. 1 01." wl'o round .11% 
a,-d 32% reduclion> i,-, Ire C ma' a.~d AI..IC of Jif amp<cin re'p2Clive ly in lilV-infected 
VC<L,-,j22f' · ..... ·;tho'-'; '·"bar-c lim;'; in compmimn ~o r,aat lhy voiunle"" contrO:, . Th e groa: Of 
rccL)clions in t),C PK measure' c>t)'.erved by Sarci e l 01. migh l be ollributed to relolively 
adval'.c.o-J C!1"i-il v",ction (2(3 of Ihe fHV -irJected goup hod (.D4 '· cd, counl , ~ 2JO), Ihc 
prfosence c{ d iCJThoeo in 1/3 of lhe liI V-i,-,fected gro"p m-d Ih, ab,cncc of tL'=:orc·J osi, 
in the control grOL'P. 
Sohui ,;1 d, 10lnd Ihnt rH(1nw';";,-, c""",enb..,ti"m '",.-vied '0 b" m,,"e marf.-edlv ,ed'Jced 
in th ",,,,, '.-\lilh more advanced H 'V~r!uction _ ,l, c;mkv Irend cO\J 'd be w'erved an1o" 9,1 
Ill", HI\'-i,v"'c',,,,d pa,ienls in II',;, ,judy ifiiJu '" 31 Wi',,,,,, 2 wllying ob,,,,-,, aiiom -."","" 
'",moYbd, b'JI Ihe number c{ pali enfl (14) wm taa ;matl 10 e,lab,," 1"0 i;qnific(l ', ce 01 
t,u:.~2 ]C, " ":"-:",,,; ,, bd"'0U' cr".co; coe n-. crG ere", ctlG -',Jet. ' e , ,,,,c l,,,~~· . " d Cl Y_' ;ec-crl 
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Th", Iii"'" 10 r",ach C:'-'-I(1< ,·.·a' prolQr1~Wc.. ,,-. HI\I'; nf"cl lQr1 ia finJin~ il1 ag.- "",.,.,,,,nl Ni'''' jik 
Irsnd ob,er,,,u by Sma: cI a!.). ;r>Jic'alinq Ihal ' yc lemic cr-"';aplion of 11" ,e uruiJ wa.\ nol 
jld ,.sdJc·c'u iI", II ' >~';'" paii0nL bll a b '" :.k·lai"u_ Inc,-",(1,,,d e.>,pr",00r, "I P iJl;coprot"ir, 
at ,une , i'e< hm bee,-, demom~ral"d in Ihe presence c:J HIV-i,-,fectiar-, '"' _ If f · H V~,-,fection 
cal,,,,, increc:tJcd inle,l;nal P qiyc"pr'c' e in c-'prc'lic., ;1 cw'd be in1p'icaled i,-, both 
,ed,-,ced ab,orplior' and delayed p"a~ conc-"nirat:o'1;, cLXlr.ermae. HIV-:nlectiol'1 wm 
m;ociated with ')"":<0:' rarid rifa"lpici" " Fmina;;0fl in t~i, ,~ ' _d!, !h'c i: a \;c ccn;i;tent w~th 
increrned P-9"coprol e'~ exc'e,,;an, as the tram"",o ,,",brar,,, e'flux pm'p I', olIO fumd OIl 
lh" (.am dicuim ,u-taco d hq_>al~'~ -,- le,,- ". /J II .0\);]1, the dtferenc", in the hCllf livc, ,_A 
rllo,,",picin between thc ,,'oup' in ~ah<.i." ,',100, were '1ct ;ig:-1ificant. '.~,y,,",pto~atic H',V 
;, d<oc :",.J i,-,.;Ji',iJ_'a l, wi il> Idutlve:y Nyly di,ea_,e had CJ ,b~:~d m eem r_a:f-:;:" Ii ",,, t', ,, 
heal thy control " wh ilo thmc with CD~+ c~ 1 courk b eb:' 20C- 1;o11ded !o f-xw e l e~'.. 
,-, I k-~_'n: d"y] ,.'lim;"c,t i0r1 !1Y:m II,,' c0r1' r'" "'-0' 'r 
1\-1,,',;, I ,'-'''' I e;,-,~,--,; d ClllUl, '-",d ~,UC '..-a:~,;, il lu,;pe;nd;;." I "I ,-,Iu;', ',,",j,,,,,,,, cb:;;/i',g, '-' lir',,:Jn:;l 
"mrorterl by thu\ of \iCJn Cr.",'el d d_" in lndonmiqr ouli"'11" Th" r"",,011 lor thi, i, no: 
"1"q'lXe' itx;iculi~ lhal it was pac.'rly u;m;oiatad ',,- ith ' ilJ'lpicin c0l'Ke,ntrat iGm; 'Helle, 
'''A w .. _" not , ig nificarlUy m,oCiatea with cteKwed Qb>'.)cpiiO! l Qi elol,,,,,,,,,,d ,,1' ," ,,--,liv[ 1 
rClte; m.J 0.'>'\1 iq Il K,rf..er 01 I:x-"d; ccrr.'~mitio n) WCl; nct m;cciaied ,,-- i\ j-, ull er",d 
bioavl1:'aI::M i _ !",,:;d<=c, the ,,-,oelicr d,ttibGtion af rikm ,picin te l ot ,,-, ccmma:hC'n tc 
",u,cle'" wO'-.J ld n al'y e-.,-enl lend tc bNer the dn.Jg " cOll"entrCltio~ \ il1 V:GmCn ~:xa 
'han 'n m en 
AlihOUg1 the do,e ci rifall 'pk'ill 'Gnged from 8.82 - '~ _ LO ,., " 0j ~O, t i>t d a;e of rifampicin 
c e, ~ikl0rar~ of body weighT Wa.\ I'o! W1 ;mpor iant d eler"''''.,nt ci iile Cm,,,x or AUC, 
even V,- ;""" '" aJjl>'-: _ -j L:or tho':' c-tht'r cC'/.:n.;> t", hdcr _ Tr,~' ',=, 01 m<odaiicn "li ;;;1 ,,:.:;nh 11",_,-
i nlri~' i c vCTiabil ty in the t'iCCl','d"'~ b<I!\\, cot r;fompicin and ,uppcn\ lhe 11 eod to inve,tig'Cl te 
facto" thd do have 111 "m=ct on ,-",ug COf')c e '1Irl1ticns:n PClt;'ent, 
The i.-..;,'"o;",J C'naX-, .', UC and l-)rolol'ojJ0d Idf- !i'e cf riIQI-" JiCicjn, in emceiation "'itl '; 
~'lVot erl bili"_A::lil' levcb h cons i,tent with the cvmpctition cf th" dnJ9 w ith bil i,,_bn 10' 
Ci rCl ~! ","minalioI1'· Th e, f indir'C' o0uid '>"0 ,,,,f;ec t r",..j',,,e(l h'T"Ji'c ccp.,c it\ ' to d,,,,, 
lA njb<n ancJ rll""'fJic;n , The tramaminol,"' AS! l1"d /" _T w,,' p- ,-,,,ooil1ted w ith op=it ~ 
e'feoh ill the ,~_Idv rchai: i""reG'~ in .-i lr:m-'n~'n CC"ClX G:¥j Al~ were Cl"o,dated '.vi':--' 
re<..tJccd A'_T value" whi le i",, ' ;e ose, in AS I w ere ,-", oc ia~e-d with eievc l"", ri'ampioin 
le ',. ," ~ _ ThB ;j '",,"r ; <'!.il ",,,iol' rno.-.J,,", u8" ,.-ib i[ ~ C ",",ax, AdCt ur.J ,\UCi were ,tr8ngth,"-,,,,, 
whan the AST/ALT ;'Cltio \uh:itutcd ALT Cll'lcJ AST ikule, 5, ~O 'r3) Ki'-'1eflinQ e l GI. " fO\Jn cJ 
Gleohe:! u,e L he (l"ociated w ith highe, ri 'amp'c"11 level, and ch'",n;c a lcoh",rc iiver 
d isease ;, m'OCil1 i ed w ith incre":" e cJ A$T/ALT rGti-os'''_ RedJced dearGnee o f ,iIClmO;C;;11 
due tc Gk.ohol"i~uced hEpati c. i,-,-,cGirment may 8xoic>n Ii" .... fir.Jiry, in fh i, , 1>.J uy_ 
oharm a c-:+cinelic, 01 6'amoicin; Ih i' ni ghl relleef Ihe wea k 10':'1 ,-"ed in lri' ,Iudy 10 
m ,e" Cl !CCho! etpc!"..-e ,1\llemClliw·p,'. irnemed ,~,sr/.A. I r 'Cllio, mCl'! ,,,,,ull d 'f"""! from 
incremed exomure to r'hmpicin_ the ICl ef thClt AS T and Ai r did not con tribute 
[Iubie 6), ;ugg&s!\ Ih"t,ublle varirni iti ot the emy,-,-,,; ie..-d, irduding Ihat,vitrin Ihe 
,,,,f,,,,enc,,, '"n,]",< i< Cl"oci<Jtpd wilh rilnmp'c'n ;::m"--"Clccrinetic, The ,talislica!l\-' 
,ignilic Clnl correlatie'." between t0ta l bil irubin leyel, a nd the AST/ALT ro lb and Ihe 
FiCl(,"' ': _ ~"',,!"';""" b e tHe," ,1=c:<'c;I" c;."u, f,x I>,~ 'e" '-"eY m,)~! A'IC :>lei Aile:; 'tvlt~ '" !~e ,,~' 
Qxel: m~,'-.-i H af'd r ,'.) 'ckj ' ih" ", "'~~ ' , ,-,,0 1 ~ ,I AS'! A " ~'" r ','(]udi"", '" the slctis"c eJ !i :;ri' koOlr'ce c+ J '" 
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The inve-rse- m<ocia!ion of Cllbl!ll1iIC' :",ye~ and rila'''picin bi0cr'iOikJbli l'l i, "LqAI-'; iry. P"'''l';a 
et cl.'" found low rila"-''Picin ccncen traiiom io be ::mociGted with 10','1 bod).' mem index 
,ilampcin i, n gr-ly Drol ein ool!nd, m<:>s llv 10 dJ;x.Jrnin-". The,efofe cibJmin smuld 
jec>oard;:",d by tre het 'hat H'B bond, betwe",n r;I'1mpicin to alblxnin are (e-Iativ~y 
WBCK", In tri , " Iud/ txdy mo" indey, wm n01 ,,,,ocicled wi lh rilc '1'.picin ccry; " nlralion. 
In conlraJ haem0Qbbin 'ev",l, "iere r:.a,it!ve-Iv ClIsock:l ted with ,i:cmr:kin bic.:lVcibbi!ty. 
and Ddient, w il h r-lghe.- hClSll1cglobin conceni[ctions al,o Clrnorbed Ihe do_<;1 ",,-"Ye 
eff ic ienl lv. m By idenced by reduced T",a;<, yal<)B,' and decreased , i,k 01 a nOllLmO i,,~­
II..-.'e, Alirough a~blJl'1"in Clnd haemagl0bin wou ld both lend to be reau'Ced ill debilitcted 
I"atient" th"" I-KJve o pp""ite efk <.L " rL the p!lormacci:.i,.,,,,I,;o,, ped-,ap, i"KlemogloLilL 
(Lnd GIe',,-,,,in a,a ma",erl d; ;pec',l ic di,cmc cffecL (X n~fritiot'a: deficic"cie, wi:h 
dlfereni ,-,1Y1'llla""".i"",tic "c~,eq'Jerceo 
.~ ':h o '_'\Jh thp ~SP wm :'1" " ,-",,1., a""'''ia led wilh Tmo." md rifompicin "C<lr-('n~ratiom tao, 
longer to r..ach peak corccnlraliO<1 ' ir preYio,-"", ~r'"CJted pat ls"t, petia,,!, w;th 
increased ;c;al pro:Gi,., ;v.-el ;, lXeC. _e,,_et'trc.t iUJ", c.nd white cell covnt" the,e factor, 
w""",,, not m,=iat",d with altered Cma;; ",r AUC yalues, Yo~nger paliet1h one patient> 
P",rl\ I"",rl "'<l1itY1ti0'1 w'" a"ociet",d with nr-rp,--,«i'Y) G<::I e ne-ati'lit'e- r-orr-..,-,tration< 
biirubit' leye;" white cell count. end ESP _ The,.,. Ii ndit'g' or.,. t'ot ,,,rp",irq P'?d~"ed '"",a; 
i, :O"gel/ e llm:t'a,ed by 'h .,. :i'<· er. propcrtic<1 i" '~xcre :ed ir Ih'~ u";ne. Th e comp,-,i:1ion of 
hilrubn Gt'rl 'iIO'''pidt' for bi l"lfY <Jxcre liar · .... a' m",,,tiore,j previol d/_ In"'''O",d ,t.'hit .. 
cel l counts a"d ESP val'-"" or" lif-pfy' 10 he (Js>o(:ialed w ith more ,sve'e illness a~d miOh' 
al,o, :t>e!'dor~" cs e~pecl"d to be m,=",ted with redL>~ed rale, 01 urug eiirnilla;ion 
Corvu,ely', the po,i;ive cs<ociciior 01 rcd ee l voi~me with rifampcit' e ' minck,,-, rub 
might be attr,uut",d:o n1or'~ eftK:icn! (jr~'g s"<erst>:>n ill pat:"n!; w ith b el le, .,ut ri tio~, 'e" 
prolrade-d ill~G" and Ie" msocioted n1ic<oc.,lic a~oemia_ SmcUt'g 'NO" ;)100 G"=iot,,,d 
with '"cr'?C1<D d si imiroMQr ratG\ , Smof:i~g ;.; m<odoled wilh :hc· i~dvc tiot' "I certoir 
hepalic e~lym"'< ("g_ CWhl' and CYP1A2 which metacoiizes Ihc"'phy1ine and 
",-,r'.,.;,-,e)' ''', bJi it' asso~ioli"" ".-ith ,,~hat'eed r,lompi",r ;:;;;minat;on 1"Kl' t'o: L,,-<.;n 
describ."d p- eviO'J'ily_ 
ISONIAZID 
;,,0 moo"", we,,,. u,,,.d to de,c, ibe jhe effect of c ovu< ia te, en the Cmw., AUCi and AiJL;, 
0' isoniwid. Ac".t;!atcr statu:; Was d".·",,,"irJ">d on a sut-g-eLIQ of pa~ienl' WhO were 
,ecru;;sd I a;-g~\' before <DC, of r'fc"'picin ':1nd i,·:>niacid '."".r". inlr·xjuc".d in the " .'Ord'_ 
Ihv;. only ene ,wject with known acetylalcr ,ta!1.h received a m e product on the day 
01 PK ,an·pling Po. S bolr formdatioC1 Ivpe ard acelv!ator ,Ia lue "I"''''' impor'ar l 
determinants cf C",ox, AUCI and /I.UCi, it was nece!sory 10 l.JSe 2 regre,sion rnodek for 
c,ach measure. 
In the l i"t model the e'lect d acelyiatar iyP<' wo, nel e'lo,ual ",d .• wo ,uuJ"ct< w il h v~ 
lew iWI)iOlid concentration, [0_&6 and 0_46 ,,·g/I) were eAciLded from the dalo ,el and 
Cmax w ac log-t ra",fc.rm_~,d in orG,~r 1.0' ,ati,t,- tt-;: a"',-lllpJ'.:·nl .:.f the lim ·or re grelskm 
model. Twen~'_eiQht percenl of tr". vo:iobiity i'l il" rimid p".aK concer'tratiDr1' was 
-,," plaine d by ti-i , model [tab le 19) _ The type at formulation and , ex w ere i"'p~'dant 
d".l"",oinanls of i<aniOlid peaK concenl ratiDr1'; male, had <:leak concentratiens 2·1.2-8% 
lower than fernalel CIld lhe L~e "I FXI wal a N'>Ciated w ith a ??_94<>; ,,,.d ucliDr1_ RMI 
and drug dos"./kg chplay",d a d".gr".e 01 multi~olin".o:ity. but as dm"./kQ >Irengthen".d 
was msocia l".d with a S_33% ~evalion 01 the pe-ak conc".nl ration_ each unit irK.'".as". in 
haemoglobin level, wa. as,ociated w·rth a 3.631". increase in 'he Cma.<.. Mirtco- increase, in 
Ii-". C,-nax occurred witi- increased 7-GT and Geuemed 'otai mo'e<n concen trations_ 
'ot! ~ 19, ". ,';pie nn ~cy 'e~'~,,"'" m c.:\ol " c ........ <::te rex!"" "" th e k-xJ_tr""''''<me d ;""-';"';0 ""eX 
ccY"~',I,," icx ' lern",x ",,, ,," ~. i 
~o----c--.--------oc------- ----------;:;: Nl>rbc, ,,< cru _ I:n ocuc e " 
, ~'.\ 
.'·.' Cod o' 1 '<3>10 
~e>idu o ' T 2.51 .~8 
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H-' C>.," a d - J .2!5? 
Aq u_2444 
Amen:;)" those pa t;",,,., \,i;lc, ~n"W'l ae"''.'a 'C'I typ<-'. the addit",,, of ace'vlat.,.- ,I;J I,-,' 
,ubl tant'a lo,.' str8'lglhened ' he model d",cribim the 'D--"Jm '001 o f C"'Ox, w h eh 
de,c·itx'd .100:, ,;·,t the var; aiJili~, CT'cc-io' ed with the d"r:<:nd"n' varioble_ Howeve'. th" 
.,,,trv crler; o (cr inclu,io" ;" thc model (Iable 20) tH:Jd t') be broadened as t ~~" 
"'.'.'x;ia tiol', v,m nol , ;,)"ifrant elt th" 8_075 level_ Inl"'fm",diot ~ Clnd f""icl acelyb lor; 
fende d to have low",r peal i,oni"zid cUlcen'roii0n'_ Th", form LJ aEon type was not 
:'ldud",d;n th, rrt0dc·I·" , ':1 ', but ·:no· ,u;;;.,ct with <nOW'l acetviator ,tCl""" ,,,·'COc-ived Jr;],,,, 
<-I,'.)g prodlds_ The ",'he.- cO'/ariale, ;"duded wilt' p < :],05 were Ic,e oOr'e m thc,se 
irx:luded it' the previO'--~ model. 
ct,,~ h' ,YtU I p'~ _W'" r~Qr~' ,"" n",;dool ot """""in- ~ \-,dm "'" tl-~ IqJCl'~ rool ~CTdor~,j i>Or'i'-loid P""" 
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"'CO,, lyl,,'O' statu, were reg r",,,e d_ TI',,, co¥mi"t e fa ct·:>!', were regessed onto tc,e ,qc'::m; 
root ct t ~ e 0 1",,0 ')Mer tc,e ;.oni""id cOIlC€"ltrotiot'· tim" cl)<v" 10 8 hour; a f ler drug 
dming. The "'Og'litude ct t~ in!iuenc8 of co'.;m""e focte<> COt1<'10t be e "imO'ed wh8'l 
jI--;, I"'n'lormalion i, u,ed. H-:>\vever 0' for tj"K' pear concoet't",!i0ll. male ,ex and FDC 
L-~8 w ere m,ocioied w;ih ~9'1 i fi'COO<lI fcUCi ooCf8,"'8<_ A, bor!y "'OS> index or<:! ',o.--.iazid 
O.WX)i UI'<.I ·~ GT ar-,j "';kai ",e pho,phojo<;", 
:Speormcm', mo; 0.+045, p = O,OOCO) dispbyed 0 d egree 01 m~~:~cd;ncarity, the variable 
in ecch paw Iho i ,I rertg ihened ihe model rroST '.'1m 'COc, () ,en iot i'lc;",ion in ihe model. 
Incremed Al)(:t value, were O$$oc-iolea w;th hig~e, cXu g cime' ikg, higher haem()(j loon 
·':'·c>r.c"" tratiO!Y, higrel u"'o b\c,;- (p = O.D72) hig:'", ~·GT level, ,,,,-,d incroo,,,d 
e-ry;hrocyte ,edimenlotion r'Jl e,_ 
I ,~-,le 71' M"..", A '''''.~ t '--'"' In"", .""'~''''''' n",,' ,. ,.< C " .. ",.", ~ lcd, " "" the "~.'''' ~ ." ," ' 1 A lie' Ie.., ~< I .c' 
"""~ ';b' ,,, ,'~I,-, w~ 0<:> "'''',,'''' " II., " ·'''·ciel, 
l oo...o,," " IN'",,, C-.hC'1 
R~'uml IOI$r'~ 








h'J01"~ ' <:> ,t, IOj I 
Ii I. 1;:') - b. ' b >, ~,O~ 
.. 2.'"::';:0: O.2nl 
;==~~~ M»I? O~N ?11 0,03(, ~ .(lC()J O.rol? 0.1".11 _1.0 1 0.= , 
0.0/2' I.B~ 0= 
O~ OJ!O?I ?S? 
Q.lOi\7 0.0611 3A I 
ccnccniration\ WHe "" r~Jd"d und 'he <qucre r80t of f·.l!C' was used in ode' to ,ati ,1y 
the OI'L-mption' of H", mod.,. M lJ ti-8c1ineaity Wm ob-;er<ed belween 8MI o nd i'.On ia7id 
dooe/kg: 1>.'.11 '.vm drc-pped itD" I th " n',odel w Il k' conrribu tlon o f drug do,e/~g to the 
mode l woo , tronger. Fernc!e" ::ow ",cety'alo", t>'",e r",c ",iving r .'-gr.,or i'ion:c.zid do,e, p"" 
I:',b;;r':l rn :;nd rlD'e ,,,-it>, 1-~g>1<" i-G: !evel' had ggalor AUet 'ia " J~, ', Th:)lc wit~ hi JhH 
plat"" "'t cmmt, >'ad Ie"",,,,' AUCI vallJe" C·"a tinir.e ,r":)".'1ed pmifr·.'", corr"laI;on, wren 6 
pCi"niKlily ,nfi"",,,iai cb'"",yoiicn, were dropped, bul "101 not irnpc<lanl when Ihe whoi", 
dotu ,el 1'.'0; ,-"ed , 
.~o!,'1 B IMfH<.>k! ~ "'Cf ,egre,,""-' "',0'" '' d c"vo-Iai e fact"" on I'x, "-.":<C.- ,col 01 '.i'C The df~ct 















'tob,'f _ O 
in ,umrnary ,eA, fO"mu ation typ"" acety,atO" stoll" and i'ionia?id do<",/kg were imporkmt 
d",te;mil'>.),·", of ti1e Al;(.t . II,creme, i" -,--G-: ","",'" QI>e ""ol">,,,I,,,.-lIlr (h;<A-iat",d w .,f-, 1\ ,Jn",r 
;','Jet '.'01 ,-"",. \Nhil " IJI<,a, i1 aernogioCin platelc l (coJn t unci ESP h",d rn;ror contribution, in 
cne mOOel 0" the other The ;ncorni;ter1cy o f the ",,,ociuticrn of t"8<'" Vatiabl8' be~Ne"" '. 
" 
:h", (fff""r'".,! models !"iith their : tiff'ring data ,de) ,u']gesl< tr.al the m'0<.;;0 Iio", me 
weaker 
It wm ooair' ,""cessery to croat", 2 r('gr""I;on modd \ In d",z;:ribe the rL~aH0",hir< 
bd','iee,' tr.e ccyanate foctl>" and AUC; []<. oo'h farmulativrl lYre and acety1ator siaL" 
Itc t"" f", t en " .:],,"! ,: ." tub k- 231 cK"tylt.,t,,· c.'"J", ViC!'] r·o ' 6'1 IHc'd '-" 'J f"d,-,' Th P 
depend .. ,,! vcrioble [AUG) wm tro'1,furr·oo by tokir -g the 'qL.Q!", '081 it"' e<dcr to >o1;,;ly 
,igr,ficot" ir' a ",odel exciuding pCltentia:ly ,.,f luen lial ,*"",',dion,: t>~t in the fi nai mode( 
i'"'eiuding aU "b>Br;otbn;. li" ,,-,y ,,;:;<e nor ~gl·It.:,a"tly """ciaied ,"j,h AUL;. ;'';018\, 
po:;on!, with rig-,,,' B,'';,o. ar.J t ~"e who ceceived FDC, had Iowa ;"""iazid .':',lle: VaiL'." . 
Graoler Allei vall)'" were m,=iClj'Jd '.vith hiq'-"" Ur .. O 10· .. ",1; C'l .j, j"twe,tir.j y, the 
p'mo'1(;() 01 HIV inf<xtio r'. n,,,, rTlOd",1 Bxplair-.ed "":v 2 1% of th", variability cmoc;ated 
wit~ t"" sq'J.Jr.e roo t of AUC; 
I c~.:~ ", •. M,-,j"l '. I""'. ! I.,I~ ~ ,~ " ' ~'J'~'';'" m ,~!-.' d , '''' .,, ; .,.~ r,d"" ," II ", '0"."'. r,,,1 d ~. II( " '''~ ~ Ir~ci 
0< cx:c'y;", ,,, ].f elt." ViCl' no< "",~"o,j n It-;, mcQC~ 
-=;----,,---- ~----~ ---
SCl~C~ Sl (f ~', l 
Ji,oael "".'6'," c.":'" 
Roi"-.d I W.8W'Il 
'ctal 
,:'"'i • ",,'h 
P,oc> , = 0.=1 
Ac",t yiabr ,tatu, -sa' " " te' ",,:J in 'he ,,,,(;o ' ld model (5; tade 24). and facmU:ati0'1 ; tail)'; 
','iQ'; omitted. The mCluei explained 40% 01 the va,;oCiI:t,. 'n AUCi c..-nor'Q,t Ih;-:, 9(} 'Lq'OC:S 
w:th lllemL-re.~·;e'1t, 01 the rele'iort r:ov:)'iak., Ir':",rr·,·,e·dial " a.·1::1 rop'd nSii-"/I·:lton. en 
average. 'md ."UCi ,-,niue' ~(}.56 rno.hr.: 1 low", than , iow a""t,10to". "1 keepir,g with the 
lindit19" in A i a,',ovei, HI v· 'r~",clion via., a;'0<-iatec ""In at' B. 10 mg. nrJ·r i"crease in t'le 
I\lJ(\ and lor eaell 1 mmoln incf'_,eoc in urCG !rL AlJC wac inoceccd b'! ·1.G I mg. l t ,i' . 
Convc","y, ,,,..<:>k;ng and i,o"iCk:id dv,c,{y,g were delerrnin'ml, in m::Jc: 5: wcal: 
""o<,;;at:o", ',-,ere h~nd bd',,'eu, -r-GT and plc:telet "'oun: and AlJCi, ana ""A a"d 3MI 
were not 'ignifi :::a d determinant<. The dftme"cm bGtwccn th e mode~, ru99Ul I , tllal illc 
eJ ist.il;ijtk''' cof the >;:,:lvenate facto" in the 6fterent ,ub ject grcllP' induded in the mcdel' 
: mgl'9 inCk'ClK' il'. " 0,,iaz;eJ do>iO, th e AUC: incrcClkeJ by 4,81 mo·"r_'- ' _ 
!~2!;. Mel"" ~ IMLJlirJc 1,-eCT reQ''''"'''' "",..." 0' co,' cw<at~ tad "" "" f,lIC; l~~ ~ II eel cO I", -'<JoIl " , I W~ 
WIT, rtC1 osso"e d 'n 1m ~ooel': 
Scuc e " " -", hurntle-0: cb, ',0 'h-J<- 6iA' <i,," 90.;<.'83" « ~2!-.'o6 
~e';-"'Jal 9931j,98' " 12 ' .1221:' ,"" lbl63.1% ~ 1&;,3~(l4 ~_ qu<:>'ec _ 0_.0-15 
Formulation Iyf--..... "1m n:lt r"ated to iS0IliU'id efminat ior, ThE' mod~ derived ('able 251 
(lccour,: , lor )/% ct the vCI'iahlity ;" the ellmir<:>tian rate c on,ta" t of i,ori a oi d amo ng; t 
the 92 ,,, l::j Bet> with dJta fe r a! the cu.'a~ate, incl·:Jd,;d i" the ,,-;ode! Irrtermediak emd 
rqoid acet/etcn hed ke value, 23% greater :hen 'low acetylata,_ The e!imi"(lji e,, rate 
eomtant w m red~ced by 25'r. in HIV-hll,.ded patient' eQrnpared to those w ithou t HI\'-
;nl edion_ fQf e-ach unit ir.::reQ';e in hOPmoglobin or cxea there were 8% inc rement> a nd 
A LT. MeV a nd ESR, and ' 1110;1 dccr ecr.;e, were ,ee" with increa>ed ;e vel, of tet e> prot~n. 
The r ~ativmhip 0 1 llalt-iite ~o the cova.~o~o taeor\ [, shown ,n ,001", 26. H-,G r(;;alioml-,p 
ref:ec: thme , """,, r. fa ",,:i;-,-,inat iGn ra t"" con;! enL 
,(I je ,.-T) 
",,", e 'J;" 'k l; " ,-, ~'"'" 'aQre\o m """ ~-' ,hN-""" CO" "';" ·O h e' o', '" i"c· b>l jrm,-fo~·od ~';-ir.ch", 'a' e 
c o o.'tc." 
j "".' ''·o " " ,,",cxl<. Cl."L'I.l , 
Re, rld W . 'l;> H:J 
To' ,," 14.=. " 
M, 
\H7~. 
0 . 1](,] 
~.15 ! ' 
-------;'""' ,c,","' J 00'-'-'-'-
'[". O;j -:, .79 
f'Too·>t-u,~ 
R_,,,. ,,od · D.?)! 
Acj 'i _'C,.JCl'c'd ~ C ;971 
T,;'/;! e 26 M ,,~ oI" "',,' re9"~'>i-c'" ~ c}o' crb '-'Q co" " i,,' e '~clcv, "" h e I'",-'''·" ,i-c~rnod h,' H i~ d 







l ok } 1 
I ~,<'(J I 
d 'A\ , '~ ."8·' 
"' O. 126} " 
, 1,'1 
"-.m b~ ' cI ~ " " , ~,J = ~ 70 Prct) > t- - O,.:;wa 
~_", ,,. ·od · " ?,',' i, 
Th<; o"~mpt;o n d the linear r",,,, re;<br mod"" , u; ;rg Tmax, ' ~lTmo.'i o~d , ·", rt iem o t l as 0 
ccr1 tinuoL' variable ccd d no t be ,ati,~c-'d . Tmox WO< tt,erdore d ichoto mized into va lue, 
bd<C·.-i 3 ! i~'-''' [':ol io bi€=iJ ,i =ci ~ 3r. ou" iVQ,ioljiO- 1J a.c patio-.;,·,;' ,-.--il i , u Tmc,;, d 3 r.ocn or 
more c-o mpriwd 0 mir:or;,y of 137, w ith eor,iderab;y' d ebyr:d pea k CO~cc'1f,a t :om i~ 
bdw eer the eeva ri at", tacten a ,-,d delaycd ]:,cal- co~centratcm Itable 77). r r:lC ' .~ c 
l a b le!, c c nhiring ',oriazid alo l''''', '>niJ rn d e, were 4.25 tim"" m ere n,dy to hay", 
Jda),,,,d p",d o1'l.!;;1 :",..",11, Ale-oho! 1.)',,,, in th", ye:::l' pric: to adrnil)icn wm wedly 
a" ociated w ith t1 72% red lXtion in the ri,k of d~ t1yed perl< c oncentration>_ for ecx h 
~/j l ;"crE'Cl'iE';" ha ",rTl')g!obln the ' isr. of dE'iavej C max Was r",d uced by ~3'l', Ea "h '~rYt 
increa _,e in ,A.ST. al b--Jmin and wh ite ce ll COlOnt, w m as,ociated with an 8%, 16% and 19% 
incremed ~,k, re'pecti vely 01 a ,ate Tmax, No HIIi-infecfed individJal, had a Tmax:::' 3 
'WI' 2/: ['><i,1e ' e\lf~"'o" n' cx~tl c,,",vl;.-,,; Ik 'e-'C>I;v e ''''' """x;;(ted w"" "',"i"'KJ' e ' 0' ""'''' I.«,.-,ia>id 
cor-.o eri,,,tI.(>1S OCCl)Il'M "I ,;< k"c, th'" ,~ h",~, 
'''U- -"!',,,,,:(,, 
l R c hi2l l) 2 '_C ' 
" 
',,,b'cr (~,-~, • '3 ' 
P,e cdo R2 = 0.25.0 
Jhe paller" a'1d t(ea lmenl fa CIC' pred", != o i d", ~K m em ures for imri t1zid Cf'B 
w mmorile d in 1"b:e ~16_ 
-oX" 20- ;"""'-""'i ~, :r.",~ ~",," "'i~ '''C '_'' ".-,~~,,~"'" ,,01 """ ~ ~',""",=,*,-"",~ ';'''---''CI~', '" ,",I""",'"" '" 
' e \lfe,5ia1 crrG~" Orfr INos e ~",'c;Oko, c'-'IlI,it>Jlr.g 10 Ih" Ih, ",,,<leI< em ""'L<led, "',e>lipc \"'''' 'cg cniDn 
",,", V>e U b cj ,:>,,)<_">d0,~ ,,(l[;"""'" cxccd TOle>:, 10" ",o)of) 'DIi"c re ll'''':oo rr.co",; , w"'"' L'seC; die: 
,-t oh,k<Yi~c" Ire vcrict:<e ,:tome ,,"In a irna>: c< .': ~ ~oc" = I, ,, ',d lh0-5e 'N; I ~ I"""" 3 n,-"-,, ci te ' "" J" 
ad,- "..,;'I'd ;o-r 0:, 
" " ; 
- ,,, ' 
" 
., , , , .-
. 
• 
~ , • • , ~ • , 
• --;- .- · • · . ,," .- .- .. . .- .- .- .- • 
. " •• " . 
• ,. , 1, • 
AI T :<.1 
" 
.- · .- .- · . , , .-
,', J' • 
,.~ 
', .' I' I , .. , , • , .-
" 
, , · 
" ,! • · • 
• " I:, .. · .- , 
, • 
" II<Y'/: • , .- · .- .-.. • .- .- , , 
~,; 
.- .. .- .- • • • , 
.' ' .. J :1 • • 
.. " .. .. , 
_'. "",.,,, '-' • .0 ',"C' ""Yc'_ ' .e •• 
j: 'r" -,,,lab e oori'butea ~~o-tiocY1; '{ to 'he ",odel de,crioi"~ the ~f rr.e",c.-e , a decre"" . ;'J ',," roie'iar' 
"Cf',tiC WG, G,>ociuled wll~J a ""G"e , val-.... h'''" f'K rn,)(",,"e. ~-v(ju~, > 'om C.,e ,,,,,""eO. 
no j,QO-""anl C 0..,1,,0(. ,:"" ;~ ire '~ "d.~ ~" ,,;vee. "~.u '"" ... ;'1e ,K, '~,-"C'C' 
t"\Q che,vGii"'l> wil rJ fmc><:: 3 r";u,, 
h;'!o,y ct '''''''';'1(' ;'1 ,iJe ,'eo: f'i~" 'u """";','('1 IU t!<ewel\<.Iovl fbfild 
oj"" , ) '" ;'O~o"~- "',' ~,-;~, c",-;,~,-;-"",;· ... -, ,'1 11-.0 ,.;.:,' ~;,Cx ;., ~'.' ; ,0 __ , , '" ; ,.,.~ :·I",~,A ... ·.;i·;t'-' 
, "'.1Iior'" n "l . W' cal~:;lOIY had no! ,'<ce".ea rr,ae thor' mootn 01 a u-;; '·~d""'-.t Of-", ,0 oy!,j,,;or; pe'ie '1l1 
ir ,ne '0j'0a'rr"nt cd" .;pi nod oro""""'1 ,,,,,,"',·,,d "J ~ Iv<.>.."cci(~;' ~v'~ 'or 0'1" rn""lt] " '-'1' 1>" '_ 
, iu: ",~,~ "',;~ ''''ri',,"''',CN \'\'~ro ""d; 1 cJo:e:, or oCP"''' o=h coc-"",-.. a "'''';0 d c-q "'e'O a,,\-,-"""01 cd 
to .,.oth," 
fOe : 'i"",,'piCi'Hoc;.r,iai+,~ i:x0d _ e COC<'lh'1al:"- 'oo~'uk1ii",_, \""' ~ u,~,( ,,;iG'"~C''' "'''' ~O"'I:>ir,.,d ',',it] 
iM,h,;d " >,;c..-,""'" ',;;a,,,,-~,,, C>JJ rf '9 ""'t] ;,0'1ic,,,;cl 1 ~) fT,;t O! r'!clfnClic. , 15C mQ with i'Cf; mid 75 ~,~), '-q" 
dn) .. IDrrf.)a:,-,-" d p,.r'-"~,,,,,: <J'(,l ~t""nh,d", ''''''~ ",ed_ 
b,-)fli<uid rKld ,ct.,J,;cmricolly ,,_operia bicY_w cii abi lity in :erna le" and peak concH,trmiom 
WRe delayed in "" u e, Tili; effect wes '.rdepenaent of iile dm",lkg c:r.d ,ex wa, rd a 
-.igt~tk;<;m' JdCerII'j n,-;mt '':>1 tl ,,~ ret" c,! ~1 ;",hetiQ r ,~n expk~nction b, 'he findir-g;' not 
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FCX> i, r~t GtT'''':Jr\' pe,c;:ei'ied Ie be ~b!ematic _ 11m.,.,,,,,,,, the ' co,,- th'_Hhd!' 
intHac' k,'l aI !uded to "CT!ier, bbtwoe'Bn 'ifampicir arK! i,on,""'lid occu"i"g with eXP<J_'L¥e 
to neal. hJrnioity an,d IlgnF' (lId :",ad Ie ,md! redu.;:ticr.' in the i:;:.nia:io <oo,;,-=-"t ai the 
product, ,tudieLi :'1 tili, ,~udi ~il" differ"nGe, .,.,ae ,ig.,;kar1! withou~ od ju;lrn"d 'at 
'Ki<"~ ,. -he Cltt",er'Ce, ,., Cino". AUu mol ,\U O t.'",."" n-.o,. w·o ~ r ~c .. ·,· ~cI 'orn'vatl"'" GC<'tarmg 
·, ·,~"" d "' ,,"" IS."i ,n" I~"'" ....,.," ' "C~",;-d ,rx; , .. ' i<o,'a,,''C C>"'" "rconp~", "," "'JI,r;Cmce ,,-~e 







,\·,·:,,-[.:,',1<' 'l' 6.69 "HJ-' 
l1",dlC>", ',-" frX;, ~_3C mQi 
I 'rim ,,,1;0 I''f, 










~ OC i 
'.';~ ::! '''' ' 'Of \D :;05 "'~.~.'i! I "",d·,'., Ie". °rx~' ?5 .'i& m g_hr/ 
fX!5l:l ra-' c "-'1; 
~ · r-,H1 
A, migh; be e;(p",ded, oc-c,t/bte: l'iPc' ·",ac cisarly on importar.~ detern'inant of 
" Iiminatio'l ,ate and bk'G..-aikJb:Jity . ,"Ithough the rn~ !li ': r::ria!" '''9-""ior , ,hoWN a w eof. 
O'I<.x:ia tKm ''''j ;h Cmm. redxFom in AUe; Cl'ld rc.!f_'ije 0.' ofX.-~(Ai"'al .. ly 10,:;0 1ll;)_"' ,I' 
ond 210/0, ,mp8eFvely, were ab;e!Ved ClmO'lgst in~~ r'-" "'>d,"Jt" myj rapid (leet'~Q~= where 
AL5C between ~ow, ar.d ''It,,,medate '-'riJ io,t Qc,,;ylajor--; iwitilout adiu'~"Ten' Ie.- Qth "" 
cO'loriate_,: i, \hCM>'r in ,'\Jure 8, 
P"OU~"d e:;mination ,ate, <:r,d ri gher ,",JCi ,alu.;:; We,c a;,ociat;od Nith i-i IV-infecticl\, 
aI_", who dHcribe Cl c""'1er~on from fmt '0 ,iow acetylot", pilenotyne w ith the 
prog'''''icn 01 H ',.' irf",c' i"f1 .. A, llho'_'9h the differe'lC'" ir the Cmax ona NJ C b<e twee., th<e 
~tOUp' in Sahai's ,tudy" were 'lot ,i""ifico., t, asymp lV"'atic: ~V-i,-,fe ct"d individual, 
wi ........ ,t <11,.......,. .. 0 i .. n o..d ;0 her/", o;Iit)hft~ hl<1"'" rr"'<'1n Cmar ",nd AUC vol ...... tl-<ln IN> 
hool..,.,. cnnt'oo. while thoso with C()h cell count. below 20J o nd dlOlrhoAO I>Od lower 
:nfoan (".ma.. and AUC .",Ius:. tk;:Jn !i'~ ;;~m"01 !,Iroup. lhe h",I!~i.-e, o! ;:.~r.CDd were 
;'mICf between l~e ;;Jrovp<)r. ~d">oi's slJdy. 
'w .. e Ille '.1r1",~"'A" . , t.""'" "U~· O'"ClIlIX. VI o..~I",,,,,, ;,P" 'c" "'"1""·. O'"ce 01 "~I. d ' I~'~'._" 
be·· ... ee'· I"" 1)''' ~,., w,,.. "yd.-deC! 0,~~ ,~. ~" ",,0".1'v ,,. , T~" , 
-- :t I ~, 
\ ! \ I I I 1\ I ; \\ / 
I • \ " 
I 
I ~,~"_ i ,. ___ • . " - - " " " "' " "" -
1t"""......,,J I"y.,b cl "'&.:I w .... '" OK> ~lOCioied ... ,Ii, ,<>dlJ(..,-d ;,I'rninotiOI) rolel and 
,,-.creased AUC ..-uil)C\; I;nj',r'!,l> <.,,.',;,,,,,,,-,, wirh :~.., ,,,,,,,,I elimir",Iior. 01 :~"iuZi<.I, o ll>'-il 
mmtly m m0'at<'!it"" A lthough the corrolatiO! - bct""~",, ' __ nea c'ld the elimi '1Uti0r- rate-
cO'1<'anl wm ,tc:,li,ticalty signif icant wi1hout adju,tm"'lt for Ihe other coYanat"" th" 
effGct wm 'lot 'Ltd'_'n'iei ISpcormar', mo' _0,1 7<'-', p = n03361 , ;" lh;: grOl)p 01 potier!; 
wilh la')olY ad"c;voh' 'e-nal fundio'l 
ii,;; i",,;reo>od ;",eI, vi i>Oi ','lOziv ,een i" palienh wilh higher ~,~GT I "',,,,~ cvuic.i l;~ ,du, ,,u 
10 r"d-Jc"d dminalion. altho~gh -,--CT wm '101 ireluded m a ~g,'ilicanl dole"r,inc",i . : 
Ihe ",uJds JacGil:-ing the ei n '''01>;),-, ,CJI e, comtCJn l w'id hu.f-life, 
:k-!C:Y 'JC p ",d, conc", r lrolion-; "'",,'" a\o msociat".d with incr",ry;".d writ". (.-~ !! cry,-, ,, I, and 
,~,ST level,; ",,,ocialic,,, wnch rright be related to dela,.e" :::b<c-.-<ot!on in mere ,evere!'.! ill 
paii,,,,r,_ AamilSior 10 a cor,ol com,Jmprion ,n Ihe year pf ior 10 adll1is~on ana ,o",e-, 
a lbu"'in 1e-,-e1, we,e we-aklY awxiated with a mduc.;ed ri'k of dekly0d cb,,,,ption. TI>0,e 
i acror, were- noi m,o:;ialed wilh aiered bioavailablily 
,1;00e 'i;ilh l,-,creQ;e,;:i pioleld co~d< and tolal prolei'l Ie,rded b have, 'educed i;-oniairJ 
b ioovailatil;ti. ard 101(;1 prot"ir wm 01'0 a",xia'ed with reduced e-I,mnation; e-ffect, 
pOl'ir_' ly mK>cimed '"itl-, n,G!e ",J'"",r-,,,,,,u (j,,,,a"'_ Corwer,dy I, igl",er eryiiYoG)' te 
,,,dirner-ta:io,, rafel WEJ:e a<>ociated w ith mafgir,-" y m",'e- e-ifd"'lt "imirlOt;o". and 0 
terden"'! '" hicrh"r i,,,,, imid le-w,ls, H""''''C<-J lobin ".'0: mc-re :tro'1gl" ",'oc:at<>d ,-,,'Ih 
carlier and highe' pea" conce-ntmlion;, in sp<t" of m,."." dficiont ~imination, lrer"med 
luKV wa; 0 1'0 m,c;.-:;;ak,:j "N;lI' rn~C::- ('lr i C" i C"~ t d iminat ian, po"ibly i.-,dicating r"dv::-::d 
c::-limi r1Ulio'1 i'1 tho,e with mae- ma.-+ed red 'Jc-tior" in i"-"1 ,_,til ;.catior c:< supply, ALT wc< 
WCClU, ',:I'"c-cia,,,,d ,·,itll ,-,1"'10 ",I IiC,i",,1 " Iiminai i"". 
Tho,e w ith a history of 'rtJ.0"incr 'nd inC"'C'""ed A,UO Vclue, ;" • .rv'-,ak '-:l"~r"-_" from 
-:-i>lCT<3tte srnokirg we metabo1D:d by 'l -uc"" '/'rar, lermes, tc-u, C0mpe-!;jiyc::- ;"I;ib'k", of 
boniozid hI' '1;",<0 " _",, tonce, in 'make-"S might b0 nvoly<'d Corwer:lp lv, ,moking 'nduc;'" 
CVP2El' ''', which i, ;'ly"ve-d in th " 'netoboi i'm of i,oriozd but tns " '" minor mc-tabo;c 
pathway 
PYRAZINAMIDE 
r,-> 'oti,'\' 'he o»' .. "'T,ri",m d !r,7 "n7"" re-] r""ien ",C'dd on'" " 'Air .. ",,, ()L;l lyin!) 
o bserva' ien f,'_;::, jc>ct iF, wl'e fKld " !' fr' Icy ,,,, d "Cl ro"cen tro'ie",; 'e" eh~tec II!) wm 
dtopp~d Irar" ' h<o d,-,ta ;"" Th ... moo,,1 Ita!c!", 79) exp!cined 47:; at the ,.-otictilil y 
a\,cx; iated with the p~, le',"c l, ",t pyrolir.O'ridc,. Srnokino in th<" Yc'c:K prior to admi«;":., 
and ma:" ,e" we,-" osK>cicied wiHl 5,23 <.>'l d 4.70 ,,>gil teduc;ion, in pyrazj(\Qm..Je C,',-,= 
re' f'>€ci ively, For each i mgikQ i"creaw ',n the' cle,e of py,-ozjn"",~de Ii,a OT0X was 
mg/Ilnereme In th" OTOX , 
- t': , 2" 10c.~>~i~ Irw '" re~e ,, ; ..., ", ,,,,",I rl", c,!H~G ft-,~ elke! ,.: o<,H ~ , ; <n J h~G~m"' .1 jG<'iorl C<1 'h~ r ""* 
",,".cor,tra' kon ct p)Taznam'de 
jlj(,<~,- ;; " Mo-..i0' 9632,2:;&6 , 
~e: ':lUai , I I?:!.! I.' .') 







C>'-<TJOoC' 0i """. ,~, 
t-I < 19r<'b.71 




Subject St' WUS o'¥N' cOcpp€d "n otdef k) ,uldy 11'." tn cx:J... us,umptions, T;,e 'T!(>d(~1 
accoun'ed I", 46% o f the vaiaiion ,n " l'Ci itoble 38), AS 101 C,nox, irlcreos", ill drug 
clthoug;, t;,e m ,=iutiOfl wa, ".'earer ftF O.06J), ,,,,oI'er; hcd AUCI reaJc:iorll oi 20.57 
mo,hr.I'· A LT "nd A~ cCI';h'w'w ';gn:r,,'cnlly' Ie) a '-'1,,,;,,,1 ,,,:,tI,,,,,':3 p:;'eniicll y infiuamiol 
observation" The trornolri nc,e, l'-'el8 ihcrdoro included in :he fi nal rrKldel oltho'Jgi-, their 
i""i'J, ion mduced Ihe ,ignil icQrlce 01 the ,-",oei;:.;ti.:..n of " UCt w i'h at/e ' 0 degree of 
covor,'''nc~ bt,!-,';"br. CJga ar.d ;he tramarni"o,\el with", ~he l1lo,j~: ~~pbm this 
p!,..,n"menon. 
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Thre<:' ob'Hvu1ion., w1 'h Ih" mmt !(>\'f',aJ'" w"re rirop"'(>Q in a-d"r 10 ,atdy the 
mlumptions 01 the lin.,ar "'Jres ~on mad,," i';Jbject 17 had high bJin.Jbh !"vd,; 93 had a 
very high AUCi and ;--;g'1 ,-"ea lev,,",; ar .J 150 had a low AJCi val<J"I, Foriy-two pL-,--cent 
at the varia! ior in AUCi wm aceo;Jt1ied for by ire mode: pabe 311 H I-/~"leciion, 
,mc+.ing ar~d h;:;jw, ,-"ca I",vel, ,-,vere mK'Ciated 'Nith lar,)C ,,,1udion,, in the ~, Uc: 1108,43 
m9.hr.fl for IIIV-infection, 96.20 mg.h r. I" fa; ,meking and 50.116 mg.hd-' fa- eaeh mrnol~ of 
,-"(',,,L Eac~ 1 umelil ;~cr·C''''\·C' n bk,' bi!i'd:>in cmd "'CTch 1 mg,ll'J ;'Cf""_,,,~ n the Q'J'''' of 
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ond I .. " Inon 0. 5%, re 'Pediv .. ly, h 'ne hol l life. 
PFoz: n::.omid", TmoA WOo lorgel',' irrdepends.,t d t:,a cO 'm,iot " tactors ,acor-dad_ Da:oyad 
peok cO;1c;;nho tiorrs OCClI"";ng 3 h0\_~' c; mc;;; oftm aruQ ;r·,;w·,lion ' '1 '·8 I",olia-,t" ""6,6 
r8lJ ' 8OSiC;1 mood i"'itn ,qCKlre roo t " on,formoticm of Tmo~i "'Aplai l-.ed crl y 5% cf ~he 
-.-o,iab;!! .,. obo .. r.ed. ::.ll-,'--! ,hcM'ed II-,<OJ' p!"l,,!,,1 c('>vll i "rrd wn itc ccll COJil~ hod , moil blJt 
S I o l ilticoIl',' ligrrificollj o ssoclotions Iloble 341_ 
1 ih'r ,<: ,IA) t ;p'~ .""0' <e~re,,'--' ) ~odel "" ,en'bO:' th e e tt,rt d OlOtient <:>r>oJ tre almont ted"" "" Ih~ 1~ 10 
ro,,, ,I, p,,,,, ""·" ,,,nkk "d r';""':","n,., ~ 
\cv~e $\ d ~, " he, ' cI 00. . W -, Q.69Ol , 3.71 " 
, , _ 3.73 
~",;dJd 12 .Y~23 13? ~" flc·~ >-. 'J,' ::3.046" " D'!,~ 
p-,,-",'17''l::;''1:de, C011lpar;;cJ to ,ifa-,'p,c:;r-_ ',oninO'id 0'10 e~horllbc;t0L o-,d ~h2 n-,·c,:::'",!, 
de,c:rib:-,g the Crnm ond AUC voluo, e~p!o;ned a grec.:ter f'J'o pcrtion cf tne o'1Cx;ioled 
'.'o 'i ob;;-;,(, Tne voriabi, t,. of Trnox Wel ' poorl', occouIl I,-:>d 'C~ b y Ihe ccvOfiote< r.,.cord ed 
The drug ame per ~j IOYI();lI ot b:dywei:;;.hl (rang',g fror', ,9_6'; to "2.63 eng/'.91 wos the 
mo, 1 ;mpo'lanl detem1inant of p,.ra~~lorl~dc co-,ccn~rCJj;o-,;_ The Cmox ;',UCt and /\UCi 
i-,creosed:n 0 1"'''0; monr ',<:-r "ilh Ine wei;;;nt o~', lS t"d dO';.,. IfiQJ C 10), 
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l ' H,~ ·'''' d>'·o co""butcd ";Jt,,'bont!/ 'c tl'.e ",c~i de,orloi,,~ '0 ' f ( m~mure; m noeos~ ;'j the r~l~vcrll 
vcriroe w a; a;,,,,,,,i e aw'j'l m i"C'ecr.~ ;" Ih. ~ d,," o[ Ih . ~(m~(~ . ~Q . p·"c .... "',.· 0_05 clIe ,,>ocI'cd 
). ",~ ','",'cH. ,,'~',H_,cted "go~''''''''I!, '0 tre m ,x!,. jeiorlb;n(.I ''l~ P( m<tO> J Q: ~ ejo,v.a;e "j II ", r~l~va'l 
Y'T;.±4e 'Ncr; """x.;"'~d '.""~ ~ mdle ' va\ ..,I·-." I -, ~ or "',,,,.o;q~ , "-. :1 .,.,,', > Q,G' "-,, sp.x'iod 
_ ,,0 ."". ,',r,,_,"; , ~un';i.>u; :~'" ; ~ 'l~ ,G"~'"'''' rr.o"'; ""'>e'UlU II',~ f~ '"eaL,e 
, MI,,-, of ,meh\<,;" h. 'i .'" 0<1" I" ex'-" ;',"" I" ,'ewcf"kXlf H,"rit" 
' ro!a\, 01 rQ\O~')f ""if" COf1'V'Tti oo n !I-e ',e:>r pr'''' to Qdm:,,,oo '0 5rewMHc", ItH<t :> 
o pdiQiL" now' ca-c,pv ""d ,,," 'ccoivod ~; C<c tr, ,,,, .. m,>!,-r, c' do:L<;" trect~' ~'lt p-io' j" Oldmj,lim; p~tient' 
,, '-," 'elreo,""""r ~"'o~"Y hxi oro';'''' O', re~~i ,wj 'O<,i IJ.'O<'''' '' ''''' '" .'J' lor "'" ~;C"., ". ic"'9"' 
','J'" IQ: "" ,,,,i'.(},,-dc , __ " "', Aue: G:';'; f,l.O ,'. ""i':_""~''',idc d""c .. ,\~. T~,,, 1i7'i--'n'' 
wa-; 'e"H <lIirQ SpOcrmC>l j ran,- ~"veldiC<".'. ;em"'" '''''- 0.0<:1" ~_xcc. AU'_ " 
AUC;; ''''':_':'.·'.[-58. P~",G='L 
I~ 
"i • " " .~o,,~ •• ~.~.~l~ L. _____ ~.'~~~-~' •••. '. _______ " 
,'c' cI the ,_,,: ''C';u\om 
rho_~_5~13, p"-'l.Coo:J; 
TOlal b'~ubi ll concentration wm po,iti'.-e ly associated with the ;,al:-lil" i'pecxn,:.>n, rh o; 
0,2228; p - 0,0071 :' and II"" c <xre,pond nSj ;nve~", in pyruzi'lUr(,;.j(: "",,"'s, r.,~k'cted by 
comr .. li!bn 10.' rc.r<J I;c cI'm:'lUti0r,! ma'.' OC'C''Alnt for thB m'0Ciatio~.' witl, reduced 
Bilm ,,,ation rate, of bo;r bil r ubin and pyrazi'lUrllide 
~(1\)[~ I 'le Q"v.;kj,,-, L e ':.- ~e" "h, Lf" -.. 'L": ",,,I !i,1 "v:"""",'"id~ elllU>.. AUCI an a Alje' l;t,~ >,cjL.:c Gil 
"<:T"lcC>'1~e d lI'e ""Qc,-,Ikm, wi""'J' cq....,tmeo, 'or othe' c"" ",;atej. wa; 0.I1cC·"'w<1 " .<i. '.f; "~a' m'-'" , 










, 1 L 
",..,ile 'ller rad reduced penr. concentrat;om, trPy cl io,,", "lmrncotACi ' '1'' rt ,_,_) "yJr._, <Iowly_ 
Advanced ago and hig l-"'f Ida' prdeinlov",l, and HIV-rlGgative ,btu; were ",;aeiated 
A r"'Quetion at approximately 247, in the pyrazinamide AUC .vm d mclibed by Sahai e t 
aJ. " in HI'!-int " ct " d i;ldividJal, ir cornpuri,o f1 to IKc'(] lti'Y cc,,,l roJ, , Becuu,., ,qud"e roo I 
trar>"lor'llation at 'h", ,~UCi 'va; ,-"e d lin t'1i , , tudyl for t ~ " rcqro" ,,-,,, m",,:le!, it ViC" not 
po"<ib l,,, to ",'imate the ,cduclion dve 10 HI'! i" lec:' ion adiu,ted lor t ~e ot~"r Inctor" The 
medan ,A,UC in co-irltccled r __'Qti",,,', 'Nm arproxi'l)(]t"p,-- 129:: lower than thot ir pa l'erl , 
with tub"fCulmi, alo"e a"d ihe effcct of KIV'inlcelion we. rot staj'"tica liy <JgrJfk:an' 
without adju<tment b- the dlce'r co .. orioks. i~e more clrarr.aiic reduction! ;ho',--,n by 
Sahai ei rl _ might be otlribu too 10 the heo lthy control group ,:",d a great", fj rOr __ "xt<x> of 
HI'/ infccJ"d >LJbject' w;'I- more advanced di'2OO'z, 
5.'::&ing wo; (mc-ciated wi'h redu(.ed p y-raLit)(]rnide leYet" bL" 'NO> not a ctaL:icali y 
,igriticant d<" tHmi"ant 01 th" ~imi t)(];ion ro lc , Without a::!jui trn ~n' fer othe' COYariate;, 
the ,,,duction in be level, '.'.'00 ",.,."all, but the d fe c: t w a; -lign ificant for Cmo:< i~G'-" c 1 ~), 
F'N- ~ 12, n, ,, dl~c d '''''*nq C(' ~''''''rarnCe cmo<, AUC' ,"0 f ,Ur:' lhe "()'1i'b",~~ ,0-' lhe ~I ' ~ cl, 'N,", 
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I .c __ 
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",::;';; ,I 
reductio", in AUCI and ,A UCi, re,,-.ectively, T~e correla;ion, wit~out ddju, tmert for o''1er 
" 
-'":"'1'::11'01"'1 O"e 10,- '. " : .. ~>1"" ! 1- ' he "':.Ie, ",or" <i-;:r.iF.o::='lv 'OC' ,,~1 . ,,'~ lncrOCS'n:J 
Al T ,-"".-J '...-.. 0 '~ ... el ... ",0,1"" '0,,, m,QC;otiOIl wlM ,,'jmirv::l'icn !al " W(H "-.;Jrif-COl'\t on ly :or 
,\ I T_ In( r.,(] .... "l " 1:r1""Jin" tk,.-, in_ !h,y,,, \'! ith h'gh;:;' t· LT I""",I'. !· r"'.:it:1y a<p k:Ji r><...x j hy ' h e 
,..,,,=iation 01 ' ''Ic,, 'rv~~ low'" All I flV « I~ "' Ilh impa, ,,rl hfofX'l tir hmc tlon ,dared to 
olcchcl .. -po:'r.r"" ,'If":~,;,;''' tt-ti, hvPOlhG1i, i- ,wt "J;')r-~.r!""'J ~"l 01'\ o~",t"'n oJ! 
e!iminu!j,-n '010 with u hi\!ory 01 O!Crhnl U<f! i .. , the ,,'eCf ;:rio' to c-.Jm;,,-vn. The 
;",1 ... ~;;;;u-':;- _ ... t .... C'o, .... """ I~, "'I' ~ l~ 1'1'.:.u .... ,:m..:d'" ., In conKOII 10 Ihol obs""v"c 'c< 
l<O<'Iiazid: hio;,;hf:, ,,,eo I~ .e~ w~" (>IIoclo'ed "'1M incremed er.." ..... otlon ~atec. O'ld 
m<'Xe d liciant " r. mi .,ol ion related to b ette. heo:ih ".,C± n_utri t i ()r,a~ : to l,J: 1., th'·, petie"t 
':l " '''P ii rd€lf><.i. Ih_ ''''01 " r..c,:l;,.- " OI\QclaHon 'o~ I".-'e"'n ''' '_'C' o .,d B'vI1 :(.11:,1", 20] 
11.'l'dlt..B 'he ",,:xl,..,.. ~ 1&' All "'~.~ ",il~ ~he .I··r",, ___ .~ ~ <T<l ~l .n· ~ I ~ ' c .. " .... ~~~ .... Ih 
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Ir.CleCll<.,d ... h·;", .:ell O11d d""'60"",<:1 plo: .. l\.1 .:.: .... '11 were o>,cciot~ wiin duJo1~::i I'~·~ 
10 C'fll ' " ,,'ld occovnte<1 tn< (J ~">ali omo,ont d the ':cri"tk>" ;,, 'r1'ax. 
ETHAMBUTOL 
Th'O p'Od' c,C'r.z:'OntreJ ti cJn wm tram\vrrn ,,·j ~y lal':niJ In., 'cr""'" rou l ;" mue, I,, ,ul;,Ty 1I'e 
') 5! 'Allp li0!" of 11' ... li, .... ') r reqe,,;on rr>:>del. Change, in haemoglobin. a,~in and II IV-
;nl",diorr l tatv~ wi thin 1h2 cchcrl e,ploined 2~% 01 the vmiobi'ly in th2 pea, 
cc,ncenl ratiom flwe 361, HIV -ir~",ct ic< r woo <m= ioled w ith r<:'d<Jred peuk .. thambutol 
high'" ('max va lues. 1110 magritude at the <J5,o.:;>Oi 'an, ,-o '~ld nol bp. u " ",,,.,d b"u,Ju;& 
of th", Iquc;r", root t'umfqmutiOl1, 
leu "", " " >,'ode' :;3= ; 
~,,'dca. 1 ~ . 3o.;3 124 
I ",ar 20./ I", I II 
M j 
I . ..' 8/>' 
, ITW 
HI 
------------,,,',0.<1)0..,,, cDs "" 
C, ,j I).", . , ... ] 
ITc-b·or · O 
R_",_ '",od - O.2~SI 
\0.;" ,c;.j "'~~ _ J ;>,:,.e , 
Ih" Ih e,elr recye"k,n rrtGc!eo :TabifO 37) d ca,'ariate laet:n en .~,L'Ct "xp la'.~ "cI 38% dlhe 
,,'anabilit,,' ""ociated with A.UC_ HIV-;n leclicn w'" o"oci,']I",d w ith 0 5_88 mg_hr_ " 
!app-ox'malely:>9%1 reduc'icn in the AUCI _ Patient; prev~ld'" tre')' erl lor 'uberQ"0! i, 
')I ,a hud ALJCt vulue ' uppraximately 16% lower than tho,e rereiving tr eutmerrt lor Ihe 
Ib' ti .-ne ~h .. e;harnbutd rio,e per r ilogram of body w~idlt w'-" 'rdepende"Hv 
,-",ociated wi th a rectx;ticn d 0_34 m fl_ hr,f' in AlJCI lor eo"h 1 mfllkg deceeus",- As lef 
the Cma, value" high",.- haemuriobir. anrllowB' dbr.;micl level, were Ulloriat .. rl with 
g reate, /\~ICt_ Gu"",',u'QI'~ tu mt'1 trur ];/<.-'ru , .,. urld ug .,. wer e <]!"" po:ilive ly u"oci')led w ilh 
the AUCt_ 
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Th e covaiol e loelo", r:nte>r02 d into Ih", 1:"02or rp!]rPI\ic n rnodel, 'K,d 'itl ke impact 011 Ihe 
ro le o f " Ii",iration a, Ihe ~ldf 1il" 01 eihambul ol. Log Iromfo,,,,,,,lion cI Ih", 
phar' :aooei" d i" "'POI''''-E'I 1'/01 IkCd'C',. !a ,alil f,' l"A a"'-'n1pt1cI~; 0 1 t he "NCO' rrxxJ o l, 
(Ial:>el 3? and 40) and tolol prol"in w'-" Ihp orly cava ria'e mlcx:ioled l abei l w 'lorlyl 
,·! ;th th e> tramlocrr>"'d m ea l,-,"e.' cI ro le 01 eii,,,it)(Jlio,,_ For eom T g.~ ir1CfP'-"" i" II, ,,, lotal 
pre l e"", the 11a1H 'e decremed Cy 0 .7% arxi t~ le eli"-~nal<:J" rOle cOl1llonl i"cr",-"o d bv 
om 
',-,,,,·c. S,' 
' .... ,y, C O fl l 
Re,d K>l 14.1'1'3 ' 
-.tc' 1 ~ 2424 
















H,,-·b<;, ~ "'", - 12) 
H' '1,,- -'.5" 
~'vI' > r " U.r>NJi 
:~; ','; : ; 00788 
rjv",,-,,,, Q/ c,r~ • I x· 
'i " I:>li_ :<'o 
r;-ob~ F · 0.0601 
O,Olll~ 
The linear re,;r.:;",,;cn mCdel i~ocl" 4; i de,cnbed 24% of ih" va riabilil) "",,ocialed ;,ith I'K 
lime ;o ken !o ,""och maximal e ll ' ar llc utd conc€11jral<:J"5, Smoki"9 ,Ialus. ,ex and 
hae"mqlobin contributed ,igrificonllv 10 t~e ,,",oj,,1 '""he<' 10 ra 'e"ldlv ;n'I"""n1;0' 
ob,ervatiom we,,, remov"d_ l'low"v"r, wher1 all ob<"",a lion, were ir>eluded, ,rnc <"I1 
,lalu5. haemcglobin and alb,x' 1i" ,,-,ere " at o;;grlificanlly a"cciated w ;th i'ma,_ Inc'emed 
el m mbu'oI dme/k.q , htol pro teir1 conc "r1I,o li""". bi lr ub n I"vei, and AST lev" l, wele 
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Pulienl a:1O treatment jocror €-rte-crs on It'1c p~ "".:"0-'-''-'1 01 c1homtn)rol are '-lXfImarile<l 
in rubl.,. ~2. 
patier" ,"-"" irl CO'YICUr1Wf' to refefP.nce rQl1gc'i , Tr;, mxiy de~10r'111r"lcd ma,ed 
redud""" of rm<)'· A l!Ct an.J A 'Y: i ir cc~nf~c'~ pa 1''''11, ;1 :'cmpO"'iSC'.'" Ie- I,~b"'r<:'_"·::;; i ! 
pal'erlj, wittvxll HIV·"I,?<:tion. The r.,aVCr"·"'1 lr AUC' a.mdo!~d wr,t'1 HIIj';"'eciion w~e 
<:rDj)ro>imalejy ~ F'Jr"!"la'more Ire effec1 01 HI'I-r'llecf'on wos ~ t::lI~1i~ol~1 'igniftcon' f:;., 
Cmro und AUO. wlrnour aajv>tme:rt to" ctt-.!< CO>iurut", :r,gu.-e 1 ~ ) There wm n<'I 
ooviou, !r,,"ti ;n elhnmbutol rc~cI' rclo' l!<i In C"I)J,;. (""'Jut, ir. IN, ~moll S<-1ft1p1e of HIV 
i"f",ctcd polier.b, 
1otdudio", in Cmn.,. AOCt and AUO. 
(;or-cenl; ;;;olic.r::. ',' ... 9 cnodal~ .• ill ; (.1~ .olotd fTWillU'E" oi .,i..,O ... JlO.:"rTy. The impra. Cd 
bioo·.ailoo:lity In =1, .. 011 .... ,Ih hi;Jh9f '">oernoglob/" cor.c .. " .. 'OtioN ""0; onl v ">oI',ific01t 
",I '''''' (,qude-d tor It\.,. .. lied. of alheo- CO\'u"o k.'> i" Ii ,., r"W"'''OI\ rl1,>< 1 .. 4, n ,w ' .... :phv .. 
""oe;alioo of Crr>Cl~. AUCI ".~d ,\UC:: .... ,11, <,bJ r,;ll i.I 'I,ongel, <1 '\<:) >LfJ"Mi.I ih::l t 
" 
dd:::!lct.:.d pal,onls hove I'.iY,c' .:-thGr"'lbvloi ....orxenhol;onc_ ;,~. ,(';1. ., lnambulol 
d.;.mJkg and rr-eo!tr.eI"!l cal~g..""i wc;c cJ,,., e<llx:.alod with inaeClled AUC ,::i,;H 
T <"It'I., ~" \ ,.."" ,~~ '" lI" V_"",u' e 1'-:1", 'co: ':c' ..... ~c ."o~ .,,~, ,'~' ~_"c""~ ........... "" ,.~, "" 
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'; II,.. ",,",t"" c,,,,,·t>o" ~"~' 'Y" .. '0 Iho -00<:1 :to" ...... ," ~,~ "" m",,,,.,' ,n;,.. ('('1<" I~ "'e ,,,"e..ml 
",,<tie 'N<Jj ",~,,---.l· ·1l ",,'!-O, " '~(".,' ........ ,~ , ',,'~" 01 '''. P( ~\e"",'~ P ~"" ~ o, ~, •• • "" ',"-"'r_ 
.' ,.,..., .,.i,j,., c""~i.'.Md "V1"'I~' ¥ '0 ,r-.e '''00'' ,,,,,,,,t.,,,, ',~" ~" m,'_~,~,' " :'10< •• rut' ,~,,~. r~ ' e-",'" 
.-"k>t<e WOJ; ",'-Ocd ~ u wi ll ' " .. ", ,,1_;, .... '" r", n-", f'I' n",a;"r~. f' v"'-->e, > Q GC "" " ' '' clieo. 
"" .• "i-'_" ,i "", "-'"" ' '-' ' I v ''' ~ '''\101\,or, """""! C"~' ;'''''' ;t ...... , __ ' ,,',',;_", 
""")' ,~, m"',," , r '" , ~ V" '" ,..." ... ~ ",,," ''-'"otl t~ 1\(, v.-"" 10<," ~:.p't , ,, • r",,,,, 01 r,,~c.ar ::ok"""" """.....,,"'."", . , IIw Y"" , ... I" """;'-';,>r' 1(, f~o,,'~ " .leol .. "U'''' 
'po .... ,., n" .. ~<.c,,".~ ~"" "'" (~oei .. <XJ .",-or. ;~:I" T -01'" :t " .... ~" .. ,; '."<.r I" ",.,,~""'" """"'~" 
;n "'" '(,,~cdm"~' """9"'1' .~~ pe~'",-1Iy ,~~ v<'<! < ".,,,,,,.<: .. ~,~', "",~. Ic' ant> " <>'It"> '" I"'-';eo-
MOle "'A... bigge< <:iow5. o ro<) ,n<.;ICO'>c<i pla.""o orol.,,',. fold b llrubln and ",Sllevels wert.' 
~cC:<:lI ",d witn oeltJ)'ed peat. ="",.:-nholior.\ :,."'...,<J.",C:: -t-GI ;evels were as'U<--;af~ 
wdh ",,-,,c rQf"d Qbi()'ptlo,,-
.. 
, 
i\ ilnougi-l elharllbul" j, eli rlli rluied by re rld mechoriml> rleilne' ur ea, rlUl, creaiini'I'-' 
le vel, were ~grli~icun l ;y QS,ocialeu wi lh 'he PK rnemcx",_ 
rq y,_ '" Toe e1e c ; c< ft \'- ..r~" , ,,,, i,i' j M-(.<>j ,-cr') ''>'1 e tr,c.rnbvIC< l ev~ I " I r,~ Kt",,- ,,-IV"" ta,t w e> ,)Sed 10 
















Whil " ihe iinecr arid KX.Ji!>tJC l eg e" ion model' Wele ,uceedul in d e-'Crtbing , omo 
;,,-.porIanl covard e e!iec;" thee·? wm con,iaerabie 1""dlKli vcriabiliiy. Unexpiained 
voca lion CC>rl be allrbu ' -= d io d okrm;nanh not m eQ\ured ::nd expcr'menlal errer. Th o 
tormer cOli d po'entiat", inc luoe fvr[lublion <.Iokil ' ('>lJCh m raw mmerial end excipienl 
deioh, conoitkJns of manuiocl lXe, c o nditio", oi ,Iorege, e lc.i ana mxn erou, 
unaccounted Iv potient loetor' inciud ng ge'>elk-; and enYf0nmenlol aet",rmirKlni.> 01 
the <e xprC<" ;C{l cI drt.."J rn<et cboliz'ng <en::yme' and dn.'9 troruxorii,'Ig pt'"Jteim. nala 
collediot'l proceaLJre' were Ilanoordized to minim;ze YCl"iction aue to experimenla l error, 
a nd J::lcc<J l,-:7".,,!inc ',', ',,,, I rc;q,H'T t ta mir in-;z," ', a riaTiom " 'he pharmacorjne tic 
measure' due to the experime~t'll c!e,ign m di,eu"ed in the previC'~s chaoter. 
The , tudy UG"'omirated t h,,1 ;n 'J "",."Ir,/ with w0r1d cia,'. dru" 'ec:J'~ l etOfv <iando!'-j< fV 
the qlKllity 01 onl!lubercul05l1 d LJg' , comiderable ya~cbiil y 01 " lampic irJ ' , bioavailabil ity 
N as conl&rred b y' ;ur',-,U;U iion ..:hcrm;l<o' ri-,t K;-,_ Hopd rJl'y', l il& ej ,ttiout:on 01 Qrug Cuklld 
that GO no ' e","'pI\' .... ilh national regLJlalions OCCLJr; ,erely. Th e re<-ic",e<-i bio a'~aibbili ty 
rifarnpicin end ~on'mid '" the l u r; appraved ' OC, rai:e, [;'Je: l ion l aboLJ t 
bic~u;valence criteria lor orOOlJCt reg , ira t;o ", ongoir>:J qlJ(J lity cr;sU"Gt)Ce pcocedu.-e, 
tor ,ubJequenl batches, ami Ihe "OIege condtior'" requ,"",a ta mnirrri~e product 
detericxalion on the shell. 
Fv .. n th", 'C) h '--'I ~ , ' 1~ "cIi&ni, '11 t t..-, , tu <.ly wer& co-inleci .. d w 'l h HIV, rtor>e 0 1 th", rn had 
d orrhea ana lyriy 4 hod CI)A+ c~ 1 cOlm t, le'.,< th(m ?r):} '-'IV-inIQct'ton w e, all i"'portallt 
dete'minant 01 the cOllcen tratic-n< 01 ihe druos memlXed The eflect, 01 HIV-inlect;Gn en 
t he phorrnocokinetic rnee"~e' 01 'ilampicill, [,oniezid end pvrali,--.amide were iQ'gely 
consislent '-,',,' ilh thp fin d'no, ,:)1 e ,hv:! } by Sat-,el i pt d .'" in H~./-; nlpded ;n c:'t-'i id LJ d, .'Nitr.~'.' Jt 
tuberculosi, Peoorts 01 low aniitcbercubii' d ug concentration< in T8/i IIV patiellt! in 
compO'i,on 10 potiellt' '".,' h lub<e-rcu'c<i, d Ol"'" ho'/E' IlGt be"n p)~i'hE'd The M~Cctl 
,tude,IOil d&,igll e<.l io a<.ldres; thi, C>..Je,thl wer", l,.Oloorpowerea to do ' 0 (withoLJI 
C~I " tm .. nl lor imrxrlanl covariat .. ,! dup to conl ic:f.e'CJbl "" voria' ;OIl in 0!'\.Jg 
concen trnl ic>", in the polient" AI'hQc>gh i'Qkltcd repo1, alld e case ",,,i,,,,. d e,c ri be low 
ethambutol leve l, in T8/HIV oalierl'" the finding 01 , cb,tenl iai reductiQIl< in e thambutQI 
1E''Iel, in TR/HIV pot; .. nt~ in c,--,mpoti'OIl 10 p<:<tie n t, wilh tube!'cc! o.;;, a lone h<1' no t been 
oLJbl',hed, Th e finding [, of oarlicc!cr [n 'e!'<,d in the light o! th", inc rem"d relar,e rate, 
IS: 
1.\(',1,.\ t'.c:d ,'~J'.JC ,"d c::;~v'lrol'c:", ci ,iian\pic;", .. Of";a.<'d ",,,d Pl,a:;",;.miJe C<Xl,;;,o',,::I 
10 I (.~ 'rlall!'. Slmiloll '/, V (1" Crevo l ",t aV' not l.'U l' (';m~ ,jfomp cin icvel, in wo,,',Cr, Th l! ,t'~ 
bo:,_' ;;j '" " ..... 1 tan'~m t.C', Ill" d:rr"''''1Ce, ~ r>",1 \."""." ' \ I'''''~ €,I'''' th'.- :o,,,-,,nt-ol;',,, ,,, ,., r '" UC! 
thai arC' subl1"Ol",~ -:-t ~OP'o'ein olld CvP3,o.,4 !.,.rd to be h9',e' in jp:":"'/:JI.,.\" , 
Ev",e!i,,~n'\ in ce': 'T-.~~ :-"';oe 'Jr..:! "'J,,""", II-'goot thm '1c:r.ablil': I,· !"e f'-jfCCr-,::ot".. .. 
e,v",;\;o r' i, '" 'n",;a- (1" I"" m,nont oj "T cw'llp:c1" COl'(:","'al irl r11, A \ llJdy d"~>f'Cd 10 
d"I':r!, .. ,,,,, II ,,~ ," 'f-"".>L'I 01 p-\iv<."",-~ol(;i" ,-'n Ir"" ,ilom'-'''-1fl-l'ldo:cit.>lo: ,-",pr",,.ry-, 01 CIP3A4 
rv'J.-.J lhot ri'o'npiciro ol.'cIJ,nvlolion i. r,mi1ro by human .'J.DR l..f)f)1;oded r-glV<.op.-Q·e-i,· r. 
Ihe c(!i ~,\;;! ..:> IW (J, • ..i ,I. (l"., . ,,~ ... <--la, ;d' full" ..... I'hsv cerr ..... l'IlrOI.,-d InOI J,Joonu arod 
r,'C1 -:O'", .. "lfo~ct" 01 ,~o.~'P'dn w~1'" ,,,,,',,,ro !,."", ; "011...- '" ,t'd lo(·/- i "', ",do I or,· f'! 
.TI<:n given d::Ole, "I " ~'J~·pd" b " ~al gavage I lobl o,; J31 '0.,. Ti'C· " ,du <,; HQ<l 0f Cr1'3/1 ·.~ Ch 
d o;", d('p<'nclerl, ~'>rir'(;Cl' ll1y I-.(fl...- iC'v"j, '" CYr3A Pf'.> I9i.,,; \'J"~O) detected helw"' ..... ' I'· 
It", If\dr I • J ,-,,,t .. h;;n do!... .... of J Ur'<.l ~ ".(ji~g "'ere (Jdnrri,lw....J. ".,"" It", ndo.o:;hOI1 ,../ 
CYP3A Ie.:,.,n; Iv u "P ... ro::! 00 the lQ~el 01 r.~ao"9.u" Ihol lit .. c.-Nt:"a pnxiuci'1\l celb.;;l<.-
O:'P"''lU !::o. ' .... "'1" CiP3A '-',::a! '1Ot aweu" i '-' lT1i1tobclize litur "..,. ";'1, t~ "Heel IlK') h:l<. <) 
i~ortant :rnplkotionl fc~ drug-drlJQ interoc! ion::. c;.-eir""r "j 01 . sho,·.ed 'J 3_ S:,:::!. l f.::l ld 
Ino"u:.e ;" p-gt>,-·co .... "I"'n e.'.;::r,,~.,., i" 0...od.:noi D<.p ;", irom e hu"«,:,, 'ubi""!! alIef 
rilampici" t'eo1rnem '<t. 
,d"" ,3 ~l'r~~'" ""~b·~ ~'"'" ,..'1'1 .-homa If"...' r,,,·,,,,, moJo-l(] (_/_) ",,<I 1·/·1 ",'ce ? h<H of,,,,, ",<1 
'.';"""'. " '" ~ ..... ;;'" ,h. '" i ,!J, , ," 5 m;JiIC;J. ~<q>Ie~ ~ ,,.,, ,,,,')eO, E, i,"""~ A, ~ ~""" ". Lt."". J. i'-
Y:'!CQ",or~' , ,, A ~q c< <ler"" '"",,,,1 :-' r '(Yr~:'-"_h-",;);"'~" ~.<p<~"klr ' " C)' QO n·,...>e r. oOJ~. '" m"~ ",d 
l-or-<t1 •. ,.."", H",I, Aco-J ~<i. U!~ 1«9.; 'h .1 30 : '305 
, , -
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MpO'I.Jf'211"Je!,t cI P-gl'y'coprctcin C><PI'ccs;on and odi'ity we.,." b pYfJr;d 'he ,cCT''' of thl, 
study. However. study of t~ l e genetic polymorph,,,,,, mwciok'Cl with P-glycoprotein 
"nv~ornmntd und d ietrry taci= infiJence the activity o f P-g1yeor ... otein: and ~h" 
eA~"Jte ul I-X'l i",,, I> on li"' s evolvotion to the,e foctcv> wo> 1"01 , l lAlio.;u in deto i. I·or 
example: Piperine. 0 rnop- con,ti tuent of blox~ pepper. irh bih P-glyeopmtein in Coco -2 
cell .::'u lt'--I"l'I ' 1' l h;' rna',' explain th ~' or-r~oximotpr( 2-lo'd "C'em~' in t"" rl(l'.mO 'e·.'e~ of 
rifo'~icin o->sociatad with p;perine inge5tiOll in a ,~udy ptJbl ished by Zut,;,i at 01 in 1985 ".'. 
V 
DETERMINANTS OF TREATMENT RESPONSE 
Compi",x 'rllerodiom velw",,,,,", polie nt, paihogen OM Ir80i,,,enT ,,,Iff,,,,i ;0 dGlc",,;,,,,, ireolmenl 
,e,ponlf"_ In Ini, chupler <,,"edcd cy,oi;i"", and c:eliui-:lr ,nex'''''''' 01 :mmuri li in th" ,Ii.xly populolion 
orYl Ih,; <l_I';c;er_' libi lity o f ,\lycobacl~"m 'uh""culo:;j, i,oIot,., "_illur,,,d f, on, ih" 'p"I" m of ° 
, Lbgroup d <Iudy palienh ,yo;, pre,ented_ >'dlown g thi', eoo1y OM lak Ireatment rc'po",e,;,-, l he 
, IudI' g:OlJP arc 'LX:lmorh"j ond r'?gre"ion " ;;)(J,,,,:, arC" rJesc-rbed fm the p ulient fClc te :-c Ijtyluding 
corrda lo;,s el ;mlT'/...Jr>ily denxrgroph< clinicd- o,,c; lawo,C>')' ,horact"""j;e') ood Irealment bdor< 
i'ncl lJck,g Q~ litubufc~~' h; i; ",o'J ~ e.-e l , '.-:.,d f-cn nulatic" fad"",) C<l l'l'" mc;r!-ers o f '-reolment 
Immune re. pon.e to Myeobacterjum lubereuio ... 
In,mud ly to Mycoix:dffium fubercurm,~ i, cGnferred preoomin:lntly D'! thc cC!I '-"ex :;:.rI1JrlC oy,bm, 
M-:lcrophogc, CT8 m ,iclcd by CD4-'- T cdl" C:D8+ T cdl', yb-'- T cdl' o"d ujl+ T cell~ 10 cemlroi" 
infedion ""_ 
CD'- t- T c"lI, sec:re"" "I,tol-i " ,,, In enhance m('l('.-ophaoe Il"'rlkm ond re-qu1oi e 'l1e IL·2 .. mcdiatcd 
expansion ef yS ond CD8+ T c",lll:ne,. Most CD4+ T cell; ,ecretc Imgc -:lmount> of intefferc,,- y IlfN-
y) Clrd 'mrioble OfllnlJ\1f\,-,1 inf",r1,.lkin-2 ilL -2) , i"ter1e,-t in ~ IlL 4) , inlerle lki n-~ II'_ -S):l"d inter1~J!dn- I () 
flL WI, 
em" ,emd roule of antigen CfPO',-,"e" Ine type of (lntige" pre",,,j:ng cd ! tc- ,timul,C)le ihe I ce~ cmd 
Ih", , tr",nq l l1 of the- T c'C'lI MIlC-cm li0"" c:omp!ex ink-rue'ion; ~"'NOy odivoted f cell s polari~e ;"to 
molurf" to fh: U- , ,,2 Ccl~ , u"d occarlingly 0 predorninanlly IYPB-l a typ"'-? resr-o,,'e l erd, to bo 
l ub<>rcule"is cmd " chamctcrizeri by Ihe, prcdlJdicn o f It 2, I>'N -y OM r~JF-a e!f",cf;ng c'C'H -modiGlerl 
om,nlJ\1i,y vdh "f.l .' on~" 'i1 ant;b"d, produclKln ""d ael i,alion of m--:'CIoj:)i-''-l;;e n,,:cdialcd 
myc:cbc:cleriai djn; inalio~_ A f'/P"'-~ re,pcnc i; m';X-;-:l led wi t" It_;, IL-5, IL-9, IL- 10 m ... --J iL-:J 
H",o!th'! indivkJ,-d, witl-, , trGllO l eb",c"li" s~in led reactiom hav" i,nm,-"" rc:",(X"c, to j" lr-:l c:elP.ricr 
b=lcri-:ll palhogem croruclenz'?d by IrN-y proo\rlion end cytoloxic CDH [ c~1 ILtlclion. n me.;! 
pa l i",,,t, wi'h -:lclive f)'.-, Imonory tuoc'fcJlo;i' dirr ; "i;herl 014+ T Cdl fJnelio~ fw;th rl"c:"''''ed 
prorterolive o"d IFN-v rc'p;:-me5 in periphera l blood to ,,,ycOtx>c:lf"IiOI a"tiqen , Iim,-"olionl il 
oose; • (.d u I ih" lim" d diogrlO, i,; at) imm tw,(;' proliie; (.<;;",,,,!,,,,t .,.,ih a f'ype-) re,'pon\e pro. "' ,', ~rz: 
p l'ronoiT",nOi" , i, i r-j_'Wh! !o b" a CQmeq-~ence of macrop,-,ago ,,,,,,<:Ii '-'1 " ,,I cyt,:)kine, ;LC" a\ lGF-1'> 
una I," iO. ,'-. 11 " , ' Mcnl', c' cnF',-":"'Occu!,:>,; , I r'Oatm"n l. !i"J - Y r;<wJL I;"n ,h"w, 'Gcc,,.e~,. '" tl- ", 
n'lojuity '-" H"\"'''-i''''', let r~O"-"h ry:-Yly '_'w:!'orsk"Jr:!, ~e pa' i"'n 's remai" anergic "ve', ofT;>r the 
oOPl;::dd-or c i 'h: -,,,,0"-"'''11 ;::ijric:,d"o,,,,,-," 
~l th\ <lvdy, ,"';ec'ed cellL>er arm cyTcicine merker> of 'rvI.--n vt)i',' wer", m ec1<lJeo it) I I L ii 9"~,1 cI the 
\t,~dy potient' after) month of in-pat ient treatment 'or t,~berC'-' m", lhe 'e,,~lts ere ',~mmcriIed it) 
fig"'" L 
,~'x,iv"';":2 """":"1,,,1',, 01 patient ciemegl'ophic end clir-ica! feqh.re" '.vith t~", ;m~u~e ",qn'.er: 
'''''-' ''--''>''·1",i~,,,.J r1 lob'e I 
Incre'::1s'n] Q:J.o '"v(l1 ::1"',ocio t",d w iH-- a t",,,dency 10 dec!!nir-,g toto! [Vmpho"yte ,::'c'..Jr,tc, pl--;sm-; Isv",[, 
of liN, V, d ecreos",d p'a:mo '''''iSI; of IL- IO, and i~{-"cmeci 'Nhc,le b k)-"d '!,-10 res::'0r1,e, to rHA 
;L I',, ~ l ot i 0r1, I.',des had iow'.., Flai; ,',":' Irl~ y' ;' I', ',dJ'", ;-,:G ." 73 pg/n~ ) and hi gher ?Hi, ,limuiukJ 
""''oPO'''''' af IFN-y (median 247 vI, 73 PQir','ri) and li- IO (modion 159 V" 90 pgil) inal r",,,,de,, 3e" 
'lormc<le, inllumcc I he ;:nlor.zotic-'-, '~,f 1 cdll '''' pOi"'" (es t'OQem and pregc,!if'":' inhibit !! - ::2 .JnJ 
II'N-'{ ,ecret;"" IrcM cmtigs~-pr'",,,r, tir'\J cdl" wNle ,tiMvlation The p'oa~ctkln "f !L -4, ' l -1 0 und Il, I 3; 
wh'!e the te,b ,t.,.,-C'tle dsr;'-''':;',.'2 D"E.'\ j:::-::ilita t::1 Il,2 \SCreti0~ and the e,tabl ~ hmel't of Thl 
c:or,c'; 1." a nd mighT ;r, pC't, expld~ 'he gender d:tference, in the iMMune ""P0'l'<'O, 
medi:::" tcta llymph(x:y te CCLl,t i 1.154 'i s, I 642 x 10',/1], CCl4' cell c:)'~ni iO : ~2 "", 0,533 t , 10'/1;, 
C;)3 celi cou,',t i; ,3,,3 v;. 1,; Yb x IV/I), (;D4+ : COO;- cell raiio ,: 2,U V" 1.3), PHA·\ lirnl.iluled Il 10 i 172 
'I<, 93 pg/rll one f'Pu-, timLla;ed Icl, -y i r" 16 v" 7GJ pg/rl) ,veee higher in ,moker". Th e in",sCJSBd 
CiA;- cel i COUnT " TC,,,, p",ripne'c> ci'CL; CJ tlon" in ~sep ir>g with tho li'cratws ;;"', Th o'o wilh a 
N,:ory 01 ai<.:oha, <.:c~sumption in the 'lee>' befcn, eJdmi"ion h{l ci h"gc,er mecil<ln CD4;- ce:1 counTS 
iO" c,c, 'V" O,u5~" 10"1~', CC3 '-Cd l COL-Ill; iL388 v" 1,:;'12 ,', 10 /Ii O',r:! Pi'iA-, I;rn'_'ui"d 11.'5 ""'por" .. , (45 
v; A pgiMI,l, A, h i,t0lie, 0f mloh":J and alcch,:>1 lI<e w.,.,-e higNy cOfTciater:! (Chi" p= O,oo:J; 
cdi~w:1itf c(.".J le pmly explain ih", fi',ding>, 
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Body mass ind"A ""en lil7'ificur.tly "'e9QliYS ly corr ;;; lo:o..:I • .-il l ·, k;" ~JC;y l ~ count. gr,.:m'-'=yt" ,,,,,,,, 1 
ana CD3 cdl pr"vporl!or1, and !ignih;anll, Pv>lll,foty correlated with lyrnphoc~ l e cwnL PHIo._ 
shmuIO!<.,d IfN-y and 11_:;, 'el.P~es and ffO , 1,,,,U<,l:<.'<J I~N-y re;pome< 
Il rf-inlected (xllic::nl, had 'owe, meciC1'1 ",vh:!<o cell G::G"I, i6,05 '·i :_ 8_50 X lD";C), !;ewer CD4' ·~ dl 
imedian 0.333 ",_ 0./18 x 10"fl!, aM !o.'.'erCD4+r:el', CD8' c el l ,atim Imedian OA v, . 2.C'j, bJII ; gher 
,(,ecian CDB+ ,-,,;I ca<Jnl, iu_ivi v;_ 0.375 x Ii}'ilj_ In add!i,,<\' In'" wf'KJlc blvvU .c-IO ,e,poe""" tv 
PHI',- and PFD- , limuatiC<1 we"" ,iQn:fic:ontlv ,edllCed I wilh mediam af 1 4 Y_'. I 51 pgimi; rnd 68 " 
164 pg/ml, 'esf.J"ctiveiy)_ 
~,~ ,,',cot, ,"'",G)h;; "'~ ,,,,,,,i,';,,·,.- p::~ oi:ur·Xler<k.- ,-," . ,~ ; oiooj~j m(l'k"" c>I ;,,,,,,,",-t,- C;:lo'C::I11 ~n 'mk 
c",ol<1;"", (,he, 'd~~d oy v,,~ ,'C> ; we,~ u:;ed r", c", I,w ,-"., ""'icXJQ\; -'><t prc-bct:i ll'" w~{~ dr".rm n.,d U "'~ r'U"'eJ-
W ""' !~ -W j i~ , ' r '-' ~,-,,'~kcti(m b. '~'."·l 2 ~ ''''--'0 win,;", """rnu "-,, ,'a;~6' by cGi"ll",;cd odi.,,! v(]'ooel . '.Jut> I~ 1'1. 
aQe "'-'""" '" "=,,co> wii hin I". ,,>,,~ per .;o'1i "",".pI~, ,orne or Ine w~C1c~; coo, . 'u-b " m'.lc' be m~ce i,,,,,"'.,,,, 
, ... '" .. ~""""';. 
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Su>ceplibilily 01 Mycobode[i~m I~be[culo.j. i,olate, to ritampicin and iloniazid 
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~'!l.>!r,,:cl.r,'Ii.q~~op;, ,,"nO c,;l turc 01 : :1 ICI',tll; "Ihi Odllli;.>ion: !h", re,uit, of t'"" ea:ty ,e>pome 
bcr.cd 9'1 de!cc.lion of t-.1yc(!bodC',~urn tub erculo<!s in tr,e sputLJrTl after 2 month, c! ho,pi'd"dicn 
are \umIlYJ';L"d in hble 3, I'etre(!tment p::i'ie<lh and roti"'n" rece'vit'Q mor'" t'lG'l I n'>O'lt'l 01 
treatment for tr.e 'i"t time I 'new' patients) did not mve ~gni'ic(T1t!y different <n;ear (",=0.185) nnd 
CL~· L ..-e ip 0.369) re,d !>. 
~ -110 'e" .' h" ~>.)I ,," -, '''' ''-' '11 $ L no'ih d-", 'n ; 'j ,>k;r lu ~' ~",~'>kbo; ~"' ri' orI Toe r>..mt,,', 0; 'r.e",· 1'0""":" tJ" .! 




N"" ,-"h' e 75 1<1 + 571 Ie i) ' 6) I Y) lej . 60 1 
0 , 
0 "Q';';"~ "-, "" :le) 21 1 , i )9 '1:< ' "-I ) < , ; > 
" c," j~ i<8 . "~ I Ii FH ' ; ,; io 1 ' <;6 ) 
D',-,,,cl ;m","" Ill icrc;.;cc-py aM cu ltl're r",,,,t; WH" ,",voilabl", ia 9:;$;;, ,137 c! 142) 0' tf)e ,tudy 
",cpulalion. lh'" concord<'Tlce w m ",ocr bet',,",,,,,,,-, po,:trve sm"CT and cu!.u--e re, d t,_ T'le proporfi0'l 
of p:1til"'1h w ith (> pa;itrv e cL lture 18,8 %! d t .. r? ffiO'1lh, of t,e·" trr1eni approxirnnt"'d I"" eX-P'~cted 
pe'centage " _ The high propc.-tion Of po'i trv", ,mear r"" ", t, moy repre,e'lt 'e~dual r:0'1y;able bacil , -
ti'e <-,mpibl ized yrO'Jp wii'l ""treatment p:1'ient> compri,iny a mqc. ity i, II>:",iy to '-.aVe hoo 
oO,"O{lc"d di,eosG "'iith p rJ nx-,nc:r, cavilaliom, thi' may heve r", rJ ted in a higi' proportion 0; 
r\O'lvhbl'" bacilli after 2 mon'h, c' tren/me",_ rLJrt<-,e rmorc, ,putum ",,;;h relatively scant nLJrrrber_' Of 
ul :Ie(l trnen i Howeye:, labomtuy ",rOr ; Iidse fX'Si tiYe ,mear,) ar,,J ,ogb:icd ",e,'eorn:"g, in 
'nQC'I"''''n "torawe ard tr''''''pe,i 'e·:.d'n:c 10 10,' d Yiabilit, !bl,a nagaFve ·"'. 'lt lJ",.,1 " 0' .. 'lrl ''") t be 
eXQ ~ded_ 
wa.' C1YC1'hbl., for 1?6 {88./%) u' ,t'.):ly 'Xliie~i" The ,emcin:rQ ,eeorci< ecu 'd not be Irac;ed. e',the: 
lJt.c.au,e ' -K) .. ec.vra 01 r',e fJOtrel,t c;ov,Q u., fCl;na all", "hey w",e a;$ctxW-l'-,d tr(.m Brew.,;,kloc-i 
Ho>pHai i , 2 patient>: 5 from · i,e ,am2 d nk), 0' tha ragi,te " W2re nd 0'.-al abl2 14 fJOt k nt> Iru'" the 
'arne cl:n ic where the re l e'.'U~t 'eg i, I"" " ou ld nvi Oe Ic'co:ed j . 
The \'.''110 de"n 't iom 0 ' treatmant O'~teame !_,un1mar'zed i,-, "hopte' II) ':" ere used in the register' a,'d 
the r2su :t, for "ha ,t, dy p::;tienl , are "-'~m::;,iLect Wow 
': " 0,] Tr~ cim"," Di, c FOJiI , d ~ roctmeni ;."'T,rr,'" j("'A._ 
oo-"",-.c !"lI e "'--"-" ee -"I 
11.,CY cohort 
" 
, , " , '" I ?/' " "J.' e , :i .: ., i~ . l c ." iC~' 
''''' 'Q~'''.-, .-, ~"." .. <", ' ; ';"; '.i;, " /,-<, 
" 7.< , ?? , P 
Ali rx,L,'(j; ' I h"y <.-Or "f-Xi\eQ a grcup al patlen" r21erred ,a i ,o';cH «:. lor I f>E, ,,, tel ',; ;ve treatl' ,,"'" ;cHK"e, 
The reg:,"",r 'ec.vrded a~'kome' oi tile ,tudy cohcd wer., si l"k ,.- ta trx"e fa, the en;ire r.,ga" ithe 
rcgi"nq l recult", kf ')(10 I <xe silown in tab le .. for compqri'o< ,)_ 
F'C,. the anaj'y', i, d f.:H: tor, 'tlith C L .. "ri,.·'ij 0" 11, .. ';ogi'ie~ ,,,':crd ed '~ul c c-r" e, tl ,,,, ~'ulc.c:.rr-,e \~ c, 
did'''JTc-r"j7,''J rn b ' l,<c e,"", fL:l treClTrnent !'c u'ed' 01 'Treatment comdetee>'j or l;mu'C'Ce_dul 
trc(ltm""i i 'died ' , 'fo re:l ' , 'intc'rupK-'<:i ire<Jl",cn t ' j, Th L;" 100 ,,,,,,,,,,,Iu l ,raolrnen l clL;teo~e$ i80~"j 
and 25 L'mtK'ecdrJ oul"am", i2070j, c (.mpri,ed th" daj (l L',ea ir, the anai .,,',. The treaT,-,-,,,,nt 
ouic-Cl:-,-,e oi th", ;:.-ai;""ri ·jram;er,.ed -Cl~ t ' oi til '" re~ion ".-m tre o,,~d ao "~ '~ ''''';; data a,; ,1',<" re" .. it 
cou l':: '10' b e t'ac ,=d. 
Fe''' '''''' 'J(. ',;,,,,'" j", _:t rJ1QI"i", P",!'C'·,!i v.'ere h"O'NC'd up thro',oh ir,e<x·ctior1 d t.,C' dillic recO"rl' 
until h,otmen: co~~,p letion: o'ld [tm those w;'r;)u l t,eo trner1t 101<.-<'-' or rieotr b0fare 'reotment 
compk;iVlj regu.a ' ,!)UtU;ll ""e'lmer>t, :'lC'''''' :''', unt" trcalrm;r11 rCliNla, d;',ec"o ,elap", a da·"tl-" 
fa a ma,im<.-<n 01 24 mor>th, aflc~ Ihe ;r arimi,,"en to B,e·N<">kI,..c-/ H",pital, 
lhirty-one p, .37:,i pal;ent. wer .. f all()\\ed up ior len,)er than 1 a manths, of l e' I,e_'p;tol ajmi,c.jo,-, ; 25 
[17 _6%1 ,) thc~~, up to 24 men; '". ''''':::r1t'/ -ene i14_80/0) pat, ,,n ll c,J lcd the ,turi,' I rom 13 10 :8 
month" 3" i27.~%) c~il ed lcorn 7 to 17 menth<: and 51 [35.%) exiled belore A man;h,_ The rl'Jmbers 
01 pa'ient, cemoreri Ilmt to fallaw-up) berer .. 24 menth! and the n'--moo" wilh reklp,e or dea lh. 
ore ,umrnorizGd below in lobko b, 
Th .. :org::: number ot early cemored eb,er'loliom is nOI s<'-<p(isirQ as ~~,ony palienh Were rrem r'Jai 
were cerl,aed in Ihe ar;aly~ , and imt te ,,--<ther fdlew UP. ,uc"""fl.ily ccmpict",d treotment within 
6 mon lh, fram the ti~ ... d the;- wt>1issk", to Brewel;Kleot I·'.o\pilal. TI·'.c,,, p::Jlier.tc rad started clinic-
based treatmen t before their arimi,~on and eliri net '<'tum to the dink, for fo llaw 'Jf:' ¥isi!>. A Icxthc r 
10 Gb'ervalions. which were cemored bell''"'' 6 month, 'N"r" cotegori7ed m hovir1Q t'eotmsr.t 
,nler,uplien in the 18 regi,;"", Six fXltient! cO\):d r1C1 be lIaced afh"r their eIi,c'1argp I'el-'-, 
Brewel'k lD<..t ~?1p;ld Iii ;, li1-.£'" Ihat the,e patier.t, intemJp teri tre? trnen:j , and :hc record, ct ? 
t<.-<ther palfenl> ccmored belDre 6 m,.-nth! c aUd no: be Iraced aiir0J<:jh they were h)0wn Ie the 
,eerral dink_ In aricflio" a k;"ge number 01 ce'-~Cl'ed ahservo tion, tre'n 6 b 12 ~~,onth, con be 
altribu:ed to patle,,!> "at re !L._ming te, ony follow_up vi,it; hPVond the treot~~,c'lt pe,iod, w h-ch in 
many cme, cor-e'l:'er1dod 10 6 C" P; mo"th, a'te, hmpitci adm;"i0r1. ShoL'ld a cati .. n!, have 
,ub!equent ty ,ufl"..-"d 0 r<,ap'e d tuberc rJ os;", it i, likely that helshe wou d have prmcr.ted to or 
beon referred !e DI'l-a al the dfrio in the reg i'.n 'q ·'eo:mer.t- and fhereb\-' th", rekJp,e showk:f have 
beer1 ick,ntificd fa thi, sturiv by the 'e(,!isle' in:;pccticn_ How"ve', if the fX1lient d;ed before re-
regi,lra.ion with n Ihe TB cli,~ c <y,lem, "_,,, ~ Ire pa,ienl prcler.ted to a heaith C<Ie lucility oui!K:fe ihe 
regianol TH d nic Wllem and w..-.. not relereed bock to ihe r" (Jien iar t""ctment' the cme we'",d be 
lest to the ;" Jdy 
SiAi,",-,n ';; J--O', pati""t, (44':'. of tne:l~ poiiHll\ w iih 0(, CiIl~"', "u,,-,b: ,; uut:::cme during the j4 ".,omh 
I:,;:.·,'·""J:· <Ji~ b " I",;" Ihe e lld d ~',,e. cbc£>fVotbn p,e.riod. eG<..)- ·,.;:'i ", inf~l;,d ~..- i i l , I IIV; one 111'1-
ir,f",c:ied pnt:e"t died d~rij';\O I'" ,;JI1':-~;';<l [,c, lube,euirni,; the reman ing 3 w",,',c cl!i'~·d Gnd d~·d 
:a te, of \ JI ',< now, ', cO!". p ! ic<Jt:on~. ()f th e: 12 pa l: :::nto '·".:fhou! IIIV-infection. ) died ",elore dk-hJ,W 
Irom the ,8 I-,;c,p,'''''; i cJi"J ct (;; G<-'-~' nGbT,vpl y,"' at ~y-Jtl,e, ,honly alter d,eharge: : 1,~;",cJ 
: re" I",e,'!; ; hac:; im oH\J;:;-lc-c:; craatn-,ant; ;me! 2 hG·j ,,,,I;cp'" <1't"" d-:)c\!m"'l t ~ci Co.fe ana h'(ll-'"""I 
cOI"p l""iotl. ' '',pec;l iv''i y_ ~ i)Uti "".,,""''' 1",olme,,1 UU'CUl,"':' , but they oed alte, ,he treat ' t'l ent 
perioo, <Jnd Ihe '''_''-'Sf' ut demh c;vu ld nut be mcertGined from t he ~inic r,"cord, ii t i< L ei-I to have 
been fe ·a lec 10 l ube,c ~l o,i, :,", " l lcm l 2 of Ihe cme". 
The 'Gte 01 ~at i eni, t o loi l treatmC't1t. rekJp'," .. "," die (figt;re 3: i·c:1V", 61 '.-'C::.I more-0'-I,." comlanl 
ove, th," ob<.e ~/Qtion pe,-ioci , but w ith ,Ightly i':gh"" rGte, in the ·0 to 12 month perioo_ The il ighe, 
rate, reecrd",d at C 12. I R and ~.o month, c;o.-e'Pcm·'" \,:i th time, "/h"" patient' '.v",-e ra C!< 'e,t",rj to 
,etum 10 :he d(rlCl lor \pu;um col k.,ction.,_ 
A 
Ti", 1"-'11= (i C,",O' wiT" "~arc" rY' '&Jr~, 'o-la;o'~ Sf do"',-, '."'. "' 0 ,;n>o to -"C c·/·o~t : ~. i. or c ''-'0 ~,cpor 'i or cT 





Th" '.IJ~/ i"a! onofy,i' prTciiderl (J 'i" d 9)% ('15% CI; 0.37 0.621 fo' trea tme'1! fer l " ,". rj,.nli, 0r 
,douw a l the u ',c 01 2 ~ rn[xrlh , lfigure 381_ The rate, of ","lop"", a nci cieGt h n~uil t lx' " X(,lUll'''''' '' '' 
m mmt 01 in", wb,lanti-.::1 ,",<)"',0.,, u; C~,·.'01,,(j i,',-j;,idual, UTe Ii,el-,- te have had G good t,,,,,,,I;-.-,,,,,,1 
vu:c;"""", imoo ! p", li"", :, de"", luping a"tl'!e t,-,be''Cl' '~, i s <i1cxid hav", be",,", c",j"c;t",c Of th" r"'gion"i 
m "Ihco an" ihe epi,,,:;e ',""01'"",d in the> I f, ,,,yiste,,:·. St;,I, 2570 G~ II .. '" 1-'2 p:o: t:8nL are "llO'l,'. to 
i,GVe failed tredmen ~, reiopwd if died \':ithil ', the 2', mvnth p""ioc:; fo' ,:ming tileir Gdn~"i()n to th" 
h~polcll. fl,., QV!c.vme 101 the '''9'0'' <>1 p,;m,;.,: • .:..t 2.1 montl" alt .. I", ulo, ,," I i";,,ol,o ... " !lol h\CIwl"c 
how.,."" th", l"""opolhOt' of · .. tr",(ll",.,nt poli",,,I. ;being equal ta Ill" ,,,,,,,lJt,, af putienh f"";'{ji~i"9 
1' ''(l lm '3 !11 'CI the 'i'; 1 lim e- in :rom! il high. FO-:IM eCf1l rr b-~lil,,! ",",0' 11<""1" :",,,1 o\!ko~'e, durng Ih!! 
")4 mOl1h< mig'll inc\'j(je' C! 'Iig, I10k c ' a J.Xl':" "IO<;I"""i) in I', ,; p a lienl '~O'"IOII w-.a wele ad lT'ill e ,j 10 
("p.w"';dJaoi Hmpitd fel (> v(l" .. h' 01 JeQSon\ wt"ich mig'" predi!pOle to 0 POOl I"JCgnmi, lpool 
Ih,;..;Il"""nl odh"",,,ce, ,e • ..,-", Ul comptic..Jle-d d"!!<lo;e. conc.o~;IOIlI ; ,nel\ OIld ~olnutrilian 10'1..0,,, 
10 '''''Pond J<> clI,..:-bo. .. d 11"",,,,,,,,lj; OIld lho, Ulo.Jp ma y = pa oj".:",OO'tv VV~'i.,rabtc 1<> 'nk."Uion 
w it', fleW ,1I<lor" 01 I"l>t)r(;v""" following I:~t",.,.'t n a f<..oQ<:Kl with I-""C .. oletlt I~cvlv;",. i.,!(.-clio<, 
pali,ml.' with c~ ", a.,e '~ap,'e i'l h e ''' .:.<1 itll 1 ~lowjng Ilealm .. nt in O'1olh'O ' We,lem Cope 
IJOp'Jlolion ''''. 
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Th .. (lgreem enll be tweP.<1 Iht: trealment r .. Spanle meO\~·r ... ' Q"t: lab'Jklt .. d belOW" I' ,*"e 7) and l'"ltl 
relo!io" ,.,ip :;.' ~(lc:h meolLile I<:> I.,,,, ri;~ ()j r"""'p,~ lY ,j\'Ol., wihin I.,I!' 24 " ,<:,<,th p<-,j,.xj 'I in ... lh.:rled 
In ~go.ir .. ~. 
, . 
The cr'cmye in Lxxiy w =i1J' II vf fi"2 f_lC1,ie"f> rlL<'ing t .. ,e fir,t 2 mOl Ith, of their hmpitai ocimi"ion wm 
nvi ',yr,:ficC)nl ly ccrrela'oo with ar.y 01 tt,e olh'--"!" ",ea\ures: il was cleariy dr] ume! ieJi:<2 predic,cr of 
th8 o tl-,er 8C),lf ",-,d leT;' r~'fJvn'" 1(,e;J'~rd ,n th:' j_KJ~2I1i cohc:fi. Many of the pot~nt' li',8d ;n 
poYOOrty", a,)d lr.e 'Aeig"l re.'pv rL,e may have been c~nfov:lded by imF-'I"O'/eO ace"" 10 IIutriliv" 
,,,lUrir>g the nmpiieJ, aon,,,ior,, 
The 1=, or conCorOance be~",een th" ? mvnlh Comear and C~tCX8 r"",-,to 'A".:JC d;cllS,ed pr'f,;v~sly. 
T"e call-( cultur2 re''.Jlt was nol preciictive of Ir-e c-utcomB Q','er 'hc 21 rtl,-",lth perioo, Howev.,r a 
iMc 24 rtlonlh period o!' oo.,.,rvc:t:vn :P = O.OSC). >,o,il;-,-e ,mear microKc-PY a:~er at leml 2 rtiOillhs of 
1,,,,---,tm'O,,t miGht indicate ",ore E<~le"sive cavitatory di,em"" wnicr- is ,:>\ ,o--.:k1kJ "-'ith (1 -", ,-,cse 
pr'C>g"mi;",". Tt,e number or pah'f11' wi:h pr}",!ti-!e re,ulh hr l;--ot" ,"''''_,r C)nd ,-" .. ,It'xe '-"'." 10:> ,,,,a ll 
Iligvre 4Di. 
deC)tr- C)cc<wJj"u to th" T~ rcgd(~", c __ nd ~ry lili""nt~,- incr" " ""d IH:s of poor (N ' ,-"or])", cl'.Jrin-:,J th" -)4 
r,O:ll h< aft'?r adrn',~cn te> ~r"-"w."MJC!-A "-:-<[:,ital (r:-- = O.OOJ] 
F->Y"'hi'i!ie, of fd,,, p0, itiv2 spufl;m ,meers anc:i 01 10" of culll;.-., vinb'li!y du--iny, or whil2 ClWditinQ, 
Ir",der tv I"e Gree" Po,,,' labuaivr)" ,huJid b e eXl,lored. 
, 
c'". "" 4. -:',,0 ",:r .. , .... ,! " ',fmOJ' e, ff,,,,,, 2 !0 2~ ''''''''''1 
'~~Sdcdin Io ~ TB rog': . " Iq 
fA ", ""~ ,"I U '~ \»)\"'''' '~ v~v' ~ -,. 
I ","on" c'mec r~ r ", oct~' Dell e r , ¥ 110 P'" " .. ~ 2· ",,,,",'h,m,C!) 
,"" ", ,, __ .", ,,.,, "'.,.,.. .. ,,, '" ,.""'., at 'm 
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DETERMINANTS OF TREATMENT R5PONSE 
Ihe ut',yorble patienl, treolment (]nd roihog e n I=+or os,06ato m wiih 'he trea tment re'ponse 
ms os,-,m aG ,ummanoca II, ;abie 8_ Ths MiC, 0; lhe f..-ticoboc'er;~m !uberc~io;is iioto:e, 10 
r:fc.rllpicin ::md ii011k:;:id ws~(; n ol irdud(;d ii', i'K i'l'JW.-<l' iatc rcgrc"iG'f1 "mOl!-i'c , m I"c :m8! ' 
YOri<1h le ,cleri",n A.< II'e (:mox, A UCt and AI}(:i for ",arh <10, '9 Wf're Ng"'" <00ITplal .. d \'!'I" """ 
a tY)l"er Cil ly I"p phamlacckinf>lic ",ease..-e wilh Ir.e " ron9";1 CCI,'ributioll to t"e mode; wm 
1(.I:'-'/A, ','-'-""c>ic' e (, ',dy,,", ""; """':) -1- ,0' .,-,-.t~,,' , -,o e e ,'l.:<C'.-,o k'tic""" l""twe er' :0 0 meas u'es ot re""'",, and "'ct"n-, 
tr e:1l,,,,,,,' crc1 QC>' NY"..,., ' ac "_<>, '~~C'mU'" ' U''' c~ •• I.·,N. " " h"" r' ~ ''' ~'J I,¥ p_vO, u l ~~ ' ~ w",'II,' +"~""'"' ' "' '-
em,",,'"'' I" , tw e,,!' ~ C''''!OlV<''-fi VI> " '~(T " " ".,)Ij (';';il;,,\ ',,,"( '''''I,,,,,, . ',,,d ',J," ,<] Ihe ,en ''-,''''._,'h*;' '(r " I",,, iK w! '''' 
em,,-.-,"'" cJ ) , "" ":-" lb. ," , cte,-,--",co(,' ,,'oiatl" ,I v.;lerin a U"I I', ,,,,-,,, ¥cr:m e.- 'ere °e """,,", Chi, ~C"2'1 ' e,t "'m ,-, ,,,d '0 
'i~,", ,e ;;'" ,.' .ACe"",; ;, '" ,;-,:, "",~c,-' ,u;-, ~~"'" ""., , .i. o~-c~a ,ocr. " .. ",OX "", arc "",'ClIla'" ";u, rCIi'''''''Xl w e<'> '~,~J U 
""t,"",",,,",,', :h e ~J,)On~t,.. 01 'no "" oo:i:1llm d h . po' ien , I' eube~ m d :)d ''''J '''' loci,", "Hr ' Ie,;, ";Ie <)1 r,,". ,, " 'x ,",,'.'(,1) 
ir0!n L "~ 2< "",'n'h', ' :J'" "I e i" ,}" """o e ' ci co""'-"" :''''''_' ""h", th," _\,',,',e pd:.- 'c -'~"', ,ome " :oe ,, " oi',e , cw"I~',()f~ 
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~ .. ,;c,,, u,'-M',;'" ,'", _,,;o,t ;",,':;,,-,'Q", , ,'''''':- ~v',"a:i"",; 10-, .:.i""" " ,'. j -,-;'-::~, K,'.J;';"," _':' c..I. ,.:; " tc'" wu • .:.--""oJ : uf 
G,,;~,pk; uI ~ '" ,y,>l e l' p-'""" c,-"I ~<J 
' I', IH, ~'''''''C;<'''- mel,-," ~ ,)b~ ,~at;'x~ w er~ in" ~Jded c, ~ GO'{ ~c1Il)[~ po'''i~ e i' -c , :, m~olh o c1lur~ ',"00 ""'--'" '"Mn 
'Cle 'ej~1 c, tr.;,,, r m" " c u lex" oNa IY.I CI"'~",', Of re""", '.~. 
t"omb"mo,ion af the rcfarc,orticna weight goh was '-!wd. >'aliw1 1, whc 105 1 w";ghl C>-J ri,-,S' the 2 
month period wefe a.\~gned a val"" c' 0, '" I ~ ,., 'qu-:'''' roat af the Ilegotive v a ue; caUj nat be 
d~':fiml"n<;ea _ A fu,ih~; limilo fion of i,--,,, tromformation " then ·"·hl,,, the cii , ~,"" livC\ ond '1at;,ti"ai 
,ignificarcG d ti", covCYia\e e ltGcll On Ih<> propc~ li unai "'-oigh t chonge cOu ld l:,£. o<se"".d. they 
could no; bP a.'.n ntil ied, 
ra lie'"t, with io'Ne, ~C)di 'na" ir >dice; at ? n'0Ilths 1""'8 'Jul""d proport,,,,,,,tely 1'e <C w'Jig"t JL!ing 
;he p,pced'ng 2 monn", Hig l,..r aibum;n ",,,d 'CYN'e r \o ld. prc;-Ie'n lev"" were '-,gni!ican l!'/ msoc'al "d 
with w"iqht a o'n OVPf II,,, 2 mnnth DerOO, !l.ll:xJmin l"v"ls d"dhP ond tdol Pfatein levels os" a, rnrt 
ot th". inflammotay re'pon,e ta infoc lion, irt(:r",osud oih<.Jmin and decremed lo'al pro loin l",v". I" 
'C;fJ<cct ,vci,/, Illay th",relae relleci a pmi1i"o to'rume 10 hoat"""" t, Sirnila rl,(. high...- Q i~bin 
cnncentrotion-l ma'( he (J;, C)ciated w iHl mO'ee ' 0 '10'" ctWQ;O lor 1",\\ d,,<;eo>e r".,rAJ lionl. and j; j , not 
\urpri, ifY) lhat toial w n.'ITl hilirl.lNn wa' n"'Qotiv".ly mscdatpd witl, '."eili ,I gain over II "" DrDcoding 2 
mon\f", 
1 ",," e 0 , I ., • ., .. ~ ·."oo """,,-, ~'" ''''*''' tr ~ · • ..,"en""" ~i <~ ' ,-,.'-e>'., t~ 'he «:, '''' . ',0'" .~ !,'~ fY ',,,~ Ii.~d weil.,,".1 ',1("" 
o"~r 1he n il " 2 """""", , ; hQ,.,iI " "",,,is,..,.., 
~ ---~. -,,,,.ce S, 
',~je 86.20;>3 
~~';";~ " : W 221'" 




"' 1 ~.3682 
1.36% 
2.00'" 
-----.. --------- -----~ 
''',rrt ,", ({ ,t·", · 1,_ 
flo. " 'I lO_~9 
Proo > < _ O 
Pa tif'nts Win, h,gt""r "l flamOuto; ;evel, i'" indicatf'd b'Y ill f' AUCII gained '"'' weight OVf'r the 2 
mvnth period ifigure 5i . Conver,ciy, incremed ethombutol If'v,,.l, w"re m,ocia,ed with Cl 9rp Clter 
li~dt"'KXld 01 Ipullxn ;reri iiLation at 2 nYlnth, iJobre 1,1, 'iCYQmi ing IflClj If'" OO J9" pti".ct on weig il l 
go:n was oppo,;t f' 10 thf' f'llccl on :outc.m ,teri imtion_ Incrp",ed dr~ \l cCllc"ntrati0t1' might. for 
ins iart(:e, 00 a;mcioted With nou,,,.o ond con>pql.X!ntly Ie" weignt gain Pati f' nis noi ,-f' cetYi'1\) 
e ti >ambuto l w".re not included in II y" mod",1 
r-:::tienh -..'.--;th hig-,er dOlel of p·,1a~im-,,,,';ds : ,-d;l.~tpd lor 'Neigh t) had lmol"" '·,-"i iJI ,j ga,,: if·dl.E' 61 _ 
Th" ranQe of p\Tminamide dm".s pre_<crihed wo, wide; from I? 6~ to 52_63 mg/kg Imedian 35.7 1 
pyrazinamide d'.Je to Cl pho:-rnocol.i ,,,, tic interaction i, lK1 1 ~:oi'i , b ecO.!, ,, nti iher il\creased 
p,TazinamidE>- conc".n lrotion<, <10<, do,e/kg was ""ociot".d with oocrea,,,d rifampicin, i,oniozid cr 
dl··..: II.,.,L ~bl i::O'ici: :dd" ~",t ,.,,,,'.'/~ I '.I'h "'J'J~" r:"',CrnnCWyl,-:.m:C i">l,.Of"·~ti",,, co",,,,,,,' "'" 
excluded. the effect is more lif,ely te> b-= r-=L-J t-=d te> tr·-= wide ly recogrliled , ide effect, of " 'J"'1e'J , 
u roar", iu und ,o",ilir1y' __ ,~ Ihul ar", m>vclCllcd w iih pyrazinamide. r"" ""'yuti .. " u;,oc",l iun wiih 
weight g L' /l i, II'''''' more I" e ly ta refied 'J d red elf",ct GIl weight go:n, ruther than a reduced 
dme/ky w m e;sanfiali'y' fha s",me fa tho,e- re-c eiving P'lrazil lClm'de dose' less than 35 mg!kg ithe 
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""'_ r~ .j ' ,~~ c-yr~k:l i'~ ' ""w~~r ~v,ad,,~ 'H,· ,j",~,'"y (rr'J/<()1 "d p·,,,,,, li,,,.,,) we",O .,,>i .. \P<''''' ' ' '-' ro" ~· .3"'o 
Ip-G .• )[·U.)i 
" 
" . • 'r; ," , 
.' . ;\;:~\, I ", , 
" 
I .I I , 
I I • •• • .. , .. ,~ ' I 
MuWrl" 10g;ltic 'egre",=,r, We<'C lfied to dctE"rrh" Iho re:ati.,.e rd; _:1"c,_:-bkd w ith covan_:1t" 
lactor; 01 a pmil i.,.e T".lt'_'m ;""'0' :tob'<:- iO! and ::;1.lllure [table II) , '""p<:octive1y. 
Increrni'1',J _:1go w::;, al.\ociated witn 01' ;.,cr"rncd (Ir of ' m cO' and ::;u't '_~e pc;;tivily ct ::> rTlQr lhl. 
eVen Ihovgh coneO'oonoe behveen ;ile 2 meal lXe' was poor. For eaen "Co-- 01 age Ii"" 
eaei, advancirg deoade. Tne ri,k 01 a pmitivc CLJ tL-<e increcr;ed by appmximat"-"y IQ9'.; per yee..-, 
thu, cartlerring a rciat ive ri,~ ci 2,53 iO' eaci I oocode. I nu'. ;rt l hi' ,judy. ,rtcremirtg age was ,trC<1gly 
mmciated witil a p::>o' 'e'pcme to trcatmc,,,1 at 2 rTl---'),ilh';, Ti ,e a 'sociatiort cet'l_/een age and 
reklp'", rat", he, 'tudied el'ewl""e. but the li rtding; e..-e incC<1,i;ierti behveen dil'ere, ,; , Iud'e, "". 
FO' eacil I A 10' cBlijl ;"creme in the platelet count, the re-i ai;vB ri,k oi a pmitive 2 mor·th ;",eO' 
illc t'(,osed by 0.3870; Ihi'; 1ranslates inlo _:1 2' or, incr",cr;", in lil", Icla live ri, ~ of a pmilive 2 monli 1 smear 
for each 50 ~ JO' celli: i'1Crern& in tna p:atalet count;, rd r&Guct ion of 37%. fO'·..-"" cmcciated with 
aach 5 g/I i",;rEease in albvrn;rr !a ;:,rg le unit i,,,,remB irt _:1lbu min beirtg mmcia1ed with a risk 
ito the ti,k 01 a pc,i1ive ear1'y w"tvm c"ll"re. Thew t j,,jirg' me con,i,tertt with a d r"ct "",social'",,, 
betweerr 'he mc::rtc" of the aC l--te pnmp rp<pome artd tne pe,,;,!ellce 01 M ycooaderium 
Iubercub,1<, '11'1 'he 'putvm 
,"c ',,,,,,C '~Q<'e,,;0'1 n-oC~ ·:JeICt;r,..) 'h~ reh:l"ve d", c~''''':,." , ~ "'"'~ "Cl"o-de '=1= c" " p~,H;,o 'P'Clc.~. , moe., 
rTK<1t111 {11 Ie< ","Dil at odm;"'on 
',c <;ji"c rc l7c .• ,;mYC- --------------
L",~ I·,d ·,~"., ·61.9~36 
N' __ ~-bc ,cTct:< _ '., 
I': d ' ?I"! - L:.G6 
Prob.> c~'2 _ 0.0:.:') 
, 
A 30% r",duc:ticn irt the ri,k 01 a posi1i"e 2 ",,-,nih ,mear ';,-m osmd a teci w ilh eoch 10 m", .;,,/I 
irr",s",,",c in tilB AUCt wi rita m::)ldn ,eacil 1 mgJril re,u lted in a 3.46% ri' k rcdv"'iC<1) The m ,oeiGt;on 
w,:" rtot ~gI';lican1 willoou t odju,lmem ior jhe otner ri,k iacl"" [ 'he ",,,diem ,ilurf,picirt Auet for 
cr",;C1f negative patiertl\ 'Na, 20.32 m!:JJ', ,' y,. 18.2J ""9 .1-.- .. 1 fa tl,o.'e with a pmitive 'putum ,rnee..- at 
~ mOllti" p=G.14:j ,: is Iniwosiing, lim : no ICi01IO<I1<,'P ot riiampk;in leve i,:o :h., ,",ui u'-', cu',;"," 
Of' the o thcr hcr1cl the p eak c oncentroiio r\S o i eihclmbwtcl wele ct·, i ll"!pcrtoni d ere,minam oi 
'pLtum stm ifzo: iC<l a, ~ monii'~ , bui did rKl i hovc (Xl imp(Ki 01- >m eet' eo(wcr~kn. Pa" en t, not 
",c,-,;v in:;J cl he,mbu lol ll-",cUlJ'," 01 cOlltra:nd catiom j were r.ot ir>eluded in the modEA 
k;b I ",',;d,,; '~('~'<Oc mn,-j,o! ,~"",~,";cJ t~,o ' olrh'o 'j" ~"",:j,-"cJ ' .... ;~ ,'0,.--"1,, e r aci"" d '-' f-'Qslli"~ T' 'IL 'Ill CL ~h0 
d 2 mort~, cite , om",t" <>c""",,-,, ' 
IRchi2iJJ _l< ,91 
.,]h,-,,, ,Lll,tol C ,' .;lA. Lv",n w i;hout adj'-"tmonl rn Ih", olher ,i,k felete,.-" ,ignifiecil tly lowc, c IharnbJ: o! 
c- OI lc ""!,oi ",, .; ... ",'", i".w.J ii', ;"-.o,e "it)-, paiii. e 'putum c",I,-,'c\ ai :: ; ' , ',,~ ' ,tl'", 1 .. · 14 ,-,'>9/;" 5.06 
('-'9/1: p=O.D26j, Tr,c i,, 'palc"1"'" oIl h ; f',r..:.Oir,g i, ,,_ppa ied by the m,eeialion in H',;, ,h..xJy of hlV-
pol i"n', rcceivin-g 8-montn rlf",m!"id"-'pcting reg' Il"!~"'~ wi lh i,or-;uzid ond cthxnbutcl ill t r. .. 
continuo lion pha,,,,, I,uy" wc-"" I, eu i I I ",1 ,I VU i .... OI ll~" Ii lOr' p<-l ti8/1tS witnGut HIV-inlec tion on ,imUet' 
rC'\Ji rr, ,,,m" Howev",,,, il contradict, g-ew ,"9 cer>eerm that he irKlu";on cJ ", r x:H"uutoi in 
"":,--,,,,,,',i,,,,d u ', the il)Ciu,ior, of ",thaIl'Dutoi, wnich apPcCT",d :0 in.,ibi: ti,,,, ;;<1':i.:i ,'I;;) acti'.'ity d 
c"mpor~oo druG" Thco ,d", of eth;::mhu;d v, il"n a tcea;,,-,ent r&g>n2n mcy be d o,e cr 
coonce"lr,,,, ti,,,,, dCP'T,d"nt, o'1d ma'( ul,o jepe~d en the (;encenlratiom wllhe ~'OI"1parhn dug'· 
and tne eenee ntratiOll ' of rila,npicin w ",ra lew in ma ny p atient> 
C.y.griatc, m -,c>G ia.\<;;d ." in, tr.e ra,u lt, ;:;1 tne regi" -o<-r_ey.y,deri t,,"crm,,,,t .yU ;\;Qrra lIP"" 
cQmpiet iOll Q; tr .. ·c;trnen; 
.-\] ti e-l1t, wii;, un voLNOU"aole ouiGo"'.e l'rE"Cltme-nt il1terruvtion, k:ilure or deoiflJ c;o ll)",,,ed 
,oo,mr,tial ly ]rE"Clime-l1t il1tOl,uvterl i i abie 4 i, who WeN d be U"'.0119 the ob,er.-wionl c;emored E"Clr1y 
" the ar;aiv,i, ·:11 fuc:-hr< defe,mn'ng the: r;'~ 01 rp!·:Jr'·p ,,' dedh 'JP to 21 ",·":'nth" tV"" tt;c'--,<;,h 
tre-c:tmenf inten~ptecl predominuted thme- with al1 un'avOU"aLJle w;:on'e in the- TB regl''''', a 
b[J"l i ~ ''-'<J'''''' ion Ll<'lClly,i, cI ~,f tact"", fa, t''o''Qtrr"""t ;"ter"-'Ptior; c.olone- inot ~'lownJ , fOlJnd that 
increased ~,ae"'.O<J lobin wc:' the OOy coYa,iate ,ignificanl lv mm':::;uted with treu'n:el1t il1te-<TuptOn 
irelative ri' k 1.81: p=v.O::2I. rc;,ients "Hith highe, hae"'.oglobin level, at :2 month, dla admhian 
might heNe ,uf'aed IC'l l evere illnel' linrlppd ,orr.e- 'YIGy heN'" been gdrrilted to ;t,C ho'vitul 
became- of poor adhefcncc to clinic based IrC'Utmer,t! or recovered n'ocp rc:pidlv 011 t,eo tmcnt 
uod a; .:J [e;u lt they miljlt hove be-e-n Ie-" motivate-d to con'ple-ted t,egtmel1t or received I",' 
encGCXc:ge-men' to comr:"ete !rea'rr:enl, 
T i],'; ;?, '>{Jo ,, '~ ,. J ""''''1 ,r,,,cc; d:·.'er""',1 --'0 r " i~,vc r; ",- ",",,,,,;,ue " 'ile, e6' "';~:,' fOLlors of "" ci-j avomb," ,"','2,-.-n~ 
!tr~crmerl irl~"'.'Plioo, :'~"'-'l1en' \j-cr~ Of c'eathi Cloo corarQ 10 lhe cl'o'o bcrsec' -, re"" le" 
I ",,",ro '~~r~"Qc 
'''' :'tel'1ocd ~ 5:i.5!5"87 
T"ct'l1on' cai<:-,c","/ 
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IRc hi?nj ' l~m 
O,ob > ""j). O.CKJ:l' 
PseL"O'O ~2 . OV-~I 
Q/4,1 
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, 5(JIQ 
OIJ I eo'"c rGcor ded in the TB ,egi,te-rs. ~etre-",tment !-)di"nts coorllprimd 04% of 'he o'udy pOPlJlation. 
and ,ubs tonHo' "rOf,XJrtion o f the' ~a t; e r.t: ir. the '8gio '1. Cle':J~ i th!\ grcu p 0' <:'a tient, i, '/u ll'.erat-~e to 
r "Dea~t->d cyclm of d i,ea,e-. 
1 ,n,'.o'/' at 1 month, 'C/C'.' os'.(!cla'ed with·:J rilk redvdion at '.5% of an U'l'o'IOCC'.bi", ou' coome. low 
CXeel conce'ltr-:J!iom m e a,"o:iat"d win, wastir'lg, and mg,t Indicate poor t:x:l:Lgrovod nu~ ritiord 
stut", or disease s8verity; the"" !ac,cr; may 00 c:'seclated ''''ith r8du:ed irr:rr:unity, al1d, or, 10'<', 
""d 01 the tre':Jtmant peltod ior c: varl",',.- 01 r~-uloru . HO-""8var, i' these ,emom ure- va lid. ureu 
catiCetdrOTiati '€'em, ia be a b eiter noark",r fcr Wdlti":) tneltl l'<\<\L w licil wm t\o, iIK' lude,,-i in lhe 
made; 
Wcrs€ autearlle, on compleTion of freaimenf wele m,ociaied vdh hij ,~" V : elk iconi:::;],; 
cancentrofion. 01 ~ rnonl~\ (lfT<'f (Idmh,ion fo fne hD'pii d Eacn 1 rngll incre ase in :he tCcn azi::l 
cot1cenfrafion wm mscciaied with 1.6% 'lncrea'e in The Msr of freatm<.; I" iI1 ;<oIlU"lic)1I, ;,,,ul tl'<mt 
la':urc or dUOl lh. Thc mcdi;:::'l i5'" to 95'" cC'lli:c ,engel CrnOlx va:ue, fa im'liazjd;tI e=h group were 
i,~2 ,,>til l i·1.:3 - !<i,06) unci ~_O "i mllli 13,,1:2 - 11.::.G] Iv fl''''''' wil, Ur:IOl'iCur,_-;'"I" c'ld la ·" ·]_' Olbl,, 
outcome" r"'pectiveiv Otle eJpiatiatioti fcr the finding could be concentrat;ot1 d"Pe nden! 
i ,a-~iu fcxicity. ul-,d r2iufed '2ductic'l'i in t,euf",,,,,,t udherence: in ih i, groJP of paflenl> poco 
1""Oli",,,,,1 adheru"ce ,,"Ol" be ""p",cled 10 b", m ore l i k~i d U'i"':;l fhe cor.ti'l<Jc~ion pnOl,e cI 
freafmem. after d,c/lQrge from fhe ho'pibL However. alH'OJoh Hemmetl! h Te rr Jpiero c.amphed a 
hgn propcfiio'l (767',) cJ th" group w ifll an lJ'llavc·urut;e auieo,ne uccordi"'J to ihb TB regi'le". 
i>cx;cuiJ lev",l, w<',,, nOli ,illrl;r",,-,,,lIy u"~x.: iu ",d '1";; :1 I, ,"ul,,, ,,,, ' ;rr l;;;,uf.) li V!" f.) e l ,", Th" i";.:I,,,i()n ()~ 
is or·ia~id '" r"gll)lem (;C"lta lring rifampbn and oy,azl'lClmide, and r"'gimem cOtlta lr,ing rifampicin, 
pvrOlzl'lCl ,nicie artCI 'l'oxlrioxa(;i'l hOlI ",,"'1 aSS'x;iOlr"d Wlm r6Quc"d Itooiizing adi,,;iy ;'1 ,nuri'lb 
'~,oJe" ;"I . . ..,. Ihe b'J,i, for th; , f:rluing i, u,,,,nown: a phomlacdinetk; Iniera(:liv, berween i,ari micJ 
atd cbrnpic;tI has D"e<l propYSed""_ m th , 'iudy, wh,e all paf ents rece"'eu i,animd n either 
;,eriazid le'l"i" '101, de·,,,;tg w...-e oo,e·eial"d "ifh d"erbus"d ,i1a,npici'l cenc""irOliiom ldab noi 
,hoW'll 
C:Y":;Hiqie\ ,:;mQC!Qld "·' il k i~ 'i ri+ d Ir"';Jt'T'en' t ;1i1'Jr" ,j'I"':;e ' r <:'!x~~- or deQfI, from ::: to 21 
I) l71l!J!.: 
imm-Jrl<=' facial'> mec,,-,,ed of 2 monih, feaiU'eu prami, ,,,ntiy in fhe r<='9<"'''Io" m,~{jel "e,cribi"9 The 
covariate, aO!ociafed with tn" r10k cf t,eatrnent la1U'2, deafh c,' relape up TO 14 monlh<_ 
HIV-inf .. c.f"'d "ntient< fend"'rl I" hovf' a ri'" ?A.~ timf" ll'"""fer than nntif"nf.\ withoLJt HIV af ·J ooor 
e-ulconw dU';ng :Ile 2·' me·'lIm [,,=0 ,066). The >;Jdv woo und<='r"o",e'oo 10 ", IOlb ';,;h Ih' ,,,"ationsl"'p 
'·'.'irn confidence, Oo_'f the f;'l::""-:; i, (;e·n,d"''lt ',vifh c·fh"", , bc:';"" de'nc_mlraiin'] a hi,:!h rr'0ct",ity 
among,f HIV-;nfec.fed oati"l',1> with tlb"rcu/mi,"', '''. Whi le !reatmeni regimens confair; r,,} 
li'amr_~(:ln iflrO<JQhout (1'" Illoughl 10 b e eqv(lily e llf,cfi" e in HI'~-il" ecie C-. or,a i-il\ -mnfectsc-' 
pat'etk, rilc,,.,-,pic.in sour'ng r2g'I~·em are Q;>QCiated wiTh inuemed rek~,e rate· ;" HIV-h-,tected 
cm2'_ Howeve,. ihe very iow 'i'amp';cin :evel, ueme,·"fraied in fi,is sfudy, :n addition fo The high 
prev,;.,',,,,,-,,-,, Qf tub&rcCJlo;i, ill thi> (.vl, II', ",,-,-t,- might have pli>di,,,,,,,,,,J irnrnunoccrnprorr;"ed 
poti"nls. in pcrticu:or, to h gb'O' ,-dap.;", ro;",,_ 
rhe whole b!ood IF~'- y w,por.'", t" PPI) ,timL,ation at 2 month, wm a "o::,;.::,teo "'.<ith a wttantial ly 
improved tr .. atment fe'pame. The hazard mho of 0.9996 retlect, Ihe effed of a 1 un,t increase in the 
(elop\f" for e\'e~ '0CWJ u,-,1t incr,=a,e in the IC fj _,{ ,e'pome to , time,atlon with P"D. !n a vniy·:riate 
ar>aIVli,. tho,e with IFN-y re,pome,;n the highe't qoJQrt:!" I> 4_~S4 pglITJ' had Q 9~. r",dudion n the 
re:a ti~ .. hOlcrd of a poor tr"atmconl r .. 'p<x~e bv 7, month,. ;n compari,on to tho,e in the 'owe,t 
quartile I:: 44/_5 PQ!mj 
-~-----~ ~" 
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Hir:lch et ai found meQn i:S0) who,e blood IFr<-y response, to PPD ,ti!".Llation of 31b PQim- i= 7{" 
97" pg/!".I I:!. 182; Qnd 2230 pg/mi i-'-- 4 I 0). r,,:;peC'iveiy. ir· tubercu iO" i' patient< re c eiving treat ",en~ 
fcr Ie" than 1 month. th"", receiving tre·:otment fcr more than 1 ",onth< ar.d ir h"CIIti-f/ cantach. A, 
i, deman,t'ated in t>,e ILt07o!". 1n figl.f" 7 the mCl(ority of patienl\ had ,til! had r .. k1·'ve:y 
,uPl"re""d DDC) ,r!",u:'::l;ed 17 ~'-Y re'pc-me, at: ""=<, ~~l\_ 11'7.'-'ever.'::l ."Jb,tantial number of patienl\ 
hOO very ad,,", 'f~l_y re'pc-ns .. , at 2 month!. proocbly indicak>g ge0d recover! ef protedive 
re'pome" in Ihi; grovp of patient;_ 
Ihe "'k of a p<x<' e~-tcorn0 (treatment 'ai iex'? reia,,'" ex d~·()'h: dL.f;~J tr-e ~~ month, perod wa_, 9% 
r igher for e-ach 100 un'l increme in the Iffj-y r"man"" to ,timulation wi'I', the mifo.yn PH.A" Th .. 
impor'ance of thi; firrlng i, no~ clear, but '1 po,,,biy ;UQge.,t\ Thai tno:;e patient, wit" increa,ed non-
specific i mm~ne activatior, wer" o· grealer ri,,- of a poor tremment re'por"e, Qtter adju;tment Icr 
the otner facta', in 'I", ",odel. 




l'ligoo crcGtin ir>C cGnc;:n lruiiom w",r", c~"ociGI",d wiil, b<..'ito: tr ",atmont O'Jtcomo, by ~ ·1 monih" j\ 
1U ,111)01/1 inc,,,,,,,,,:,, uca'ir)'"e '."/0 ', a\;(""ia'"d ,',ilI-, a --:'C % rCdl J(: 'i cn in tr,-, ri,k c t t'c" iment bill,"". 
deall, OJ re l<+,'" by 24 monn,.;. Like exeo l eV(,~,. I,;"-'~'er c reat;-, ir>e co~ce~tra t iom rrinrt indcGte '0" 
on,ien', of "" unlnvDrnble cutcome. 
DISCUSSION 
T!_", ,~,c-_)I'd",y,e. b,,!wi'-en thi'- eJfl i'-:-i'-nt mi'-.:m,;-i'-' ""'00 'U'!--";";"9. The. "'i'-Ih -:c"is u,ad fc; - 'pu le,;-,' 
miCfc<coP'i ,wd u ,It. ",., at 2 mcnth<. nnd r,.cc'd 0' tr",uime r,J a< "cune, in I h" r"'gH" r, ",,,,,' tf] ()\:· 
a lter Gdmi"i·,,~ to tl,,,, hos p itG: w m likely to b e cc-dounded by altered ayailcbi ':y 01 nu te ed;_ Some 
p:ltied, re-c;e;'.-ed ,treotmnycin duri~g the in!e~ ";'.-e plme of tr eatme~ t il tOle L-~e 0\ e,l,amou'Cli wm 
etiYJmhlJk,l rlu'1ng tl,,,, cont'nl!"tb~ rm,,,,_ Tr",,,t,,,,,nt a<Jh,-,r"'Xf> '.VCJS not n~c",,.-,terl 10f ",ftf>' 
raspital cf'ch_lrQe a"d muy rx1VC codounded Ire m eo "--f " , 01 outcome aft'-'r 2 month, Th ,' 
the,e weoknesse" ;everol impor1-:l I,i hd'ng' emerged ~ r()f'll the eYnlu(Jtion trentmen: re'ponse (Jnrl 
'.",,·xiderl ~'1c:IG! ",'kmjC'",;n rC)f'lb-H '.1nd (':f],.,m~":C'! c'''rv.-'''r tr'.11io", '1"1-:' r"ir'1jMr" id-
dose/kg, remect;vely. -:1<,=;o ted wi th rlifferenl effects Q~ the treCltmen t re,p--"J",e memu,e,_ A 
r'le dosf" r~atf"d rsduct iorl in weight oain 'T.<·:·d·:ts·j ',i'/r. p,.,-azirlol-,-'do ,uppartl cCrlkmp·:~cry 
dosing ouiOOlnE'.,1 "', ,,!r;cr. odvvc"t" bwE'r do,&; thm tito.,e prelcribed for m"rlY d the patient, ,n 
tr.', study_ 
'Wh'e higher ehc.-nbuia l c"ncerliratiom were mlvciated w;th red '_'ced w eight goin, they w ere oi'>O 
m .mciaied with irrproved op.Jtwm ,lerililOtion ot 2 month,- The l irdirlgs might ,ugge,t that torget 
e thomb_,trl conc.,rltrol10m lie '0me'."here wil~in the rOrlge, achievE'd ~1 thi , potiE'rlt cohort. ~t 
arguably, it may be moOre i.-,-,portorl' for notient, ~o od' eve 2 ,Ieril izotbl "I ~he 'Puj,}m a t 2 month, 
lho<l tel gain w eight 
Both rifampicin and etr.ambulc-Ilevels was impc<~a"t delamirlarlt, of ;he spdum r""witl ai the ",nd 
of the int"",i',& pha,e of trea tm&nt. Vm y ofampicirl lE'v&l, wC",e rTlV'o ob:ely o%odated with the 
, meaJ' rdult yet e t:-,ambwtol i",'e:, n=la t"d;o cuit<Xe rmult, i, a qu;:;,iion beyor.d the ;copG oj thO, 
irwe'liQoticn ond i' not r€solved by the €mor-kai firdings ,ep<.:;-t€d here_ PC$Sibl'j. i hl> diffe'erlt drug 
e ffectl on the m"ioboiicai ly aiflaren t ",b-populotiom 01 ,\1ycobacl€rium tu'bercu,'os,;; m ay OCCOUrlt 
tor the; d isparClt ., lirld~lg, . 
Th .. pha'macc*i""tic mem'JI'e hr each del'J cor'''mondirlr:J ma,1 cb,ely 10 efficacy ho> not beerl 
determined for IhE' ont;/,k:""rcu o,;, ogerll<_ II ha, been sugges ted that peak cat"\CentratiC:Ol< ore 
in,o()ffor:t::;, the or:til1'lbobioL acting 0'1 il·,t:ac<C'liu lar tCW-;;lOl>, wh..-em tile time obo',e the ,',lie 
ni g ht be 'he memure tha t mo,t acc,-,"otely predich the oc:iOrl 01 drL'", on ce! 'Na il comoonent,_ 
Haw"'''ff. il i, ,impi i,lic to opfJIy t:'1e,," prirKirJid 10 iitis ''';iil''.;) ,.r"",,, ,,;Iicao), i, rnamured by t~ 
ore,erlce and .iol:<l;ty 01 orgoni,m, in the ,pul'_'n l_ f urthermore. C¥Jg ac tion may bt' cvmplicat"d 
by Fador, ,uch m pv,tontib0tic eff",ct" urlbound dwg o-'=t)e~ral on 10, and ,-,=ciden"e tirr>:::' a t 
d i fl ",re"i l ite, witl~ n the lung. the chor\fJ;'-,g ,u,eeptibilty of ' he orgo<lilm, dE'Q"'I)dil)g on their 
mdobo)·(. o"'i;··, i1'/ ot tr.':) ,;1", ·:·1 tr.::;. 0GGupa'i0f1, etc. !n 11---':, ,tud,.- AUCI '.Jpr""cr-; to b~ thte ~· ;·.:d 
lmovrtorll mE'alLTe 01 rilampiGin fa" e'ea,,,mce 01 _'.'ycC'bocie.-i,)m tub~,- c'JI05i'; hom lhe 'Pulum 
,mear. w,",le the p,.",I' cC'rlce<ltr(ltkorl <or .. thamb'_ 101 appear> 10 bB the memur., rrn,r d C',;>!,! 
reiated to .'putum Iteril imlivrl_ 
''''hile bvih ,pL'i Lm rnicr0<COj':ii cmd culture ore recugni7ed as mo.-keel "j i<m"- I,,m, 0"fcc-me"·I >l "'. 
tI':e pa, itive medlClive value of I~, f; ecoiy rn0.1,u,e, i, low ,,,,. w.,,~ _ Irl Ih;, ,iudy the 2 month mco~er; 
w8le ,,"'GordCVlt ol)d only the ,mea, ,e,ulr wo' q;,oclateu with the 24 mOrltr. pm(JnQ;;'. 
PK consequences 
Immune suppression earfyin treatment has been associated with better sterifl2ing activity of drug 
treatment l65•166• This might, in part, explain the dispaitybetween the 24 month outcome and the 
early culture result. and why drug factors were important for sputum steri·fization at 2 months but not 
the 24 month prognosis; perhaps in those with better immunity, the treatment had reduced sterilizing 
activity, but their superior immunity may have protected against reactivation or reinfection after 
treatment completion. Protection against reinfection is of paticulor importance in high prevalence 
communities; in another Western Cape community, a high proportion of patients presenting with 
tuberculosis in the months following treatment in hod infection with a new strain of Mycobacterium 
tuberculsosis 157. 
The association of higher isoniazid levels with w~e TB-register recorded outcomes is of concern 
and deserves further investigation. 
Other studies have found gender to be a prognostic factor-43.4s. In this study, in spite of significantly 
lower nlampicin, isoniazid and pyrazinamide levels in men, sex was not a significant determinant of 
treatment response. 
Some of the analyses were underpowered: in particular. the regression of highly variable continuous 
covariates (like the measures of rifampicin levels} and dichotomous covariates with only a few 
subjects in one group (e.g. HIV-infection) on the 2 month sputum culture (where only 12 subjects 
hod positive cultures); and in the survival analysis {where there were many censored observations 
and the variability attributable to adherence was not accounted for). Furthermore. the patient 
group studied might have hod inherent differences to the majority of patients who do not require 







As ouffined below, most of the study objectives were met. The important findings are 
high6ghted. The need to establish target drug concentration ranges and confirm the 
determinants of treatment response in adequately powered studies amongst more 
representative populations of tuberculosis patienfs is errphasized. 
Objective i; The concentrations of rifampicin, isoniazid, p~ozinamide and ethani:>utol 
measured in 142 adult patienfs at Brewelsldoof TB Hospital on the oufskirts of 
Worcester, Western Cape. Relatively intensive sarrpling was used over. an 8 hour time 
period foHowing administration of the patienfs' roufinely prescribed medicines. The 
pharmacokinefic profile for each drug was obtained in each patient on a single 
occasion after 2 months of antituberculosis therapy in the hospitat 
Objective ii; From the pharmacokinetic profiles determined, the 5th to 95th centile 
ranges for the pharmacokinetic measures for each of the drugs in this patient 
population were determined. The study did not address the alterations in drug 
concentrations that might occur over time. For example, changes in rifampicin 
I 
concentration due to autoinduction following repeated doses; and changes in 
protein binding with resolution of the inflammatory response leading to altered drug 
distribution. Neither did the study evaluate interoccasional variabDity in drug 
concentrations within a patient; thus, the accuracy with which drug measurement on 
a single occasion predicfs the drug exposure on other occasions was not assessed. 
The study was not designed to determine the optimal drug concenirations for 
effIcacy or toxicity. SInce the ranges of drug concentrations found within in this cohort 
of patients affected the treatment response, it is suggested that concentrations are 
not .o.ptimal in all pofienfs. Properly designed .and adequately powered s1udies should 
be implemented to deme the optimal ranges for the drug concentrations. 
Objective ill; The drug level at a single time point 2 hours after drug dosing was highly 
correlated with isoniazid, pyrazinamide and rifarrpicin peak concentrations; the 2.5-
hour and 3-hour time poinfs, respectively, reflecfedthe Cmax of rifampicin and 
ethambutol more accurately. The amounfs of rifampicin measured in the urine 
(volume x rifarYl>icin concentration) identified those patienfs with very low systemic 
rifampicin concentrations. But the urindry collections were less accurate than a single 
systemic plasma concentration for -prediction of the peak concentration or AUC of 
rifampicin. The amounts of isoniazid, pyrazinamide and ethambutol excreted in the 
urine were not measured. 
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conclusions 
Objective jv; Several patient .and fomdation characteristics were identified as 
important determinants of the pharmacokinetics .. ·.of rifaf11)icin, isoniazid, 
pyrazinanide and eiharrbu101, respectively. 
FOl'l'OOiation factors were confrmed to be important deteminants of rifampicin 
bioavailablility. The relative coniributions of the raw material properties, the 
manufac1uring processes and storage conditions to the variabiUty in bioavailability 
are uncertain. Further studies are required to guide poley to ensure that the variations 
in bioavaDabffity attnbutable to product quality dre nininized. 
The influence of HIV-infecfion in reducing rifarrpicin, pyrazinamide and ethambutol 
levels in a tuberculosis patient population was es1ablished. A $\.Ney in 2003 found ihat 
55% of tuberculosis patients in South Africa are co-infected with HlVl68. Therefore, 
significant reductions in the drug concentrations in this patient popuIGfion may hove 
important implicafions for tuberculosis conirol in fhe couniry. Further studies ore 
required to establish the effect of HIV progression on the drug levels, and whether 
dosage adjustments should be implemented in certain categories of HIV-infected 
1uberculosis patients. 
Other significant covariate effects included sex. smoking habits, and various markers 
of disease and nutrition. CleCJrIy our understanding of the interaction mechanisms of 
genetic and physiological constitution, disease, nutrition, environment and 
pharmacoldnefics are rudimeniary. Expanding our knowledge of these may 
ulfimately lead to more refined dosing sirategies. 
The considerable residual variablity could be the result of various facm as discussed 
previously. P-glycoprotein expression and activity may be of particular inlXriance for 
rifampicin conceniraflon. Moreover, as the amount of rifaflllicin is a de1errrinant of 
CYP3A4 expression106: rifampicin concenirafions might be important for prediction of 
the severity of drug-drug interactions. The converging epidemics of tuberculosis and 
HIV dictate that large nurrbers of patients in Africa and e1seYt'here will sirnlltaneously 
require antirelroviral and antituberculosis ireatments. Rifaflllicin containing regimens 
offer fhe best available antituberculosis ireatrnents for HIV-tnfected tuberculosis 
patients. Pharmacokinetic interactions between rifampicin. and the antfretroviral non-
nucleoside reverse transaiptase inhibitors (NNIUIs) and protease inhibitors (Pis) are 
described but have not been adequately "evaluated to guide treatment r~n 
and dosing sirategiesl69.160. As the NNIUIs and Pis are P-glycoprotein and cytochrome 





of concorritant rifarrpicin per se on the antiretroviral drug concenfrations in variOus 
HAART (highly active antiretroviral treatment) regimens prescrbed with rifampicin in 
TB/HIV patients; but the impact of the wide variations in rifampicin levels seen in 
patients on the severity of the drug interactions deserves investigation. 
Obiective Vj The response to treatment was measured in the cohort of patients by 
means of the proportional weight gain, the sputum smear conversion and the sputum 
sterilization {meas!Jl"ed by.Jlactec culture) after 2 months oftre~tment in Brewelskloof 
Hospital; and also the TB register recorded outcome at the end of the 1reatment 
period; and the treatment faiure, relapse and death rates up 24 months after the 
time of hospital admission. The weaknesses discussed previously should be addressed 
in more rigorously designed pharmacol<inetic. studies of drug efficacy and toxicity to 
verify the resuHs and to establish target therapeutic drug concen1rations. None-the-
less, higher doses of pyrazinarride and higher ethambutol levels were associated with 
reduced weight gain, higher concenfrations of rifampicin and ethambutol were 
associated with sputum conversion· at 2 months, and higher concen1rations of 
isoniazid were associated with unfavourable TB register outcomes. Furthermore, 
markers of immunity at 2 months were the predorrinant deterrrinants of the prognosis 
at 24 months after adrrission. 
Objective vi; As described above, /ow rifarrpicin and e'iharroutol conceniraffons 
were associated with an increased risk of the persistence (at 2 months) of 
Mycobacterium tuberculosis in sputum smears and cultures, respectively. Neither low 
levels of rifarrpicin, isoniazid, pyrazinamide, nor etharrbutol were associated with an 
increased risk of a treatment faDure, death or relapse during the 2 years foHowing the 
time of admission to Brewelsldoof Hospital. AsoutDned in the 'Methods' chapter, the 
study was underpowered to detect a significant differences in rifarrpicin levels 
between responders and nonresponders (based on sputum cuJture resutls at 2 
months) without adjustment for other risk factors. 
Objective viij The cytokine markers of immunity were measured in most of the study 
population, and, as described above, had irYlX>tiont bearing on the prognosis 2 
yeas after the time of admission to the hospital. 
Objective viii; The susceptibiJity of the infecting s1rains of M. tuberculosis in this 
population to isoniazid and rifaf'Tl)icin was measured in only a smatl proportion of 
study patients; thus preventing evaluation of the impact of the mni-MIC on treatment 
response. However, the narrow range of susceptibDifies observed indicates that for 
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conclusions 
most patients with drug sensitive organisms, the mini-MIC is unHkely to contribute to 
differences in trea1ment response. 
finally the extent to which the results can be generalized is limited by the atypical 
na1ure of the study populaflon. Patients adnitted to hospital for treatment comprise a 






1. Burden of Disease Unit (2000)."Exl!cutive Summary of The Global Burden of Disease and 
Injury Series, http://www.hsph.harvard.edu/organizations/bdu/summarv.html 
2. World Health Organization. Global Tvbercvfosis Control: SvrveHlance, Planning, Financing. 
WHO Report 2004. Geneva, Switzerland, ISBN 92 4 156264 1. 
3. Hart CA, Beeching NJ, Duerden BI. Tuberculosis into the next century~ J Med Microbiol 
1996; 44:1 - 34. 
4. Epstein H, Chen L. Can AIDS be stopped? The New York review of books 2002; 49( 14J. 
5. World Health Organization. Global Tuberculosis Control: Surveillance, planning, financing. 
WHO Report 2002, Geneva, Switzerland; WHO/CDS/TB/2002.295. 
6. Department of Health in the Western Cape, Worcester and Cape Town Offices; personal 
communications 24/05/2004. 
7. Maurya V. Vijayan VK. Shah A. Smoking and tuberculosis: an association overlooked. Int J 
Tuberc lung Dis 2002; 6(11): 942-95l. 
8. Karyadi E. West CE. Schultink W. Nelwan RHH. Gross R. Amin Z, Dolmans WMV, Schlebusch 
H. Van der Meer JWM. A double-bHnd. placebo-controHed study of vitamin A and zinc 
supplementation in persons with tuberculsis in Indonesia: effects on clinical response and 
nutritional status. Am J Clin Nutr 2002; 75: 270-277. 
9. Gajalakshmi V, Peto R, Kaneko TS, jha P. Smoking and mortality from tuberculosis and 
other diseases in India: retrospec11ve study of 43 000 adult male deaths and 35 000 
controls. lancet 2003; 362: 507 - 515. 
10. Wilkinson RJ, Llewelyn M, Toossi Z, Patel P, Pasvol G, lalvani A, Wright 0, latif M, 
1c •• ;~idson RN. Influence of vitamin 0 deficiency and vltamln 0 receptor polymorphisrns 
on tubercutsis among Gujarati Asians in west london: a case-con1ro1 study. lancet 2000; 
355: 618-621. 
11. Enerson DA, Beyers N, Zhang L. The tuberculosis pandemic today: Routes of 
transmission an new target groups. Scand Infect Dis 200 1; 33: 9-12. 
12. Munch Z, Van UII SWP, Booysen CN, Zietsman HL, Enarson DA, Beyers N. Tuberculosis 
transmission pattems in a high-incidence area: a spatial analysis. Int J Tuberc Lung Dis 
2003; 7(3): 271-277. 
13. Verver S, Warren RM, Munch Z, Vynnycky E. van Heiden PO, Richardson M, van der 
Spuy GO, Enerson DA, Borgdorff MW, Behr MA, Beyers N. Transmission of tuberculosis in a 
high incidence urban community in South Africa.lnt J Epidemiol. 2004:33(2):351-7. 
14. Richardson M, Van lUI SWP, Van der Spuy GO, Munch Z. Booysen CN. Beyers N, Van 
Heiden PO, Warren RM. Historic and recent events contribute to the disease dynamics of 
- 190-
references 
Beijing-fike Mycobacterium tubercuosis isolates in a high Incidence region. Int J Tuberc 
Lung Dis 2002; 6(11): lOOl-lOll. 
15. Davies POO, Grange JM. Factors affecting susceptibiliiy and resistance to tuberculosis. 
Thorax 2001; 56 (suppl Il): ra3 - ii29 
16. Frieden TR. Sterling TR. Munsiff SSt Watt CJ. Dye C. Tuberculosis. Lancet 2003; 362: 887-
899. 
17. Beyers AD, van Rie A, Adams J, Fenhalls G, Gie R, Beyers N. Signals that regulate the 
host response to Mycobacterium tuberculosis. Novartis found Symp. 1998;217:145-57; 
discussion 157-9. 
18. Corbett El. Watt CJ, Walker N. et al. The growing burden of tuberculosis: global trends 
and interactions with the HIV epidemic. Arch Intem Med 2003; 163: 1009-1021. 
19. Fox W. Ellard G, Mitchlson D. Studies on thefreafment of tuberculosis undertaken by 
the British .Medical Research Council Tuberculosis Units. 1946-1986. with relevant 
subsequent pub6cations.lnt J Tuberc Lung Dis 1999; 3(10): S231-279. 
20. Rieder H. Interventions for tuberculosis control and elimination. International Union 
Against Tuberculosis and Lung Disease 2002. 
21. Progress Report. 1997-2002. CHy of Cape Town/Metropo/e Region TB Control 
Programme. 
22. Frete M. Roscigno G. Joining forces to develop weapons against TB: together we 
must. Bulletin of the Wood Health Organization 2002; 80(6): 429. 
23. World Health Organization. Strategic framework to decrease the burden of TB/HIV. 
WHO Geneva, Switzerland 2002; WHO/CDS/TS/2002.296. 
24. Mitchison D. The Garrod lecture; Understanding the chemotherapy of tuberculosis -
current problems. Journal of Antimicrobial Chemotherapy 1992; 29: 477-493. 
25. Dr A Jindani. personnel communication re results of IUATlO Study A; 10/05/2004. 
26. Hawken M. Nunn P. Gathua S. Brindle R. Godfrey-Fausset P Githui W. Odhiambo J, 
Batchelor B, Gilks C, Morris J. McAdam K. Increased recurrence of tuberculosis in HIY-l-
infected patients in Kenya. Lancet 1993; 342: 332-337. 
27. Enarson OA, Jindoni A, Kuaban C, Lamothe F, Louissaint M, Ottmani SE Ramarokoto H, 
Ridderhof JC, Urbanczil<. R. Correspondence: Appropriateness of extending the intensive 
phase of treatment based on smear results. Int J Tuberc lung Dis 2004; 8( 1): 114-116. 
28. Ellard GA. Fourie PB. Rifampicin bloavailabiHty: a review of ftspharmacology and the 
chemotherapeutic necessiiy for ensuring optimal absorption. Int J Tuberc Ung Dis 1999; 
3( 11): S301-S308. 
- 191 -
references 
29. Acocella G, Nonis A, Perna G, Patane E, Gialdroni-Grassi G, Grassi C. Comparative-
bioavailabUity of isoniazid, rifampin, and pyrazinamide administered in free combination 
and in a fixed triple formulation designed for daily use in antituberculostschemotherapy 
II: Two-month daily administration study. Am Rev Respir Dis 1988; 138: 886-890. 
30. Acocella G. Human bioavailability studies. Bull Int Union Tuberc lung Dis 1989; 64(1): 
38-40. 
31. Fox W. Drug combinations and the bioavailabinfy of rifampicin. Tubercle 1990; 71:241-
245. 
32. PHlai G, Fourie PB, Padayatchi N, Onyebujoh pc, Mcll\eron H, Smith P J, Gabriels G. 
Recent bioequivalence studi&s on fixed-dose combination anti-tuberculosis drug 
formulations available on the global market.lnt J lung Tuberc Dis 1999; 3{l1): $309-S316. 
33. Official IUA TlDIWHO joint statement. Assuring bioavailabilify of fixed-dose 
combinations of anti-tuberculosis medications. lnt J Tuberc lung Dis 1999; 3 (11): 5282-
S283. 
34. Walters S. Background document for meeting on Fixed Dose Combinations for 
HIV IAIDS, Tuberculosis, and Malaria; Current status and future challenges from clinical, 
regulatory, intellectual property, and production perspectives: Pharmaceutical 
Development and Qualify Assurance of FDCs. World Health Organization 2003 
35. Improving TB drug management; Accelerating DOTS expansion. MSH, WHO, Stop TB 
Partnership 2002. WHO/CDS/STB/2002.19 
36. Cavenaghi R. Rifampicin raw material characteristics and their effect on 
bioavailability. Bullint Union Tuberc lung Dis 1989; 64 (1): 36 - 37. 
(3. Singh S, Mohan B. A pilot study on four-drug fixed-dose combination anti-tuberculosis 
products.lnt J Tuberc lung Dis 2003; 7(3): 298-303. 
38. Acocella G, Lamanna A, Nicofis FB, Pagani V, Segre G. Kinetic studies on rifampicin. II. 
Multfcompartmental analysis of the serum, urine and bile concentrations in subjects 
treated for one week. Eur J CUn Pharamcol 1972: 5: 111-115. 
39. Acocella G. Clinical pharmacokinetics of rifampicin. Clinical Pharmacokinetics 1978; 3: 
108-127. 
40. Aspesi F. Dissolution testing. Bullint Union Tuberc Lung Dis 1989; 64: 37-38. 
41. Pefoquin C. Tuberculosis drug serum levels. Clinical Infectious Diseases 200 1; 33: 584-
585. 
42. Santha T, Garg R, Frieden T, Chandrasekoran V, Subramani R, Gopi p, Selvakumar N, 
Ganapathy S, Charles N, Rajamma J, Narayanan P. Risk. factors associated with default. 
- 192-
references 
failure and death among tuberculosis patients treated.in a DOTS programme in Tirvvallur 
District. South India.lnt J Tuberc Lung Dis 2002: 6(9): 78().-788. 
43. Tam C, Chan S, Kam K, Goodall R, Mitchison D. Rifapentine and isoniazid in the 
continuation phase of a 6-month regimen. Fina1 report at 5 yeOfS: prognostic value of 
various measures. Int J Tuberc Lung Dis 2002; 6(1): 3-10. 
44. Peloquin CA. What is the 'right' dose of rifampicin? Int J Tuberc Lung Dis 2003; 7(1): 3-5. 
45. Vernon A, Burman W, Horsburgh CR. Another step on the path to better TB therapies 
(editorial).lnt J Tuberc Lung Dis 2002: 6(1): 1-2. 
46. Villarino M. Tuberculosis due to environment. biology, or both? Chest 2001; 120(5):1435-
1437. 
47. Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by 
culture at 2 months. Am Rev Respir Dis 1993; 147: 1062-1063 
48. PerriE!ns JH, st. Louis ME, Mukadi y, Brown C, Prignot J, Pouthier F, Portaels F, Winame J, 
Mandala JK, Kaboto M, Ryder RW, Roscigno G, Piot P; Pulmonary tuberculosis in HIV-
'infected patients in Zaire. A controlled tria of treatment for either 6 or 12 Months. N Engl J 
Med 1995; 332: 779-784. 
49. Driver CR, Munsiff SS. Li J. Kundamal N. Osahan SS. Relapse in persons treated for drug-
susceptible tuberculosis in a population with high coinfection with human 
immunodefICiency virus in New Yor!< City. Clinical Infectious Diseases 2001; 33: 1762-1769. 
SO. Pulido F, Pena J, Rubio R, Moreno S, Gonzalez J, Guijarro C. Costa J, Vazquez J. 
Relapse of tuberculosis after treatment in human immunodeficiency virus-infected 
patients. Arch Intern Med 1997; 157:227-232. 
51. Weiner M, Burman W, Vernon A. Benator 0, Peloquin CA, Khan A. Weis S, King B, Shah 
N. Hodge T, and the Tuberculosis Trials Consortium. Low isoniazid concentrations and 
outcome of tuberculosis treatment with once-weekty isoniazid and Rifapentine. Am J 
Respir em Care Med 2003; 167: 1341-1347. 
52. Berning SE. -Huitt GA. Iseman MD. Peloquin CA. Malabsorption of antituberculosis 
medications by a patient with AIDS. The New England Journal of Medicine 1992; 327: 
1817-1818. 
53. Patel KB. Belmonte R. Crowe HM. Drug malabsorption and resistant tuberculosis in HIV-
infected patients. The New England Journal of Medicine 1995; 332: 336-337. 
54. Barakat MT, Scoff J. Hughes JMB, Wa/port M. Calam J, Friedland JS, Ind PW, McKema 
C, Taylor-Robinson SO. Persistent fever in pulmonary tuberculosis. British Medical Journal 
1996; 313: 1543-1545. 
- 193-
references 
55. Morehead RS. Delayed death from pulmonary tuberculosis: Unsuspected 
subtheropeutic drug levels. South Med J 2000: 93~5): 507-510. 
56. Peloquin CA. Therapeutic drug -monitoring of theantimycobacterial drugs. Clinics in 
laboratory Medicine 1996: 16(3): 717-729. 
57. Gilbert N, Moellering R, Sande M (editors). The Sanford Guide to antimicrobial therapy, 
30th edition 2000. Antimicrobial Therapy, Inc. USA. 
58. P.eloquinCA, Nitta AT. Burman WJ, Brudney KF, Miranda-Massari JR,McGuinness ME, 
Berning S. Gerena G. low antituberculosis drug concentrations in patients with AIDS. The 
Annals of Pharmacotherapy 1996; 30: 919-924. 
59. Peloquin C, MacPhee A Berning S. Malabsorption of antimycobacterial medications. 
Correspondence. The New England Journal of Medicine 1993: 1122. 
60. Mehta S. Malnutrition and drugs: clinical implications. Dev Pharmacol Ther 1990: 
15:159-165. 
61. Hooijberg JH, Jansen G, Assaraf YG, Kathmann L Pieters R. Laan AC, Veerman AJP, 
Kaspe~ GJL Peters GJ. folate concentrotion dependent transport activity of the 
multidrug resistance protein 1 (ABCC1). Biochemical Pharmacology 2004: 67: 1541-1548. 
62 Poscussi J, Drocourt l, Gerbal-Chaloin S, Fabre J, Maurel p, Vilarem M. Dual effect of 
dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of 
glucocorticoid receptor and pregnane X receptor. fur J Siochem 2001: 268: 6346-6357. 
63. 0' Neil W, GilflX B, DiGirolamo A, Tsoukas C, Wainer I. N-Acetylation among HIV-positive 
patients and patients with AIDS: When is fast, fast and slow, slow? Clin Pharmacol Ther 
1997; 62: 261-271. 
64. Polosa K, Murthy KJ, Krishnaswamy K. Rifampicin kinetics in undernutrition.Br J elfn 
Pharmaco1.1984; 17(4):481-4. 
65. Tam YK. Individual variation in first-pass metabolism. CRn Pharmacokinet. 1993; 25(4}: 
300-328. 
66. Hardman J, limbird l, Goodman A (editors). Goodman and Gitman's The 
pharmacological basis of therapeutics, 10th edition 2001. McGraw-Hili Companies, Inc. 
67. Klasco RK (Ed): DRUGDEX® System. Thomson MICROMEDEX, Greenwood Village, 
Colorado (Edition expires September 2004). 
68. Peloquin CA, Berning Sf. Huitt GA Iseman MD. Aids and TB drug absorption. 
Correspondence, Int J Tuberc lung Dis 1999: 3(12): 1143-1147. 
69. Sahai J, Gallicano K,.Swick L TaHorS, GorberG, Seguin I, Oliveras L WalkerS, Rachlis A, 
Cameron W. Reduced plasma concentrations of antituberculosis drugs in patients with 
HIV infection. Ann Intern Med 1997: 127: 289-293. 
- 194-
references 
70. Choudri S H, Hawken M, Gathua S, Minyiri GO, Watk.ins W, Sahai J, Sitar OS, Aoki FY, 
Long R. Pharmacokinetics of Anfimycobacterial Drugs In Patients with Tuberculosis. AlDS, 
and Diarrhoea. Clinicallnfecfious Diseases 1997; 25: 104-111. 
71. Taylor B, Smith P J. Does AIDS impair the absorp.tion of antituberculosis agents~ Int J 
Tuberc Lung Dis. 1998; 2(8):670-5~ 
72. Jarurutanaslrikul S. The phamacokinetics of oral rifampicin in AIDS patients. J med 
Assoc ThaHand 1-998; 81: 25-28. 
73. Zent C, Smith P. Study ·of the effect of concomitant food on thebioavailabilHy of 
rifampicin, isoniazid and pyrazinamide. Tubercle and Lung Disease 1995; 76: 109-113. 
74. Kimeding M. Phillips P, Patterson P, HaD M, Robinson A, Dunlap N. Low serum 
antimycobocterial aug levels in non-HIV-infected tuberculosis patients. Chest 1998; 113: 
1178-1183. 
75. Van Crevel R, Afisjahbana B. De Lange WCM. Borst F, Danusantoso H, Van der Meer 
JWM. Burger D. Nelwan RHH. Low plasma concentrations of rifampicin in tuberculosis 
patients .inlndonesia. Int J Tuberc lung Dis 2002; o(6~: 497-502 
76.. Mehta JB, Shantaveerapa H, Byrd RP, Morton Sf. Fountain F, Roy TM. utility of rifampicin 
blood levels in the treatment and foHow-up of active pulmonary tuberculosis in patients 
who were slow to respond to routine direcffy observed therapy. Chest 2001; 120: 1520-
1524. 
77. JsraDi ZH. Rogers CM. El-Attar H. Phannacok.inetics of antituberculosis drugs in patients. J 
CRn Pharmacol 1987; 27: 78-83. 
78. Lopez-Cortez LF, Ruiz-Valderas R, Viciana P, Alarcon-Gonzalez A, Gomez-Mateos J, 
leon-Jimenez E. Sarasa-NacentaM.lopez .. Pua Y. Pachon J. Pharmacokinetic 
interactions between efavirenz and rifampjcin in HIV-infected patients with tuberculosis. 
Cnn Pharmacokinet 2002; 41 (9):681-690. 
79. Conte JE. Golden JA. Kipps JE. Lin B. Zur1inden E. Effect of sex and AIDS status on the 
plasma and intrapulmonary phannacokinefics .of rifampicin. eRn Phannacokinet. 2004; 
43(6): 395 - 404. 
BO. MOnnistc~ P. MOntylO R. KHnge E, NykOnen. Koponen A, Lamminsivu U. Influence of 
various diets on the bioavailabMfy of isoniazid Journal of Antimicrobial Chemotherapy 
1982; 10: 427-434. 
81. Naita M. Hisada M. Thimmappa S, Stambaugh JJ. Ibrahim E, Hollemer ES, Ashkin D. 
TuberculosiS recurrence: Multivariate analysis of serum levels of tuberculosis drugs, human 




82. Douglas JG, Mcloed M. Phormacokinetic factors in the modem drug treatment of 
tuberculosis. Clin. Pharmacokinet. 1999; 37(2}: 127-146. 
83. Burman WJ. The value of invitro drug activity -cmd pharmocoldnetics in predicting the 
effectiveness of antimycobacterial therapy: a critical review. The American Joumal of 
the Medical Sciences 1997; 313(6): 355-363. 
84. Jindani A, Dore CJ, Mitchison DA~ Bactericidal and sterilizing activities of 
antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med. 
2003; 167 (1 0) :1348-54. 
85. Cote $1, Telenti A. Drug resistance in Mycobacterium tuberculosis. Eur Respir J 1995; 
8(suppl20): 701s-713s. 
86. Verbist l, Gyselen A. Antituberculosis activity of rifmapin in vitro and in vivo and the 
concentrations attained in human blood. American Review of Respiratory Disease 1968: 
98(6): 923-932. 
87. Schilke K, Weyer K, Bretzel G, Amthor B, Brandt J, Sticht-Groh V, Fourie P, Haas W. 
Universal pattem of Rpo8 gene mutations among multidrug-fesistant isolates of 
Mycobacterium tuberculosis complex from Africa. Int J Tuberc lung Dis 1999.3(7): 620-
626. 
88. Victor TC, Warren R, Butt JL Jordaan AM, FerlX JV, Venter A, S"wgel FA, Schoaf HS, 
Donald PR, Richardson M, Cynamon MH, Van Heiden PD. Genome and MIC stability in 
Mycobacterium tuberculosis and indications for continuation of use of isoniazid in 
multidrug-resistant tuberculosis. J Med Microbiol1997; 46:847-857. 
89. David HL. Probability distribution of drug-fesistant mutants in unselected population of 
Mycobacterium tuberculosis. AppJ Microbiol1970; 20: 810-814. 
90. Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and 
pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001; 40(5}:327-
341. 
91. Leos U, Musch E, Jensen JC, Mikus G, Schwabe HI<, 8chelbaum M. Pharmacokinetics 
of oral and intravenous rifampicin during chronic administration. Klin Wochenschr 1985; 
63: 1205-1211-
92. Long MW, Snider DE, Farer LS. U.S. Public Health Service Cooperative Trial of Three 
Rifampin-Isonlazid Regimens in Treatment of Tuberculosis. Am Review Resp Dis 1979; 119: 
879-894. 
93. Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc 
Lung Dis 2000; 4(9):796-806. 
- 196-
, :' ~ ','-.. -: .... ".-, 
references 
94. Jayaram R. Gaonkor S. Kaur P. Suresh BL. Mahesh BN. Jayashree R. Nandi V. Bharat S. 
Shandit RK. Kantharaj E. Balasubramanicin V. Pharmacoldnetics-Pharmacodynamics. of 
rifampicin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 
2003; 47(7):211&2124. 
95. Combs DL O'Brien RJ, Geiter U. USPHS tuberculosis short-course chemotherapy triaf 
21: effectiveness, . toxicity, and acceptability. The report of final results. Am Intern Med 
1990; 112: 397-406. 
96. Chan C, AlrYeang C, Yew W, Hul M, Cheng AFB. PostantbioHc effects of 
antituberculosis agents alone and in combination. Antimicrobial Agents and 
Chemotherapy 2001; 451l2}: 3631-3634. 
97. Arya SC. Correspondence:Quafity of anti-tuberculosis drugs offered to patients. Int J 
Tuberc Lung Dis 2003; 7(4): 403-404. 
98. Mcilleron H, Wash P, 8urger A,. Folb P, SmHh P. Widespread distribution of a single drug 
rifampicin formulation of inferior bioavailabllity in South Africa.lnt J Tuberc Lung Dis 2002: 
6(4): 356-361. 
99. Nau R, Prange HW, Menck. S, Kolenda H, VISSer K. Seydel JK. Penetration of rifampicin 
into the cerebrospinal. fluid of adults with uninflamed meninges. Journal of Antimicrobial 
Chemotherapy 1992: 29: 719-724. 
100. Darouiche R, Pelkins B, Musher O. HamiD R, Tsai S. Levels of rifampicin and 
ciprofloxacin in nasal secretions: correlation with M1C90 and eradication of 
nasopharyngeal carriage of bacteria. Journal of Infectious Diseases 1990; 162:·1124-1127. 
101. Gurumurthy P. Rahman F, Narayana ASl Raghupati Samna G. Salivary levels of 
isoniazid and rifampicin in tuberculous patients. Tuberde 1990; 71 :29-33. 
102. Pagal A. Rani S. Non-linear pharmacokinetics of rifampicin in healthy Asian Indian 
volunteers. Int J Tuberc Lung Dis 2001; 5(1}:70-79. 
103. Jamis-Dow CA. Katki AG, CoRins JM. Klecker RW. R'tfampin and rifabutin and their 
metabolism by human liver esterases. Xenobiotica 1997; 27( 1 0): 101 >24. 
104. KImRB. Leake Bf. Choo EF. Dresser GK. KubbaSV. Schwarz UI. Taylor A. Hong-Guang 
Xie, McKinsey J. Sheng Zhou, LlrBin Lan, Schuetz JO, Schuetz EG, Wilkinson GR. 
Identification of functionally variant MORl aUeles among European Americans and 
African Americans. Clinical Pharmacology and Therapeutics 2001; 70(2}: 189-199. 
105. MarzoJini C. Paus £, Buclin T. Kim RB. Polymorphismsin human MDR J (P~lycQPrOtein): 
recent advances and cUnical relevance. Oin Pharmacol Ther 2004;75:13-33. 
- 197-
references 
106. Schuetz E, Schinkel A. Reiling M. Schuetz J. P-glycoprotein: A major determinant of 
rifampicin-inducible expression of cytochrome P4503A in mice and humans. -Proc. Natl. 
Acad. Sci. USA 1996; 93:4001-4005. 
107. Fromm MF. Importance of P-glycoprotein for drug disposition in humans. Eur J Clin 
Invest 2003 ; 33 Suppl 2: 6-9. 
108. Kim RB, Fromm MF. Wandel C. Leake B. Wood AJJ. Roden OM. The drug transporter P-
glycoprotein limits oral absorpt-ion and brain enfry of HIV-l protease inhibitors. J Clin 
Invest 1998; 101:289-294. 
109. Singh S. Mariappan T, Sankar R. Sardo N. Singh B. A critical review of the probable 
reasons for the poor/variable bioavailability of rifampicin form anti-tubercular fixed-dose 
combination (fOC) products, and the likely solutions to the problem. Intemational Journal 
of Pharmaceutics 200 1; 228: 5-17. 
110. Capelle P. Ohumeaux D. Mora M. Feldmann G. Berthelot P. Effect of rifampicin on liver 
function in mono Gut 1.972; 13: 366-371. 
111. Ponchnagula R et aJ. FIXed dose combinations for tuberculosis: lessons learned from a 
clinical, formulation and regulatory perspective. Wortd Health Organization 2003. 
112. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto K'T. Pharmacokinetic 
interactions with rifampicin: cOnical relevance. Clin Pharmacokinet 2003; 42(9): 819-50 
113. Fuhr U. Induction of drug metabolising enzymes. Pharmacokinetic and toxicological 
consequences in humans. Clin Pharmacokinet 2000; 38{6):493-504. 
114. Oesch F, Arend M~ Strolin Benedetti- M. Castelli MG, Oosterf P. Inducing properties of 
rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UOP-
gfucuronosyltronsferase superfamiJies in femafe rat liver. Journaf of Antimicrobial 
Chemotherapy 1996; 37:1111-1119. 
115. Lehmann JM, McKee DO, Watson MA, Willson TM, Moore JT, Kliewer SA. The human 
orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene 
expression and cause drug interactions. J Clin Invest 1998; 1 02( 5): 1016-1023. 
116. Center for Disease Control guidelines (draft form): Updated Guidelines for the use of 
rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease 
inhibitors or nonnucleoside reverse transcriptase inhibitors; version 11.21.03. 
117. Jaruratanasirikul S, Sriwiriyajan S. Effect of indinavir on the pharmacokinetics of 
rifampicin in HIV-infected patients. Journal of Pharmacy and Phannacology 2001; 53: 
409-412. 
- 198-
.: • ';- - .,-; ::..... :. ".~. > 
references 
118. Zutshi RK, Singh R, Johri RK, A tal CK. Influence of piperine on rifampicin blood levels in 
patients of· pulmonary tuberculosis. The Journal of the Association of Physicians of (ndio 
1985; 33(3): 223-224. 
119. Bhardwaj RK. Glaeser H, Becquemont L Klotz U, Gupta SK. Fromm Mf. Piperine, a 
major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. 
J Pharmacol Exp Ther. 2002; 302(2): 645-650. 
120. Engelhard 0, Stutman H, Marks M. Interaction of ketoconazole wi1t1 rifampin and 
isoniazid. The New England Journal of Medicine 1984; 311(26): 1681-1683. 
121. Jain A, Mehta Vl, KuJshreshtha S. Effect of pyrazinamide on rifampicin kinetics in 
patients with tuberulosis. Tubercle and Lung Disease 1993; 74:87-90. 
122. Sfayden RA. Barry CE. The genetics and biochemistry of isoniazid resistance in 
Mycobacterium tuberculosis. Microbes and Infection 2000; 2: 659-669. 
123. Parkin 0, Vandenplas 5, Botha F, Vandenplos M, Seifart H, Van Heiden P, Van der Walt 
B, Donald P, Van Jaarsveld P. Trimoc::IaIity of isoniazid elimination. Am J Respir Crit Care 
Med 1997; 155: 1717-1722. 
124. Kergueris MF, BourinM, larousse C. Pharmacokinetics of isoniazid: Influence of age. fur 
J Clin Pharmacol1986: 30: 335-340. 
125. Zuber R, Anzenbacherova E, Anzenbacher P. Cytochromes P450 and experimental 
models of drug metabolism. J Cell MoiMed 2002: 6(2):189-198. 
126. O'Shea 0, Kim RB, Wdkinson GR. Modulation of CYP2E1 activity by isoniazid inrppid 
and slow N-acetylators. Br J Clin Pharmacol 1997; 43( 1 ):99-103. 
127. Torrent·J, Izquierdo l, Cabezos.R, Jane F. lheophyUine-isoniazid interaction. DICP 1989; 
23(2): 143-145. 
128. South African Medicines Formulary (SAMF), 61h edition. Edited by Gibbon CJ. et aI. 
Division of Pharmacology, Faculty of HeaHh Sciences. University of Cape Town 2003. 
129. Hurwitz A, SchIozman Dl. Effects of antacids on gastrointestinal absorption of isonizid in 
rat ~nd man. Am Rev Respir Dis 1974; 109:41-47. 
130. Ofoefule 51, Obodo CE, Orisakwe DE, lIondu NA, Afonne·OJ, Maduka SO, Anusiem CAt 
Agbasi PU. Some plasma pharmacokinetic parameters of isoniazid in the presence of a 
flouroquinolone antibacterial agent. Am J Ther 2001; 8(4): 243-246.South. 
131. Lee BL Tauber MG, Chambers HF, Gambertogfio J, Delahunty T. The effect of 
zalcitabine on the pharmacokinetics of isoniazid in HIV-infected patients. Program Absfr 
tntersci Conf Antimicrob Agents Chemother. 1994 Oct 4-7:3. 
132. Zhang Y1 Mitchison D. The curious characteristics of pyrazinamide: a review. Int J 
Tuberc Lung Dis 2003; 7( 1): 6-21. 
- 199-
references 
133. Zhu M, Starke JR, Burman WJ, Steiner p, Stambaugh JJ, Ashkin D, Bulpitt AE, Beming AE, 
Peloquin CA. Population modemng of pyrazinamide in chUdren and adults with 
tuberculosis. Pharmacotherapy 2002; 22(6): 686-695. 
134. Mcllleron H, Gabriels G, Smith P J, Fourie PB, Biard GA. The development of a 
standardized screening protocol for the in vivo assessment of rifampicin bioavailability. Int 
J Lung Tuberc Dis 1999; 3(11): S329-S335. 
135. Conte JE, Golden JA, Duncan $, McKenna E, Zulinden E. IntrapuJmonary 
concentrations of pyrazinamide. Antimicrobial Agents and Chemotherapy 1999; 43(6): 
1329-1333. 
136. Peloquin CA, Bulpitt AE. Jaresko GS, Jeniffe RW, Childs JM, Nix DE. Pharmacokinetics of 
ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents 
Chemother 1999; 43(3): 568-572. 
137. Wilkinson D, Bechan 5, Connolly C, Standing E. Short G. Should we take a history of 
prior treatment. and check sputum status at 2-3 months when treating patients for 
tuberculosis? Int J Tuberc Lung Dis 1998; 2( 1): 52-55. 
138. Smith p, Van Dyk J, Fredericks A. Determination of rifampicin, isoniazid and 
pyrazinamide by high performance liquid chromatography after their simultaneous 
extraction from plasma.lnt J Tuberc Lung Dis 1999; 3(l1}: S325-328. 
139. Cockcroft J. The development. implementation and vaUdationofa plasma-based 
high performance liquid chromatographic assay for isoniazid and N-acetylisoniazid: an 
acetylator stotus population study at Brewelskloof Hospital. A project submitted to the 
Department of Pharmacology, University of Cape Town in fulfillment of the requirements 
for the degree Master of Science (Medicine) 2001. 
140. Blner JJ, Hirsch CS, Whalen CC. Correlates of protective immunity to Mycobacterium 
tuberculosis in humans. Clinical Infectious Diseases 2000; 3O(suppI3): S279-S282. 
141. Hussey GD, Watkins MLV, Goddard EA, Gottschalk S, Hughes EJ, lloni K. KlbelMA, Ress 
SR. Neonatal mycobacterial specific cytotoxic T-Iymphocyte and cytokine profiles in . 
response to distinct BCG vaccination strategies. Immunology 2002; 105: 314-324. 
142. Lo Bue PA, Perry S, Catanzaro A. Diagnosis of Tuberculosis; in Tuberculosis. A 
comprehensive international approach, 2nd edition edited by Reichmann LB and 
Hershfleld es. Morcel Dekker, Inc. 2000. 
143. Harries AD, Chilemba PE, Greya D, Nyirenda TE, Bane~ee A, SaJaniponi FML. Monitoring 




144. Jacobs OS, Demott WR, Finley PR, Horvat RT, Kasten BL. Tilzer lL. laboratory Test 
Handbook. 3rd edition. Lexi-Corp Jnc., USA 1994. 
145. Zevin S, Benowitz NL Drug interactions with tobacco smol<ing. An update. Oin 
Phcirmacokinet 1999; 36{6J:425-38. 
146. Harries AD, Hargreaves NJ, Kemp J, Jindani A; Enarson DA, Maher 0, Salaniponi FM. 
Deaths from tuberculosis in sub-Saharan AfricQ'l countries with a high prevalence of HIV-
1. lancet 2001; 357: 1519-23 
147. flamer CWo Factors associated with pharmacoldnetic variabifi1yin HIV-infected 
patients.. Northwes.tern_ Universi1y Feinberg School of Medicine Office of Continuing 
Medical Education; iMedOptfons. LlC;19-03-2004. 
148. -Greiner B, 8chelbaum M, Fritz P, Kreichgauer HP, Von Richter 0, Zundler J, et a!. The 
role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J CJin Invest 
1998;104: 147-153. 
149. Hoffmeyer 5, Burl< 0, von Richter 0, Amotd H, Brockmoller J, Johne A, et al. Functional 
polymorphisms of the human multidrug-resistance .gene: multiple sequence· v.ariations 
and correlafion of one aDele with P-gJycoprotein expression and activi1y in vivo. Proc NaH 
Acad Sci USA 2000;97: 3473-3478. 
150. Stenger S, Modtin RL T celt mediated immuni1y to Mycobacterium tuberculosis. Current 
Opinion in Microbiology 1999; 2: 89-93. 
l51. Hirsch CS, Hussain R, Toossi I, Dawood G, Shahid f, Siner JJ. Cross-modulation by 
transforming growth factor ~ in human tuberculosis: suppression of antigen-driven 
blastogenesis and interferon y production. Proc Nat1 Acad Sci 1996:93: 3193-3198. 
152. Jo OC Pork JK, Doekrell HM. DynamiCS of cytokine generotion inpatients w1th octive 
pulmonary tuberculosis. CurrOpin Infect Dis. 2003;16(3):205-10. 
153. Daniel TM, Boom WH, Siner JJ. Immunology of Tuberculosis; in Tuberculosis, A 
comprehensive intemational approach, 2"cI edition ecfited by Reichmann LB and 
Hershfield ES. Marcel Dekker, Inc. 2000. 
! 
154.Spellberg B, Edwards JE. Type 1 rrype 2 immuni1y in infectious diseases. Clinical 
Infectious Diseases 2001; 32: 76--102. 
155. Park LP, MargoIick J8, Giorgi JV, Ferbas J, Sauer K, Koslow R, Munoz A. Influence of 
HIV-1 infection and cigarette smol<ing on leukocyte profDes in homosexual men: The 




156. Wewers MD, Diaz PT, Wewers ME. Lowe MP, Nagaraja HN, Clanton TL Cigarette 
smoking in HIV infection induces a suppressive inflammatory environment in the lung. Am 
J Respir Care Med 1998: 158: 1543-1549 . 
157. Van Rie A, Warren R, Richardson M, Victor TC, Gie RP, Enerson OA, Beyers N, Van 
Heiden PD. Exogenous reinfection as a cause of recurrent tuberculosis after curative 
treatment. N Engl J Mect 1999; 341 (16): 1174-1179. 
158. Comstock GW. Epidemiology of Tuberculosis; in Tuberculosis, A comprehensive 
international approach, 2nd edition edited by Reichmann LB and Hershfleld ES. Marcel 
Dekker, Inc. 2000. 
159. Grosset J, Trvffot-Pemot C, Lacroix C, Ji B. Antagonism between isoniazid and the 
combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob 
Agents Chemother. 1992;36(3): 548-51. 
160. Nuermberger El, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, 
Grosset JH. Moxifloxacin-containing regimen greatly reduces time to culture conversion 
in murine tuberculosis. Am J Respir Crit Care Mad 2004; 1-69: 421--426. 
161. Badri, M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence 
of tuberculosis in South Africa: a cohort study. The Lancet 2002; 359: 2059-2064. 
162. Churchyard GJ, Kleinschmidt I, Corbett EL, Mulder D, De Kock KM. Mycobacterial 
disease in South African goldminers in Churchyard GJ, Kleinschmidt I, Corbett El, Mulder 
D, Smit J, De Kock KM. Factors associated with an increased case-fatality rate in HIV-
infected and non-infected South African gold miners with pulmonary tuberculosis. Int J 
Tuberc lung Dis 2000; 4: 705-712. 
163. feng-zeng Z, levy MH, Sumin W. Sputum microscopy results at two and three months 
predict outcome of tuberculosis treatment. lnt J Tuberc lung Dis 1997; 1 (6): 570-572. 
164. Rieder Hl. Sputum smear conversion during directly observed treatment for 
tuberculosis. Tubercle and Lung Disease 1996; 77: 124-129. 
165. Johnson JL Ssekasanvu E, Okwera A, Mayanja H, Hirsch CS, Naktbali JG, Jankus DD, 
8senach KD, Boom WH, Ellner JJ, Mugerwa RD for the Uganda-Case Western Reserve 
University Research Collaboration. Randomized trial of adjunctive interleukin-2 in adults 
with pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 168: 185-191. 
166. WaDis RS, Perkins MD, Phillips M, Joloba M, Namale A, Johnson JL Whalen ce, Teixeira 
L, Demchuk B, Die1ze R, Mugerwa RD, 8senach K. Siner JJ. Predicting the Outcome of 
Therapy for Pulmonary Tuberculosis. Am J Respir Crit Care Med 2000; 161: 1 076-1080. 
167. K Weyer, National Tuberculosis Research Programme, Medical Research CouncR, 
Pretoria; personal communication, 24/05/2004. 
·202· 
references 
168. K Weyer, National Tuberculosis Reseach Programme. Medical Research CounciL 
Pretoria: communication with Professor GMaartens. 2004. 
169. Center for Disease Control. Updated Guidelines for the Use of Rifamycins for the 
Treatment of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or 
Nonnucleoside Reverse Transcriptase Inhibitors. Version 1.20.04; 
http://www.cdc.gov/nchstp/tb/tb hiv drugs/PDF/tbhiv.pdf (last accessed 17/6/04). 
170. BlA'TYlOn WJ, Gallicano K, Peloquin C. Therapeutic impications of drug interactions in 
the treatment of hum<;m immunodeficiency virus-related tuberculosis. Clin Infect Dis. 1999 
Mar;28(3) :419-29 
171. Wallis RS, PatH S, Cheon S, Edmonds K, Phillips M, Perkins MO, Joloba M, ·Nomaie A, 
Johnson JI, Teixeira l, Dietze R, Siddiqi S, Mugerwa RD, Eisenach K, Blner JJ. Drug 
tolerance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 
1999: 43(11): 2~2606. 
- 203-

append; .. 1.1 
PROTOCOL 
S-P2: PHARMACOKINETICS OF ANTITUBERCULOSIS DRUGS IN 
PATIENTS RESPONDING POORLY TO TREATMENT 
Investigators: H Mcilieron , P Wash, A Burger, J Wilkins. G Gabriels, J 
Cockcroff, P Smith, P Folb 
lITEPA.TURE REVIEW AND BROAD SCIENTIFIC GOALS' 
Thi: in~"menlation 01 DOTS fl'09rammcs ir.crn"W>n""~ hCIS ,,00 to promisi ,'9 
in>provenlerllS in tt>e COlltro l rt n It>ern ""'",: with many co l 'ltrK;s ac\li;cving 11igh cure rJles 
u:.i ,, ~ II~s WHO T8 co ntrol r"")::rg,, (1 2). L""! """'''5.> ,,'tt~" U'1<lc1 00 I::; ,'''Il' ",,,,,.e, ir 
Africa (average 58%; Sol~h AfricJ 69% illl 9!l6) ale 1 ~'ll"'Y dlI) t~ f ai lure cI' D"knts to 
complctc trcat"",nt arKJ incomplt<te t"JiuJli<J n "I trealrro rl OLItU,lITICS (2) Ho 
"IE,',,>;r II ,,;re r >;t"din~ d ,."all i>l~ sO:J llif·""r··! 91 ('up o! p"t" nt~ '''00 ,""".,',, , ~~I~",,;j c., 
inadeqllaj;c r~spon"" t:l t",aln""nt urldt:r co,ldilions of close supervisiOr1 alld suwnrt 
Trese patients who 00 rot ,espond 10 t,~atn'kOnt as e"llt'Glood, ~nd in wham Or., is a",;ured 
tl ", I lh ~ t"':lcdJ""· tc.'~,',,, tub~(w,'=s ory~n l srn IS suscept,1Jje 10 111e jl\,\;s gi'oen, J, lJ II ", 
PJtient is tJkillg the rnediC<ltir'll as rrescriOC<l. ~sent a manage"ICnl diloomlTla 
F ailuIB to achieve ;xJeq"~te d!ll~ "" LII" CGrv:oert'~'t;_'n$ ie' !'tliev,.,] te Iy, c,nf or -",'i£",,1 
",as<lOs wh.,. 2 t~ 5% of compliant tut>c rculo!is p.;t"'nls ~iU"'f f ai l drug tl>e'JPY or relapse after 
U", r aM i24). Low serlln> kycls of ""t~Wi:retlhsis drugs in p.;t"'nts on stJ,ldard doses h~,,", 
been lCPO'ted ill ~ nUlTllJer '_-.f Sludies (;1 4,~\. In S0rne slu dio'>< o)w levels nf tho> 
JnliluLi:relJosis a9<"nts ar" CW;\rii)utood to HIV infec,""n (3, 5). This relation»t\lp hJS r,ot lJeen 
suppDrtcd b.,. attICr stuiics: low dl UIJ Icvels coukj nDt 00 ,clat ... <i to HIV dec,""n, d':lrlf1oe~, 0, 
CD4 iYlllp\ucyro COllltr in tllOO' CU!""';s patier/::" pr ~SO' '1ti''9 tn u IK",;.. tZll i l'l fI Ji r'_'L'i (·1), SlU(Iii:s 
in too..rcul0Sis patiellts at hospitals in Cape Town (1) ",iii DIlrllan (8) fourld rl() signifICant 
differellces ill drug levels betwecll AIDS patients alld HIV ""Qati", pat",nlS; and a study 
among'" Thai A IDS pat>cnts hle,j to llo.;mo nSlr"'" dela",d or relluced absorpbJr '· 01 MJmp;cin 
(321 _ A further stlKJ.,. (5) smwed a signt icant number of HI,' r"'gati'" pati"nts w ho w~'" 
reslXl,lding poorly to tIlerapy to 1'<'\Ie low 2 hO\.-!e\lels of rJ~ml'icill (5<1'1") ~rId fsQrliil!id 
(f0'% ) 
F Cldors j,lI'lwncing "''''''s of [lJe an litwen,u).)";" drugs Jre p'Xl rly cJefioJed: Jratt Iroon lhe 
m ntr<lve reia l elfocl rt ~IIV inf~r:I"'rl. l"CIor~ t 11 '" m~y be JS'<"lciaterJ wil l1 I<M' drLl(llevel~ m.'y 
include gene~c differences in nJetaoo i c rales, e lly;,-onmenl~1 influe<1ces on metClboI" ""' (9), 
mncon~tJllt focd I: 1 G.l}), concomitant iilr'e&5, Wllwml Ji'lt n'kOd icatio n 13,1 1,12) , nLItlitionJI 
S!Jtu ~ JrlJ rlie t i9,4). The inrr"",n(;e l>i al.etylJlor gerllJlype on the e.mr""ion or i5lKliai itl ha~ 
l>E>en _ I (1.,fi,red (14), JrId is belie",d to "" of jmport .. lC~ lor on"" w~~kly oosi ,'9 reg i"",s, 
out not to significartly iml""n"" tI", 01i10011., of 5 0 .. 3 tllI~S \ •• :"kl~ dosir-,g '>C 1",d ul~s( 15, 23), 
The dn.OJ e'I' )<,'f e in DJtient<, Qi',,",,, ~Qo;es ('<"l(;e w"'e k~i anJ ':;1, ) r:l rlli~arr: tile ell .o;; r "I-,,,11y 
is rlOt sltrlCit:nt \0 'Ua,d g,owtl1 cI' U", orgarusm for tlng cmugh arid more r~g[{lwtll occurs 
Uctw~"r" J""",. In sh.i "Aot,'ldt{l( S, ct '_'" c'+""'llI~ is 3 tll"_" S g,eal~ l, and su'ficie llt I"!) In the 
0" __ ,,,,111 of II'" orqa,lisms is x;-"'""d for on~e w~~~ly dosirlq to be dlccti",1151. Combir",d 
WIth othe, factors wl10ch ,""Crease levcls ot IsoniaZKJ, irtcrrT>Cd iate Ic ,,,'s '" orgallism 
r"slstanc~. Or a compr(Jl1~scd immt"'" syst"m tile acet)1atnr status may"" all imrort~nt 
fJctOf in tll .. ice week lv ar··d da~" OOsi r··g r~\l i rT>Cns 
Tile " lit: of once w<xkly isoniJ"id coml';ned wijl, nraptnt"", in tile cooti 'lIJal ion f1hase of 
tleJl"", ot in ~I I '.'-')WQjX",t;',,, ;>Clt ie ni~ 'eOO '0 n-.., '-,,,,crweno-, of ai' ald"""lIlIy Inllh ~!J!"l't"'" 
of acquired ,HamyGin rnonoresi-StJnce in thoolit: patielltS: a findong n'" secn in HIV-
semlJeg ative lft')l'ienlS (23). It is 11YlXll ilesised 1I1a( th" ""'i,,'g U><-~ '" r' a",.,.ci r·· ,,,sistar><-c was 
a reslJit ('/ f"'rio<1 ic furtiionJI mono ll)(lrarY in 11"":;1) pJtienls ; a sitmtioll whi cil wOl,d 
treorctically be awr~VJtoo oy a r~jlid JCdylJtiC'l' jl\)onotypt: or otre r factors which tcnd to 
dec,easc is(JniaZld !C .. , 's. T~ SJlll<; ell ldy de trr' nsl.'Jted ~ re latiYeiy Iligh relapse, ate in HIV-
,;erOiX':;<tive pa!ierrts, whether t r,;.,y rn""i,'P(j Olle!' weekly rit"fJ"ntine plus isoniJlid "O' 
'>lJ 'IdJrd IherJry or twie<; wee kly rifampicin pillS isoniazid (23). n os f inding demonstrates lhe 
importancc of hosl immur~t}' , ~nd crymi)""d With the IXlssillility that certain HIV-sc'Ofl"Siti",-, 
TI) , dmldo;>rncrt of 3n M,"C sitp i~ [)o,Jrb~n hy Dr Colr~ Pilar to wrld,"t simila, bhI'!3 il~hil lt \' 
SlLxJ ics in conj(JnctICn with tI.., WHO Il<ls Jdde,~ data from a differcrt p<Jp,Jation. The ,~ata 
3CCl.Iffi\t;,tOO II1" s f;;< c"" 00 ,,,,.,q to devekJp I1\01Jels 0( t"" ~'.3tion rjro:tlcs fef til(] nrU9' 
Howe'."'r tti~ ~at~ hil' . m;tJtion~ tor tI.., (jf> IIe'opme r~ of gllide lir,..", I", t ""r.'fl'li.lir ~n '9 
morwtonng. Mesl ef tile "JtJ has bee" gener<>led lrom stL.dics ;11\101.,,"9 hea~hy vo llinl ee'~ 
who tr;Jve different pI1Jrmac~i ' !et'c ~ rof""s tu patients, in partic;Jar their CYP-450 en/ynle 
s'!"tcmc,;>rc I10t imL",oo by expo Sl ..-e to 'ifamp;an, In addrtion ' 00 he'>lthv ",lin",,, 
P<JI)Lllatien hJS been ef ",el ,ounshed. no n-srTlO~lro;1 io::I;;iduals who have minimal expos...-e 
to ~wt>:O arid q~"Jlmitant dn~' 
The d"pmtm"nt W"-' ~~r"();1d1'l<f hy cl i ni~~ns crt tile Bre't.'el<kIDOf Hospit,., in Wnr""st~r to 
lTle asure drug G<Jnc'''''r;ltion~ in the hIoo<f of IX1 l ie r~s who respo ,<j pXl~y to tmatroont yet ar" 
known te h~"" sensitive orGJrw ~n's JIld ,,,der rosp t<rl supcr;iscd DO I 
AR IS!ljG Cf',IF 0!\'''3. 
TI~s project aims 10 help to r~S<lI", rome of the di emmas lac"" I>ji c~niciar1S treatirl(J 
tu be<CUlosis pat;"r~s who are ffisp:1Il1i"G poo~y to t'eatmer~, F Jetors asS<lCiated with a poor 
OIAwme will be sought. Too val"" ard (Jse ef TI.,rapelilic Drug Monitorin\] ri tuoorCLJlosis 
patients"";l1 be explo re<! in tits context 
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patients may acMie"" lnadeqlJat~ serum roncentrations 01 the drugs on staooar~ drull <1<Jses 
supports the lise 01 therapeLt ic dm'] monitoJ irlil in these patients. 
Tht- uetectil)n of <1 .... dc,'iI Ie\'eis may be ev~n rmre imp:lrtant fur libllp;cin. An ea r:,,, study 
~emons\raled rifampicin doses of less than 9mglkg may be inadequate for the treatrnellt or 
pulmonary tuberculosi s 125). Early ilaL1e<iUdai <>ctio_y sh.rlies sUPPJrt the dose-<1eperdeocc 
uf I if Jlll p; cj,,':; antibacldicid,,1 <>di,~ty \ 2~,2~,JOi. Couple,] w'th a '"n<'lll~' CIl la'. rJ!2 r.:tiu 101 
rifampicin tI1an isoniazid ao;j greater protein binding, iower th.'lI1 normal concentrations of 
rifampocin may be more critical. In xidilO)n , too f~amy:;'ns am less ,eliably aiJsorbc<J than 
iso nia/id (23\ 
Consi~tent w~h theory that drugs acting on irtra- rricrobla l targets """"rally exh,bit 
coocentr at",n-deperdent ~j !irL';l and require higM r'a;rn~ conr:entratinns 'In relation tQ M UC fQ[ 
opt imal antin ; cr ohall'ffects (31! 
TherapcutK; drll~ rronill ri rlil is a tool that GOliki be ' !Sed 10 idet1C ify patiet1CS who require 
inue&ei.l w...,~ ur II., "t1Ciill l£ l cub" , J, UjJo an~ IQ Jder","'e 00'"'" whiell w(Juld bring ti t!! 
~[lJ!.Ilevels witl,in too m[mallartges (16,17. 18.27), Patients at risk of low drLJg levels should 
i<Ie ~ly be dentifieo:1 as early as possible to prevent treatment fal ~"e or the development of 
,~ sist'lIl" ~ 
Data from boioava ilatJ; lily stlldies in butll patients and healtlly wllll1teers (in the Department 01 
Ph31 mocoloQv at the Uni", rsity of C""", Town) 51XJ<1e~t5 wille inter-indi .;Otlal .ariabi lity of the 
maxim~ COfICentralJons (Cmaxj and area unde! the GOIx:ertratO?n-t,ne GlIr~ (AUC) for 
rifa mpidn and ISOniazid. 
The re is flttle pL,,"ished atJolI tile !nter-{lCCasi<ll13i ""flabllity ot the pharmacokinetic., ot anti-
tuberculosis dn'iJS within tI1!! sa'Tle ino:1i llioiual 
IrIlra- " I'd inter· ind",'jj LJ ~ v<~·i"I.,n;; Maw impo' lat1C C<lrrequerIC\J~ I", the lecl1,,""ue 01 
therapeutic 01 ug monitDring Some studies Ma"" used a single bIDo<1 !;amrOO taken 2 to LJrS 
afte r ~rLIg a:1 ni nistration tD detect low drug 1e""ls (3,5) . A""ther stLKlJ' (7) foun<l that the 2 
h<)ur level ~rne did ""t <>OOqllately reflec:l tI1e Cma> Oe!i>"ed form ~ more extensive sampti"'l 
schedule Further sfll(!y GOukf allow the l1evelopment of YlIKJeines on ilOOd and I Or unne 
s.3m~ing SCl'tl!d l'es thaf co ll id oolllify patients with low dru!llevels in too nO)~t ",,,1 effeL1i"" 
manner 
A b€ner un6ersfanding of the reiation,chip between drlL';l concentrations, organism sensitivity 
immLmitv ~11<1 tile resoonse to dfl>J therapy GO uld facn;!:3te aprrepriate t,e3tmont fe, these 
patients wto fail to resp:lrd as expected to standa,d treatment ley 'nens 
WORK Wl1ICH HAS LED UP TO THE PRO.tECT 
A stcny on too effect ct concomi!""', food intake on the bi:J availability of I~ampicm isol1laZid 
am pyra~i l13Tl'i<1e (1 0i inrtiiied an interesf in the philrmacokinet;cs of too antl-tuoo rcu kls;,; 
rl" 'J' In the c..p~rtme"t 01 PharmJwiOill' J llhe Uni,-e rlit,· c{ Cap.:: T C·, ·n. Sl t-'''''~ l k'ntly ., 
furtoor st(X1y of the kinetcs of rifeonpidl1, isonia;:id aoo pyrazinamide in AIDS patienl5 an<l 
HfV negative patienls (7) IXOyid ed father opportunity for the developme t1C of val idated assays 
for the se dr'Jgs Since 1 \l!'Ml twenty sinq le <lose cmss-ooer s!u~ies to assess the ~" aya;I"b1litv 
of new Iormulalions or anti-(ubercli o sis ~rugs M3ve been conducted by the dep1lftment in 
coI laoorJI:on w;t!1 the Nalionat T lIbe,ClJ!QS;'; ReSl!3[cM Program me of lhe South African 
Mc di c~ 1 Pe,",3rrh C"ur¥Oil IMRC) lInder Dr Berfk1fd Fomi ~ om tlr \'In'" H~'I1M 
O,ganisa!ion (WH O). This work Ilas led 10 lhe accUllllj ation of a consiOOr3ilie amoum ot ~3ta 
on tile Dheoma cokinetlcs ~f rtam>,cin, i"""i;Jzld, p,..-a;:inamide and et113mhutol in butM ""althy 
" -'J I LJ~lee rs ~ n:f patiet1Cs. In ~cldiHo n ""n;;ide r~ble e:.: [1e1 'se hils t",~n ""hie"e" in ~,e 
fat>orato",; enail ' ng th' reliable am co nsistent processing of large qllantities of th>!! aoo 
urine s.3m~es auordirlil to vatiOated HPLC me lhods. The ·Lnfra,1Il>!.tule arid expe~ise 01 the 
tatm.-,tmy ,ke"'.!y estC>l:'",hed farm ~ >;trOll(] biickrrQlIld on wl'ich tr t>\,ik1 II '''he, 
pharmacokinet;c slwies. 
,I u-, ','iO'ot'st&r 'S ,);;,; ", ,.,,,t,,,d ,,"m~1 jy t~,. t il e II-'-I';uI<)r' Cilr~ ot 
Jre retetTed to Brewelsldoot tram tul)ercLlIosi s cljnics 
;)I)<j OGC<lOOn;J l y fu rther <iield. ReJSOIls tM fetetTJ I in dLJde 
r re&[l0n~ to tfe'ltmen1 , POOf ~{:ioeoonomic d rcum '>fJnr::es 
It is hosp ital with 4 m"diCJ I doclors and competent nco'sing 
braochosc.{)flY taciitles are ava ilable. Srd"m samflles <Ye sent to 
CJpe Town, for microscopy. culh.-e Jnd sensitIVity teSling 
• 
• 
• or splllllm r.lt lllre 
• " " • rilamp"'in_ 
" 
Svmoic {UG. A Sd,,,p!e size rt 200 at Brew"skloof Hospital is c stimal:cd to re pre sent 
a,'." <J>jmately 20 (1 [r'i, ) patients in wilolll tile reSfJU"'" ',,'uukJ "" reg~ ,.~",j 3, f\C'.1r h)' il'" 
d nllians ca ring forthem. A samf*e S:~e of 20 in this group is estimated to be req" ired to 
del,;..;1 J si~"ili" '" II Jiff~ ,ern! betwoon those who resj,)(lIld well 3m this gro"p. witll 80"/. 
[>G'·:,'er illl d d 5% chdnce d irrorrectly Illject'ng t'1e nu ll ~ypo!cpsrs 
,_. t· Or> 'ldmission;ll l f)<J lentiej ll' elilJ ible pat " ''/::, wi~ hd'" bdSC li "" datd CO I., ctL'tJ 
. incl l>1e' 
• SI' Ill p/(l< lIS 01 ~1, dySpl1Oed, 'ligilt sweats, chest pain 31)j appctlt~ 
• w~ight 
• chest x- r~y 
• direct spllh.-n mcro soopy for x'd fast bClCi Ili 
• SjJlIl,,,,, c""-",e lor MjGo~ade"ium lllb8'~u.)'.i~ J I1d :lLJ;(;e[ll ii;ilily to isoniazid Jnu 
rilamp<cHl, 
• past "",<li"aI histolY 
• luberc liloss treatment history 
• concomitant I I...,ss ur diseases 
• qJrre'" tuberculosis Ire~ l me rf ind lKii"" dru<l doses ~nd dosir<J i,t"f";)' 
• COlX'.omit<ml rne<.lication or trlJdt,,,ent 
• n n ent s)""ptoms of mugh, n",st pain, ni ght sweats am "!)petite 
1 f; P,,'nq ' ,in C A T~~rm,,'iC drc>J ",Orltoli"" ct llle ~n~'mymh~c_t~ri ,' t ~",g~ eli"," , i" 
laboratory Med icine 1996; 1 &: 3): 717-729 
17 Attooo J A, Reid"''''/l L B, Tilf Trea1n",1i cj Tui.>f!rClioSlS. Re,pHtioo 1998; 65.237-255 
Ie C0!r S T, T rht ' .A, Drl>;) '"sisIJ n(;;C in MyooiJJcif!l " '" tLI h"'~"'n,;lS. Em Rr,'1~: J D%: 
8{SlJil~20) 701s-713s_ 
19 PeI04U II \ C A Using the, <l\lt'utic d rug rr.JnitOnl'>;J to rJose the 3IliimYCiJbactc, ial drugs, 
C~rMr:s i n Che<;l ~4ed i~ine 1997: HI( 1 )- 7'J-87 
20 MltChison D A TIle Garrod Lecl".-e_ Urderstard lng th" ch<emoth<e , apy of tuberculosis -
CU ffe"! pmblems . Jou<nal of AntioKrobial Chc"1Othefapy 1992. 29 : 477-49J_ 
21. S,, '';lh ?J, ',','JIl Dy~ J. Frederus A_ An HPLC "",U OO 10.- Ih" ~i'l,,_~,"',:;ull& ()dcrllli""li<J~ 
r:J, Rifampicin, tsonoa/id and Pyrazinamide I ~ ~c:rum _ lilt J Lung T uberc Dis 1999: 3{ 1 '1): 
S325· S328, 
22 ~ee CS, 'i,'dt>J ~H. Iml~coed GLC ,j~lerll~ 'l<Jtian cf dh"" obut", J PIl<J,nla-tu, SO 
1980: 69: 262-263 
23_Verrrofl A, Burman W, Senator D, KI1311 A, Bweman L. Aquired rifam)'Cin 
,l'-';" ' Csi::.lJ';Ge in pJ Ii<: nIS will', ~j l 'i-"'klted tll t.>''''-I ~",;is t"·,~t,,J with J "'~­
wookly ti fapertine 1'Ild iSOfi,uld_ Lar=1 1999; 35J: 184J- I847 
24_ Peloquin CA Serum Coocentralion, of t ile A"hmycoIxlCleri;J1 Drugs (ed~orialJ_ 
Che st 19DfL 1::; (5j; 11().l 1155_ 
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26 Hart CA, Beech it>J N.J, Duerden BI. Tlbercojosi s "to lhe ,leU celi1$)'_ J Moo 
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PROTOCOL 
OBJECTIVES 
1, To r,u,,,jify I~'" ""mI:.<'" I)f pat""," in I~C study p'," lliatKln rr-,spo rn,,,,, paOl ly to 1~ ~iflOC 
antitlJbernJo,,;s l""raP'{ 
2 To detmmi"" II'><. r~latiOl1ship ootwe~n resporose to treal:ment ar.:t dr1..\lIeV1Jls 
} To ev" I'.Hlf lhe assvci,,[iun bet"""'C " (~" dl-glce el in .,~ro scn," t;.,rt'l 01 too path.lgcn tD 
r~~cin ard isonia'id . arid (00 resp:m", to theraP'{_ 
4 To eVo luJte l~le <>s=iatiu" bctV'L'0 " the lype of LmmUilC response, ard the rc5pJnsc to 
tlY>rc_py 
5_ To explore a~sociatio"" between dr\.\jlevels ard <liY', gerder. race, acctylato r status, 
extent of ~ isease, "moki ,,), the """ r:J wrx.omilJIlI "'ugs. Jlwl <) 1. w.nl1dtJ;s. mdrld"lX, 
H",.' irte-::t<J n -11>1 c,"Q'-;C (Ii~'r_, 
6_ To tieterm ine efficient methods of blood 00:11 ()f lI' ine &Jmpli' l\J for l he ident ifocali<Jn of 
~atie , lls w~h low drug !evels 
7_ To ~va l '''' te !n1~r-oa:asio".lt (j;1f~ffiTlCe' in tuoo'U J osis dmg levels 
METHODS-
,~llJd'{ rk'§iClf' A prospect;"" CO ~lOrt pharm <lCokir.etc study 
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• ''''e'>illt 
• heiyllt 
• cl",ical ~'ml1il1 ~t io n 
• chest , · ray 
• lllllJlucod C()()01t ""J a ltere"," 
• e<yt tvocyte sed""ent~tion rate 
• l.<ea, cr~"tinirlC , ALT, /l,ST GGT, ~.P, Tfl. "i:oumll', IotJlpfvt€in 
• .V 
• CDJ, CD4 arxl CDo co""'" , ~~"",B ~)ltol;, ine Ie"""',> ,nd who.., b!oot.l C)ilokirl€ 
[lH>i w"", n 
• acetyiatorger>:JtYPB 
• 'l)lJtum dnect mICroscopy for AFBs, aJ ltur~ for TB a'," scnsiti'ltv <0 r~ampicin ,nd 
,sarn;dd, t sbll positi"" 
PhalmllC':+:i",;)/"C assQssmont Alte r 5 to 9 week' (JI treatment tlJJ pharmocokinctk profiles for 
'(~mil'dn, i,."rll3Zid, p\1"z",;mjOO ~M ctllambu!ol ,..,1 be dct~rm iood a<:Gorr./inq to tr..' 
fcWlowing PlDC{'(too>, 
• Alter <lI1 overnigl't filS! rif;:nlpicin, isa nia,:;d , prrali nJm,le an<.! eth Jmi)l,iol Of 
stfeplom)'Cin will be adrrl"'ist~red "mlJt~neoosly with 200m1 01 wJt~ r ~=rdirlQ to the 
stilr<\md doS<"s fO<' the p3ll€r~ wnce<rled. The dnl9 doses 3<Tmon istered wH l rl()! be 
tile J_e<ed for tile stL.<Ty Drug ;ngeslioll will be C>tt<Rtved by;'" inwslig:lIor or 
",vesllg"tor's as";sI""t ar<T tt.> ,.,act t inle r)l dfu{J admin;,w<ltion will he r"Wrdo>d 
• Blooo ' ampK!S tor too detellTinalioo of pI.,;ma 19Vrn., 01' fifamp!Cln , isoo iazid. 
p'.,-,zlr" m.k ,' r~ "tM?n'h!,tol '.\011' ~ nr." .. in ,~tho t~ ! h',";r>;J ~""'s 1) wltr;n 4~ 
minutes oolore dlllg administr~lio " 
~) 0.5 holIs alter dlllg 3CIn>nistralion 
1\ 1.0 1>:J1Irs after rfru~ admini81faoon 
4) 1 .5 hours after r.lfL>g iJdmir'OSl'ilwn 
5\ 2.0 l>:Jurs g(tef rtn>{J adminj5tfatio~ 
m 2.5 IKJ1II2 afte , rfn'J .'!dmilli ,,i:rat ion 
7\ 3.0 hours after rJrlJg arfministr iltiorl 
5\ 4 0 hOUf'; illte< rf rlJg a-JrninistrJtion 
9) fi .O hours afler rf rL>g admiflistration 
10) 8,0 hGl-O"s ofter drug admmistraliGll 
• Cnm [J'~ lp ,~ino c<:>l ~ction, ""II b~ m~.y, !rom 2 to 4 oollr~. 4 t" 6 h"",~ and 6 to ~ 
hours afte< drug a-.fmini~1' aliGn. The vcWumes and 9xact times (j the collecti<Jn" wiI be 
'ecord9d 
• SUIJi~cts ",II fffilain ~em- upriglrt f'" 2 rours alter dru<J 3ClmKliSlrat:ion and n<l lood 
or fiuit.! will be allO'M"d dlO'ing t tis peri ",.f 
• 1he timing ""d """n.rot of meats, """,ks and ~ui,"" taken during th e obser;atioo 
p"'iod wO! t>f' recmded 
Assessment ri theraoevt'c Qrwres.. aod 19/ilij8Q deIQcu'!X' ('Late' response to tre:Jtment): A 
spr.~um SiI"lpie will be examined boctl)fiologicaly (by direct ""Ie"r and GU~'-"") OOtwCgn 7 
aoo 9 weeks after <l<tmi'ision for treatment in B"lWelskkxJf Hospil<1l (as s!at~d Joove) and at 

Ch('mic2" DalhQl.:nx h,'cm ,,·,,'og'{ ,-V>Q .. ,,;"~:[don ~i-';I1 :~I:Q,"" ' T~ h"", m~10 1t'ay 
biochocnwh1,y, ,.,ro lu\lV and ,mmun<lfGgy service laiJuratGlies al the Unive,sity ut Cape Town 
wi ll arl3lYZIl til[! rckr .. ", t Uood tests t~~"" dt 8 to g we~ks 
,Ct, ! .. ,,!,""" fi';'kt{S/:;, P"srna CJ) "c~"t, :.uo" IHDfi ln" , .... rn be dH",e d 1m cad, pa!ie,tt lor 
, ifampicin, isoni31i<l pyr31inamld!! anti ethambutoL Th e pharmacokirl[!lic pararrortm5 ot 
impo,tance lu' bioavailabi"ity will 00 calculated using too WinNonLin 3OftNa", package 
The ,ci.'itior,,;h;p t.,twe,," It", responSl:' tu t ITH"''''' f~lilrm1JCClkinetic p"'M"'t~rs, immu,,", 
stall/S m3(i<e<s, arid orgJl1 ism sensi ti"ty til nt1lnpidl1 <lO1 isollazid will lie described. 
The effect of :'Qe, !Y"1(\ef, rore , ace!y1ator $latus, e<lent ot lli5eJ5e, smoking, use of 
CI!fICOI11itant dr~s , JlrOhol, CCIO'lr'k'bi S, ",-.mra>, HIV iriecti(t(l:l(1(t ctlron; r (jiar~~ 0" the 
phJrmaw_ineUc protiles w.1 be assessed USl rJ9 NONMEM rro:Jel;rlg systems 
Intel-occasio "ill differences in tile phClffll<lU)krrletics of too drLgs w;1I be ooscnbcd. 
Too r~fatiol1~ hi r ""tweel1l"" ~n'J "0.-.:»rtr~li(t(ls , am s,,~P\ i lJil it\' ot the {lrp:mism to 
j"",-,;azia <lO1 rf<>npicin, ill R to 9 weeks aller admissiorL aoJ IreiliJneril oulcome will 00 
assessed 
I u[)(lm~t~[)(1 til"" tile study IS b impmye Ilw urHJcrsl~rtdir>g of tww drug levas, 
III berC\lk" i ~ s(!ns itivily In drug I"vd~ ~nd oll,,,r indivi d u~1 ~Flli",'t tRcbrs inflll(lnce tile 
cft()ctivenes~ ofT8 Ire~tmellt 
: Hnderslal1d Ih;;( (he ~ ILJdy :'TV()lve~ the documentation (If perwl1 ~ ;mj trC'Jimel1t 
rl etails, ~ physicHl exa!11in~lia l1, c1J i l(!cti(l11 of blood samples (aI)()Ill 25ml of bkxHI). a 
che~l x"ray ~nd sputum collechon Laooratory evaiuatlen ef \Ile bkxxl W1lllnciude 
testir>g fe' the HIV virus . ~acmatole<;1ic31. biochcmita ""d immllrtolrtg;CClI stmu~ 
In ood ition, on on(! Dr Illrc(! ,}ccFt<;i()ll s: I will fast nvernigll t b(!fore seri,,1 blood 
~,ampl~~ total lir.::T 3b<!U t 1 I nml \'~'I!:tP t"~ffi ov~r,~ pe~oo of e'nh( hO<.", an"" th ~ 
5wailowI119 of my medic"tiol1 the next d,W A canrlU l<l WIll be il1serted into ~ n arm ',eu' 
for the colicctieOl (It these b!"od ~~mp lc<; Three, 21100' urine coll()c~ons wi ll ~w be 
roilrcted dilrino tho ~ Ile", pcnod(s) 
l understand that the study also Inw':,es the coilcction of 3 spu tum samples at2 
fTh)~th5 ~rtd CIt 5. \1, 12 . til Clrtd 24 month, ofter thp Inir1!ion ef tre.'lt!11ffit ill 
8rewclskloof Hospital I understand that I am obliged to present at th e cliniC 10 ",heh 
I ~m referred <It the required IImes_ 
IllndorslClrtd !h::o! pmticipClt..,n in the slurly dO':) , oot hold my tr(>~tm(mt hcnofit 
I \lave been given tile orportlJnitl' to as_ any quc~lions concerning the study and am 
s ~ttsfie~ \· .. ,th lhe ewlan<l tion 0< OO.,i'::e ni'len 
lllave IruUlfuliy ",,~wcrl.-;j dli Inc quc~"en~ n,,(;e~~my to L')nLplde lll (; J8t~ cn lk,dkln 
f'Jfms_ 
I agree to comply with Ihc instructions gl',en to me by the inveslig3\Grx; or their 
3ssi~t3[lls 
I underst~[lrl that the inkl,malion eolleeled ",.;11 he Irealed CGnfiJcmU~r.y. and t~at only 
thC' invP5~'1~tms alld their assistallts will he able to I;nk any Of Ihe information 
collected to my 1lar-rtC 
I under;;lanrl I~all am free to ,,;lhdrf<Nfrom the ~tud\-, ~ t ,my lime wi!llm,t rrejlldice b 
me fm <:bng so 
-, - ---
NAME OF SUBJEC, SIGNATURE DATE 
NAME OF INVESTIGATOR SIGNATURE 




CONSENT TO PARTICIPATE IN A CLINICAL STUDY 
PHARMACOKINETICS OF ANTITUBERCULOSIS DRUGS IN PATIENTS 
RESPONDING POORLY TO THERAPY . 
. -. . 
appendi~ LJ 
CASE RECORD FORM 
OAT A COLLECTION FORM 
Subject no: 1
m 







Place of birth: 
ELIGIBiLITY' 
C PuirrlOllalY Iuoolwlos/s confirmed by positive spu/wn for M 
!i..iUc ru.iiu;:;is.- ;1.';"(.'(;/ r;lIUOS;:Opy or culture 
n Informed consenl 
n COrlsent 10 /-IN testing 
o ;;::.i8yBafs 
male I fumalc 
~ On daif; inpali€nllreatment w.1h rif;'>.'!lp/cin. isoniilzid pyr,17inam,'de, +/-
ethambutol, +/- an aminoglycoside for 8 weeks al BrewelskkJOf Hospifal 
n not crM~'al/y ill and no contri'Jindici'Jtions lornult:p,/e Nood sampling 
C no known resistance 10 isoiJiazid or rifamp icin 




I-Hi. ,,,.,,""'" '"'''''",,'''''' R!-: '",,,,,,,,,, (,'"" " 
i R R: ''''''''''''''' ,"""', "', 
I "' - "-;">d.,, 
I p,]st medical 
history 
[









I /" ye8r before admission 
I Since admission 
I In 'lear belo18 admi.ssio!l 
I Since admission: 
In yedr befurv <Julflissiun: 
Since admlssiorl: 
o Illel locreallO!la I In 'leaf befiJ/B d(ililissi()n: 







"','",",,,"',. ____ --"cS~i~,c,'''_'','',m"'~','',",''c· ______________________ _ 
I CURRENTTB 
OlayrlOglS 
Tr"l;ltnl(Ont prior tD 
admiSSion: 
Dale of unsel: 
Dare 
Souium - uired microsco v. 
0><1 .. of iniliHIK.HI oflrealmerll· 





S ulum - cullum. 
{;,n cr.; CI"!oOde 01 TO eonI 
I$ymploms on • COugil 
I admissiOt'l Dyspnoea: 
: i Chesl p.lin: 
I 
' 111'1101 : s:.w<ol" 
: Appc!ite 
I I b ammallOn on I 
I 3dmission: 
I 




- .. - - -





. Comment· , 
I Date: 
, Dwe-cl ,m;,uscopy, 




I Chest pam" 





CXR' ! Date' ~C-----
, Comment: 
I Sputum i Date 
I i Dtrel;t nn;;ltlscopy 
. ..._' (_/"!,,,>;/+/ H / ' .+; 
I
I Treatment during I H: mg de/ails 
admISSIOn I R. mg 
. IE. m~ 
Z mg 
I S' mg 
; Other: 
------- , 
n=ber ___ __ _ 
l;ultw-e 
(-,r<.la~.!t> ~ C<.o/t~· rt),1 
number"' _ _ _ _ _ _ _ _ 
culture ' I 
_..i:'·"'!'Ls..!? ~ c;,;:m", _I 









I ,- J 
RES ULTS 
, 
d:Ea!:l,j( response to treatment 
I I Response rat ing at 2112; 120 
, .. 
'Late' rcspi'~5f! {f treatment.. 
I 
.. 
~_~putum ; , 2m 3m 'm 5m 6ry; 1m 8m I . _ .... , I Dale: , , +1 OlfVU IIUUO.sCOP t- , , -+ ,~- .. - ... I Cu/tur£:;, L , . , - , . -
~ 
, 
:: ~ 'elf: . ------ I r- I , 
, 
MICRO · 'mini-MICs' 
, , I DatI!. 
L 
i Isomazid. 
I RifampTrJti --- ------ _~I 
1 Date: I Haemilfology: _.I 
I Chemical pathology : 




PK SAMPLING I ADVERSE EVENTS FORM 
DATE of PK sampling: I I 
Drug administration: 
~ 
! Dose I Ex ~ r! arlmini - I F(Ym' ll<1 ti m.' : Catcl1 no ' " 
, 
Drug i eXp, date 
I 
I [ brand I stratlon time 
Rifampicin I i J I 
[ Isoniazid 
-- ~ I 
I I I I I 
Pyrazinamide , 
~ 1 Ethambutol 
I I ~ 
-
1 --+ I ~ I I 
~~ 
-
, --- - - - • 
Notes: 
I - .-~ 
Blood sampling limes: 
~~=~----Sample 
- -- --








6 - 7 











Urine sampling times I volume: 
i 
CS.,O"O,~p"I,~----CT"/~mo.c'0ft".o,Cd.riig -· r Eiac{ COllec"tlCoC"C-~i "V"o"I"Cm"",~o"f~'~o"I"o,o,c/oc"o-, 
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appendix 1.4 
LETTERS OF fTH/CAL APPROVAL 
14 May ]9<)9 
IU:C REI': II 1221')') 
Dr H r.kllle,,,n 
Pharmacology 
Dear Dr )"le llit ro n 
H" _"_'Ilrch /OIIIi(;.,' Commift"" 
FM.-"lty of ,\I.-d'.-iul' 
\mio ROMrl, ObSen'M(ory. i925 
QlIcrir~ : Marlha Jacohs 
Tri : (021) 40(,-64,)1 FHX: (O~ I) ..\06-6390 
I~-", a i I : ,\1 ""/lu(Ol m rd'rinr. uc1.ac."," 
THERAPEIITIC DRUG 1\\o'IITORL~G 11\ TLBERnlLOSIS PATIENTS 
RESI'O~llI:-':G I'OORLY TO TREXI'J\IENT 
I have 1'lea<;urc In LnlixnlLng you lhat lh~ ahove study ha, heen formnlly "PI,ro,ed hy 
the Rcsci1Ich Eth ics Conl,uitrec on 1-1 t-lay I 'N9 
Itlcluded is a li;;l ni"Rc;;calch E\hl~' COlllllllllCQ t>\clllbcrs who have lOllnally approved 
your pre\toeul 





R~sear~h Ethic, ('ommiucc 
I{oom 212 V\,'erner and f-l~il 
UCT \kdical School 
"'"7.i o Road, m}'~""atory, 7925 
rei (021) ,tn(,-(492 I:ax_ (021) 40(,-63,)0 




P,.OfC"M P I rolb (.\Ial<) 
\ meltll. '\lLl. H,C P. I, 0-' (SA) 
F."ult, of \ktlid,,,, 
A,u:io Road, Oh""'rmtor~. 1'12~ 
rrO"""OT 01 Plmrtoac'Ology' Llucctor W,)[ld Ile"itll Oil'"ni,a{ion 
Colbbor"linM Celltre 1\)[ Llrug PolK' 
,'"db,,,,· JP de V "an ~ i"klTk (M:lk) 
MRCHR. \fD. \f~lcd (Raull)llll! (RCP&S) 
D;.;:ln of r",,,, II ), or ~vkJicil"-' 









MRChR. \(nX'd (\'(;cTOholOO\.") PanKl log" 
Pr~fc,,'Or \l;di o" l ~'h"ml'''ol~, & 
D;.;p.lIy Dean 01 Mew"",,c 
I)r P \1it"hd: (M.k) 
'\HlChfl , Fcr (SAl 
CIl L"r ~'kwcaj SLEJl"nntencrnr 
Prof",,",,· I) Ik:on}' (\b),,) 
MIlChR. MD FCP(bcJ) (SA) 
['rob,,,,, ,,,,d Hc"d or LJe,,"rtnLCn! or Pacd,alrics & ChLid [leahh 
P .... ),·"",. SR Ikna!nr (M"le) 
~-JUCilLJ, I'FA (SA), M1KP (UK), FRcr (! ,ond(~l) F ,\CP (Hon,) 
PmiCssOl ,,><I I lead of D;.;pmlm;lH or 'v1cdiCtnc, Djr~C{or ,of 
lTT l1ioelhio Con'", 
P",fc,,,,1' U.\l I)<nl (M.,le) 
\ lIlCh 11, CHr.L I'RCS (L,K), rcs ISA) 
i'miC,,,,, or SLL"~er)' 
1),- L llelLlc} (~coual"J 
PhD 
[ oemoe'''' :';..,:i" 1 '",i" •• li :;( ' " L.\:orarunent of Paedmric, & 
Child Hc"lth 
P .... re,.,,'" I{ Ki,,,,,h (\1aT~) 
MUC'hU, .\-ILl. Ll$c I.\kdl. Fcr (SA) 
Pmfessor of .\1odic; .. " F,x,culj,'e DlTcC{m ,,], .\1ReiUCT 
Ll\'er Research (:',,,Ir(' 
S,. L .\]t" i,I1.' (rcou"I~) 
!lA, LlLplo,r(l III \llI.-,ing; n,<,ll ro T ccomi,!lLe 




lie .\ 11 R,~,jn, ( \I~rr) 
\ffi("1tB OP\ 1. MO 'I.' /(( (Ps-.ChJ 
s"molo' L_ ... ~ur::' In l,lfp"",".nI 0( Ph"nD;""';"~'· 1\ laic) 
'I> \ "t:".~, (hm:ol.·, 
·\n~i=' Ch'rlaoJ'. (,~ Ii 
--- ---

Cl\'!VERS!TY OF C \P E 'I'O\V:\ 
- -._- - - _ ._--- --
2~ July I <m 
ERe REI': 1,1 1221'J9 
Dr II :"ld llcron 
Pharmacology 
U,,,<!,,,,,h Ellti,.,> C"mmi//<!<" 
hc"!I ~ of -'1e,li,'; "< 
,\",io Rna,l, Ob"'n"lnr~, 7'125 
Que ri"" Ma,'lila ,,"cob, 
T "I , (1121) ~u(,_r.~n 1'"" (1f 21) ,11)!;_6J 91) 
r _"",i l, 'lat1h"";m,·d H: ;ne. uc1 .,,c.," 
TI1ER\PU 'TIC llIU,I G .\'101'0 n OR I ~G I N It IH RUII.OSI" I' '\ I 11")\ I S 
HfSI'O'\ f)J'<G POORI .Y TO TRF:.,\ T\J .. NT: D[TAIL[D PROPOSA i. 
Thank V()11 i(,r \ 'OUr le l l~r to the Re,~al"ch ahies Comrnil l~e dated 20 July 1999 
rhe conimts have bcrn !lorN and £!~p~owd 
Yours sillcerely 
I'Ron:SSOR I' FOLB ~ _" 
CHAIR: RES .. ARCU ETJlles(:O-'I\lnT~~L 
QUNie, Id arth" Jacob, 
Resear~h f:thi~s ('ommitt"e 
R,><J1n 212 \\" emcr,md Ikit 
1;('1' \fedi cal School 
An?;o ROild. Ohser'iaro')', 7925 
---'- . .., -.-

lINJ,\'FRSITV OF C'A!-'£ '1'0\\';\ 
I 7 April 2(XI(l 
I::RC REF NO. 112/99 
Dr H \1cIlleron 
Pharmac()logy 
n~ar Dr McllitrUIl 
R,,<,w,h Elhi<'> C"'"mille~ 
F a,""h~' of M<dicine 
·\n,io 1'1""'1, Ob,c,",',l!ory, 7n~ 
Q""';" ': M'''1ha Ja"ob; 
rei , «(Ill) ~(l6-('{92 Fn: (1)2 1) ~1""_(dQO 
[-Im,il; M"rlh~":m ... lit·i"c.,,<"1."".~" 
'l1ll:RAPHITlC DRlG l\IO_'HTORl~G L~ TLBERCTLOSIS PATIEI'ITS 
RfSPQriDlNG POORLY 1'0 TREATl'tIt:.·fr: AMl:NDi\l.!<:l\TS I & 2 
Thank :.Oll lor ;"Ollf leiter to the Research Ethics Commiltee, daled 15 March ~ooo 
Please quole ,lbo"e Rererence number in 'lll correspondence. 
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Room :12 Werner and Jlei l Bui lding 
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appendix 2 
SAMPlE SllE EsnMAnON 
SAM PLE SI ZE CALCUlATIONS: 
22 "atients with lKteon'Picd"d pu;,no",xy t, """"",'0", p", tj"'; ;x>terl in '1 
bjc0q,,;v..,lcm:e ,llxJy '1t or' Marc>, Ho<pitd in W cdbKe, Cape IWIn:' , ',9Y! Ihe 
C""l' anrl ,\ UC~ "'';u~o uoed in t~'io ",al",~!c:,ion '.-;ore do;"''-'' " ,,6 afte r do. ,\) ti,,,y 
,ee"",,,,; a (,()J n'lg "'>'e of the ,cicrcr.co product fo< rilarr,:."'i" I Ri r"y:wt", ',e Ielba) 
LC,c ',-.g ""p""Ic'i, ~ta :C1 7,0 [StC1taCo<p, 2(() 'J i, u ",>(j 1<1 the e(k~at""". 
S".-nmmy o! Cma, o ,>d AUC! ."1"",, 
Voriabic 00' Mean 51d. D,., ,.-. Min Mo> 
Crr"" " 3 .~m32 3.45659 2.0067 150.; II AUCt 22 34,7Qe 12,VI?76 ~Ae;'2 5~.]l41 
The p<.Jf.X.'rlivr; of ""l ied" 0t Br,,'.c-I i::"c-f f"~'rit~ ''''th '1 ,putum ro~tiv" 'IX M. 
tuiJeH:l,o/{X'" (li t", 2 n--on th, 01 trc-atm"" t i~ hmpital was e-;ti<Y'<Jt"d t" b e 
LJ PPfO~; tl "'tc : { 10%, 
TG cJ,,~,,~ a Cm<:lX \'ail;,., ;-' 10%,,1 fX"tiF'nt, that i, 25% Ie,; ~I','''' , \I',a t d ~ '" ,,,,,1 d Ih " 
.,~I)d)' F()pui(ltio~, with () power of 0.8 and alpha 01 OS 18 pal ;en~' would be ''''-lUTed 
in Ihe 9'Oll' ,e,pordng rOOfly to troa", roe, Ii und I i ~ w" " d '''' t "'-1 " ' ..".j ;- , '1']" grQ<J;> 
' '''po' '''';n,) . 
~,,_,,"c'or,' 
o .:c~ - ,] ;Y.:,] fon , ,dec, 
~O'I''' u,iIU.~' 
'111 - «,,-'1" - 0,52 
<01_ J .• ; 
d2 ' , .• , 
'''in1 _ n, 
nl _ In 
T,,') j~j.;,d::m ,~ I,X-t -ml,!C in ',0% of pati",,,!; tl-,ul;; ~57, Ie". Ihem the:' 01 the re ;t of th e 
, Iudy pOpJbtion, with a power 01 0.8 and alpha of 0.5, I ~paticn:' wO<J1d be reqli,ed 
;-, th e gfOU;> rO'lX"1ding porriy to treut"",nl ""d :5 1 'NG,,~-j be required in tha g'oup 
, e, pand. ,~ 
a 'DI", · 0,0= :0-""00""" 
no'.','" _ ON"" , 
~, '- . J' " c,2 _ "0.'" "i, . I",'" 
mO ' D." 
",/'" _ 0,10 
F<t,,-at,,; wMd " 'j ,±;.- .:'." 
01 ' lSI 
Co;> 16 
oppendlx 3. 1 
DETERMINArION OF PLASMA RifAMPICIN, ISONIAZID AND PYRAZINAMIDE 
CONCENTRATIONS 
!. Titl,,: ,\ Ili~h I'.rfo("(ll:«'~' Uq!l id Ch'"{In",!"~r:lrhic (III'L(,) ~lt'I ]wd fM Ult 
Simulta<l""'" Drtr,.,nio",ion of ],oni~zid. 1'~·,:uiJlamid~ .ad Rifompkin in H"m,m 
1']a'lIla 
2. Senp"' 
rif' ,, ~)icin in hum,,,, blooll " ORljl ks colle,,'cri timi ng. clinic.ol q,.:h, '" tberapcmi. mouitori (1)', " I p",icn' 
" 1\1" l c; 
}. p","!""c: ]" Jdcribe • Iligh l'erjonll'Il1~" I.iquill (:hrom:j['Jwaphi,· ,11PLCj IJ ",d",J lUI Eh. 
~i trojll~ncou., d. termi nalion of i,~ui",id p}T""mamidc ,md ri I. "v ic';n itl lnlln" " p l"~lll;l p~rI;."."",d ,,1 Ih~ 
Oi, i"ion oj" l'h.'lllJCology. Dep.rtment of Medicin e, Uni,',.,-,i ~j ~f (:, pc ·i'o"" 
4. Gent,al: ·i'hie< OS") i, • ,inlliIWlcou.> c>.lf"cUO n of ;soni"~iJ. P)o-azilLl"~U~ ""d rila~iciR bm only. 
sirrul ;an",,,,' r",~h"i"n "i' isou; • .,jd "nd p;-razimm:idc Dirtercn l resolution conclilitms "Wly "-, 
nliln"I Cill. 
~. 'bh'rbh: 
J. I. De.,uiphlln of U"·"Y ""'np""~"f> 
Malrix 
Smllf!'" Volw"" 







,o r) ~d 




0. 2 IS flr/ Llll 
j,on;,.id 13~ IOg.'ud 
Pyrwinami'k 123 109/mol 
323,00 1'/"~)1 
Rlrnml'ic;n 
5 . . 1 fn <lrumcnlnrioft SpedjicI11ioN5 
1I,lrd"ul"\' \1(),"","~ SUill)li~r 
iio l,J Ph."l.'~ r " f.1<" io", C ('1 1"" '" f\.'"d I hn (""Il!. , " onl \';"i:,;, ' \ ,-,.-'{ ,,:J, 
F _ acuum \'anifdd ~l1d 1'1lInp . An"f} l id.;m '" 
1I ... ,h'l1l"l' '1,~1I8r;uHI SUPlllirr 
S"".;nt rump ~ n YH(l" Speclr;] l'h};;e, 
.'..uIOO<'''' I' ' ' 1' SP ~no Xl< SpcClr.1 Phy&ic& 
D",~"lO{ UVIS I.;n.;;;" 
l lll ~5'-.,10'· sr~2()<' ~P<-"'lf~ Ph""ics 
Anahumi C"lumn ~ pl,oroW(b S5 ell W'<<:f5 
(Kd-'< ,,_ Oi 113m~~iJvi1! 15 em .'. ;ql, em 
Guard Column UpCI"ltch C~ T~\" pha~c 1',,,,.C<.l ,,;(h ~cllig":ltd L( , An",,,,,h 
2.5 ,rnxOA6 em Packed in hous~ 
lIar.t-. ..... \l0""'lIDrond ,..,..,.... 
""h ell1 ~".'"' SP 8S00 Sl'''<'l''' !';l;d;C, 
.~ \llo,mIV ler ~p S7~U Sl"('ln, Physics 
['eleeL'e sr ~·L<n SptttrJ Ph),Ji(', 
Inl~"IN SP ~no SP"w~ Physics 
,\LJ:.Ll}lic:.d l:O lWllll ~)liL",igrom Uety] 5~m \",u,c], 
;1'd'l\LJ. l~()4Glll C~,4nunx ] 5U llllll 
-
Ci'OLl J LU]U"~l UP'"h"rch Ct ,,~. pl"s~ i;;;~<u ",i,lll~~1i;!',,,"nJ Analech 
2.5 Clll x 0,46 e111 LC S P""hd in l l()Lb' 
5.4 Chemic«/ Sped/indu"" 
nWlI;<'.-,I Sp.c,r.<:III ..... Supplier "· .... 0""'" ,"umber 
\Va ,,,, 1,1" ' , r "W·,nt 5,,00 ; Ti11j l,,-n' I" ].)lJ.'~ 1'''' j j iC~li()I' 
MC-l~"nol -""9.9% CDH 15?50 
A;;W'l"lrilo 'KI. ""; GGH 1 :5' j I 
Tritlu ('t'O>IC~ic ,\cid nc'>:, lej"clei·dc 6lU:~j 
11,,'11 
r()(a""U Lll J)i hyJOll£tll Phosphale '1" . C.~·, M<lck 4S73 
i.;<lni""iJ Rcicrcncc SlOnJa;u --~')j'" Si)/,iW 
i 
! Jj II 
i;unirolilli~ Acid ll),Ll" zidc ,Cer tinC"le al an , l,~ is 
i 
:."1 ;'v 11.,6:11 :7') . ;",,-i10<l) 
l'jr.an.n~dc Releienc(: SWlluanl ·~99 % Sip", P 711 ~ 
I'Y"'L"-,n,,,~ Au" An~J< '.l e," ';~. I< ui 
I.~I NO W9H12b ,., n, 1 y,i, ,1I1""hcd J 
kita~cin Crysunin. 91.1 % "igma I K 3;01 
Ll>! No. 0/6H~!)j I(·.ruticat~ 01 
i '\n"l)~i , " ""~~«ll 
II~~ Q(' Md;",,. tlf · I .• ," · (1< 
!1/ , .;:Im! j: ;;:t.,.! :.~ )./g"': 
I,,, .. ,,.,, t 'mk (I' .... " "'I'"~ "1'<1) X-IW 
4 .,("1" O~ (, ".. (.II ~ 
• I '<-'""I<" ". III:, W -'".) I, ... r. ' , , I", I -~~ i!("!'o",,,' 11)5 ·1 I I? I 11 'I ~ 
, " - .. _. _. 
" " 
l.' " .J ' - -
/lilt" Qr ," ...tiN'" (!C • f .... Q( ' • 
I /11 '1l:,.J _' !~ mI : .' !4: "" 
, I "''''1:'' f.~,J· ""- ., ..... ' -Pif..(l ,.""'~ 
o.;cr '" 73.\ ' ' ;' 
': L '", -II .. '" % m: I. "'-" C 'I .", ~ j,.)~. ' Ir( ~ 
0-; i!c"my)- 70,15 6~.6c 7(,, 0; , -
" " " " I 
-
II':" QC .I1n1ill'" '1(" I." .. ' QC 
1$0 ~ 1'/1 J'J J1/l '"'-! I.f #1;1"" 
,h-..rr.ce pt~,~ (I_I • l" I'~ " <"'0100 2'.~'\j" 
"U.T ~w -, ~-~ .) 'I!-
.11<'''':1'' '-', "('("~'I"'Y I"" -' l "~ 3 "-IX 
--(, II,\"I);'''''Y ? I ~.l. l U2 .6 " " 
" 
I 
Ac~,u • .., , \ """n.,: j: " A",,",", ~) " , 
I'lm. iOl1 " I'l"""io,,_ " )',« i.ion: " : 
• ", ~ 
• ; .. 
I 
• , 
" I " I' " \~ 1,(,.. ,. 
I ~ , 
" 
h. M.tJ", • .h: 
6. I. p"'p,Jj '"li"" vJ Sun:Jr Sol,uion.'· 
6_ ,_ I l'rqJamli,,'I or a Se"'fld""r R,jerem'" S!lIndarri. 




T''''I' ,ohtn! (""crn" "(in~ '\'0'\1:" r emil 
P."''''' Tcmp 1(1 mg \'.'."", I il ",I 1 nw1ml '"0"(" 
R(!('011 T enl' 40 m l( Mtlhanol 10 ml 4 ",<\'m1 _80 cC 
_7We dc:;;",. ,,·d ] 0 "'g MeL],,"'lJ] 10 nrl 1 m.~iml 80 0 (" 
RepulJbl. Ch. ll,",,1 c<''''fl''n',-,; "'!lr l)' "II T~r".,""r~ 'tlllua r<E ,"_g. Sign ... Merck \ A. ".,-lil1".,,· ~r 
"n.I )"i, accomp,nies all rcl(~",c" ,I,nJorw; ,illo<l' ' ~rrli .d by Ibe company, cc d0Wnl()l['ded lion, 
Ihe Tn t<:rn,1 ",,,ql <1:.; "I' Ihe Lui 00"." .. , of It.. 'tandard, '" cd 'Irc m:,inl ' LI"'d IJL .. ,,~gh,ml the <'Dur,e 
of any , tud y 
A 'ec"ndary rderenc. standard IS a"",'" .,""lJarU pn'p'f~u "" nIp, th. rrim.1ry retewICC 'l"nJard 
and ,,,u.d "".y [or ih;; dumlilJL1 lJf . <tudy. New ,.eondary standard;; '''~ pT'P,r"d [00' '","h ne", 
study 
. _ On" <:a l: Iw,,'eil 'H . I )'!Lcal hol",,~., ",eit',h ont "ppr""",.,,'I), 10 m); "I' L,,,n'''';Lu "ccLJJaleJ) i ow " 
('k"n G[;,,\e A I 'J n~ ,o iu""c\lk l1 as~ 
b A(kl "PllllJ,Ln,.!el)' 9, nrl di,Tilled dcionisoo ,,--,11''' __ IOI",{ling up Ib" nas~ 10 !he demarcation \l;tb 
"glass Pa,!ellr pip"lI e 10 pTodL1c,'" fill,l <''-'''~'''H,"ILon of I mg/ ml Vonn wel l u"ii l lin,' is T~) 
P1'O'<1P""1<' rc~n;""Ln!, 
1'1"1'" I " • ,,' I o f [,01 'JHOP) leue oni ('r('oC m!rifugc luh.\S, ". i[,,1>1< ,,, " il 10" , .. ,,1 __ ~r."(' and " I')!I rp'" 
d _\ liflUO< I GO " I of the 3econdar~ stc>ck sto"d.,-d into C<l('h '"b<' ,""l inl( LIlXIICdL,td y 
. _ Sir,,, Ihcse1 in" I"hcl lcd <'r'iOOOX ,I -SWc. unlll ""lllLted r,~ use_ 
(o! I h /1 'm::itl {lmil/p "'pro",/,,,,' Sllim/""I/'''7'',mlirm 
._ On" ",lil;4-,,,,d ,n"l) ILc,1 h,I."te w";f, b mll ' P[I('Qxim;"d y 4() m!; lJ I- r YTa?LH.nriJe .Ctu,"te!v 
inl,c., clean Grad,· A 101111 cI"'LJll",,,d ,ulUJ1",lric n, ," 
h_ AdJ approximatel y 4 'i mllfPLC grlld. ""'lh"""I, (OflIlm~ ' IP the 0.,. !lJ 1"" dem"r<,.tion with l 
glass f'asl eur P;P ,'!IC '" prod"c" • lina l wnco.nlration of ,1 n~\,' \1lL Von,,, wdt unli I Ill ,"", is II " 
rrec ipilate r"""'Lllln~ , 
6:.1 
c !"q}.re J ,<,I ,~ 1"'!H>lVI' .. I .. ," n~~rvc .. ~"I"g~ ,"be.;, "",,,ok 1<> ~ilh:;l.mu _~!n-.: "1>.1 (IlX, 
om 
u Aliq uOI Inn j.! 01 Ihe ,ocond. ry ;toek , I"'''UICI mill ",.clt l1Ill c " , III !!; "" "",."IO'e ' "I I<J I> ",li~ 
""""',,h pipette. ~eal in g inln .edi, lel, 
e Strt'e th e sel ill _~UOC, lL~ti l required I", llie 
6! / c RljiImp!ril! ~""dary Stm,dnrd l'ccp<rrnlION 
" On" c~lib<" I<'d 'TI"l yti,~ 1 b"bTI'",- w,;!'h 001 "w cori mll ely IQ m~ ol"Tibmpid TI "«,, ,,"kly inl o 
• clea~ lir,.1. A I U n\l \ oi.Jlueu ic ll""L 
~. Add "i)jllO-, il\1,te!y 9.~ ",I )1l'LC ~r.de melhanoL ~}WiLlg 111' the na,ll<> Ihe dcmarc.Hi"" wilh a 
glass Pas\eur pip ette 10 I'rc.ducc" lin.! wilccntrati.)ll of J m&'n~. Vortex woll wHillhcrc is no 
pr,cipil"le R."., ininR 
~ fT',!,"T,' :.L ,.:1 or P0)}I~'0PJkl1" TI~"r,""""U'ifu[;e '"u'~, oUlI,uk W \,.,;,,,-> ,,,".1 swc "nd .1 ()OQ 
rpm 
u A!iq ll~l I I){) , II ur Ihe Sero.utLl y .. "d. ;\.ooOld ,nl0 <a~h tulle, . e.I LII!" LlllI1lCdi~lcjy. 
c S:c<" Ihc .el .1_80'(' UIl li l .. "-),,in:o re< u; ". 
n.5 m.tf j'ulas.sium phos{'lwle buil~" {'II " -' 
•. Weigh Q 6S [; ,. ,n.!l ,PO; ""J cli.,,,, h e in 1000 m] di " llted, ,kionis"<l ",al.: ... 
b Wh;1e ;>.,lulion i, . li,riu!" .uju"llhel'l l 10 ~. ~ wilh 1'h;" I)h",i~ ;u-id ,,:;mg" ~"libT"",d pH metcr 
c The pH or,hi , ,,~lurio\l i, ,'hoc"'d.1 tl1< l>eV '\Ili"g of . aeh day and adjusted ;rn=ssary . 
. \c et"nilfi le I. Line A 
n Linc 11: OJ)6% Tritluoroar.tie ,rid (Expiry 1 "" nth) 
{j (j6~o l'rljl'~iI',~u',"Ji , A, "I 
a. Fi ll JIl A graJe 21100 1111 dlfoillaled ' ·"]U".'"IL n.,k wi lh ,li; lilt<.>.l, d"jwi se'\! "'"In 10 Ihe 2 OlIO 
m) dCIlI''';J tiuTI 
11. l'<.mo. ,", Iihr. ted ' ese., ch l'il' e11c , emOYe 1.2 ,,~ \\,. \el and di,c.rd 
C R'l11n<'" II" ! .~ ml ,-,·ilill 2 m! oftri lllLCO'oacclic acid 
d Sh"k~ well unll l ll", ,d",,," lines disappear 
')1}% Acetouiuile . 4()% (0 . I %) Tri!I",~ ,,,,,,,,tic .OK) 
i. I.m,- 1\: Acetoni!!iie 
i i. Line R 0, I % T ritluC>£o>wic acid 
IJ !'{ Trifl"oroncNi, .1,M 
a Fill . n A gr',,\c 2000 mI ch'ol11,ated voiul1'-'1ric flask wilh d;'lilled. (!ri,,,,i , ,,,1 ",·.Ie,,- 10 Ihe 2 000 
ml d"m • .lc"~"n 
t Using " "libr""1 Te",,,",cn pipcn e, [-'l1>On 1,0 ml ""leI' end di_<card 
c. R~pl.tt lhe 2_0 mI wil]' ~_o ,,-,] "i"riH'~i(t;;,cetic acid_ 
d Sh:lke well umilll!.: sckr~Jj lin~; Ji;~ppear 
6. 2. 3. 1_ SlIill(junl ( '"n'~ Ilmll,jualiry Um/I'{)i )aiill'l,~ I i" i-Ig"iiiii 
ROlh I~, ,t.l>(brd CUIY"" "nd qu.lily c"nu "I, ale IX'oV"' oJ by , pili Uio\ Im'l;~ vol " ,,><::5 of drug-
I,,, pl"m. wil h '~r'HbTd, "hi r"mpicin ( I mgimJ "'''' 1 no Itg/mll_ i"""i" id 11 " .. ,1ml ,,,,d 1 
ps/mli .nd t"mZi U""11d~ (4 m&iml "nd 41W) f'l?iml" 000 slOring {he oliquoto al -~O'C llnlil 
rt:\lUirM tor us.. Lli lul;'~lS "I t ile __ "",;k .I."d • .-.! a.-~.!i h;l",1 immobile pru., " 10,- each I JPU' 
'ystem E""h SlOc~ plasHllI ,olu!ioH " I"e~"rcd by "cn,-winl' !h~ approprim, volwlIC "I 
plasm" Irom {OC I" n~mlitr. totol ,~hm.,. h,-f,q . 'piki"~ wilh lim)': ; tandanl A blank 
cxt,-,rction i, nUl pri<I 10 using" i'atch of bum." 1,i>8UlIl I" 1",1 1,,,- inl"Trcri n~ pc;oks_ Thi. 
CbrOlll'HOg.!·.lli" rt1,~j'cd I",' ii-<1"r~ .-d"r.nc<; . Iimin"i";; the ,,=1 !~ ['un 111Lih;pl~ blJlli.., 
d"ri)l.~ .""'P1c 'ml}~j" p~"" .r, " is p\(}Hrd a,.:timl CotlC,,,,,"!ion (,LK mn "n(1 Inc 
.~bti()",~ip is line., 
I'he nr""1piein e"li\>'J!ion ,'un'c nJng~ is from 'J.l v_giml Lop '" 2' ~'_~i"'1 in rh",,,,_ Ihc Ii mil 
or qU8 ,,,j];C.I;'~, l><:in~ 0 JI-,!'/ml_ SUKl':""led q ~alily control conC~ll1"il;~n< "r~ 1.0 ( I.ow), 
'i.0 (M-wum) anj i 'i') ~'wrnl (lligh)_ 
The i,oni.ad cnlibr.lion cur"t range lS Ii-urn U. L ,lgim! LiP "" 15 ,L>I" uI in P",,,,,", ,he lin~' 
of quontificatiol! being 0.2 f'~ m! SL1gg", It(1 qu;,li l j co nlrol co"ccnlrmions 'lU O. ~ {Low), ~ 
(~looiunil and 1 0 L1~/ml (j li~h) 
The P}r:''';ILlU~d" c"lil':;,lioo cun-~ lange i.' [tom 0.:' "l.'ml Llf' I" 7n ,,_~ .'ml in rb;m;" 111(' 
li"~t uj' quaUliiic'lio" beiug 'll ~,,..'mL S,,¥%eN lcd qu.lily coni",) conCl~lIr"l ion; 'j[~ 0 5 
'Low). 30 'MOOium) .00 60 ~'l.ilIli t'l h~I]j_ 
Durin!; Iho \ll i,I",;on p..-ioJ, ,I",,<la,d CLlnts ore run 1<1 dc l ~'lIIino linearity aoo 
reproo u,jl.'i1ilJ', CU1l<.'"mralioo, a t .: ",i<: LLI;,;cJ ",in!', llle <qu"ti"", tc' __ , ":rH'.~ t' UII' Ibe 
, ol;dl tiot, ~urH", and lil e COl"'"" reill during an"' y,;, .. " 1I1n 10 encure conl;nu<"j ,in",nl y, 
Lhe ~u"lll Y "('1"",1 , TolH ", or.,"," Goy-w-d ,,)' lCj,,,klHC;bii i,y dIlJ S"" l'ic ,n" 'j'" 
hum::>)"<'ll,,i Ly. 
'. 10 H':"'] sw"uord in mch ,[., pi""" l,r ,>v""",iJ .nd ,ilampi,in ,wi a "Il i l ~ n, I ,1.",JaJ d in 
m;,., ilc ph. ,. " f I'yr "zj n"mido "c~ nm I'" i'~~c'. II}' 10 ensur< "u'ur.,I. ido~li lica,ioo "i' each 
,10 ,,1:;[<:-
F,,· ""d , _,liun,11 '-''' SI.nJJni 1he peak area i, d r l(~min,,,j A li" o" regr c"ion degCTi~i,,!., lil" c"lih,.tion. 
cu,-..-e i, U .. n co iculOied U, ;TI~ Ib e 100Im,in~ rc~r""i"" "4 Llal;,",· 
mIX) + c 
:' "h3<lll1l" I'C'~ "'c, of lilt O"ObH 
x - COTI,"'lra~'m or II,.. """ lyle 
Ll\ - ; iop" ,,1 11,,· ,'"li l)t,!i~Llline 
~ - Y_IHl ewel'l or tile ca!;~ratio" )io" 
T~<' ,Idi. r q~.''',1 f'" ">e h CL"'" n1",1 ind"'k Ih,' lin,' "lu ,l i i,m, th, ,X)! rd "Hln ,'(lcm"ient (r1 '"" the 
r,,,;id,,,! , " m or"I"'rt'l IS.,y), Seo SOP enlilled "QC m;.;;.SUl'C' <Iuri n!' Hpi ,f· ",~I I,,· MS ;moly,is". 
L" A.na(11;,'all'rocetfure .• 
.. . .,., ,,,,l; Ik J.;""J 1', 1,.1 ",lr"';lun ~,"'Inug", I"'c~ "ilh 1 ml """b'l~)l l" Lee '~ilb l ll~ '~ "lC' ",>1 Vilc~ 
" iil1 I 0;;1 DI""ph.lc IJLJ Il<:L , pH 4.5 , ~n,u~ lh" lh~ bull'" is con~:Mld)- pulled t);w",g,h Ul~ OOlUlllll. 
u ;"pply 'M : ,1 or , ,,,,..pk ",,!o Ihc· cul m"" 
c Dr.w;1 ,J,.,wly (Onlo lilt cOlLlmn and kl il siand lOr len ll~nUl "" 
d, l'LilI thIOUJ;o'l to ":::0[" 
c W.sh ".ilil I ",I pho>ph'le buIT,,', pH 4,5 "",I wil'" I ]~ "e .. ll e< dO.1l 
Acol<nlirrik 2UG .'! 
lfWI ""I 
I f)0 ,u] 
1r)0 , LI 
If)0 , Ll 
1'~ 1 III 
swnd rOr!. mi n,,,,, lil~n p"l l 11"-0,, ",11 
","1 j~r C ~~"m':' t~e" pHil t~'~".~h 
'land ror I min"l< D.,n pullll1roug lL 
'l"n(1 for 2 rw.TI"le; II LO" plll lll"" >t.lgh 
"lllnd for 2 minutes Ilion i>'-~ ] !hmLl ~h 
m',~ lOr 1 m" lH' ~ ,I"," pulllhr~"gh 
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DETERMINATION OF PLASMA ETHAMBUTOL CONCENTRATIONS 
I . TiU. ,.\ II., """ .. ·" .. n •• 1 "I"''' Cb .... ' .. 'OtJ'lO»I~' ." ..... 1>1>«1'· ........ 1") ,\1<11."'" , .... , iI< l.Itl<r"~""'~"'''' 
E I"~"~IUI'" ill .... """ .. 
2. Sr"]'" Tm. ""V appl;". 10 , 11 rbs m., """ Irs I ~Ctj\"{ct tc>'- Mh""~"'T'" '''" I )~ i" b:. Ih~ " "" lyl;c,, 1 
] .:.bur"lOry, 
! . ' '''1'''''"' '1"" tIM .. "';n~ I~r , ..... ..,. "r ",h,nlo,,,,,1 in r l"" .. "sin~ hi~ I""rrornl.1"'~ !i.j":J ,·hr"cl.1lnS' ~l'h) 
OOU~lM 10 n...." ~pKuoo, .. "y 
~ ...... ... ,·oJ, mi. a;,.,.;l, 1.1;1; . , . , up 00 Th' ',\""cr .. !\h"'~Il"'''' iIliU L1l11~j'l I,,, "L. I )~L~ Th. purpuoc of Ih;,; 
""'Y" 10 dc{<fmill e C~Jl,cntnti'm.i "r ",I"llllb u'hi iu "tUl\'> ""l,k,. pri"",ri l), fm It..; PU'l}(j,q; of 
dini",l "udi,." C<'''1l.nn~ lix oo do>. roml"u'U'~1i 1(, " agio ~I~!, prep",""""'" 
!S..,.-c;""" Coil...""", lJ!<ooJ """'''''''''-~ ""'''-..... 1 U\ I .uln"", I "-'runn "'"""-.... I-L.;: •• ;~I\4 ,0 ,e. ;:>1 "'1=< .... A. "-~ 
SCX"I!d ofhl"". ,. ... ~", .. , r.. ' .... , .. "" !bt: IU!' ..... • ~,""I' IIIlXCd 10 .mln""e 'Il< ."', .... I , ~""!! r.",,,. 'iw>J!:I'''''_ II>(-
"",".' ".,1 :~d "" "'t. 11 .. '''1 ..... .", 'JUII do,.." ,,. ,lotH' IJ'TI r",- 1" minuI"" 10 ... ,.,....,.,. I!or I~'"'''' "nn I!IC ""tim .... , ., 
1'1""'0 ,., U .. n ,1<>,.-.Lnt .. 1 "\I,, r,totll,,\ 'w.. . oJ flu .. -,\! <II 80"( ' L"~LI rul"irul h ........ ), II''':!AA~ lily of MlIombJ,o) ., • 
~(t"\: j, ""ll,iiLr.hk 
5. 1. R .. "X"""·' 
S 2. ' 
r lk- IhlkJl. ,nil '''''g. ...... ". r<:qui."", lor , I\( ... SO)" 
Ac''')lIIuil~ IJI'LC grade 
M<I ~:","l HPI (' )'J:ld e 
n'';QI\i ,,·d "'''!'tTll rr.de " .. ., ! Millil '~" 
'1 ' l!lu'~l"'\'C"~ a.,d (. ".1) II ,,, I ;:Io J, ) 
Elll.lmh"lol· f,.., l .il l anli",,,!,,, :'''oJ """1,,,1 ~b.>" .. do.- niH" ~"~.1 " . , ~ u;olill- C<J<U,,,I 
.. ""I~;'. cklnaled b~ <laIT " Iffi'i) .. ' 
1',,,,,,t>ulo1 hydwd llm;de - supp'.,'ll by ~iwm 
........ 'i!""inr ;~1<Tl>,1 "".>d"d - supp,jtol by Sigm..t 
I.l ,,~ poI)·l"op~·kn'· ImfmeL ... rri I;,~~ IIII).· S 
,\ mmonjum ,OOOle 'I m),.1 
5 ~ Z 1 n.'l.f Ammo"i"m {w,·I"I,_ + (II'/', 'ii 'in"'Jr(>(ICNic " cid (TfC1) 
).2,2. 1 Weigh oul 0 .31 ~ Amm"n;"m oe<:'"I~ I "TI"lytic.1 )',fad.), 
5." .:,2 ~bh up [u 101)0 n~ will! dcionj"cd w:ll.." 
5,2,2". Rem,H'C I llli o l' ,~lntjcn :md add I ml TFA 
;,2,24 Filler yOO!J;]o- p h",,, ",iTl,~" V,eUll", ti ltn- "PI'''"IU' 
5,~ , 2. 5 w ni""le ,,<,,,h ooUle Ie.- 1 (I " . "ute; 
).2,2" SlOle i ~l:>cl1ed al room tc-rr-,.,<.:<'Hure 
clhomhulol 
)0'," jVle01 UO}. '.',' "ICT 
).2.J , L Wciglt ,",I I m~ clh. ml" ,lojl 
5, 2,3,2, Disooh-. in 1 1111 )0% MeOl l W.,e, rn~ 
I "'t 
1 ml 
).2, 3,J Prl1'''-'' Ji lLr li",,, o f Ih~ "''Ok '1,,.,~'wd to co\le. ntr"liom or Wi! fli'intl ( l HI) ; j(\ ,ug,lm l 
(l lOQ) and 1 ~~im l (1. l(~~I) HI mol"le phil,e 
j,-',J.< Slillt !'l>dloJ ,1\ I ;oj, ,lkj"olS,1 _8WC 
5,2-3 ;; , COll'i' Ie1< Ill" ' GhKiu"'; dc..::un" m.li(m lo!(hc,, ~ in \11(' wci !,~hiTl!,~ room 
:'<u.li;,;mi!!" 
5 ~," McOH 50% 'Voler 
;;,2A,i Weighoul 1 I"<,(){',,,,,,,,, ig.!nin< 
5,2.4.2. l)js;.:lhem I wi 01' 5(1% ~Ifflll "01 ... mi~. 
1 mg 
I nol 
5,2.4 3 PL""",," In F:;.'ml diHion oj' lll~ stock sl",,,l:ud b) dlluLi,,~ : (; fIl ",,,,,\, sui" I<wu H, "HI ,d 
l110bile ph",e, 
5.1. .. 4 Swrc 1"l;;; lIcJ m "l .quuls of Ion )ll '"' -80"C 
5,2 -),) COI"4,ielo Ill< ,,,luliOl" J(X"""'''I,l iOl ' lo);uool, in til~ weighing IDom 
5, J. O,/ih,""'" 
C"libt,liom con(";TI I 0 nO"-~'TO calibnHo.-s The l~)minal ,'al"" 'K" (I L 0 ,2: 0.3; n,4; n.5; 1: 2: 3. 4 
,md 5 AA ' ''~ ' A ,,,1hwion emv. j, nm ,,'ilb e\ <"y b"ICh Ihl""gl1<'llI II" . n"ly. i, ])<.7i()d iO eboct lb~ 
falih,-"ion , 1"lu$ "Uhf ",,,,y ,md to "",IUlial , conc.lllratian, few: ~""h " ""Ie within \h" h~(ch, Th<;,c 
:r'. "",M up in ~th'''~l" ,ol , ,,""tjg"'iil ~ ir e, phhLL" so mplo!, OOI~;n'.,d !i-"lll !Iv.: W <'S!= Pm,i"c~ 
8hx1 Tnm, ru.,ion ' ~n' i",.: "I (If')oto SehUlll' Ho , pi,,,1 
5.3.1. ('" I'Uralol' /-'r~p", III ,v., 
Calihrator, are roulinely IIllHk up lO l n rni Uiiilre, 
\'<>1" mr of stock Swek eoneenl""lioo ]'nlal ,olu me ,".h~rnhuloJ Cooe. Cal. j\jn. 
.' ~ulml "" ,,:!Iml 
"" '" '" 0. 1 ~, 
2(Xl '" '" '" " ' 00 10 , " 0 .. 1 SJ 
4'~1 '" " ~4 " 
'iW '" '" 0.< SS , "" ](K) , " 1.0 ~~ 
'00 ]r~) 10 2 .0 S7 
WO 100 It' :< II S~ 
~no , "" '" 4. 0 S9 ,00 '00 '" ,.0 SIO 
AliquOl Ihe ".libmor, iolO I. helle<! I 2 !l~ polYl'rop ylene lullos ".""h tuu e should con,aill aT le"l 
)..; u ~I St ore rro'e n ., "pp<oxi",alely -~O"C 
.f .4, QIIIII;',. ( 'MlrFnl .\'~mpl,"· 
Three cOTIlml "nl,le, (nom.LlI.1 CO<lcenlr,liO<l' 0 15, 0.45 ,00 1.5 fl!, . .'rr~) " e u..,eJ 10 mrn ilor 110< 
pnlbmwlee 0]' ""y. [1 i' ,)(lm ,. [ p,"el;ce I" eW...:-I , [ [ Thrce WIl .. ol "mples ill duplicOle \<' i1 II """"Y ,el ai' 
" ",,,Irs .". Iysed. ",lod 1<) di,pcr,I' II .. "" IhTo<,!'II<HII II", Tlm. ernl",1 s. "VIes ,hould can'litui e , mini 11~"" o r 
I V}. af lile lOla) bOlCh, 
5A. I. !.!""lily Con lrol Sample i'l'epnrmwn 
Qu, lily c,mlrob '" e rot.Ll..inely m..Je up 10 [0 milli I;IJ~, "8m!, <lh arrtuJ.lOi .- ou" ligrninl' "ro< pl.,m. 
sall1'le:< , obl,illN n-~m the Western Pro,'ine" Blood T,,",,fusion ,mice , t G,oote Schullr Ho,pilO) 
['h",e .~ m' c[,111"'''''' all y " ·.il ,, l1 le (Itl.li I), 'X~lLlOl, fm " 1~,rnl1" 101 
Volume of,"b Slock eu.ernlr.lion T Olal H,llI me f:lha,nblllol Cone, QC No. 
sloe]" 
,-,wml m' !lRlml 
~ 
110 '" ,<> () I < " , 
" j()(i '" o.~~ ('2 
[ '<0 '''0 '" I " ('-" 
,\li~,, ~t tb. CnllU.--.[, ;"t,-. lot."lle<! I 2 ml ['Inhp"lj,),I",,,, l~bL~ - e.ch (uk ,bould cOll'.,ill al ]"'., 1250 
uJ Slore frozen.1 -800(:. 
.m'''lJos (5 £ '(){) llO!''''A) . J"'''llOS n",cor ""I'> limsn p;lIU>DJ ",d ,.,,, ,.~'" l.;xl.l0 trOllP.til' llFl 
.IOI,)·'''' P . 4' ",a..[J 'tLJI'~) "qJ IU"".u pw, ~I~,,) IdH ,'~ J 1"..[100,' aI p.,," <~ i~ l U~!'''''') • ..[" "lJo, 'lL'cor ""1'1 
-J.0l"'"W..LI""d, SS"'" I)!'tl~ ~I"U~. ,'q o ~ UO)l"'I>U -("unl"" pJl:n~ 
~I.') ' ]!T[m I'" '1 1"'1"" l~,,1 rn. 1P\(> '"""I"" • *L" :l,Oc (0 r"""'l"'"lU U""']'" llrrl "' lU'" , X 'Jt IS- ,) 'I 
1!,0Jpdns < ~o SL .. ;:~d",";Oll'tUO-"l,} 'jU:lULOJPld"p OA !\ Lsod ;:q ..L01"" (u, mne U~ ~U(Sll p"ujo,]J>d " 1I0,'1:<,r01 
_](\,,<>; (0, 0, ;, V J.l. '~,;, [ 0 -;- °lrl"'~ OllnHL onH,," 1-':\11 t "'1 "ILlI',""" J" ,';C)","',) "'"1<1 "1" 1'-' '' "'ll '", !LU~" , ILl< 
I: 0 ;:Pll",,,,,,,,dd, l" m; <i.und .q l 'm 'I'-" .')cor,l\! ""''''(IIY Sm"M " " msn p, .. \Onp" " "''',\ II~P '" " lOS 
:",,'!"'_'!f!-uds ';:'L -, 
-'P"I'I 
",,""os "I' '''',L(( '11OI" 0< 100"'I'U"~!l jO j>..L"I.".ms uO'I'..L""' :luo.> ~LL .',iu (H". ,0. S,<,ctll nl-C P, (ul 'Z' l i , C 
- ~l)'>.iiO! I ,"d< , " ,,,-,, '""I' 
'" ~L"n"U"" ,' "":1."1 ,,), n' ''L'' ,1 LnJ ",urol'''' ,LII "I"" I'IL"I", I~" ."." ."Io~, aLl",;:, JI<l H '''II ' ' ' ~ IV Il L, 
:,.mp~,'''Jd d" IJ"I,\' '/:L', 
"'''IO,,'''UIIUI,\'U/ 'L ' '-
' TS'I""U 10.1 " 'Ullla, "'11 Ol"O pi 7 POrU] O[ 9-, 
'\J.""~! sse]" ,'--'p ~"'P GI"! 'U"I''Ul;ldil< "~1 J" I'l n. 'l',id),] -6 'q' <; 
'," ,",,!,u ~.>;)j mdl 000 1: [ I" '~"J!,IU'J \i") <; 
'TT.·" XO IJO,\ 'L' ~ ' C; 
-~]lJlnrop~v JO I'i 00<: PPV '0'0', 
]P'" x'JJOi\ ,'9 <; 
' IUl'UOI"JV JO l'iUm PPV t 9'. 
H'," x' ]JOA I: ' ~ ' ;: 
'''-''1''1''' '-'"P,""l' ]U,"Pl'" )\Il\u~ n''''' ' IU'i~'i U 1 J" I'i ~ PP" ~lI" d,d \l"! !",,,!>.! 
"~Ul"() ;,qnl ~U"I{oo..Ld,\[od u'"l~ " 01rr( (pi OOll ~ I "'''''' ,m l),d 10 10"uo~ '..L01 '..Lq!l.~ ~ll.d'd i"9', 
Ol'P no p.oOO>..L Ol 4,nj-" UllOO'f'''''' ,'Kllrroq"1 "UT ~q'V"" "rs<. u. ,,,"<to..L,] 
' "lllL"" pu", "I"..L)UO'J '"O '''..Lq~I''' II" '!"-' "14li 'IO..LO'U ','..[",.",,"u,O '.IO..LIUO~ ..Ln.-1'"e ,Jo,H"q'l " ""'LL I'as 
'P"'I~'1r ""!IJII_I/X.'I '9'. 
·r,'w..!'!!]··l 
'''10) r,l-l11 mit (r,," -"II 'p.l_",d.lJd <! no!),,]", po"r"~1< I"",I"I"! ~"!~,(O,, ... H, " '''''''''','4\\ ·,' un.' 
UGH"-'(('Wl . IG4,It " IS~t GJ uOP 'ljos P' ~P""I' I"u.,~,"! :! u!~. u ... ID~ !.'ltJ'L' ' ! .... ~~J '"~I ~J'''D ~i ' 1I ." 
-JJl~- ·'Ill''''' ~';)..LUd" I" 1"-"'1"" '1 l'I!L0\j s ' " ''' 1''1 ''' 1,101,'<1'" p~" '1"'1< ."1.1. 
- (~tr/il' 1 (I 1) vor;qn, c ,,)npo..Ld 01 (~>"'4d "I 'qolU In fl66 1 ~-"'lS rn (I I ) 0 I "! I uo!,nlas 1-""" o~, 
.;11'1'<.] ~l," '''' 1'' ''''41."-'1 '; ,,0,, J u IW I u, ;;m 0 1 ~~l.-\IO'-;S'P ' q ~UXU"" l "-' ,l1' .10 "Ollnji.lS l-"'IS [ur..-,"" I "",1O(\,)J.1 
""!!n/",,,, pnl'''D/\' !"UU/IlI -~"~' 
:'lS Sdling:;_ A Wu ... '~' M;cIQma" Z~jD "in~lc \jUJU nm .' spectfDmdeJ equiW'_'u ,,;Ih J lurbu iun spro )' 
(heated . I«:tro'pray, ESI1 wur~c he,""" 10 330', i, u,ed to introduce Ihe ,:Imp Ie ;nlu lbe n .. S' 'pectrom<1er 
N;troo:c'Il;' I1<C-.1 '" lh~ nt"b"lj'iTI ~ gas 
Sampl . ll1 ProduN Ion (mil) 
posiriH' 
ID.2 
5,8. A _'W)' AUCJ!fIIN~<' ami /{,'p~rli" g of /{,""'f'< 
U,inl< lh. ~b," L) lL' ,o ll"'"re (,er,ion 110,35), imq;r'IC Ihe dhamlxllul ,md inl ~m"1 'l"n<lard p"al area, 
lor e.eh ,"hbr.lOr, C<J<ltrol ,md unknown '.,")]~ lIhiljjl!J",uI coucCllualtum !Ol COlllToIs and pUlionl ' ''''1'1" 
"ill lJe co kulu!\'d Ii'om Ihe c,l;b",1 ion cU'" 0 ElllnLll],,,..,1 ,<,,,11.$ 10.- unluown .. n,,]es should be reporled 1\J 
1 dcc;n",] plot'f 
Tll~ "ppel Ii",il ul' 'lU'"lifi<'.UUll ( t.:LOV) of 1~" LI:;,M~ ' 11l.1mbuto] ",,,ay is the nomi"al \al"e of tllC 
h' gb"" ""lit-mloI, namd. ~ J.lgiml. An}' " ,",pic "1>0,, eil'~n,hul(}] resull j, cllkubl.d to be ,I>m. 5 fl-!:/ml 
, IKJuiJ h< Ji IUl.cd \I ith elh" n~'"! nl-h~ ~ I ",m" 'Dd r."",I\"OO. The " ",II 1'"" Ihe diluted "'''l' Ie ,h,~, Id be 
nlllltipliro by Ih. dil"tioo lact"l' 10 give tbe ~Tl:l 1 r('su l! r"" 'hrol ,.rnpk This i, .dJed lu tl'i~ JOllo"ing 
dh.l1,c.LJI.(,t ."') nal.<:h 
The 10""" IiJl~l ()f qu.n]ific"tion \L J.OQ ) of the LC/"IS dh,mbLnoi :bS>Y h» 1""11 sci .1 " I ~g ml 
Th",.!o.-. "'Y ," o~l . with erh:nDbmol C""cffitr"ti"" iJe10w lb. LI ,00 ,hould be rq><lned ,,':G. I J.lglmI 
J . 9. RunAcceplD"u 
5_9. I ndihmli"" Cun" A(-""l'!II!~'" Criteria 
• fool' oLlI ui',he SlX "" Iib,,,,,-, \(1[ I"" lhi,ds) ,houki be wi thin 15% "fth.i, llOn~TI al 
cOI lc".Jroli"n. T .. ml Y I'''' "<"II <1<" i.,io" i, .1I"wed f,,, 1l1~ IOW~l li",i t "r \j """ Ii ucali"" 
-'- 9 2 Qua/a}' CutalOl ,!cceplwJce Cmel'la-
• 'I W" "Ill ur the Ime" wnlr"l, rem m",,1 be WilbiTI ] 5~' of lhcir Durnin. I {'OTlCC1llwiun 
• 1 f run in duplic.le_ 1 wo Wi "flhc ,j, cIlI'Jrol, run may r,Ll I oUI,ide (hese Ii l1~ts, but both llla; not 
be of tIl< ,an". c~nf..ntra liQ" 
NUTt:: Iu (ho mlfr,,,, of I'",jen' ""-', 11,. lahuro(u') dir .. ~nr ma)' ... 1 ..... of h,' 0; ...... 1.<.", '-e>!''', that "'" 
"j,lIj" tho th.'-'~.ulic ,-~ng. "jth 'h. ><ldod in.«",·,~ 01' the co"tro)' ,hou]d 111<) ~e "ul .r r."I\<_ 
appendix 4.1 
IMMUNOLOGY METHOD FOR WHOLE BLOOD CYTOKINE STIMULATION 
!}, . tho d 10, 5; Vlokirlel' pho'mo<;:orogy o'"I~el, 
• U;lut" bk>od I 'n 2..5 wiih XI-'M IMv (note r"",1 <~I"tl()n or blood i, I in ~i, 
':'cnhilugc .~nUnd(·, ,,' UIoo,L f ...... , .. pk,,'n. ~, 3 "Fo:l""f.. al -?O-r fry 
.. v,*,<1~on of IfN...,. 11-5 '~nd IL - :0. 
• Plale iOCilJ per ","'I 01 dk:l.,.j Vood it." \'6.y;"J ",_I rricroti~e pial." lor S 
d"", Pk,lo. w, !t~I;cul" "b'X~.,.c-...r.d PItA I~.;rl';'d l'hv1rtJ~gg't'l;n'nl 
"r,d f'PD Ip""t,,,d po" I""" ",,'''"'utiv .. ,,' Myo:ubod",j:.rm l~fCUk>;isi. rIotc 
",f~~;enl "-.,,,1:\ I", II ~ I -i , I L-~ m,d Il-1O Ii ... . lhree x:l wo'k let b"c~gound 3 
we~; tal ~H" ortd 3 ""' .. 10< ~ f'(').\, 
• llda ITdC!J"n 01 n",I:g"" 1<:, th .. uPpoof"'tiur" well 01 di~,!ad b!ood in 0 IOC\U 
"0/...,,.... 10 lha I~ I" · ... 00;. odd n-wt09'-'n 10 COWIe a fnnl concenlrahon 01 5.7,; 
y 1<l''''''J! rrI ['~" ...... ,r-;-ri<- l'ril,: . ~ ~he OlD w.rIl. \ldd unbuen '0 cn,"' <:" 
fi",,1 con",,,nITo,i.:m 01 3ug/rrJ. iQ tt ... b-,dg,,,,,,,d w.,I, ud(1 HXJ,d o· P'1"vI1 
If,.OO 
f"'ul cJi"-,j,,-., ~.r L',-"XI ~ he,""'''' ' '1 ~ ··,,110 ~~H ),qr 
• 1",:"001,, fe, S day' " I 370(; in [1 1~ ",-.,kJ, n ... d nlrr.:r;p!, ... " contt;l.n:nQ 5% Co" 
• Afl.,. 5 <YJYS inCI,hatioo. c<:>", fuiy I ~n (lve loc-.. 01 ·,"p.,.",otOO1 I from " " en ",d , 
""",T~'t; :*Id :h& h;,;ltvn i< n", Jilh . . ~d. hx,~~ or..:.<J<olt. at - 10" C t", 
~oruIu'lIio~, oJ II N...,. II _!; and Il - IO 
Co~,c .. 1y "vdbb'c <1rl~bO<!\ pci,.. W&'" u_'Id I", In..:..,.. Il-.'; ,~,.,u ;; - I;) "'''','' ''_ 
\nl "d ,rr'fl).Joc..vlxnl a~><:I', rHJi,~, P!':urM",~ 'to ~(]n Oi.:.-go C,II, ~""",'Ar.g 
OPtnualion R"'=ntllt1(~.1 ~to~,ne' ........ '9 u*d o:l> ,k:mc'orn\ !i'~$""" "'~ c.po=cd 
'n PQ!m ;;;'ter It,,,, "'"..:luet,o:" of ut\. i. nu',,, 1t;<.J " " ,..,ko, ii·", W'-'ll' .... " ,d wd~i. 
T no- I"'" ·~ , ,"';1 0' ': ' "",,',!<: " I")" ro- ih '" 'JIl\" ~'-''':I~ "~<'Tl~"" \"'" !I ~/rrt 
oo~ 1 gO<Jnd I",v"t-; b .. lo;ow till !c .... ~ "''''IT",d 'l "'vel 01 Il. Th" Pf'O ",nc ffiA . 1",,,,I<lI!"d 
!eva,," ' ... ",,, c:oIoU'lk:d tly d<!duct:on ~. Ih" ~W&'" d"'cdild '- t"'" ':'<1"'1-7"'_"" '.':;o!1< 
Ifo n ' Iho IOvcl, deloc1od in tho PPO and ... lA s~m..lcJiod w.~k H lhe- '0· ~U wm j"", 




Surrwn<lf)' 0 1 !he .land<3'd ope,di"ll p'o~I>du'I> u;\>d b V Ih l> SA IMR 1 a Ooportm"". 
at c.. ....... Fon 10, Iuba'~"" ... r< mI~'",~op;~ uomnotion 
stjd~ \ or", p!"~=r~d ,)CC1:'Idi"Q 10 .Ior.dad ::-Pe"''l'Tlg ",,o:,~ .. d~,,,~ u;na tf.~~· 
~Ioinj"g with £",h~N.;eten ~o,bol·f...:.hI", or th" 1\ou.oc.h,Otne ~oil"o-<3u,ornne 0 
",.. I~.~d. '·o.,;'t .. " .;rid "&g:r'''''' CI,>.)frC>l ~jd .. \ w'""e U'%. 5""""'01 pre"",.,,, ... ns 
i,."uJe<l o'.<.>idu""", 01 ~"d ... ,ielc"':o";w':.v" ,l,lh ac'd o~<>~ ho!, '1~{lidonce (II 
IltorJu<:inU tt.-,,~ , m."", •. "''''';''' 1 .... nO o T c o,m'enloin in » with r-otOllium 
l>e" "CI" gG n"JIt, ;0 (,.,.",,1 (IU~ l ~ h v l" o! rlo""exfi g b=il l , ,eod~g of flu or(l 
c hr ome ,'ai"" wh , ,, i ,e\h~ .ra,ned 10 a..{lid fading, and 'l'id OdlC 'Or>e O to IOfo ty 
procedure •. 
;"""r<J<Cop', ,',m pr .. le>m "",I a~di"J Ie .Io~d",d uperatir.g rAoced .... ~I. u~r"l 
r.ighl r,.Vl """o<COPV to, t>.ro,oiGont m'uc'lC.cpy 
fe, t.:...t-,1 lie'd mO'OSCOf'Y 01 l'tO$l IO:! m"'"",-cpr Ii<·U, """"e <;>'1" .. , ... oJ in .., 
~l"lc....-.olr<: ll"lOI'.nH When no GOd fa~' bo<-n [AIel we<e round n roo I",k" . 0 
"Cfe tt"",ough ".-,..:"-';, "''''' moclo!- ;n ,00 "" ..... f;"kh. 
Ihe ..,..,.,. lech,,;que woo ~~ tor floor&>C&n1 rri""o '>C"'PY A rrv>lm..rm 01 30 reich 
w ... e .. ",,~r .. d 01 0 ~nol n'JoJ"rfoc;uhon 01.:11 1so,1~,( 
II 'In """"..at ,Y"n+-, nl '",.....", w .. ,~ I,~.''';hv.. 1.-.--.l"n"Iio:ll ''''JI"" .... nl loll'" IX'>"Jtive 
' f"re"or. we,,, "on"".;.road, ,1\1":I'IOlig <':ol\l<I" ,l>ul;"" 01 wate r OI\U "'<II", ''''IIIVOOI 
,,, I,, ArB, "'o",-"o~'O"n r>ut,_", bt-t...·e"" ~~te' dJ,ing to .. ,iainin9 poc-a',;, "0" ll~ 
0 ' Af~.-. Ihe 0 ; u.ed fOf 0 '; ; ..... rnr~o" ,,",cro;cop,(. 0 00 i""'''P'''' '''l<:ftd 
n , crul(X;fJ i,L 
Cfg"n .. "" 0'11<:-< ih<ln "",,,coha<: 1 ... ;0 ("-U Noo:.voo", if4"' , LogkrC:l(l r-.eckrdM . 
... ~I '"~>I' "I r::'\'Pt"",,,,,dioJfn 'fJIJ • ..:rna i. "'''''''0 'PF'.j mT, dSpla-t v""'(,(!s ""1'''''1 
of <> cid la>me" . 
A' .. ,>i.:Ji I g:"' ... .. Q my<;:Qbocl~rio mo, vary n lr .... ",torr. f i.:.. ,,,1. .. ., """,.1",,1 >kM~. 
and """,,1.,.,,;11 nol oppo:or I.''' .. ''eoccnl on ftuac d-.ome-,loil .. d illI&Qr'S 
, 
appondi. 4.2.2 
CULTURE OF Mycobacterium tuberculosis 
s ...... mo,y of lhe ,Iand~d "",e,a!ing p<oceduo " sod br the SA,IM~ 18 Dcp.xImer.l at 
Gre en I'oonIlor primary i~,*"ion a ll'n\l' cobocl"" " ..... ng u.., 8odr:c mclhod 
Sp",,:illc "'Jdly ,,('~t'o l rlO"e<i lJr ~~ ;n c~JCtcd ,1lO"'lh "I " ct(Y,"<wii: cd " _'<Pcn,,,,n cI 
H37Rv A TCC2729~ in BACIK 12 e /Moolcb'ooi: 7H 12) m.."<:IL'11'\ pCffufmc:",ec tc,t" il 
o f th" Bodee <IoCJ i ... humcnt (E\o:!CfOn Oi-:kmon]. oud rout"'e ir.~hum.::nt 
moilrenam'e 10 cnw,o Opl.mo' fvnclion ... g ~ld avad C'O'iJ oonto "";nofion ~twccn 
,pec:,,-.>. 
Prior 10 inoctAotion, Ifu: I?B rnedlJm conkl;,fn\o1 ,"01\ were 1 .... I\'d loT contorrinoSun . 
.,." eher ,'intl Ih ... S'Jl'WIh ir>rl,,"y ..... cJ p ~ NT ~ ' 0 rlM 'I~ "I "'., ""lirriNn,",*,k po/>''''''''''n 
B. d " ",""teflci n :;, " addl., dCid, If,ne lh o pri l\ dr~j aziocil f" l woo a d:.'"d 10 Ih e vid l 
'0 ''''PP'!!.'' c:onm ""'alk<1, 
0 .5 mI ;;;1 de=nlotTina~ed ,pecimenwm added 10 ~ e 12 e -OOn10 ... ing viol !Wi1h 
PA N1,.,) 
'iid; " .. e re i"cd:,ot . cJ 01 ~ 7:!: 1'C ','br; CO~"To~rllr , '.l Ie> ''' ''''''<m~, w'th ,., ro-i!""" 
"''''17 wet"e,.., oo ..... ,,'Y ,.... dilY "", ' j ro~I"e \I'C1 ~ COIfe'cpOndong 10 ,mell' ""'t/<Ihe 
' paci .... "' W"'i'i .ood .......... ry tot 5 wtteh _ 
A 9'~Hlh ir.Je' [GIl:' row,,, C(,,,J,,Jtf'ed ",,,·j'I ... ,r'(l~ dcnfrfr:od !;." '" ']:0''"''11) indc ' ~ 
20 Were ,Opora led or~j 'ead d ai ly A dail-,. 'nC<IIO$e In the G of 2·3 X w m typ callo! 
;;..·<,',.col.>oc le,i"", con, .... x " net 'J- eo I", than J)( I", o lher mvC<ltxl::;I",i<l _ One" Q GI 
'> ltV! ... '<1, ."''""''..--. (I ." . ...." wa. <:"Iepcr"d Irom the f,,,--dum 'n the vi,,! u~ng ~r;-.eaf­
fixi"tl soIu lion. and \'.<Orrlned und", ort IIlTrJ<rion. Thc mcrphology o f Ihto OI>JOr);'m 
we., ";Pllcl"" '0 p!"'w .... .,livcty rIr~rnrc'c bel . ,.,;.cn ioll',;ol.>ut.I"",,,,,, <,,0<) ~:.;.~ oll)er 
" ¥,,oboclerlo. 
A:r ;x:>oitovc ~io' , '.';;:rc c~orrined I", tho IX",eroca 0' COfltOo'lW,afioll: if CO(,'an-;"oted 
~ .. c:o!lU'e -¥m '''"'t"(.)cC'..:ed "'no" 'kmrhrtcd '>'!"'a"c oro<:'f!d~.e 
l imi'ot"urY. ",-,ted; 
Colon'l ""''''"0100'1 carm"t be oh<Cf\lcd 
Mixed growth of IT«C thon 1 kind o f mycooocte~um CC1mo t bf:I d .. t=lod 
A >1Ib<:,lt'!leln 0 -"",d rrK'cfuml! nlHd&dto i>o!o'c 0 ni>ad OJ"~r ... 
, 
appondix 4.3 
RIFAMPICIN AND ISONiAZID SUSCEPTl8IL1TY; MINI·MIC METHODS 

MICROUK:lLOGY 
r,,1YCOb;l,C, LRIOLOCY UE:i';CH S,-NSrT:vrry PROTOCOL 
DRUG suscEimBILrrv TESTING 
ALL. PR.OCEDURES TO BE CARRIED OUT IN A BIOLOGICAL SAFETY 
CABINET 
Isolates lil :11 am to he vo~essed further fo r sel"rsitiv;ty test~'lg must fulfil the 
follo',slill) ~ri l er,a 
• Pat.ent l1'l ,;;1 aiready L'2 on Jnti-TB thHJpy and stil l havo a posit ive cl..llture 
• f'aiA')m'~ St<:2IlIly trea'_e,: T8 (up to one year ago) and has a positive 
cull xe a~sln 
• 01' '·e::;L.; (c' st 
Sensl tl'.'itio ~, and i'\~R ar" also dono 01' ad isolates slIbmitted from Red Cross 
Ilosp lle:1 
each se'e~:~T,ei1 IS l:l,tn8Weci il".dexed and sent for registering after wh ich the 
fo rm ;s 'iloG illt 'w ; ,fN ai-tr~l) SOI".S · file. 
Tile 5,Oee SII"~2Ptib il ty IS rccomme~ded only for M.1l1berculosis 
INTRODUCTION 
H12 ~i\C - ,---C oroceckre 'or cirug suscee,tibility testing of my:::obacteria is 8ased 
on ,he same 8,;siG pr Inpi" orrmloycd in the conve~tiona l method, TIle only 
dlfforol".ce i'; II'al a li~r; irj r-lod iulll is use d and instead of counti~g colonies after 
aboL:1 :1 "s'O~ ks, 1J1e JrO\'i1l1 IS lllo ~ltored radiometrically a~d the resl,lts are 
report,;nl '1,vl ll' ln L to ~ cays -I,,, criticJI pror;.orlKlI"r for resistance is taken JS 1% 
for all dlti tl.bw~I.l lo ';IS rjr l.l l)s. I lllS mea r~s Ulat if 1 % or more of the test 
myco ~dckrla , por;'l:lauofl r~ ,,,,,,,'tant. the cul ture IS considered resistant for 
labOlate,,), 'G I:-;X;'I"'J e';:rI:-O;;8~ r!e~istance l s Getermir,ed by comparing th" ra te of 
glo',sti' .. h e c,~'nlr(ll and 1'18 ':28 vials contain ing tost drug 
To rj(~ter nl F F~ I'le 1 *' Pl'q~" .. ;tl'~'n of reslstmce. the bacteria l inoculum used i ~ the 
Gonlrul'ii e:1 i,' 100fuld lessli'al' U1St used fort1e drl;g-contsln,1g vial 
PEge ., " r S 
TB - OO J - 00:1 
AUGUST 7G oJ~ 
-',IICROBIOLOGY 
MYCOB."'C-EIl,O:"OG Y 8:NCH - SENSIF;(ITY P"!OTCCO:" 
PREPARAl lON OF DRUG DILUTlQNS Iwhcn using commercial kit! 
ISONI~ZIQ,(O. l ,.glnlI12E>,1 re(;olls~tutc tho lyophilized drug With !:ml stellie 
distill !!;: w,nn ,I.i,girnl! <lne s~l'! k o wol ll; llI;i the drug IS completely ('Msolvec 
A l i q~ot 0, 15~" Sl1,ounts ~f tillS stoCk In!:) TEKL,A,B lube s ane freeze at _WeC 
RI FAM.PICIf.'t ,2 ~;gJml 128) re :::) lislliute ti'l'l lyoJphiliz~d erug ' .... ,th !jml stor' le 
Clst:119ll l'Ia:el {GO"g/IIII;' alld shJ~e well until tl1~ drug's completc ly dissolved 
Aliquot G,l timl amoJnts 01 tiTS S:oCk Into TEKLAB lubes am:: freeze at _10°C 
WHEN PR EPARING INH FRO_M POWDER 
Weigh out 0 O::'-'g 111ng l 01 II ;,-1 powcer (0,00 tg= lmg:::: 100.;Oug) 
OISSOI\e In 1 56:n1 wa~er 
ThiS So l,troll IS :he i'!ql.iv;;uenl of 640jJglrnl 
Mako :~ 1, lC· ciIJti()ll, i e ! ml ~'6AOjJglml'~ gml slen!e drsil licc wa:or = 64 jJg/ml 
F,ltor stcril:7c us ng O,2pn> ,\,\l lIl r:~ro flltor available from the ,·nCCla lab 
AlllluO: 1 31111 a'-;:oL:nts into Tc/<Iab tubas, date allC store 111 the -'10'C freezer 
ThiS s\(Jck ~;() iltun has :~n OXpl"l date of 6 munths, 
For 'I'."011o;il1;/ SL'lutiOI1'~:~ko a 1 16 dllutKl (1 0: 64fl;!lml 10 obtain 4i-Jg/ml. 
I.e Inl' INII + 15r(l1 wat,u 
Ahq(.(.)t 1601-1 per - eklac '.:.:be .3nC fi'eezo. Usc t tuuo porSOI1S1tI~rty 
WHEt! P!!EPARIN!i RIF FROM POWDER 
WOIO') oul u,01g i1Or:1g) of ~:- pOVA!er iO,001g=lmg= 1000ugi 
Dlssol~o Ir, . 5,6ml "n~lh. 1I1()' 
FI"Of slenl:7Q loSing O.<'!.lfll fhlhp()ro filter available fr :.>m the med.a lab 
Tnls so cl,ol) IS the eL;(.I"iil enl cf GAOp;)iml 
AIi'i liOI • 31111 ,"-;:Glnts il1to TC/<Iab tubes and store in the -W"C fr0971:! r 
Th, s stm;k so: ~ton 118S :'n expllY date of 6 rno l1th~ 
F()r w::rk:n,; 501~tion n'a~e a , 8 d,lllt,on uf 640f.lg/11i1 to obtain 80f.lg/ml, 
I I:! ',111R iF I 7'111 water 
AI;q(.o: 1601--l: pe ' Tek at t(.te and freeLe Use I tube per sens,w.jy. 
fREP:\RA:ION QE 126 DRyG MEDIUM 
Thall d tub,,:.>; fmzen Sj..;ck (I, Jg so:(ollcn. Using a !(.oerculin synnge add ° llT'l 
of thiS ~tock ~oLlhon in!:.; a ':?6 vial U,>e a "gpara!e synnge 'or each dr Ig Ad the 
120 v_,iS lh2d in Ihc 1e:)1 should bo Fro-Iesled on !he 8actec460 10 eSlaDilSh a 
C:); a:rnosr:i'cre In Ihe \Ial,md ',0 SCf(len out any ~ i als wrth a GI20 or more 
Pa~e ~ 1;1 S 








;\,IVC8~,~,CT==<:8 _()GY 8Fc'jC" _ SENS IT IV~Y PROTCCOL 
SP EC IAL Dr LU TI N G FLU r D fe,;' " r. ti\' oo~ r,,, ""i.,. .. "", .r",."; O-p"P' ''" 'r ro, ,""'"' ~ ') 
Tile te,~t inln_I ' 1111 's j III:':;(] JUO~O bOlng addod into the control 126 vi .,1 1\ 
speci,; Jilu, II'9 f Jill -_i 'I:r:! 1 lloes Ilot corn pete Witll the I"bolled substrate ill tile 
126 ITIr~Jil,ln , S LS2r.j jc; ,;ssisl j, I .j ispe~sillg .11ycob2cto n" 
PREPARATIQ}J OF INOCULUM FROM 12B MEDIUM 
BelA2 per~'l llIn~ ,j SJsr:2ptib, lity test, collfilm the 10 of the organisrn This wil l 
aVO'Ci Uli ller:essc'r., 3Ijsce<:li:; li:l test'II9 of MOTTS "I'd M,bO'Iis BCG' s 
• If tr,e (; 1 ulille '23 'Jld i3 99:-; sL;b 0,05.111 of th is to ,,11 appropriatoly labelled 
12P ', i, ; ,nd pl,;~,' l:ii,~', d i1 \f'lC ' awaitillg growth for sons ' rack 
• COI'II I"~; , of W,e '31 VIc:,ls T-Ie G I rnu st be betweell 300 -SOO before perforrning 
d S'OI1S I,IVI:Y l%l~s per , p:o :~, ~o l 
PREPARfIT.lQN QE INOCULUM FROM MGIT TUBE, including H37RV ATCC 
27294 
BdDI":; oel"(; I IT,i':'] ,; S' IS coptib i lit y tesl conf ir.11 tile 10 of tile organism first This 
wi ll avo;,j _IIT2ceS"dl., " ", sr:eJ tlbdity testll l,] of MOTTS alld M,bovis BeG 's 
Vortei the :"'1GI - t-l:;':; 
• Ir lDeL I,;I,' 0,251;-" fl,;11I t' ll' ,',M; IT into " n "ppropriatcly l<lbc licd 12B vial 
• "Ic,r:,~ i! ' :I',e' :;"N:; ,I,ill'j 9 r'-;',.~: I', fm sens" rdCk, 
• ~>~;i:iUI ,r e '31,~' 1 U·S 'in I C:,j I)' I'he Ci must be betweell 300 500 
• \/-,,'1 ' <)1  ~l, c:,J'-,' <: ,·" t ':( 111 Ihe se lstvit)' as per pi'Otocol 










t,'YCOIl"C '[RIO~OCY B!:t-.;CH SEONSITN rTY PRo TOCOL 
Prepdre Jrug mr.rllil t>;. al.l:i'llg O. l ml of eacll tesi drug stock sol!J~On inlO 
1f"l:lI~KJ\.L," 1 llLl v.<lIS 
Arr;:"ln~]C' I~C' v, ... I!' 11 '" ",;;k and I<lbel p:operty (CONT~O:.. . ,NH. RIF) 
PIe-il8(~ ;; ur,:onl, t;il;:;~gnallnOCU\lm, by vortexing the 12R vial. ThiS 
If"lOCl.lUlI1'l> usee :11"€(':iy 
CI~ .. n 1.1l1:! 12:.3 VIe. S90td \Vo th 70% alcohol. 
U!'ln!J <I luOe-:;:;ul.r Sr' n;;9 noculate 0.1ml of Ihe bacler.al suspenSion Inlo 
e ... ch 0' :tle 12:.3 Vlell" contil ,nlrg a dru!J 
F(lr Uit! v)nt:ol Vial do rOllnoculat9 directly but fi~: d::ute 1. 100 by 
tran.~:E!Il ["£I Q 1".1 ~f t,'e S'JSilElnsion Into 9.9011 specml dliutong flU id, After 
rY'llx'r;; ttlur<l'lgll;y InOe(1 at;: 0 .1 ml of \his diiutDn, 'Jsin g a Ilew tubefOJi ln 
~;'n Ige, 1 1:~ :1 '9 con tro.l lf.i v!al (WitilO',lt a dr,lg) 
• ;n cdlal'~ ;11' 111C' V l d l ,~ II" 3ic Jo not i ncuba~e below 3</C 
Q8J!.,Y R E./).DI~I G SC HEDULE (Inc luding weekends and public holidays) 
• Test Vlil:; ;): 'hC' '~ "lnr. Illn C' edch day, li s ual~ a~ 2pln 
• re~ t fo' " In 1l1l1111nl o:..j (la'/~ ;lI1d a m;;)(lrll '.l rll of 12 If there IS nO g'OWlll by 
da)' ·11r 1I",Q cortlol VIII; cor''')lIe to 1rC'.lvale the vlais and tes'. dally 11l1lil tile 
conlrO, vlill r{1ilC"I:'~ ;; ( )I of 30 ~'r rno~e ' 10 a maximum of 12 days 
• Rr.=:;-,r:1 )'lC" U~IV::; rt:'.idln!.l~ ir.lhe worktoooi< 
INTEHPnr 'fAl iON OF HE511L T5 
vi ~ e<ll.lin'J l> r,j '"' ::il,l>Cep: t:.hl/l!;lSI ~eqlllre more Interprel ahon Ular. do the p ~lmary 
isoiall :.;r VI •• s I 01 II)'" hrsl "''''0 to t :-oree days, the Gl ln the controi vial WI !! be low 
but tn"'or wll ::,1;11"': n:::, ;:i,i ,>,n:; ~y '" f ... clor ::If!WO to Illree Smce the v !1lIS conta!nlng 
dr.lgs '/C'~'~ 110:.;..,1<119::1 wiltl d 1 :X;· lold larger IflOCulurn. lIle GI readings are 
usu ... ly "19: ,~r !lIar t:-oe ;:;::Tlrol-::n the first d<ly or two if the strain ;s :;usce~lI[.~e 
10 Ille .t:!:>t r1IU:; ::'e G level« 01 :;.~ decreas~s or the subsequent days However, 
the G, valu E"' c<.-rn;l(If:'> I,' InC'C'::Ise ~:;.r fflsistant strains and IS much higher than 
the COl t«l' 
TtliS IS :he r"<lfOl1 lh<l' ''' n~I;;'(I!l' ~1I"'ln can 00 de(ecloo and reported earlie r 
Ulan <l SU", .. ~t;:() ~' (lIn 
p~~ ,,4 )15 
TB -OC3-0,':~ 
AUGU!" T ?nr.? COPY 
M,CROBIOLOGY 
~,IYCC0,~,CTERIOLOGv BENCH - SENSITIV ITY PROTOCOL 
• rle ~i;le21Ic2 b2twee1 the current GI vall-Ie and the GI value from the 
pre "ious day is rj",si~I-':l t erj j.5i, 
• Whe!' h e ::mltrol ',";a l reaches a 5 1 of 30 or more the resl-Ilts sheuld be 
in;crprelerj ~s 101 D\'.'~; 
\GI C:l'1rel -, , \,(C; ,_811_:g ~;L'~;::epj ble 
\ GI C'I'trol "' cVC; dr,_,qiL_CceC'C'c'ctoctctt __ ~ 
Expecc:o:oci ,-.,s Llls ol.!,oDtr'~" '137RV 
The r37RV cGlllr':} S:lDL,!rj al\v:lYs 8e S81,sitive 10 r~Jth INH and Rif 
C9Jlf:~I,lve /\'" tlun i' cen lro i 's resistant 
Chec~ ;he ?xpiry d:lle,~ 01 11e dru ~s II the dru~~; have bee!' Iised r)(!yond the 
expirl ,hie , In,;Ke L,p a fresh ba;:;h of urugs 
Retes: tile H3/f,'-/ w:n ::Ie ne'.''-!i macie drugldrqs, ,md ')11 samples that were 
resi~;;:l'lt in I'-I;; ba:::I, 
• R;;:;ord r;;SIII;S in I'le \I..-ork:::-Jk ~nd in the senSitiv ity file 
• R;;l1love 1'1;; D-j~ i l-~i forT Ir::r:', the ' 2w~i;ing sens" file, recGrd the 'es ult Gil 
;h~ Ilonl ul :1'2 fU11ll ''''.'1,111'2 8ale, anci en ter result on cGlllputer 
• Pla ,;e ' Cri ll un the +12'",e 
• If S,:;;Gil "en is ~ RXI I Dr TP'1 Gne, GO a ll cf the above and then place the form 
':::'fl -he 'o:I'e(' q'"ic;l,e 
• I,\.':'V !II ',' fJo l--S are prililed sen~ to TBH or RXH 
• All :; res":iI ~;h::".<;m~ leslst~I',ce to eill'N ene or bo;h drugs tested IllUSt be 
fax ':!J tu f(a leil Sheen a; ,=)r(JCklyn Chest Hespital -- fax 5103898 
• PIa::e t-t 2 ' u)i',tml" 1::'0 vial ul INt-l and P ,! resistant patients 111 the ' awaiting 
gr,, '/In lor ;(' :lnd 3'" :1I1C r<lcK, inGubale and Gh,,"~k the GI ever/213 l1,lYS, 
un':' ,t rhKlkS ~ I ::~;e 1:: UI at 999 
• F-II '11 a ~, ()!lSI:I"/lli8(ll,esl j.:JrI~;, make a GOPy G! thi~; fGrm Stap le the copy 10 
112 ::li]i l18.i ,'2'_' U2st f"rlll, place in ~rcertin<l fiie 
• Sel',~ 1::'fl file ')II~ :'Jrr:', tD \J' ILS Green Poin; 
• :'il II tie recurd ill itle s2n siliviti ir'dex 
• '.JVI Holn :I ',e r2sulls al' ci ,-.;'efence nUIll~er dre retll:'n2d, enter them onto the 
c~:lllplll e!-, ')I'd 11110 Ihe T6 sens ,ncex 
• SI<lfl,e II-Ie reSlI,t sh.,et frol~; C,yen f-'o int 10 the Grginal reqllest !rGITl 
• I-'I<: l,c; 01 queue f-::r aU; " I'J.',;:~ t v~r, 
Pa[1l" :, ",1 5 
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TO MAKE A STOCK SOLUTION OF RIFAMPICIN AT 640uglml 
Weigh out 0,01 9 (1 Omg) of RIF powder (0,001 9 -' 1 mg = 10001J9) 
Dissolve In Q,6ml methanol. -Then add 15rnl-distilied water _L ',' •. ''''' I "":. c~, I "" .. :.0- hI. 
Filter sterilize uSing a 0,2l-1m Millipore filter available from the media lab tvv ! 1.",->, 
This solution IS the equivaient of G40l-lg/ml ~, [,,_ v -I ",,_ I "-
Double diluting with 3ml amounts is convenient Dispense tile rest into ',. . l.;::(Jd~_;",_ 
appropriately labelled Teklab tubes cmd freeze ".\, -.- .... , , ;--, \. j 
' --' - iO'\" 
Eaell 12B vial contains 4ml of medi um and by adding 0,1 ml the dl uti on factor 
IS 40 
, '.:l 1 :1 I. -, \-,,1 
'" ,-",-,-, 
DOUble di lute G40)Jg/m l to 32Ul-lg/ml 
Take 0, lml and add to 12B = Bl-Ig/ml 
Double dil ute 320lJg/mi to 160l-lg/ml 
TakeO,lmlandadd\017B=4l-1g/m l ) 
Double di lute 1 GO)Jg/ml to 8U)Jg/ml 3t, Take 0,1 ml and ;'idd \0 128 = 2l-1g/ml 
~,;H-·i Double dilute 80l-lg/ml to 40)Jg/ml 
T;;ke 0,1 ml <lnd add to 128 = 11Jg/ml 
Double dilute 40lJg/mi to 20l-lg/ml 
Take 0.1 ml ,md add to 178 = 0,5l-1g/ml 
Double di lute 20j.Jglm l to 10l-lglml 
Take 0,1 ml arid add 10 128 '" 0,75l-1g/ml 
DOUble dilute lO)Jgim l to 5~I g/ml 
Take 0,1 ml and add to 128 = 0,175l-1g/ml 
i Double dil\jle 5~lg/ml to 2,5l-1g/ml 
Take U, 1 ml and add to 17B = O,OG)Jg/m l 
Double dilute 2,51,Ig/ml to 1,75J--1g/ml 
Take 0,1 ml and add to 12B "' 0,0311giml 
Double dilute 1 ,75J--1g1ml to 0.G25)Jg/ml 
Take 0,1 ml and add to 12B = 0;015~lg/m l 
For each di lution 
Or make alB dil ution in ( 
stor il e distl:led water of ,' ~01 <0,,1;,\< 
640lJg/lni to obtain BOJ--lg/ml : '1JU J ~ !"" , ' and continue di luting as I 11\\(', 
Ind icated below le:lml RIF + ) 
-Im l w;;\er 
Dispense U, 15ml into appropriately label:ed Tekiab tubes and freeze 
I-'or use Take 0,1m l ;;nd ;;dd thiS to a 17B via l 
TO MAKE A STOCK SOLUTION OF ISONIAZID AT 640uglml 
Weigh Olil O,001g I. l mg) or INH powdor (O,001g = 1 mg = l000IJ9) 
Dissolvt! ill 1 ,56ml dlst lll~d water 
rllt~r ~leflllze uSing a O,2IJm Mil lipore filler avallatllo from Il'lo media lab 
This solullon IS In.:. eQuivalent of 640IJg/mi 
Make a 1,10 diit;t ion 
ie:l ml of 640iJ9lrni oj. gml steril e dlslill tld W3ler" 64tJQlmi 
DOlJble dillilm9 With 3ml amot;nts is COlwell lent 
DISj)dllse the rest IlitO 3ppropfiately labelled T eklab tubes and freeze 
Each 128 Vial COI1i<lInS 4ml of medium and by adding 0 l ml ~he dilution faclor 
IS 40 
Double dilute 6 4fJQlmi iO 32IJQlmi :1 
Take 0 1 ml and add to 128 " a,Opg/ml 
Double dilute 32IJy/mi to 16IJg/ll11 
Take 0,1 mi "'IIid add 10 128 " OA!-Ig/ml , 
p ouble dilute 16fJg/mi 10 8fJ91ml 
T ake 0,1 ml and add to 128 " O,21,lg/mt 
Double dilute 8IJglmi iO 4IJg/mi 
TakoO lml and add to 128 " O,llJgiml 
Double dillilo 4IJgimlio 2IJgimi 
Take 0, lml and add to 128" O,05fJg1m l 
DOlibie dilute 2IJglmi to 1!-19/ml 
Take 0, 1 ml and add to 128 " O,025pg/ml 
\ Double dillite l!-1yfmlto 0,51Jylml 
, Take 0,1 ml and add to 126 = 0,0 125J,lglml 
Double dil ute O,5tJg1ml to O,25 11glm l 
Take ° lml and add to 126 = O,0C6fJ9lml 
ifr. I<'IW Double dlMo O,25IJglmi \0 O,1251J9/ml 
Take ° l ml and add to 128 " a,003jJg/mi 
For each dilu(l::JrI 
Or mako 0 1 16 d11uU011 In 
l slenle distilled waler of . 64fJgfml 10 oblalnt~ flglmlW"ld 
QOntmw(i'4.!IJ't1~~d 
V'QJ,l-t~: 1ml INH " 15ml ...... ater 
fO!: tII l (~ ------
~ 
{t~l K,o , , , 
C«tl.In tl 
DI Sp(lIISe O. 15m! into approprj,, (ely labelled Teklab tub(ls arid freeze 
r or (;s~ Take O,1ml8lld add th iS to a 128 Viol 
appendjx 5. 1 
PlASMA CONCENTRATIONS OF RIFAMPICIN. ISONIAZID, PYRAZINAMIDE AND 
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appendix 5.2 
DRUG CONCENTRATION-TIME PROFILES fOR EACH SUBJECT 
Cvr:,, <: nirati2!') ' Erl:!!'->>:;/It:' OrriLurCl< ic n isoniazid pyrazinarride ard ethaniJutoi in 142 <ub;ect,. 
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